[
  {
    "text": "Immunoassay for pyruvate kinase M1/2 as an Alzheimer's biomarker in CSF.",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "SE(1), Carlyle BC(3)(4).",
    "entities": [
      {
        "text": "SE(1",
        "label": "ORG"
      },
      {
        "text": "Carlyle BC(3)(4",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Author information:",
    "entities": []
  },
  {
    "text": "(1)Massachusetts General Hospital & Harvard Medical School, Department of",
    "entities": [
      {
        "text": "General Hospital & Harvard Medical School, Department",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Neurology, Boston, MA, United States of America.",
    "entities": [
      {
        "text": "Boston",
        "label": "GPE"
      },
      {
        "text": "MA",
        "label": "GPE"
      },
      {
        "text": "United States of America",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Physiology, Anatomy & Genetics, University of Oxford, Oxford,",
    "entities": [
      {
        "text": "Physiology, Anatomy & Genetics",
        "label": "ORG"
      },
      {
        "text": "University of Oxford",
        "label": "ORG"
      },
      {
        "text": "Oxford",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "United Kingdom.",
    "entities": [
      {
        "text": "United Kingdom",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford,",
    "entities": [
      {
        "text": "Institute for Nanoscience Discovery",
        "label": "ORG"
      },
      {
        "text": "University of Oxford",
        "label": "ORG"
      },
      {
        "text": "Oxford",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Alzheimer's disease (AD) is characterized by amyloid-beta plaques and tau",
    "entities": []
  },
  {
    "text": "tangles in the brain, but these markers alone do not predict disease",
    "entities": []
  },
  {
    "text": "progression. The intersection of these pathologies with other processes",
    "entities": []
  },
  {
    "text": "including metabolic changes may contribute to disease progression. Brain glucose",
    "entities": []
  },
  {
    "text": "metabolism changes are among the earliest detectable events in AD. Pyruvate",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "kinase (PKM) has been implicated as a potential biomarker to track these",
    "entities": [
      {
        "text": "PKM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "metabolic changes. We have developed an enzyme-linked immunosorbent assay",
    "entities": []
  },
  {
    "text": "(ELISA) to assess PKM levels in cerebrospinal fluid (CSF). First, we verified",
    "entities": [
      {
        "text": "ELISA",
        "label": "ORG"
      },
      {
        "text": "PKM",
        "label": "ORG"
      },
      {
        "text": "CSF",
        "label": "ORG"
      },
      {
        "text": "First",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "the relationship of CSF PKM levels with cognitive decline, revealing a",
    "entities": []
  },
  {
    "text": "correlation between elevated CSF PKM levels and accelerated cognitive decline in",
    "entities": []
  },
  {
    "text": "preclinical AD patients in a tau-dependent manner. We developed the ELISA using",
    "entities": [
      {
        "text": "ELISA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "two PKM-specific antibodies and validated it through quality control steps,",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      },
      {
        "text": "PKM",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "indicating robust quantification of PKM. We showed that ELISA measurements of",
    "entities": [
      {
        "text": "PKM",
        "label": "ORG"
      },
      {
        "text": "ELISA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PKM correlate with mass spectrometry values in matching samples. When tested on",
    "entities": [
      {
        "text": "PKM",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "an independent cohort, the assay confirmed elevation of PKM in AD. These",
    "entities": [
      {
        "text": "PKM",
        "label": "ORG"
      },
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "findings support the use of PKM as a potential biomarker for tracking early",
    "entities": [
      {
        "text": "PKM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "metabolic changes in AD, offering a novel tool for investigating metabolic",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "alterations and their intersection with other underlying pathologies in AD",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "\u00a9 2025 the author(s), published by De Gruyter.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "De Gruyter",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Conflict of interest: B.C.C. has received",
    "entities": [
      {
        "text": "B.C.C.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "sponsored research funding from Ono Pharmaceutical, and GSK. S.E.A. has served",
    "entities": [
      {
        "text": "Ono Pharmaceutical",
        "label": "ORG"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "S.E.A.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "on the Scientific Advisory Board of Allyx Therapeutics, BioVie, Bob\u2019s Last",
    "entities": [
      {
        "text": "the Scientific Advisory Board of Allyx Therapeutics",
        "label": "ORG"
      },
      {
        "text": "BioVie",
        "label": "PERSON"
      },
      {
        "text": "Bob",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Marathon, Jocasta, Sage Therapeutics, and Merck. S.E.A. has acted as Consultant",
    "entities": [
      {
        "text": "Jocasta",
        "label": "PERSON"
      },
      {
        "text": "Merck",
        "label": "ORG"
      },
      {
        "text": "S.E.A.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "for EIP Pharma and Daewoong Pharmaceuticals. S.E.A. has received sponsored",
    "entities": [
      {
        "text": "EIP Pharma",
        "label": "ORG"
      },
      {
        "text": "Daewoong Pharmaceuticals",
        "label": "ORG"
      },
      {
        "text": "S.E.A.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "research funding from AbbVie, AC Immune, Amylyx, Athira Pharma, Chromadex,",
    "entities": [
      {
        "text": "AbbVie",
        "label": "ORG"
      },
      {
        "text": "AC Immune",
        "label": "PERSON"
      },
      {
        "text": "Amylyx",
        "label": "PERSON"
      },
      {
        "text": "Athira Pharma",
        "label": "PERSON"
      },
      {
        "text": "Chromadex",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Cyclerion Therapeutics, EIP Pharma, Janssen, Johnson & Johnson, Ionis",
    "entities": [
      {
        "text": "Cyclerion Therapeutics",
        "label": "ORG"
      },
      {
        "text": "EIP Pharma",
        "label": "PERSON"
      },
      {
        "text": "Johnson & Johnson",
        "label": "ORG"
      },
      {
        "text": "Ionis",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Pharmaceuticals, Novartis, Seer Bioscience and vTv Theraputics.",
    "entities": [
      {
        "text": "Novartis",
        "label": "GPE"
      },
      {
        "text": "Seer Bioscience",
        "label": "PERSON"
      },
      {
        "text": "Theraputics",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Toxicity of glyphosate accelerates neurodegeneration in Caenorhabditis elegans",
    "entities": [
      {
        "text": "Caenorhabditis",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "model of Alzheimer's disease.",
    "entities": []
  },
  {
    "text": "(1)Department of Toxicology, School of Chemical & Life Sciences, Jamia Hamdard,",
    "entities": [
      {
        "text": "Toxicology, School of Chemical & Life Sciences",
        "label": "ORG"
      },
      {
        "text": "Jamia Hamdard",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(2)Department of Pharmaceutical Chemistry, School of Pharmaceutical Education &",
    "entities": [
      {
        "text": "Pharmaceutical Chemistry",
        "label": "ORG"
      },
      {
        "text": "School of Pharmaceutical Education &",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Research, Jamia Hamdard, New Delhi, India.",
    "entities": [
      {
        "text": "Jamia Hamdard",
        "label": "PERSON"
      },
      {
        "text": "New Delhi",
        "label": "GPE"
      },
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "INTRODUCTION: Pesticide-related environmental contamination poses a growing",
    "entities": []
  },
  {
    "text": "global concern, threatening human health, wildlife, and ecosystems. Glyphosate",
    "entities": []
  },
  {
    "text": "(N-phosphonomethyl-glycine, GLY), a widely used organophosphorus herbicide, has",
    "entities": [
      {
        "text": "GLY",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "been associated with neurotoxic effects. This study investigates the potential",
    "entities": []
  },
  {
    "text": "neurodegenerative impact of glyphosate using a Caenorhabditis elegans",
    "entities": [
      {
        "text": "Caenorhabditis",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Alzheimer's disease (AD) model.",
    "entities": []
  },
  {
    "text": "METHODS: Transgenic C. elegans strain CL4176, which expresses human amyloid-beta",
    "entities": [
      {
        "text": "CL4176",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(A\u03b21-42) upon temperature induction, was exposed to various concentrations of",
    "entities": []
  },
  {
    "text": "glyphosate (12, 15, 18.5, 20, and 25 mg/L) for 24 hours. Behavioral assays (body",
    "entities": [
      {
        "text": "12",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "DATE"
      },
      {
        "text": "18.5",
        "label": "CARDINAL"
      },
      {
        "text": "20",
        "label": "DATE"
      },
      {
        "text": "25 mg/L",
        "label": "TIME"
      },
      {
        "text": "24 hours",
        "label": "TIME"
      }
    ]
  },
  {
    "text": "bends, head thrashes, body length, and pharyngeal pumping), oxidative stress",
    "entities": []
  },
  {
    "text": "markers (catalase activity), and A\u03b2 protein expression were evaluated.",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "RESULTS: Glyphosate exposure induced a concentration-dependent decline in",
    "entities": []
  },
  {
    "text": "locomotor and feeding behaviors. Catalase activity was significantly reduced,",
    "entities": []
  },
  {
    "text": "indicating elevated oxidative stress. Additionally, a marked increase in A\u03b21-42",
    "entities": []
  },
  {
    "text": "protein expression was observed in glyphosate-treated CL4176 worms.",
    "entities": [
      {
        "text": "CL4176",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "DISCUSSION: These findings suggest that glyphosate exacerbates A\u03b2 toxicity and",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "induces AD-like phenotypes in the C. elegans model through behavioral",
    "entities": [
      {
        "text": "C.",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "impairment, oxidative stress, and increased A\u03b2 accumulation. Glyphosate's",
    "entities": [
      {
        "text": "Glyphosate",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "potential contribution to neurodegenerative processes warrants further",
    "entities": []
  },
  {
    "text": "investigation.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 Rani, Alam and Parvez.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Rani",
        "label": "PERSON"
      },
      {
        "text": "Alam",
        "label": "PERSON"
      },
      {
        "text": "Parvez",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "DOI: 10.3389/ftox.2025.1578230",
    "entities": [
      {
        "text": "10.3389",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: The authors declare that the research was",
    "entities": []
  },
  {
    "text": "conducted in the absence of any commercial or financial relationships that could",
    "entities": []
  },
  {
    "text": "be construed as a potential conflict of interest.",
    "entities": []
  },
  {
    "text": "Development of a method for large-scale single-molecule analysis of tau",
    "entities": []
  },
  {
    "text": "proteoforms.",
    "entities": []
  },
  {
    "text": "Flaster ME, Grothe R, Guha S, Kaneshige K, McVey K, Nelson N, Perera RT, Tan SJ,",
    "entities": [
      {
        "text": "Flaster ME",
        "label": "ORG"
      },
      {
        "text": "Kaneshige K",
        "label": "PERSON"
      },
      {
        "text": "McVey K",
        "label": "PERSON"
      },
      {
        "text": "Nelson N",
        "label": "PERSON"
      },
      {
        "text": "Perera RT",
        "label": "PERSON"
      },
      {
        "text": "Tan SJ",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "S, Forton A, Sartori ER, Brereton PS, Chen K, Darcy MA, Golnabi HR, Hartley R,",
    "entities": [
      {
        "text": "Sartori ER",
        "label": "LOC"
      },
      {
        "text": "Brereton PS",
        "label": "PERSON"
      },
      {
        "text": "Chen K",
        "label": "PERSON"
      },
      {
        "text": "Darcy MA",
        "label": "PERSON"
      },
      {
        "text": "Golnabi HR",
        "label": "ORG"
      },
      {
        "text": "Hartley R",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "SK; Nautilus Biotechnology; Kapp GT, Patel S, Temple S, Bertucci T, Blanchard J,",
    "entities": [
      {
        "text": "Nautilus Biotechnology",
        "label": "ORG"
      },
      {
        "text": "Kapp GT",
        "label": "ORG"
      },
      {
        "text": "Patel S",
        "label": "ORG"
      },
      {
        "text": "Bertucci T",
        "label": "PERSON"
      },
      {
        "text": "Blanchard J",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Proteins exist as diverse proteoforms resulting from a combination of genetic",
    "entities": []
  },
  {
    "text": "variation, alternative splicing, and post-translational modifications. Current",
    "entities": []
  },
  {
    "text": "methods struggle to capture this complexity at the single-molecule level. Here",
    "entities": []
  },
  {
    "text": "we introduce Iterative Ma pping of P roteoforms (IMaP), a method that enables",
    "entities": [
      {
        "text": "Iterative Ma",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "the massively-parallel interrogation of millions to billions of single-protein",
    "entities": [
      {
        "text": "millions to billions",
        "label": "MONEY"
      }
    ]
  },
  {
    "text": "molecules through iterative probing with fluorescently labeled antibodies. Using",
    "entities": []
  },
  {
    "text": "12 site-specific antibodies, the method is capable of measuring 2 12 (4,096)",
    "entities": [
      {
        "text": "12",
        "label": "CARDINAL"
      },
      {
        "text": "2 12",
        "label": "CARDINAL"
      },
      {
        "text": "4,096",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "potential proteoform groups. We used IMaP to measure proteoform group profiles",
    "entities": [
      {
        "text": "IMaP",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "of the tau protein, a key player in neurodegenerative diseases, using two pan",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "anti-tau antibodies (Tau-13, Tau-216), three isoform-specific antibodies",
    "entities": [
      {
        "text": "three",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(Anti-0N, Anti-2N, Anti-4R), and seven phosphosite-specific antibodies",
    "entities": [
      {
        "text": "seven",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "and Anti-pS396). The method demonstrates high sensitivity (detecting proteoforms",
    "entities": []
  },
  {
    "text": "at 0.1% abundance), high reproducibility (median CV <5.5%), and broad dynamic",
    "entities": [
      {
        "text": "0.1%",
        "label": "PERCENT"
      },
      {
        "text": "CV",
        "label": "PERSON"
      },
      {
        "text": "5.5%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "range (>3 orders of magnitude), outperforming conventional techniques in",
    "entities": [
      {
        "text": "3",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "resolving closely related proteoform groups. We demonstrated that the method can",
    "entities": []
  },
  {
    "text": "be used on relevant biological samples by examining various neuronal models",
    "entities": []
  },
  {
    "text": "(iNeuron cells, organoids, miBrains, and mouse brains) and human samples. This",
    "entities": [
      {
        "text": "iNeuron",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "examination revealed 130 distinct tau proteoform groups with as many as six",
    "entities": [
      {
        "text": "130",
        "label": "CARDINAL"
      },
      {
        "text": "as many as six",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "phosphorylation events. The non-random distribution of these phosphorylation",
    "entities": []
  },
  {
    "text": "events suggests ordered and site-specific modification processes rather than",
    "entities": []
  },
  {
    "text": "random, stochastic accumulation. Certain combinations of phosphorylation events",
    "entities": []
  },
  {
    "text": "were more abundant than others; for example, pT217 preferentially co-occurred",
    "entities": []
  },
  {
    "text": "with pT181. In validating the applicability of the assay to human disease",
    "entities": []
  },
  {
    "text": "samples, we noted a specific pattern of multiple phosphorylation events in an",
    "entities": []
  },
  {
    "text": "advanced Alzheimer's disease patient that suggests a sequential pathway of",
    "entities": []
  },
  {
    "text": "pathological tau modification. Iterative Mapping of Proteoforms provides",
    "entities": [
      {
        "text": "Iterative Mapping of Proteoforms",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "insights into proteoform complexity at the single-molecule level, with",
    "entities": []
  },
  {
    "text": "significant implications for understanding protein regulation in",
    "entities": []
  },
  {
    "text": "neurodegenerative diseases and beyond.",
    "entities": []
  },
  {
    "text": "Sex-Stratified Transcriptomic Meta-Analysis of Alzheimer's Disease Reveal Brain",
    "entities": []
  },
  {
    "text": "Region and Sex Specific Dysregulation.",
    "entities": []
  },
  {
    "text": "OBJECTIVE: Alzheimer disease (AD) is a neurodegenerative disorder leading to",
    "entities": []
  },
  {
    "text": "cognitive decline. Despite growing recognition of sex differences in",
    "entities": []
  },
  {
    "text": "epidemiology, symptomatology, and clinical outcomes of AD, the molecular",
    "entities": []
  },
  {
    "text": "mechanisms underlying these variations remain poorly defined. We performed",
    "entities": []
  },
  {
    "text": "transcriptome association studies of AD aiming to identify sex-specific and",
    "entities": [
      {
        "text": "AD",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "sex-dependent transcriptomic profiles that could provide insights into the",
    "entities": []
  },
  {
    "text": "molecular mechanisms underlying sex differences in AD pathogenesis.",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "METHODS: We conducted a meta-analysis of bulk-RNAseq data derived from human",
    "entities": [
      {
        "text": "RNAseq",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "postmortem brain studies. Specifically, we analyzed gene expression differences",
    "entities": []
  },
  {
    "text": "between individuals diagnosed with AD and non-cognitively impaired (NCI)",
    "entities": [
      {
        "text": "AD",
        "label": "ORG"
      },
      {
        "text": "NCI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "individuals across two key brain regions: the prefrontal cortex and the temporal",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "lobe. We performed stratified differential expression analyses separately in",
    "entities": []
  },
  {
    "text": "males and females, alongside combined analyses across sexes. Additionally, we",
    "entities": []
  },
  {
    "text": "assessed the data in relation to known AD genes, proteomic studies, and drug",
    "entities": []
  },
  {
    "text": "repurposing opportunities.",
    "entities": []
  },
  {
    "text": "RESULTS: Beyond the genes commonly dysregulated across both sexes, our",
    "entities": []
  },
  {
    "text": "meta-analyses identified multiple differentially expressed genes (DEGs) between",
    "entities": []
  },
  {
    "text": "AD and NCI that are either altered in only one sex or show different effects",
    "entities": [
      {
        "text": "NCI",
        "label": "ORG"
      },
      {
        "text": "only one",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "between sexes. Some genes are known AD genes from genetic studies, but others",
    "entities": []
  },
  {
    "text": "are novel. Correlation with proteomic data suggests that these transcriptional",
    "entities": []
  },
  {
    "text": "differences have functional significance, potentially contributing to the",
    "entities": []
  },
  {
    "text": "biological mechanisms underlying sex differences observed in AD. Finally, we",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "identify drug compounds that are potential candidates for treatment.",
    "entities": []
  },
  {
    "text": "INTERPRETATION: Our findings enhance our understanding of sex-related",
    "entities": []
  },
  {
    "text": "differences in disease etiology and progression, and underscore the importance",
    "entities": []
  },
  {
    "text": "of incorporating sex as a critical variable in transcriptomic studies of AD.",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "These insights help pave the way for more precise, personalized medicine",
    "entities": []
  },
  {
    "text": "approaches that account for sex-specific molecular mechanisms.",
    "entities": []
  },
  {
    "text": "In vivo palpation of anisotropic human brain tissue using MRI.",
    "entities": []
  },
  {
    "text": "The mechanical stiffness of brain parenchyma varies across physiological states",
    "entities": []
  },
  {
    "text": "and pathophysiological conditions, such as during normal and abnormal",
    "entities": []
  },
  {
    "text": "and traumatic brain injury (TBI), neuronal activation, and sleep via the",
    "entities": [
      {
        "text": "TBI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "glymphatic brain waste clearance mechanism. Despite its biological and clinical",
    "entities": []
  },
  {
    "text": "importance, relatively few techniques exist to measure and map mechanical",
    "entities": []
  },
  {
    "text": "properties of brain tissue non-invasively and in vivo . MR elastography (MRE) is",
    "entities": [
      {
        "text": "MRE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "an established method that has been widely used to estimate tissue stiffness in",
    "entities": []
  },
  {
    "text": "the liver by applying mechanical waves using an external tamper and measuring",
    "entities": []
  },
  {
    "text": "their resulting deformations. However, applying MRE in the brain is more",
    "entities": [
      {
        "text": "MRE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "challenging due to the skull and cerebrospinal fluid (CSF), which impede",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "mechanical wave propagation, and tissue mechanical anisotropy, which requires a",
    "entities": []
  },
  {
    "text": "4 th -order tensor description. In this study, we propose using the intrinsic",
    "entities": [
      {
        "text": "4",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "deformation of brain tissue caused by periodic cardiac pulsation to measure the",
    "entities": []
  },
  {
    "text": "4 th -order stiffness tensor throughout the brain while simultaneously",
    "entities": [
      {
        "text": "4",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "estimating the 2 nd -order diffusion tensor in each voxel throughout the cardiac",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "cycle, which we use as a priori information in the reconstruction of the",
    "entities": []
  },
  {
    "text": "stiffness tensor. While the DTI-derived mean diffusivity (MD) appears uniform",
    "entities": [
      {
        "text": "DTI",
        "label": "ORG"
      },
      {
        "text": "MD",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "throughout brain parenchyma, stiffness maps obtained at about 1 Hz (i.e., at the",
    "entities": [
      {
        "text": "about 1 Hz",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "fundamental cardiac frequency) show contrast within gray matter, and within",
    "entities": []
  },
  {
    "text": "white matter pathways such as along the corpus callosum, internal capsule,",
    "entities": []
  },
  {
    "text": "corona radiata, etc. Generally, stiffness differences at internal tissue",
    "entities": []
  },
  {
    "text": "boundaries are expected to lead to local stress concentration, which may",
    "entities": []
  },
  {
    "text": "predispose tissues to damage in TBI. Therefore, our novel tamperless MRE method",
    "entities": [
      {
        "text": "TBI",
        "label": "ORG"
      },
      {
        "text": "MRE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "has the potential to not only identify such interfaces, but assess changes in",
    "entities": []
  },
  {
    "text": "tissue stiffness there that might occur following injury.",
    "entities": []
  },
  {
    "text": "APOE4 drives widespread changes to the hepatic proteome and alters metabolic",
    "entities": [
      {
        "text": "APOE4",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "function.",
    "entities": []
  },
  {
    "text": "Morris JK, Wilkins HM.",
    "entities": [
      {
        "text": "Morris JK",
        "label": "PERSON"
      },
      {
        "text": "Wilkins HM",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "Apolipoprotein E (APOE) is essential for lipid homeostasis and has been",
    "entities": []
  },
  {
    "text": "extensively studied in the central nervous system, particularly in the context",
    "entities": []
  },
  {
    "text": "of Alzheimer's disease (AD). Individuals carrying an APOE4 allele have an",
    "entities": [
      {
        "text": "APOE4",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "increased risk of AD and exhibit deficits in energy metabolism, including",
    "entities": []
  },
  {
    "text": "glucose utilization and mitochondrial dysfunction. While the role of APOE in the",
    "entities": []
  },
  {
    "text": "liver is well characterized, the impact of APOE genetic variation on hepatic",
    "entities": []
  },
  {
    "text": "health and metabolism remains poorly understood. We sought to investigate this",
    "entities": []
  },
  {
    "text": "using young female and male APOE3 and APOE4 targeted replacement mice. We also",
    "entities": [
      {
        "text": "APOE3",
        "label": "PERSON"
      },
      {
        "text": "APOE4",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "used APOE isogenic induced pluripotent stem cell (iPSC)-derived hepatocyte-like",
    "entities": []
  },
  {
    "text": "Proteomic and functional assays show that APOE4 causes extensive changes to",
    "entities": [
      {
        "text": "APOE4",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "liver mitochondrial function in a sex-specific manner in mice and alters glucose",
    "entities": []
  },
  {
    "text": "and lipid metabolism. APOE4 also impairs mitochondrial function in iHLCs and",
    "entities": [
      {
        "text": "APOE4",
        "label": "ORG"
      },
      {
        "text": "iHLCs",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "shifts metabolism towards glycolysis while modifying expression of extracellular",
    "entities": []
  },
  {
    "text": "matrix proteins. Additionally, APOE4 iHLCs display a greater reliance on fatty",
    "entities": [
      {
        "text": "APOE4",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "acids as an energy source and show increased lipid accumulation. Taken together,",
    "entities": []
  },
  {
    "text": "our findings show that APOE genetic variation causes mitochondrial dysfunction",
    "entities": []
  },
  {
    "text": "and rewires hepatic metabolism.",
    "entities": []
  },
  {
    "text": "Structure-specific Mini-Prion Model for Alzheimer's Disease Tau Fibrils.",
    "entities": [
      {
        "text": "Mini-Prion Model for Alzheimer's",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "MP, Melo AA, Tse E, Shea JE, Shell MS, Kosik KS, Southworth DR, Han S.",
    "entities": [
      {
        "text": "Melo AA",
        "label": "PERSON"
      },
      {
        "text": "Shea JE",
        "label": "ORG"
      },
      {
        "text": "Shell MS",
        "label": "ORG"
      },
      {
        "text": "Kosik KS",
        "label": "PERSON"
      },
      {
        "text": "Southworth DR",
        "label": "LOC"
      },
      {
        "text": "Han S.\n",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "A critical discovery of the past decade is that tau protein fibrils adopt",
    "entities": [
      {
        "text": "the past decade",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "disease-specific hallmark structures in each tauopathy. The faithful generation",
    "entities": []
  },
  {
    "text": "of synthetic fibrils adopting hallmark structures that can serve as targets for",
    "entities": []
  },
  {
    "text": "developing diagnostic and/or therapeutic strategies remains a grand challenge.",
    "entities": []
  },
  {
    "text": "We report on a rational design of synthetic fibrils built of a short peptide",
    "entities": []
  },
  {
    "text": "that adopts a critical structural motif in tauopathy fibrils found in",
    "entities": []
  },
  {
    "text": "Alzheimer's Disease (AD) and Chronic Traumatic Encephalopathy (CTE). They serve",
    "entities": []
  },
  {
    "text": "as minimal prions with exquisite seeding competency, in vitro and in tau",
    "entities": []
  },
  {
    "text": "biosensor cells, for recruiting tau constructs ten times larger its size en",
    "entities": [
      {
        "text": "ten",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "route to AD or CTE fibril structures. We demonstrate that the generation of AD",
    "entities": []
  },
  {
    "text": "and CTE-like fibril structures is dramatically catalyzed in the presence of",
    "entities": [
      {
        "text": "fibril",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "mini-AD prions and further influenced by salt composition in solution. Double",
    "entities": []
  },
  {
    "text": "Electron-Electron Resonance studies confirmed the preservation of AD-like folds",
    "entities": [
      {
        "text": "Electron-Electron Resonance",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "across multi-generational seeding. Fibrils formed with the full AD/CTE-like core",
    "entities": []
  },
  {
    "text": "show strong seeding competency, with their templating effect dominating over the",
    "entities": []
  },
  {
    "text": "choice of salt composition that tunes the initial selection of AD- and CTE-like",
    "entities": []
  },
  {
    "text": "fibril populations. The mini-AD prions serve as a potent catalyst with",
    "entities": [
      {
        "text": "fibril",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "templating capabilities that offer a novel strategy to design pathological tau",
    "entities": []
  },
  {
    "text": "Sustained Lysosomal Delivery of Enhanced Cy3-Labeled Acid Nanoparticles Restores",
    "entities": []
  },
  {
    "text": "Lysosomal pH in Retinal Pigment Epithelial Cells and Astrocytes.",
    "entities": [
      {
        "text": "Retinal Pigment Epithelial Cells",
        "label": "ORG"
      },
      {
        "text": "Astrocytes",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Lysosomal pH is frequently elevated in age-dependent neurodegenerations like",
    "entities": []
  },
  {
    "text": "Age-related Macular Degeneration (AMD), Alzheimer's Disease (AD), and",
    "entities": [
      {
        "text": "Macular Degeneration",
        "label": "ORG"
      },
      {
        "text": "AMD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Parkinson's Disease (PD). Tools that restore lysosomal pH to an optimal acidic",
    "entities": []
  },
  {
    "text": "range could enhance enzymatic degradation and reduce waste accumulation. Acidic",
    "entities": []
  },
  {
    "text": "nanoparticles offer a promising strategy for restoring lysosomal function, but",
    "entities": []
  },
  {
    "text": "accurate tracking of organelle delivery and long-term retention is needed to",
    "entities": []
  },
  {
    "text": "optimize dosage. To improve detection and enhance delivery, nanoparticles were",
    "entities": []
  },
  {
    "text": "synthesized from Poly(D,L-lactide-co-glycolide) (PLGA) polymers covalently",
    "entities": [
      {
        "text": "Poly(D",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "linked to the fluorescent Cyanine3 amine (Cy3) probe. Nanoparticle concentration",
    "entities": []
  },
  {
    "text": "and loading times were optimized to achieve >90% delivery to lysosomes in",
    "entities": [
      {
        "text": "90%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "cultured induced pluripotent stem cell-derived retinal pigment epithelial",
    "entities": []
  },
  {
    "text": "(iPS-RPE) cells. Uptake was heterogeneous, varying between adjacent cells. Once",
    "entities": []
  },
  {
    "text": "loaded into lysosomes, the nanoparticles were stably retained, with no",
    "entities": []
  },
  {
    "text": "detectable changes in concentration, distribution, or size for at least 28 days.",
    "entities": [
      {
        "text": "at least 28 days",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "iPS-RPE cells internalized more nanoparticles than the ARPE-19 cell line or",
    "entities": []
  },
  {
    "text": "mouse optic nerve head astrocyte cultures. Functionally, PLGA nanoparticles",
    "entities": [
      {
        "text": "mouse",
        "label": "PERSON"
      },
      {
        "text": "astrocyte",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "restored an acidic pH and cathepsin D levels in compromised lysosomes. In",
    "entities": []
  },
  {
    "text": "summary, Cy3-PLGA nanoparticles enabled improved tracking and long-term delivery",
    "entities": []
  },
  {
    "text": "to lysosomes, supporting future in vivo applications to restore lysosomal pH in",
    "entities": []
  },
  {
    "text": "NEW AND NOTEWORTHY: Tools that restore acidic pH in compromised lysosomes can",
    "entities": []
  },
  {
    "text": "enhance autophagy and waste degradation in degenerative disorders marked by",
    "entities": []
  },
  {
    "text": "excessive accumulation. Here, we describe the novel synthesis of",
    "entities": []
  },
  {
    "text": "lysosome-targeted nanoparticles composed of PLGA polymers covalently bound to",
    "entities": [
      {
        "text": "PLGA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Cy3 fluorescent dye. These Cy3-PLGA nanoparticles enabled improved tracking of",
    "entities": []
  },
  {
    "text": "lysosomal delivery and demonstrated sustained long-term retention within",
    "entities": []
  },
  {
    "text": "lysosomes, supporting their potential for future applications to restore",
    "entities": []
  },
  {
    "text": "lysosomal pH in aging and degenerating tissues.",
    "entities": []
  },
  {
    "text": "Discovery of an Achiral Small Molecule TREM2 Agonist with Improved",
    "entities": [
      {
        "text": "Discovery",
        "label": "PRODUCT"
      },
      {
        "text": "Achiral Small Molecule TREM2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Pharmacokinetic Profile and Validated Target Engagement.",
    "entities": [
      {
        "text": "Pharmacokinetic Profile",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "The triggering receptor expressed on myeloid cells 2 (TREM2) is a lipid-sensing",
    "entities": [
      {
        "text": "myeloid",
        "label": "ORG"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "TREM2",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "immunoreceptor on microglia that has emerged as a therapeutic target for",
    "entities": []
  },
  {
    "text": "Alzheimer's disease. Here, we report the discovery of C1 , an achiral structural",
    "entities": [
      {
        "text": "C1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "analog of VG-3927 -the first small molecule TREM2 agonist to enter clinical",
    "entities": [
      {
        "text": "VG-3927",
        "label": "GPE"
      },
      {
        "text": "first",
        "label": "ORDINAL"
      },
      {
        "text": "TREM2",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "development. C1 was synthesized via a modular and enantioselective-free route",
    "entities": [
      {
        "text": "C1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "using sequential Suzuki couplings, enabling rapid scaffold diversification.",
    "entities": [
      {
        "text": "Suzuki",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "Compared to VG-3927 , the stereochemically simplified derivative ( C1 ) exhibits",
    "entities": [
      {
        "text": "C1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "superior microglial phagocytosis and validated target engagement. C1 induces",
    "entities": [
      {
        "text": "C1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "TREM2 activation in HEK293-hTREM2/DAP12 cells, and its direct binding to TREM2",
    "entities": [
      {
        "text": "TREM2",
        "label": "PRODUCT"
      },
      {
        "text": "HEK293-hTREM2/DAP12",
        "label": "ORG"
      },
      {
        "text": "TREM2",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "was confirmed using both microscale thermophoresis (MST) and surface plasmon",
    "entities": []
  },
  {
    "text": "resonance (SPR). Importantly, C1 also demonstrates a superior pharmacokinetic",
    "entities": [
      {
        "text": "SPR",
        "label": "ORG"
      },
      {
        "text": "C1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "profile to VG-3927 , including enhanced metabolic stability in human and mouse",
    "entities": []
  },
  {
    "text": "microsomes, favorable PAMPA permeability, and a LogD 7 . 4 compatible with CNS",
    "entities": [
      {
        "text": "7",
        "label": "CARDINAL"
      },
      {
        "text": "4",
        "label": "CARDINAL"
      },
      {
        "text": "CNS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "penetration. Docking studies suggested a potential binding mode of C1 at the",
    "entities": [
      {
        "text": "C1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "extracellular domain of TREM2, revealing key polar and hydrophobic interactions.",
    "entities": [
      {
        "text": "TREM2",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "These findings position C1 as a synthetically accessible and pharmacokinetically",
    "entities": [
      {
        "text": "C1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "favorable lead for the development of TREM2-targeted therapies.",
    "entities": [
      {
        "text": "TREM2",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "Population-specific brain charts reveal Chinese-Western differences in",
    "entities": [
      {
        "text": "Chinese",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "X, Liu Y, Shen Y, Huang X, Ji GJ; Alzheimer\u2019s Disease Neuroimaging Initiative;",
    "entities": [
      {
        "text": "Liu Y",
        "label": "PERSON"
      },
      {
        "text": "Shen Y",
        "label": "PERSON"
      },
      {
        "text": "Huang X",
        "label": "PERSON"
      },
      {
        "text": "Ji GJ",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "CHIMGEN Consortium; DIDA-MDD Working Group; MCADI; Chinese Lifespan Brain",
    "entities": [
      {
        "text": "CHIMGEN Consortium",
        "label": "ORG"
      },
      {
        "text": "MDD Working Group",
        "label": "ORG"
      },
      {
        "text": "MCADI",
        "label": "ORG"
      },
      {
        "text": "Chinese",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Human brain charts provide unprecedented opportunities for decoding",
    "entities": []
  },
  {
    "text": "neurodevelopmental milestones and establishing clinical benchmarks for precision",
    "entities": []
  },
  {
    "text": "brain medicine 1-7 . However, current lifespan brain charts are primarily",
    "entities": [
      {
        "text": "1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "derived from European and North American cohorts, with Asian populations",
    "entities": [
      {
        "text": "European",
        "label": "NORP"
      },
      {
        "text": "North American",
        "label": "NORP"
      },
      {
        "text": "Asian",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "severely underrepresented. Here, we present the first population-specific brain",
    "entities": [
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "charts for China, developed through the Chinese Lifespan Brain Mapping",
    "entities": [
      {
        "text": "China",
        "label": "GPE"
      },
      {
        "text": "the Chinese Lifespan Brain Mapping",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Consortium (Phase I) using neuroimaging data from 43,037 participants (aged",
    "entities": [
      {
        "text": "43,037",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "0-100 years) across 384 sites nationwide. We establish the lifespan normative",
    "entities": [
      {
        "text": "0-100 years",
        "label": "DATE"
      },
      {
        "text": "384",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "trajectories for 296 structural brain phenotypes, encompassing global,",
    "entities": [
      {
        "text": "296",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "subcortical, and cortical measures. Cross-population comparisons with Western",
    "entities": []
  },
  {
    "text": "brain charts (based on data from 56,339 participants aged 0-100 years) reveal",
    "entities": [
      {
        "text": "56,339",
        "label": "CARDINAL"
      },
      {
        "text": "0-100 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "distinct neurodevelopmental patterns in the Chinese population, including",
    "entities": [
      {
        "text": "Chinese",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "prolonged cortical and subcortical maturation, accelerated cerebellar growth,",
    "entities": []
  },
  {
    "text": "and earlier development of sensorimotor regions relative to paralimbic regions.",
    "entities": []
  },
  {
    "text": "Crucially, these Chinese-specific charts outperform Western-derived models in",
    "entities": [
      {
        "text": "Chinese",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "predicting healthy brain phenotypes and detecting pathological deviations in",
    "entities": []
  },
  {
    "text": "Chinese clinical cohorts. These findings highlight the urgent need for diverse,",
    "entities": [
      {
        "text": "Chinese",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "population-representative brain charts to advance equitable precision",
    "entities": []
  },
  {
    "text": "Identification of Chlamydia pneumoniae and NLRP3 inflammasome activation in",
    "entities": [
      {
        "text": "Identification of Chlamydia",
        "label": "ORG"
      },
      {
        "text": "NLRP3",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Alzheimer's disease retina.",
    "entities": []
  },
  {
    "text": "Gupta VK, Mirzaei M, Black KL, Meyer JG, Arditi M, Crother TR, Koronyo-Hamaoui",
    "entities": [
      {
        "text": "Gupta VK",
        "label": "PERSON"
      },
      {
        "text": "Mirzaei M",
        "label": "ORG"
      },
      {
        "text": "Black KL",
        "label": "PERSON"
      },
      {
        "text": "Meyer JG",
        "label": "PERSON"
      },
      {
        "text": "Arditi M",
        "label": "PERSON"
      },
      {
        "text": "Crother TR",
        "label": "PERSON"
      },
      {
        "text": "Koronyo-Hamaoui",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Chlamydia pneumoniae (Cp), an obligate intracellular bacterium, has been",
    "entities": [
      {
        "text": "Chlamydia",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "implicated in Alzheimer's disease (AD), yet its role in retinal pathology",
    "entities": []
  },
  {
    "text": "remains unexplored. We analyzed postmortem tissues from 95 human donors and",
    "entities": [
      {
        "text": "95",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "found 2.9-4.1-fold increases in Cp inclusions in AD retinas and brains, with no",
    "entities": [
      {
        "text": "2.9-4.1-fold",
        "label": "CARDINAL"
      },
      {
        "text": "Cp",
        "label": "GPE"
      },
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "significant elevation in mild cognitive impairment (MCI). Proteomics revealed",
    "entities": [
      {
        "text": "MCI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "dysregulation of retinal and brain bacterial infection-related proteins and",
    "entities": []
  },
  {
    "text": "NLRP3 inflammasome pathways. NLRP3 expression was markedly elevated in MCI and",
    "entities": [
      {
        "text": "NLRP3",
        "label": "ORG"
      },
      {
        "text": "NLRP3",
        "label": "PRODUCT"
      },
      {
        "text": "MCI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "AD retinas, and its activation was evident by increased N-terminal gasdermin D",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(NGSDMD) and mature interleukin-1\u03b2. Retinal Cp strongly correlated with A\u03b2 42",
    "entities": [
      {
        "text": "Retinal Cp",
        "label": "PERSON"
      },
      {
        "text": "A\u03b2 42\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "and NLRP3 inflammasome components, which tightly linked to cleaved",
    "entities": [
      {
        "text": "NLRP3",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "caspase-3-apoptotic and NGSDMD-pyroptotic cell death. Although retinal",
    "entities": []
  },
  {
    "text": "microgliosis was elevated in AD, Cp-associated microglia were reduced by 62%,",
    "entities": [
      {
        "text": "62%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "suggesting impaired Cp phagocytosis. Higher retinal Cp burden correlated with",
    "entities": []
  },
  {
    "text": "APOE\u03b54, Braak stage, and cognitive deficit. Machine learning identified retinal",
    "entities": [
      {
        "text": "Braak",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Cp or NLRP3 combined with A\u03b2 42 as strong predictors of AD diagnosis, staging,",
    "entities": [
      {
        "text": "NLRP3",
        "label": "PRODUCT"
      },
      {
        "text": "42",
        "label": "DATE"
      },
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "and cognitive impairment. Our findings suggest that Cp infection contributes to",
    "entities": []
  },
  {
    "text": "AD dementia but not initiating pathology, whereas early NLRP3 activation may",
    "entities": [
      {
        "text": "AD",
        "label": "CARDINAL"
      },
      {
        "text": "NLRP3",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "promote disease development, warranting studies on Cp's role in AD pathogenesis",
    "entities": [
      {
        "text": "Cp",
        "label": "PERSON"
      },
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "and early antibiotic or inflammasome-targeted therapies.",
    "entities": []
  },
  {
    "text": "Tau Clearance Reverses Neuronal Dysfunction in Both Young and Aged C. elegans.",
    "entities": [
      {
        "text": "Young",
        "label": "PERSON"
      },
      {
        "text": "Aged C. elegans",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Carroll T, Johnson GVW, Nehrke K.",
    "entities": [
      {
        "text": "Johnson GVW",
        "label": "PERSON"
      },
      {
        "text": "Nehrke K.\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Alzheimer's Disease (AD) is an age-related dementia and presents a growing",
    "entities": []
  },
  {
    "text": "medical and economic burden as the average human lifespan continues to rise. AD",
    "entities": []
  },
  {
    "text": "is classically diagnosed via the accumulation and aggregation of two major",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "proteins: amyloid-\u03b2 and tau. To date, potential and FDA-approved therapies",
    "entities": [
      {
        "text": "FDA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "designed to clear these aggregates at best delay rather than prevent disease,",
    "entities": []
  },
  {
    "text": "indicating that the root cause of AD lay upstream of aggregate formation. Tau",
    "entities": []
  },
  {
    "text": "protein's phosphorylation is critical for AD progression, and phosphorylation at",
    "entities": []
  },
  {
    "text": "Threonine 231 is thought to be an early disease-associated, \"gatekeeper\" event.",
    "entities": [
      {
        "text": "Threonine 231",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Previously, we showed that genomic, single-copy insertion of phosphomimetic",
    "entities": []
  },
  {
    "text": "human tau (T231E) into C. elegans mechanosensory neurons induced age-dependent",
    "entities": [
      {
        "text": "C.",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "deficits in light-touch sensation. Herein, we have generated new C. elegans",
    "entities": [
      {
        "text": "C.",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "models which express pan-neuronal human tau to assess the idea of selective",
    "entities": []
  },
  {
    "text": "vulnerability and whether specific neuronal behaviors might be impacted",
    "entities": []
  },
  {
    "text": "preferentially. We also tested whether tau clearance via an Auxin Inducible",
    "entities": [
      {
        "text": "Auxin Inducible",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "Degron (AID) could reverse these deficits. Despite our hypothesis that prolonged",
    "entities": [
      {
        "text": "Degron",
        "label": "PERSON"
      },
      {
        "text": "AID",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "stress in older animals would induce irreversible metabolic rewiring or",
    "entities": []
  },
  {
    "text": "maladaptation, tau depletion rescued known behavioral deficits at all ages",
    "entities": []
  },
  {
    "text": "tested, including in old worms which displayed the most overt phenotypes. Taken",
    "entities": []
  },
  {
    "text": "together, our data suggest that neuronal dysfunction induced by phosphorylated",
    "entities": []
  },
  {
    "text": "tau is reversible and provides reassurance that current early-phase therapeutic",
    "entities": []
  },
  {
    "text": "efforts aimed at reducing soluble tau levels in AD patients may prove effective.",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Redox reactivities of membrane-bound Amyloid-\u03b2-Cu complexes and their targeting",
    "entities": [
      {
        "text": "Redox",
        "label": "GPE"
      },
      {
        "text": "Amyloid-\u03b2-Cu",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "by metallothionein-3.",
    "entities": []
  },
  {
    "text": "Alzheimer's disease (AD) is characterized by the accumulation of amyloid-\u03b2",
    "entities": []
  },
  {
    "text": "peptide (A\u03b2 1-40/42 ) in the central nervous system (CNS) and its aggregation in",
    "entities": [
      {
        "text": "A\u03b2 1-40/42",
        "label": "PERSON"
      },
      {
        "text": "CNS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "senile amyloid plaques. Copper coordination to A\u03b2 triggers A\u03b2 1-40/42",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      },
      {
        "text": "A\u03b2 1-40/42",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "aggregation and, in the presence of biological reducing agents, it promotes the",
    "entities": []
  },
  {
    "text": "catalytic generation of reactive oxygen species (ROS) via Fenton-type and",
    "entities": [
      {
        "text": "ROS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Haber-Weiss reactions. Due to its amphiphilic nature, A\u03b2 1-40/42 can interact",
    "entities": [
      {
        "text": "Haber-Weiss",
        "label": "ORG"
      },
      {
        "text": "A\u03b2 1-40/42",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "with cell membranes and compromise their integrity by thinning the lipid bilayer",
    "entities": []
  },
  {
    "text": "and forming channel-like structures potentially leading to cell death. In this",
    "entities": []
  },
  {
    "text": "work, by applying biophysical and biochemical approaches, we characterized the",
    "entities": []
  },
  {
    "text": "insertion of A\u03b2 1-42 into an artificial lipid bilayer system mimicking cell",
    "entities": [
      {
        "text": "A\u03b2 1-42",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "membranes and demonstrate that the A\u03b2 1-42 -lipid interaction does not prevent",
    "entities": [
      {
        "text": "1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "the Cu 2+ coordination to A\u03b2 1-42 . We performed a comparative analysis of the",
    "entities": [
      {
        "text": "A\u03b2 1-42",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "redox reactivities of membrane-bound A\u03b2 1-42 (memA\u03b2 1-42 -Cu 2+ ) species with",
    "entities": [
      {
        "text": "A\u03b2 1-42",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "soluble A\u03b2 1-42 -Cu 2+ establishing that membrane insertion leads to memA\u03b2 1-42",
    "entities": [
      {
        "text": "A\u03b2 1-42 -Cu 2+",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "-Cu 2+ complexes featuring an enhanced detrimental catechol oxidase activity",
    "entities": []
  },
  {
    "text": "towards the neurotransmitter dopamine. Moreover, memA\u03b2 1-42 -Cu 2+ efficiently",
    "entities": [
      {
        "text": "1-42 -Cu",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "catalyzes A\u03b2 di-tyrosine crosslinking and hydroxyl radical production in the",
    "entities": [
      {
        "text": "A\u03b2 di-tyrosine",
        "label": "PERSON"
      },
      {
        "text": "hydroxyl",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "presence of ascorbate. In addition, we establish that memA\u03b2 1-42 -Cu 2+ redox",
    "entities": [
      {
        "text": "1-42 -Cu",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "reactivity catalyze lipid peroxidation in membranes containing polyunsaturated",
    "entities": []
  },
  {
    "text": "fatty acids (PUFAs), such as arachidonic acid (AA), leading to the generation of",
    "entities": []
  },
  {
    "text": "malondialdehyde (MDA) toxic end-products. This reactivity compromises the",
    "entities": [
      {
        "text": "malondialdehyde",
        "label": "PERSON"
      },
      {
        "text": "MDA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "structural integrity of the lipid bilayers resulting in membrane leakage,",
    "entities": []
  },
  {
    "text": "further substantiating how important is to control aberrant A\u03b2 1-40/42 -Cu 2+",
    "entities": [
      {
        "text": "A\u03b2 1-40/42 -Cu",
        "label": "PERSON"
      },
      {
        "text": "2+",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "interactions in AD. Metallothioneins (MTs) are key metalloproteins central to",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      },
      {
        "text": "Metallothioneins",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "neuronal and astrocytic transition metal homeostasis and buffering. These",
    "entities": []
  },
  {
    "text": "cysteine-rich proteins bind with high affinity d 10 metals (Cu + and Zn 2+ )",
    "entities": [
      {
        "text": "10",
        "label": "CARDINAL"
      },
      {
        "text": "Cu +",
        "label": "ORG"
      },
      {
        "text": "2+",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "forming two metal thiolate clusters in their N-terminal \u03b2-domain and C-terminal",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "\u03b1-domain. The metallothionein-3 (MT-3) isoform is central to metal homeostasis",
    "entities": [
      {
        "text": "MT-3",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "in the CNS, but it is downregulated in AD patients, possessing a neuroprotective",
    "entities": [
      {
        "text": "CNS",
        "label": "ORG"
      },
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "role in AD. MT-3 can control aberrant protein-Cu 2+ interactions and the",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      },
      {
        "text": "MT-3",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Cu-centered redox reactivities of amyloidogenic protein-Cu 2+ complexes such as",
    "entities": []
  },
  {
    "text": "\u03b1-synuclein (Parkinson's disease), PrP (prion disease), and soluble and",
    "entities": [
      {
        "text": "PrP",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "aggregated A\u03b2 1-40 (AD). In this work, we unravel that the detrimental memA\u03b2",
    "entities": [
      {
        "text": "A\u03b2 1-40",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "1-42 -Cu 2+ catechol oxidase and redox reactivities can be efficiently silenced",
    "entities": [
      {
        "text": "1-42 -Cu 2+",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "by MT-3 via metal swap reactions, effectively scavenging and reducing Cu 2+ to",
    "entities": [
      {
        "text": "MT-3",
        "label": "NORP"
      },
      {
        "text": "2+",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Cu + in its \u03b2-domain using thiolates as electron source, forming the redox-inert",
    "entities": []
  },
  {
    "text": "species Cu + 4 Zn 2+ 4 MT-3. Consequently, MT-3 can efficiently prevent lipid",
    "entities": [
      {
        "text": "Cu + 4 Zn",
        "label": "ORG"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "MT-3",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "peroxidation and protect membrane structural integrity. New strategies targeting",
    "entities": []
  },
  {
    "text": "membrane-bound A\u03b2 1-42 -Cu 2+ complexes as key players of the AD etiology could",
    "entities": [
      {
        "text": "A\u03b2 1-42 -Cu 2+",
        "label": "PERSON"
      },
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Synergistic effects of APOE \u03b54 and Alzheimer's pathology on the neural",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "correlates of episodic remembering in cognitively unimpaired older adults.",
    "entities": []
  },
  {
    "text": "Amyloid-\u03b2 (A\u03b2) and tau pathology begin accumulating decades before clinical",
    "entities": [
      {
        "text": "Amyloid-\u03b2",
        "label": "PERSON"
      },
      {
        "text": "A\u03b2",
        "label": "PERSON"
      },
      {
        "text": "decades",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "symptoms and are influenced by APOE \u03b54, a key genetic risk factor for",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Alzheimer's disease (AD). Although the presence of A\u03b2, tau, and APOE \u03b54 are",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      },
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "thought to impact brain function, their effects on the neural correlates of",
    "entities": []
  },
  {
    "text": "episodic memory retrieval in preclinical AD remains unknown. We investigated",
    "entities": []
  },
  {
    "text": "this question in 159 cognitively unimpaired older adults (mean age, 68.9\u00b15.8",
    "entities": [
      {
        "text": "159",
        "label": "CARDINAL"
      },
      {
        "text": "68.9\u00b15.8",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "years; 57% female) in the Stanford Aging and Memory Study. Participants",
    "entities": [
      {
        "text": "years",
        "label": "DATE"
      },
      {
        "text": "57%",
        "label": "PERCENT"
      },
      {
        "text": "Stanford Aging",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "completed an associative memory task concurrent with functional MRI. A\u03b2 was",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "measured using CSF A\u03b2 42 /A\u03b2 40 or Florbetaben-PET imaging and tau was measured",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      },
      {
        "text": "42",
        "label": "DATE"
      },
      {
        "text": "40",
        "label": "DATE"
      },
      {
        "text": "Florbetaben-PET",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "using CSF pTau 181 . Hippocampal univariate activity and cortical reinstatement",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      },
      {
        "text": "pTau",
        "label": "ORG"
      },
      {
        "text": "181",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "- that is, reinstatement of patterns of neocortical activity that were present",
    "entities": []
  },
  {
    "text": "during memory encoding - were measured during successful memory retrieval.",
    "entities": []
  },
  {
    "text": "Analyses revealed that APOE \u03b54 was independently associated with greater A\u03b2 and",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      },
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "tau burden, and that associations of AD biomarkers with brain function and",
    "entities": []
  },
  {
    "text": "memory were moderated by APOE \u03b54. Among APOE \u03b54 non-carriers, A\u03b2 burden was",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      },
      {
        "text": "APOE",
        "label": "ORG"
      },
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "linked to a pattern of hippocampal hyperactivity. Among APOE \u03b54 carriers, CSF",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      },
      {
        "text": "CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "pTau 181 was linked to weaker cortical reinstatement during memory retrieval and",
    "entities": [
      {
        "text": "pTau",
        "label": "ORG"
      },
      {
        "text": "181",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "lower memory performance. Thus, abnormal AD biomarkers and genetic risk",
    "entities": []
  },
  {
    "text": "synergistically impact neural and behavioral expressions of memory in",
    "entities": []
  },
  {
    "text": "preclinical AD. These findings highlight the critical role of APOE \u03b54 in",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "moderating effects of AD pathology on brain function and identify candidate",
    "entities": [
      {
        "text": "AD",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "mechanisms that may contribute to increased risk of memory impairment in",
    "entities": []
  },
  {
    "text": "critical mechanism supporting episodic remembering that contributes to",
    "entities": []
  },
  {
    "text": "individual differences in memory performance in older adults. However, the",
    "entities": []
  },
  {
    "text": "contribution of early Alzheimer's disease (AD) pathology to variability in this",
    "entities": []
  },
  {
    "text": "mechanism is unknown. We demonstrate that associations of AD biomarkers with",
    "entities": []
  },
  {
    "text": "hippocampal activity and cortical reinstatement are moderated by APOE \u03b54 in",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cognitively unimpaired older adults. Amyloid-\u03b2-related hyperactivity was",
    "entities": [
      {
        "text": "Amyloid-\u03b2-related",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "observed in the hippocampus among APOE \u03b54 non-carriers, while CSF pTau 181 was",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      },
      {
        "text": "CSF",
        "label": "ORG"
      },
      {
        "text": "pTau",
        "label": "ORG"
      },
      {
        "text": "181",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "linked to weaker cortical reinstatement during memory retrieval and lower memory",
    "entities": []
  },
  {
    "text": "performance among APOE \u03b54 carriers. Our findings highlight synergistic effects",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of APOE and AD pathology on brain function and identify candidate mechanisms",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "that may underlie increased risk of memory impairment in preclinical AD.",
    "entities": []
  },
  {
    "text": "Tau-seed interactome analysis reveals distinct functional signatures in",
    "entities": []
  },
  {
    "text": "Alzheimer's disease across model systems.",
    "entities": []
  },
  {
    "text": "Martinez P, Patel H, You Y, Lopes D, Amaro A, Jury-Garfe N, Min Y, Redding-Ochoa",
    "entities": [
      {
        "text": "Lopes D",
        "label": "PERSON"
      },
      {
        "text": "Amaro A",
        "label": "PERSON"
      },
      {
        "text": "Jury-Garfe N",
        "label": "ORG"
      },
      {
        "text": "Redding-Ochoa",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Tau aggregates propagate through the brain in a prion-like manner in Alzheimer's",
    "entities": []
  },
  {
    "text": "disease (AD) and other tauopathies, but the molecular identity and functional",
    "entities": []
  },
  {
    "text": "partners of the seeding-competent Tau species remain poorly defined. Here, we",
    "entities": [
      {
        "text": "Tau",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "present an unbiased proteomic profiling of a high-molecular-weight (HMW)",
    "entities": [
      {
        "text": "HMW",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Tau-seed isolated from AD patient brains. We contrast this interactome with that",
    "entities": [
      {
        "text": "AD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of a biochemically similar, seeding-incompetent HMW-Tau species from age-matched",
    "entities": [
      {
        "text": "HMW",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "healthy controls. Despite comprising less than 5% of total Tau in the brain,",
    "entities": [
      {
        "text": "less than 5%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "Tau-seed associates with a distinct set of proteins enriched in synaptic,",
    "entities": []
  },
  {
    "text": "mitochondrial, and vesicle-trafficking functions. Cross-species functional",
    "entities": []
  },
  {
    "text": "screening in Drosophila and mouse models identifies interactors that modulate",
    "entities": [
      {
        "text": "Drosophila",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Tau toxicity and seeding. Spatially resolved analysis of postmortem AD brains",
    "entities": [
      {
        "text": "AD",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "reveals heterogenous co-deposition of these proteins with Tau aggregates,",
    "entities": [
      {
        "text": "Tau",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "suggesting functionally distinct Tau-seed complexes. Together, this dataset",
    "entities": []
  },
  {
    "text": "provides a framework for understanding selective Tau-seed toxicity and",
    "entities": []
  },
  {
    "text": "identifies candidate regulators of Tau propagation with therapeutic potential.",
    "entities": []
  },
  {
    "text": "Proteomic and metabolic profiling reveals APOE4 -dependent shifts in whole",
    "entities": [
      {
        "text": "APOE4",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "brain, neuronal, and astrocytic mitochondrial function and glycolysis.",
    "entities": []
  },
  {
    "text": "Lysaker CR, Johnson CN, Csikos V, Franczak E, Benson M, Gilmore CA, Birky CJ,",
    "entities": [
      {
        "text": "Lysaker CR",
        "label": "PERSON"
      },
      {
        "text": "Johnson CN",
        "label": "PERSON"
      },
      {
        "text": "Csikos V",
        "label": "PERSON"
      },
      {
        "text": "Benson M",
        "label": "ORG"
      },
      {
        "text": "Gilmore CA",
        "label": "PERSON"
      },
      {
        "text": "Birky CJ",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Davis X, McCoin CS, Smith KP, Puchalska P, Crawford P, Slawson C, Thyfault JP,",
    "entities": [
      {
        "text": "Davis X",
        "label": "PERSON"
      },
      {
        "text": "McCoin CS",
        "label": "ORG"
      },
      {
        "text": "Smith",
        "label": "GPE"
      },
      {
        "text": "KP",
        "label": "GPE"
      },
      {
        "text": "Puchalska P",
        "label": "PERSON"
      },
      {
        "text": "Crawford P",
        "label": "ORG"
      },
      {
        "text": "Slawson C",
        "label": "ORG"
      },
      {
        "text": "Thyfault",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Apolipoprotein E ( APOE ) genetic variation is the strongest genetic risk factor",
    "entities": []
  },
  {
    "text": "for late onset Alzheimer's disease (LOAD). Studies on APOE genotype dependent",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "changes have largely focused on amyloid beta (A\u03b2) aggregation, disease",
    "entities": []
  },
  {
    "text": "pathology, and lipid metabolism. Recently, there has been increased interest in",
    "entities": []
  },
  {
    "text": "the relationship between metabolic function and APOE genetic variation. In this",
    "entities": []
  },
  {
    "text": "study, we examined how APOE genotype can alter metabolism in the brains of young",
    "entities": []
  },
  {
    "text": "male and female APOE3 and APOE4 targeted replacement (TR) mice. In combination",
    "entities": [
      {
        "text": "APOE3",
        "label": "PRODUCT"
      },
      {
        "text": "APOE4",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "with this, we also examined cell type-specific differences using induced",
    "entities": []
  },
  {
    "text": "pluripotent stem cell (iPSC) derived astrocytes and neurons. We found sex and",
    "entities": []
  },
  {
    "text": "genotype dependent changes to metabolism in the brains of young APOE TR mice.",
    "entities": []
  },
  {
    "text": "Specifically, APOE4 mice show signs of metabolic stress and compensatory",
    "entities": [
      {
        "text": "APOE4",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "mechanisms in the brain. Using proteomics and stable isotope tracing",
    "entities": []
  },
  {
    "text": "metabolomics, we found that APOE4 iAstrocytes and iNeurons exhibit signs of",
    "entities": [
      {
        "text": "APOE4 iAstrocytes",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "inflammation, mitochondrial dysfunction, altered TCA cycle and malate-aspartate",
    "entities": []
  },
  {
    "text": "shuttle activity, and a metabolic shift toward glycolysis. Taken together, this",
    "entities": []
  },
  {
    "text": "data indicates APOE4 causes early changes to metabolism within the central",
    "entities": [
      {
        "text": "APOE4",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "nervous system. While this study establishes a relationship between APOE",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "genotype and alterations in bioenergetics, additional studies are needed to",
    "entities": []
  },
  {
    "text": "JASMINE: A powerful representation learning method for enhanced analysis of",
    "entities": []
  },
  {
    "text": "Ballard JL, Dai Z, Shen L, Long Q; Alzheimer\u2019s Disease Neuroimaging Initiative;",
    "entities": [
      {
        "text": "Ballard JL",
        "label": "PERSON"
      },
      {
        "text": "Dai Z",
        "label": "ORG"
      },
      {
        "text": "Shen L",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Alzheimer\u2019s Disease Metabolomics Consortium.",
    "entities": [
      {
        "text": "Disease Metabolomics Consortium",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Integrative analysis of multi-omics data provides a more comprehensive and",
    "entities": []
  },
  {
    "text": "nuanced view of a subject's biological state. However, high-dimensionality and",
    "entities": []
  },
  {
    "text": "Existing methods for incomplete multi-omics data are scarce, do not fully",
    "entities": []
  },
  {
    "text": "leverage both modality-specific and shared information, and produce task-biased",
    "entities": []
  },
  {
    "text": "representations. We propose JASMINE, a self-supervised representation learning",
    "entities": []
  },
  {
    "text": "method for incomplete multi-omics data that preserves both modality-specific and",
    "entities": []
  },
  {
    "text": "joint information and enhances sample similarity structure. JASMINE produces",
    "entities": []
  },
  {
    "text": "embeddings that achieve superior performance across multiple tasks for two",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "different incomplete multi-omics datasets while requiring only a single round of",
    "entities": []
  },
  {
    "text": "Epigenetic genes are differentially methylated in the blood of persons with mild",
    "entities": []
  },
  {
    "text": "cognitive impairment and Alzheimer's disease.",
    "entities": []
  },
  {
    "text": "BACKGROUND: Environmental factors play a role in AD pathology and are mediated",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "by changes in DNA methylation levels.",
    "entities": []
  },
  {
    "text": "METHODS AND RESULTS: We investigated whole genome methylation sequencing (WGMS)",
    "entities": []
  },
  {
    "text": "data from the blood of participants with mild cognitive impairment (MCI, N =99),",
    "entities": [
      {
        "text": "MCI",
        "label": "ORG"
      },
      {
        "text": "N",
        "label": "ORG"
      },
      {
        "text": "99",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "late onset dementia due to Alzheimer's disease (AD, N =109), and who are",
    "entities": [
      {
        "text": "N",
        "label": "GPE"
      },
      {
        "text": "109",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "cognitively unimpaired (CU, N =174) to test for differential methylation in 812",
    "entities": [
      {
        "text": "CU",
        "label": "ORG"
      },
      {
        "text": "N",
        "label": "GPE"
      },
      {
        "text": "174",
        "label": "CARDINAL"
      },
      {
        "text": "812",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "genes with roles in epigenetic regulation ( e.g. , DNA methylation and",
    "entities": []
  },
  {
    "text": "demethylation, chromatin remodeling, histone modification, and RNA modification)",
    "entities": [
      {
        "text": "RNA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "curated from the EpiFactors 2.1 database. 71/812 genes were differentially",
    "entities": [
      {
        "text": "EpiFactors",
        "label": "ORG"
      },
      {
        "text": "2.1",
        "label": "CARDINAL"
      },
      {
        "text": "71/812",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "methylated comprising 190 unique differentially methylated positions (DMPs) in",
    "entities": [
      {
        "text": "190",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "MCI (MCI vs . CU pairwise comparison). 60/812 genes were differentially",
    "entities": [
      {
        "text": "MCI",
        "label": "ORG"
      },
      {
        "text": "MCI",
        "label": "ORG"
      },
      {
        "text": "CU",
        "label": "ORG"
      },
      {
        "text": "60/812",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "methylated comprising 220 DMPs in AD (AD vs . CU pairwise comparison). The",
    "entities": [
      {
        "text": "220",
        "label": "CARDINAL"
      },
      {
        "text": "AD",
        "label": "DATE"
      },
      {
        "text": "CU",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "majority of differentially methylated genes in both MCI (41/71) and AD (33/60)",
    "entities": [
      {
        "text": "MCI",
        "label": "ORG"
      },
      {
        "text": "41/71",
        "label": "CARDINAL"
      },
      {
        "text": "33/60",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "were histone modification genes and 23 differentially methylated genes were",
    "entities": [
      {
        "text": "23",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "shared in both pairwise comparisons. 96 genes were differentially methylated",
    "entities": [
      {
        "text": "96",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "comprising 243 DMPs between persons with MCI and AD (AD vs . MCI pairwise",
    "entities": [
      {
        "text": "243",
        "label": "CARDINAL"
      },
      {
        "text": "MCI",
        "label": "ORG"
      },
      {
        "text": "MCI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "comparison). 10 differentially methylated genes were shared between the 3",
    "entities": [
      {
        "text": "10",
        "label": "CARDINAL"
      },
      {
        "text": "3",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "pairwise comparisons, including CUGBP elav-like family member 2 ( CELF2 ),",
    "entities": [
      {
        "text": "CUGBP",
        "label": "PRODUCT"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "histone deacetylase 9 ( HDAC9 ), RNA binding fox-1 homolog 1 ( RBFOX1 ),",
    "entities": [
      {
        "text": "9",
        "label": "CARDINAL"
      },
      {
        "text": "HDAC9",
        "label": "ORG"
      },
      {
        "text": "RNA",
        "label": "ORG"
      },
      {
        "text": "fox-1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "TATA-box binding protein associated factor 4 ( TAF4 ), and thymine DNA",
    "entities": [
      {
        "text": "TATA",
        "label": "ORG"
      },
      {
        "text": "4",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "CONCLUSION: Genes that participate in the epigenetic regulation of gene",
    "entities": []
  },
  {
    "text": "expression, particularly histone modifications, are differentially methylated in",
    "entities": []
  },
  {
    "text": "blood between persons with and without MCI and AD, warranting further",
    "entities": [
      {
        "text": "MCI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "elucidation of their role in the molecular pathogenesis of cognitive decline.",
    "entities": []
  },
  {
    "text": "eCollection 2025 Jul-Sep.",
    "entities": []
  },
  {
    "text": "Cardiorespiratory fitness modifies the relationship between arterial stiffness",
    "entities": []
  },
  {
    "text": "and cerebral blood flow independent of physical activity.",
    "entities": []
  },
  {
    "text": "Johnson SC(1)(2), Asthana S(1)(2)(4), Christian BT(3), Cook DB(5)(6), Wieben",
    "entities": [
      {
        "text": "Johnson",
        "label": "PERSON"
      },
      {
        "text": "Asthana",
        "label": "GPE"
      },
      {
        "text": "Christian BT(3",
        "label": "PERSON"
      },
      {
        "text": "Cook",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Wisconsin Alzheimer's Disease Research Center Department of Medicine",
    "entities": [
      {
        "text": "Disease Research Center Department of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of Wisconsin School of Medicine and Public Health Madison Wisconsin",
    "entities": [
      {
        "text": "University of Wisconsin School of Medicine and Public Health Madison Wisconsin",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine",
    "entities": [
      {
        "text": "2)Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and Public Health Madison Wisconsin USA.",
    "entities": []
  },
  {
    "text": "(3)Department of Medical Physics Department of Medicine University of Wisconsin",
    "entities": [
      {
        "text": "Medical Physics Department of Medicine University of Wisconsin",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "School of Medicine and Public Health Madison Wisconsin USA.",
    "entities": [
      {
        "text": "School of Medicine and Public Health Madison Wisconsin USA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Geriatric Research Education and Clinical Center William S. Middleton VA",
    "entities": [
      {
        "text": "Research Education",
        "label": "ORG"
      },
      {
        "text": "Clinical Center",
        "label": "ORG"
      },
      {
        "text": "William S. Middleton VA",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Hospital Madison Wisconsin USA.",
    "entities": [
      {
        "text": "Madison Wisconsin USA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Department of Kinesiology University of Wisconsin School of Education 1300",
    "entities": [
      {
        "text": "Kinesiology University of Wisconsin School of Education",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University Avenue Madison Wisconsin USA.",
    "entities": [
      {
        "text": "University Avenue Madison Wisconsin USA",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "(6)William S. Middleton Memorial Veterans Hospital, Department of Medicine,",
    "entities": [
      {
        "text": "6)William",
        "label": "CARDINAL"
      },
      {
        "text": "S. Middleton Memorial Veterans Hospital",
        "label": "ORG"
      },
      {
        "text": "Department of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Univerity of Wisconsin School of Medicine and Public Health Madison Wisconsin",
    "entities": [
      {
        "text": "Univerity of Wisconsin School of Medicine and Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(7)Department of Radiology E3/366 Clinical Science Center University of",
    "entities": [
      {
        "text": "Radiology E3/366 Clinical Science Center University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Wisconsin School of Medicine and Public Health Madison Wisconsin USA.",
    "entities": [
      {
        "text": "Wisconsin School of Medicine and Public Health Madison Wisconsin USA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "INTRODUCTION: Central arterial stiffness and cerebral blood flow (CBF) are",
    "entities": [
      {
        "text": "CBF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "inversely related. Poor cardiorespiratory fitness (CRF) and low physical",
    "entities": []
  },
  {
    "text": "activity (PA) are related to both higher arterial stiffness and lower CBF. The",
    "entities": [
      {
        "text": "CBF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "present study examined (i) whether CRF or PA moderate the relationship between",
    "entities": [
      {
        "text": "CRF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "arterial stiffness and CBF, and (ii) whether the intensity or the type of PA",
    "entities": [
      {
        "text": "CBF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "needs to be considered.",
    "entities": []
  },
  {
    "text": "METHODS: Participants (N = 78, MeanAGE = 64.2\u00b16.14, 72% female) from the",
    "entities": [
      {
        "text": "78",
        "label": "DATE"
      },
      {
        "text": "64.2\u00b16.14",
        "label": "CARDINAL"
      },
      {
        "text": "72%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "Wisconsin Registry for Alzheimer's Prevention and the Wisconsin Alzheimer's",
    "entities": [
      {
        "text": "Wisconsin Registry for Alzheimer's Prevention",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Disease Research Center were categorized into low, average, and high fitness",
    "entities": [
      {
        "text": "Disease Research Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "groups based on maximal graded exercise treadmill test performance. PA was",
    "entities": []
  },
  {
    "text": "assessed using the CHAMPS (Community Health Activities Model Program for",
    "entities": [
      {
        "text": "the CHAMPS (Community Health Activities Model Program",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Seniors) questionnaire. Based on hours/week, participants were classified as",
    "entities": [
      {
        "text": "Based on hours/week",
        "label": "TIME"
      }
    ]
  },
  {
    "text": "meeting the recommended 2.5 h of moderate intensity PA per week (PA Rec Met).",
    "entities": [
      {
        "text": "2.5",
        "label": "CARDINAL"
      },
      {
        "text": "PA Rec Met",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Weekly hours of moderate and low intensity PA were calculated as activities of >",
    "entities": [
      {
        "text": "Weekly hours",
        "label": "TIME"
      },
      {
        "text": "PA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "3 or < 3 metabolic equivalents, respectively. Activity type was categorized as",
    "entities": [
      {
        "text": "3",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "exercise-, sports/leisure- and work-related. Arterial stiffness was measured as",
    "entities": []
  },
  {
    "text": "aortic pulse wave velocity (aoPWV) by 2D phase contrast magnetic resonance",
    "entities": []
  },
  {
    "text": "imaging (MRI). CBF was assessed by 4D flow MRI in the internal carotid arteries",
    "entities": [
      {
        "text": "CBF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(ICAs), cavernous ICAs, middle cerebral arteries (MCAs), and via two composite",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "measures of total and global flow.",
    "entities": []
  },
  {
    "text": "RESULTS: The association between aoPWV and CBF differed by fitness levels, with",
    "entities": [
      {
        "text": "CBF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "a negative relationship in the low fitness group and positive relationships in",
    "entities": []
  },
  {
    "text": "the average and high fitness groups (all Ps<0.05). Significant moderating",
    "entities": [
      {
        "text": "Ps<0.05",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "effects on the relationships between aoPWV and CBF were also observed for PA Rec",
    "entities": [
      {
        "text": "CBF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Met (all Ps<0.05), moderate intensity (p = 0.05), and exercise-related (all",
    "entities": [
      {
        "text": "Ps<0.05",
        "label": "GPE"
      },
      {
        "text": "0.05",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "p's < 0.02) PA.",
    "entities": [
      {
        "text": "p's < 0.02",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "DISCUSSION: Average or high fitness, meeting the PA guidelines, and more",
    "entities": [
      {
        "text": "PA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "specifically, moderate intensity and exercise-related PA seem to attenuate the",
    "entities": []
  },
  {
    "text": "negative relationship between aoPWV on CBF.",
    "entities": [
      {
        "text": "CBF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "HIGHLIGHTS: Higher cardiorespiratory fitness (CRF) reduces the negative impact",
    "entities": []
  },
  {
    "text": "of aortic pulse wave velocity (aoPWV) on cerebral blood flow (CBF)150 min of",
    "entities": []
  },
  {
    "text": "moderate physical activity (PA) also mitigates this impact, depending on",
    "entities": []
  },
  {
    "text": "activity typeInnovative methods: use of cardiac magnetic resonance imaging (MRI)",
    "entities": []
  },
  {
    "text": "for aoPWV assessmentInnovative methods: use of free-breathing acquisition during",
    "entities": []
  },
  {
    "text": "cardiac MRIInnovative methods: use of cranial 4D flow MRI for CBF assessment.",
    "entities": [
      {
        "text": "cardiac MRIInnovative",
        "label": "ORG"
      },
      {
        "text": "CBF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "\u00a9 2025 The Author(s). Alzheimer's & Dementia: Translational Research & Clinical",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Translational Research & Clinical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's",
    "entities": [
      {
        "text": "Wiley Periodicals",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Association.",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: Dr. Ozioma Okonkwo serves as the treasurer of",
    "entities": [
      {
        "text": "Ozioma Okonkwo",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "the International Neuropsychological Society. He is also a guest editor of this",
    "entities": [
      {
        "text": "the International Neuropsychological Society",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "journal but was not involved in the peer\u2010review process of this article nor had",
    "entities": []
  },
  {
    "text": "access to any information regarding its peer\u2010review. Dr. Sterling Johnson serves",
    "entities": [
      {
        "text": "Sterling Johnson",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "as a consultant and on advisory boards for ALZPath and Enigma Biosciences. Dr.",
    "entities": [
      {
        "text": "ALZPath and",
        "label": "PRODUCT"
      },
      {
        "text": "Enigma Biosciences",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "Sanjay Asthana receives royalty as an editor of a textbook entitled, Hazzard's",
    "entities": [
      {
        "text": "Sanjay Asthana",
        "label": "PERSON"
      },
      {
        "text": "Hazzard",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Geriatrics and Gerontology, McGraw Hill, Publisher. All other authors have no",
    "entities": [
      {
        "text": "McGraw Hill",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Chronic ethanol administration exacerbates memory loss by altering",
    "entities": []
  },
  {
    "text": "(1)Department of Anesthesiology, Rutgers University, the State University of New",
    "entities": [
      {
        "text": "Anesthesiology, Rutgers University",
        "label": "ORG"
      },
      {
        "text": "the State University of New\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Jersey, Newark, NJ, United States.",
    "entities": [
      {
        "text": "Jersey",
        "label": "GPE"
      },
      {
        "text": "Newark",
        "label": "GPE"
      },
      {
        "text": "NJ",
        "label": "GPE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Pharmaceutical Sciences, School of Pharmacy, SUNY at Buffalo,",
    "entities": [
      {
        "text": "Pharmaceutical Sciences",
        "label": "ORG"
      },
      {
        "text": "School of Pharmacy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Buffalo, NY, United States.",
    "entities": [
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Division of Gastroenterology, Rutgers University, the State University of New",
    "entities": [
      {
        "text": "Gastroenterology, Rutgers University",
        "label": "ORG"
      },
      {
        "text": "the State University of New\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Department of Pathology, Case Western Reserve University, Cleveland,",
    "entities": [
      {
        "text": "Pathology, Case Western Reserve University",
        "label": "ORG"
      },
      {
        "text": "Cleveland",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "OH, United States.",
    "entities": [
      {
        "text": "OH",
        "label": "GPE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(#)Contributed equally",
    "entities": []
  },
  {
    "text": "BACKGROUND: Chronic alcohol use disorder (AUD) is recognized as one of the most",
    "entities": [
      {
        "text": "AUD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "critical risk factors for the progression of Alzheimer's disease (AD).",
    "entities": []
  },
  {
    "text": "Epigenetic and neuroimmune alterations are closely associated with the",
    "entities": []
  },
  {
    "text": "development of memory impairment related to AUD and AD.",
    "entities": [
      {
        "text": "AUD",
        "label": "ORG"
      },
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "METHODS: Adult APP/PS1 transgenic mice received intermittently intraperitoneal",
    "entities": [
      {
        "text": "Adult APP/PS1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "injections of ethanol (EtOH, 2.5 g/kg, i.p.) or vehicle with two \"drug\"",
    "entities": [
      {
        "text": "EtOH",
        "label": "ORG"
      },
      {
        "text": "2.5",
        "label": "CARDINAL"
      },
      {
        "text": "i.p.",
        "label": "GPE"
      },
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "treatment days, and one and two \"drug-free\" days every 7 days for 10 weeks. The",
    "entities": [
      {
        "text": "one and two",
        "label": "CARDINAL"
      },
      {
        "text": "10 weeks",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "novel object recognition (NOR) and Y-maze tests were performed to determine",
    "entities": [
      {
        "text": "NOR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "whether chronic ethanol treatment exacerbated memory impairment in these mice.",
    "entities": []
  },
  {
    "text": "The brain tissues were collected for pathological changes through",
    "entities": []
  },
  {
    "text": "MeRIP/RNA-sequence analyses and molecular biological assays.",
    "entities": [
      {
        "text": "MeRIP",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "RESULTS: The results suggested that chronic intermittent ethanol (CIE) treatment",
    "entities": [
      {
        "text": "CIE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "for 10 weeks exacerbated sporadic and spatial memory deficits in NOR and Y-maze",
    "entities": [
      {
        "text": "10 weeks",
        "label": "DATE"
      },
      {
        "text": "NOR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "tests in the APP/PS1 mice. The pathological assays revealed that CIE procedure",
    "entities": [
      {
        "text": "APP",
        "label": "ORG"
      },
      {
        "text": "CIE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "increased A\u03b2 plaque burden in the brain of the AD mice, which were consistent",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "with memory behavioral deficits. The subsequent MeRIP/RNA sequence analyses",
    "entities": [
      {
        "text": "MeRIP",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "showed that two genes, e.g. Rbm15b and Hnrnpa2b1, were related to",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      },
      {
        "text": "Rbm15b",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "N6-methyladenosine (m6A) methylation that plays an important role in the",
    "entities": [
      {
        "text": "N6",
        "label": "CARDINAL"
      },
      {
        "text": "m6A",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "development of memory loss. These results were further supported by molecular",
    "entities": []
  },
  {
    "text": "biological and mRNA-microRNA-lncRNA ceRNA network analyses that demonstrated",
    "entities": []
  },
  {
    "text": "that the increased Rbm15b and decreased Hnrnpa2b1 were involved in synaptic",
    "entities": [
      {
        "text": "Rbm15b",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "dysfunction and neuroinflammation in CIE-induced memory impairment in these AD",
    "entities": [
      {
        "text": "CIE-",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CONCLUSIONS: The conclusion is drawn that m6A mediated epigenetic dysfunction",
    "entities": [
      {
        "text": "m6A",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "related memory loss in AD mice.",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Copyright \u00a9 2025 Liao, Xu, Yan, Zhou, Liu, Dou, Srinivasan, Wang, Zhu, Ye and",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Liao, Xu",
        "label": "PERSON"
      },
      {
        "text": "Liu",
        "label": "PERSON"
      },
      {
        "text": "Dou",
        "label": "PERSON"
      },
      {
        "text": "Srinivasan",
        "label": "GPE"
      },
      {
        "text": "Wang",
        "label": "PERSON"
      },
      {
        "text": "Zhu",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "conducted without any commercial or financial relationships that could",
    "entities": []
  },
  {
    "text": "potentially create a conflict of interest.",
    "entities": []
  },
  {
    "text": "21. Front Psychiatry. 2025 Jul 1;16:1570594. doi: 10.3389/fpsyt.2025.1570594.",
    "entities": [
      {
        "text": "21",
        "label": "CARDINAL"
      },
      {
        "text": "Front Psychiatry",
        "label": "ORG"
      },
      {
        "text": "10.3389",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Cognition in virtual reality: assessing user acceptability and feasibility of",
    "entities": []
  },
  {
    "text": "virtual reality cognitive screening for older adults.",
    "entities": []
  },
  {
    "text": "Darling C(1), Whittington S(1), Lowe JA(1).",
    "entities": [
      {
        "text": "Whittington",
        "label": "PERSON"
      },
      {
        "text": "Lowe JA(1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Social Work, Education and Community Wellbeing, Faculty of",
    "entities": [
      {
        "text": "Social Work, Education",
        "label": "ORG"
      },
      {
        "text": "Community Wellbeing",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Health and Life Sciences, Northumbria University, Newcastle, United Kingdom.",
    "entities": [
      {
        "text": "Health and Life Sciences",
        "label": "ORG"
      },
      {
        "text": "Northumbria University",
        "label": "ORG"
      },
      {
        "text": "Newcastle",
        "label": "GPE"
      },
      {
        "text": "United Kingdom",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Mental Health Research Centre, The Hong Kong Polytechnic University, Hong",
    "entities": [
      {
        "text": "Health Research Centre",
        "label": "ORG"
      },
      {
        "text": "The Hong Kong Polytechnic University",
        "label": "ORG"
      },
      {
        "text": "Hong\n",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Rehabilitation Sciences, The Hong Kong Polytechnic University,",
    "entities": [
      {
        "text": "Rehabilitation Sciences",
        "label": "ORG"
      },
      {
        "text": "The Hong Kong Polytechnic University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)School of Psychology, University of Sunderland, Sunderland, United Kingdom.",
    "entities": [
      {
        "text": "Psychology, University of Sunderland, Sunderland",
        "label": "ORG"
      },
      {
        "text": "United Kingdom",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)School of Health & Life Sciences, Teesside University, Middlesbrough, United",
    "entities": [
      {
        "text": "5)School of Health & Life Sciences",
        "label": "ORG"
      },
      {
        "text": "Teesside University",
        "label": "ORG"
      },
      {
        "text": "Middlesbrough",
        "label": "GPE"
      },
      {
        "text": "United",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Faculty of Health Sciences and Wellbeing, University of Sunderland,",
    "entities": [
      {
        "text": "Health Sciences",
        "label": "ORG"
      },
      {
        "text": "Wellbeing",
        "label": "GPE"
      },
      {
        "text": "University of Sunderland",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sunderland, United Kingdom.",
    "entities": [
      {
        "text": "Sunderland",
        "label": "GPE"
      },
      {
        "text": "United Kingdom",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "INTRODUCTION: The global demographic shift towards an older population",
    "entities": []
  },
  {
    "text": "necessitates innovative methods to assess cognitive abilities, particularly",
    "entities": []
  },
  {
    "text": "spatial working memory, which is crucial for daily living and early detection of",
    "entities": [
      {
        "text": "daily",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "neurocognitive conditions like Alzheimer's disease.",
    "entities": []
  },
  {
    "text": "METHODS: This qualitative study utilised the Virtual Reality Working Memory Task",
    "entities": [
      {
        "text": "the Virtual Reality Working Memory Task\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(VRWMT), a semi-immersive VR activity using keyboard navigation, to assess",
    "entities": [
      {
        "text": "VRWMT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "spatial working memory in older adults. Participants were recruited from",
    "entities": []
  },
  {
    "text": "community centres and categorised by age and technological familiarity. Focus",
    "entities": []
  },
  {
    "text": "groups evaluated user perceptions based on the Technology Acceptance Model",
    "entities": [
      {
        "text": "the Technology Acceptance Model",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "constructs: Perceived Usefulness, Perceived Ease of Use, Attitude Toward Usage,",
    "entities": []
  },
  {
    "text": "and Behavioural Intention to Use. The study aimed to assess the acceptability",
    "entities": [
      {
        "text": "Behavioural Intention",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and feasibility of VRWMT across diverse populations, examining its navigational",
    "entities": [
      {
        "text": "VRWMT",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "simplicity, emotional engagement, and willingness to endorse VRWMT for routine",
    "entities": [
      {
        "text": "VRWMT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RESULTS: Findings indicated significant variations in perceived usefulness, ease",
    "entities": []
  },
  {
    "text": "of use, attitude toward using, and behavioural intention to use across different",
    "entities": []
  },
  {
    "text": "age groups and socio-demographic characteristics. High-technology-familiarity",
    "entities": []
  },
  {
    "text": "participants found VRWMT easy to use and engaging, while those with low",
    "entities": []
  },
  {
    "text": "familiarity struggled with navigation and engagement. Socio-demographic factors",
    "entities": []
  },
  {
    "text": "such as limited digital literacy and lack of standby support impact technology",
    "entities": []
  },
  {
    "text": "adoption. Higher technological familiarity leads to better acceptance and",
    "entities": []
  },
  {
    "text": "feasibility of VRWMT.",
    "entities": [
      {
        "text": "VRWMT",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "DISCUSSION: VRWMT can enhance cognitive health monitoring and therapeutic",
    "entities": [
      {
        "text": "VRWMT",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "interventions. The results highlighted that personalised pathways and",
    "entities": []
  },
  {
    "text": "user-friendly interfaces can improve accessibility and engagement, making VRWMT",
    "entities": [
      {
        "text": "VRWMT",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "a valuable tool for cognitive assessments, as part of Occupational Therapy, in",
    "entities": [
      {
        "text": "Occupational Therapy",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Copyright \u00a9 2025 Lai, Yee, Wang, Butler, Graham, Hai, Darling, Whittington and",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Lai",
        "label": "PERSON"
      },
      {
        "text": "Yee",
        "label": "GPE"
      },
      {
        "text": "Wang",
        "label": "PERSON"
      },
      {
        "text": "Butler",
        "label": "ORG"
      },
      {
        "text": "Graham, Hai, Darling",
        "label": "PERSON"
      },
      {
        "text": "Whittington",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "22. Free Neuropathol. 2025 Jul 14;6:15. doi:",
    "entities": [
      {
        "text": "22",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "10.17879/freeneuropathology-2025-6382. eCollection 2025.",
    "entities": [
      {
        "text": "10.17879",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Neuroinflammatory mechanisms may help identify candidate biomarkers in chronic",
    "entities": []
  },
  {
    "text": "traumatic encephalopathy (CTE).",
    "entities": []
  },
  {
    "text": "KW(2)(3)(4), Cherry JD(2)(3)(4)(5)(6).",
    "entities": [
      {
        "text": "Cherry",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)California Northstate University College of Medicine, Elk Grove, USA.",
    "entities": [
      {
        "text": "Northstate University College of Medicine",
        "label": "ORG"
      },
      {
        "text": "Elk Grove",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)VA Boston Healthcare System, Boston, USA.",
    "entities": [
      {
        "text": "2)VA",
        "label": "CARDINAL"
      },
      {
        "text": "Boston Healthcare System",
        "label": "ORG"
      },
      {
        "text": "Boston",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Boston University Alzheimer's Disease and CTE Centers, Boston University",
    "entities": [
      {
        "text": "3)Boston",
        "label": "CARDINAL"
      },
      {
        "text": "Boston University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "School of Medicine, Boston, USA.",
    "entities": [
      {
        "text": "School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Boston",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Neurology, Boston University School of Medicine, Boston, USA.",
    "entities": [
      {
        "text": "Neurology",
        "label": "ORG"
      },
      {
        "text": "Boston University School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Boston",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Department of Pathology and Laboratory Medicine, Boston University School of",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Pathology and Laboratory Medicine",
        "label": "ORG"
      },
      {
        "text": "Boston University School of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Department of Anatomy and Neurobiology, Boston University School of Medicine,",
    "entities": [
      {
        "text": "Anatomy and Neurobiology",
        "label": "ORG"
      },
      {
        "text": "Boston University School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Boston, USA.",
    "entities": [
      {
        "text": "Boston",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease that can",
    "entities": []
  },
  {
    "text": "only be diagnosed post-mortem via pathological autopsy. The primary risk factor",
    "entities": []
  },
  {
    "text": "for CTE is a history of repetitive head impacts (RHI) received through contact",
    "entities": [
      {
        "text": "CTE",
        "label": "ORG"
      },
      {
        "text": "RHI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "sports including American football, hockey or soccer, military-related head",
    "entities": [
      {
        "text": "American",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "injuries, or intimate partner violence. Recent findings have demonstrated that",
    "entities": []
  },
  {
    "text": "neuroinflammation is a critical compo-nent of early CTE pathogenesis and is",
    "entities": []
  },
  {
    "text": "likely part of the mechanism driving disease onset and progression.",
    "entities": []
  },
  {
    "text": "Additionally, the innate specificity, or 'signature', of a neuroinflammatory",
    "entities": []
  },
  {
    "text": "response may function as a dis-ease-specific marker for various",
    "entities": []
  },
  {
    "text": "neurodegenerative conditions. This would suggest an enormous repository of novel",
    "entities": []
  },
  {
    "text": "CTE biomarker candidates to be added to ongoing clinical trials, helping bolster",
    "entities": []
  },
  {
    "text": "diagnosis. However, few studies have truly leveraged immune mediators as",
    "entities": []
  },
  {
    "text": "candidate CTE markers. In this review, we argue and provide support that",
    "entities": []
  },
  {
    "text": "inflammatory mechanisms could serve as a viable source for novel biomarkers that",
    "entities": []
  },
  {
    "text": "are specific to CTE pathol-ogy. This includes an evaluation of inflammatory or",
    "entities": []
  },
  {
    "text": "damage-related markers such as CCL11 (C-C Motif Chem-okine Ligand 11, also known",
    "entities": [
      {
        "text": "Ligand 11",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "as Eotaxin-1), CCL21 (C-C Motif Chemokine Ligand 21) and GFAP (Glial Fibrillary",
    "entities": [
      {
        "text": "GFAP",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Acidic Protein). We discuss the neuroinflammatory responses that give rise to",
    "entities": [
      {
        "text": "Acidic Protein",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "these biomarkers in addition to the advantages and limitations of using each to",
    "entities": []
  },
  {
    "text": "diagnose CTE with particular attention to sensitivity and specifici-ty. Although",
    "entities": []
  },
  {
    "text": "further research is necessary to validate immune mediators, the latter show",
    "entities": []
  },
  {
    "text": "promise as diagnos-tic biomarkers for CTE and may also eventually serve as",
    "entities": [
      {
        "text": "CTE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "therapeutic targets for mitigating chronic inflamma-tion in at-risk populations.",
    "entities": []
  },
  {
    "text": "\u00a9 2025 The author(s).",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "DOI: 10.17879/freeneuropathology-2025-6382",
    "entities": [
      {
        "text": "10.17879/freeneuropathology-2025-6382",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: The author declares no conflict of interest.",
    "entities": []
  },
  {
    "text": "Visual Memory Performance Correlates with Alzheimer's Disease Biomarkers in",
    "entities": []
  },
  {
    "text": "Cognitively Normal Individuals.",
    "entities": [
      {
        "text": "Cognitively Normal Individuals",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "INTRODUCTION: Alzheimer's disease (AD) pathology evolves silently for many years",
    "entities": [
      {
        "text": "many years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "prior to disease, and early identification of individuals at greatest risk is",
    "entities": []
  },
  {
    "text": "critical for improving outcomes.",
    "entities": []
  },
  {
    "text": "METHODS: We conducted exploratory factor analysis (EFA) using neuropsychological",
    "entities": [
      {
        "text": "EFA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "testing from 1,697 healthy adults. Factor scores were submitted as predictors",
    "entities": [
      {
        "text": "1,697",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "for structural MRI, functional connectivity, and cerebrospinal fluid (CSF)",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RESULTS: The EFA model identified five latent factors. Factor 1, Verbal Memory,",
    "entities": [
      {
        "text": "EFA",
        "label": "ORG"
      },
      {
        "text": "five",
        "label": "CARDINAL"
      },
      {
        "text": "Factor 1",
        "label": "PERSON"
      },
      {
        "text": "Verbal Memory",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "included high loadings from Rey Auditory Verbal Learning Test, and Factor 2,",
    "entities": [
      {
        "text": "Rey Auditory Verbal Learning Test",
        "label": "ORG"
      },
      {
        "text": "Factor 2",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "Visual Memory, included high loadings from Rey Complex Figure Test (RCFT).",
    "entities": [
      {
        "text": "Visual Memory",
        "label": "PERSON"
      },
      {
        "text": "Rey Complex Figure Test",
        "label": "ORG"
      },
      {
        "text": "RCFT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Factor 2 positively correlated with hippocampal volume, precuneus and posterior",
    "entities": [
      {
        "text": "Factor 2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "salience network connectivity, and negatively with CSF tau. Factor 1 correlated",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      },
      {
        "text": "1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "with hippocampal volume but not with network connectivity or CSF biomarkers.",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "DISCUSSION: Results demonstrate a significant relationship of visual memory with",
    "entities": []
  },
  {
    "text": "AD biomarkers. RCFT may be an important assessment for evaluating and tracking",
    "entities": [
      {
        "text": "RCFT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "individuals during the earliest stages of Alzheimer's pathology.",
    "entities": []
  },
  {
    "text": "Integrated genomic analysis and CRISPRi implicates EGFR in Alzheimer's disease",
    "entities": [
      {
        "text": "EGFR",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Genome-wide association studies (GWAS) have identified numerous loci linked to",
    "entities": []
  },
  {
    "text": "late-onset Alzheimer's disease (LOAD), but the pan-brain regional effects of",
    "entities": []
  },
  {
    "text": "these loci remain largely uncharacterized. To address this, we systematically",
    "entities": []
  },
  {
    "text": "analyzed all LOAD-associated regions reported by Bellenguez et al. using the",
    "entities": [
      {
        "text": "Bellenguez",
        "label": "ORG"
      },
      {
        "text": "al.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "FILER functional genomics catalog across 174 datasets, including enhancers,",
    "entities": [
      {
        "text": "FILER",
        "label": "ORG"
      },
      {
        "text": "174",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "transcription factors, and quantitative trait loci. We identified 42 candidate",
    "entities": [
      {
        "text": "transcription",
        "label": "CARDINAL"
      },
      {
        "text": "42",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "causal variant-effector gene pairs and assessed their impact using",
    "entities": [
      {
        "text": "causal variant-effector",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "enhancer-promoter interaction data, variant annotations, and brain",
    "entities": []
  },
  {
    "text": "cell-type-specific gene expression. Notably, the LOAD risk allele of rs74504435",
    "entities": [
      {
        "text": "LOAD",
        "label": "ORG"
      },
      {
        "text": "rs74504435\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "at the SEC61G locus was computationally predicted to increase EGFR expression in",
    "entities": [
      {
        "text": "EGFR",
        "label": "LAW"
      }
    ]
  },
  {
    "text": "LOAD related cell types: microglia, astrocytes, and neurons. Functional",
    "entities": []
  },
  {
    "text": "validation using promoter-focused Capture C, ATAC-seq, and CRISPR interference",
    "entities": [
      {
        "text": "CRISPR",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "in the HMC3 human microglia cell line confirmed this regulatory relationship.",
    "entities": []
  },
  {
    "text": "Our findings reveal a microglial enhancer regulating EGFR in LOAD, suggesting",
    "entities": [
      {
        "text": "EGFR",
        "label": "ORG"
      },
      {
        "text": "LOAD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "EGFR inhibitors as a potential therapeutic avenue for the disease.",
    "entities": [
      {
        "text": "EGFR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "25. Iran J Basic Med Sci. 2025;28(5):553-564. doi:",
    "entities": [
      {
        "text": "25",
        "label": "CARDINAL"
      },
      {
        "text": "Iran",
        "label": "GPE"
      },
      {
        "text": "Med Sci",
        "label": "PERSON"
      },
      {
        "text": "2025;28(5):553-564",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Bacterial endotoxin-lipopolysaccharide role in inflammatory diseases: An",
    "entities": []
  },
  {
    "text": "overview.",
    "entities": []
  },
  {
    "text": "(1)Galgotias College of Pharmacy, Greater Noida, U.P., India.",
    "entities": [
      {
        "text": "1)Galgotias College of Pharmacy, Greater Noida",
        "label": "ORG"
      },
      {
        "text": "U.P.",
        "label": "ORG"
      },
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Banasthali Vidyapith, Department of Pharmacy, Rajasthan, India.",
    "entities": [
      {
        "text": "2)Banasthali",
        "label": "CARDINAL"
      },
      {
        "text": "Department of Pharmacy",
        "label": "ORG"
      },
      {
        "text": "Rajasthan",
        "label": "GPE"
      },
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Pharmacology, All India Institute of Medical Sciences,",
    "entities": [
      {
        "text": "All India Institute of Medical Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Despite advancements in antimicrobial and anti-inflammatory treatments,",
    "entities": []
  },
  {
    "text": "inflammation and its repercussions continue to pose a considerable challenge in",
    "entities": []
  },
  {
    "text": "medicine. Acute inflammation may cause life-threatening conditions like septic",
    "entities": []
  },
  {
    "text": "shock, while chronic inflammation leads to tissue degeneration and impaired",
    "entities": []
  },
  {
    "text": "function. Lipopolysaccharides (LPS), a well-known pathogenic trigger",
    "entities": [
      {
        "text": "LPS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "contributing to several dysfunctions, is a crucial part of the outer membrane of",
    "entities": []
  },
  {
    "text": "gr-negative bacteria. LPS are well-known for eliciting acute inflammatory",
    "entities": [
      {
        "text": "LPS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "responses by activating a pathogen-associated molecular pattern (PAMP), which",
    "entities": []
  },
  {
    "text": "stimulates the innate immune system and triggers local or systemic inflammatory",
    "entities": []
  },
  {
    "text": "responses. LPS also activate numerous intracellular molecules that modulate the",
    "entities": [
      {
        "text": "LPS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "expression of a wide range of inflammatory mediators. These mediators",
    "entities": []
  },
  {
    "text": "subsequently initiate or exacerbate various inflammatory processes. Beyond",
    "entities": []
  },
  {
    "text": "immune cells, LPS can also activate non-immune cells, leading to inflammatory",
    "entities": [
      {
        "text": "LPS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "reactions. These excessive inflammatory responses are often detrimental and",
    "entities": []
  },
  {
    "text": "typically result in chronic and progressive inflammatory diseases, including",
    "entities": []
  },
  {
    "text": "neurodegenerative, cardiovascular diseases, and cancer. This review delves into",
    "entities": []
  },
  {
    "text": "the mechanisms by which the bacterial endotoxin LPS contribute to multiple",
    "entities": [
      {
        "text": "LPS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "inflammatory diseases. These insights into LPS signaling pathways could inform",
    "entities": [
      {
        "text": "LPS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the design of new treatment strategies such as TLR4, NLRP3, HMGA1, MAPK, and",
    "entities": [
      {
        "text": "TLR4",
        "label": "ORG"
      },
      {
        "text": "NLRP3",
        "label": "ORG"
      },
      {
        "text": "HMGA1",
        "label": "ORG"
      },
      {
        "text": "MAPK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "NF-kB inhibitors. This enables precise targeting of inflammation-related",
    "entities": []
  },
  {
    "text": "\u00a9 2025. This work is openly licensed via CC BY 4.0.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "CC BY",
        "label": "ORG"
      },
      {
        "text": "4.0",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: The authors declare that they have no conflicts",
    "entities": []
  },
  {
    "text": "of interest.",
    "entities": []
  },
  {
    "text": "26. Front Public Health. 2025 Jul 1;13:1585711. doi: 10.3389/fpubh.2025.1585711.",
    "entities": [
      {
        "text": "26",
        "label": "CARDINAL"
      },
      {
        "text": "Front Public Health",
        "label": "ORG"
      },
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "10.3389",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Global Burden of Alzheimer's disease and other dementias in adults aged 65 years",
    "entities": [
      {
        "text": "Global Burden of Alzheimer",
        "label": "PERSON"
      },
      {
        "text": "65 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "and older, 1991-2021: population-based study.",
    "entities": [
      {
        "text": "1991-2021",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(1)Department of Geriatrics, Chongqing University Central Hospital/Chongqing",
    "entities": [
      {
        "text": "Geriatrics",
        "label": "GPE"
      },
      {
        "text": "Chongqing University Central Hospital/Chongqing",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Emergency Medical Center, Chongqing, China.",
    "entities": [
      {
        "text": "Emergency Medical Center",
        "label": "ORG"
      },
      {
        "text": "Chongqing",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "OBJECTIVES: This study aims to analyze the prevalence, impact, and disparities",
    "entities": []
  },
  {
    "text": "of Alzheimer's disease and other dementias (ADRD) among adults aged 65 years and",
    "entities": [
      {
        "text": "65 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "older worldwide, across different regions and countries, spanning the years",
    "entities": [
      {
        "text": "the years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "METHODS: GBD 2021 obtained data on dementia from vital registration systems,",
    "entities": [
      {
        "text": "GBD",
        "label": "ORG"
      },
      {
        "text": "2021",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "published scientific literature and surveys, and data from health-service",
    "entities": []
  },
  {
    "text": "encounters on deaths, excess mortality, prevalence, and incidence from 1991 to",
    "entities": [
      {
        "text": "1991",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "2021, through systematic review and additional data-seeking efforts. Individuals",
    "entities": [
      {
        "text": "2021",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "aged \u226565 years from 21 regions and 204 countries and territories (Global Burden",
    "entities": [
      {
        "text": "21",
        "label": "CARDINAL"
      },
      {
        "text": "204",
        "label": "CARDINAL"
      },
      {
        "text": "Global Burden\n",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "of Disease and Risk Factors Study 2021) from 1991 to 2021 were analyzed. Primary",
    "entities": [
      {
        "text": "Disease and Risk Factors Study",
        "label": "ORG"
      },
      {
        "text": "2021",
        "label": "DATE"
      },
      {
        "text": "1991",
        "label": "DATE"
      },
      {
        "text": "2021",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "outcomes were ADRD related to aged \u226565 years age-standardized prevalence,",
    "entities": [
      {
        "text": "years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "deaths, disability-adjusted life years (DALYs), and average annual percentage",
    "entities": []
  },
  {
    "text": "change (AAPC), and the fractions of these metrics that were attributable to",
    "entities": []
  },
  {
    "text": "three risk factors (high BMI, high fasting glucose, and smoking) that met GBD.",
    "entities": [
      {
        "text": "three",
        "label": "CARDINAL"
      },
      {
        "text": "BMI",
        "label": "ORG"
      },
      {
        "text": "GBD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RESULTS: The global mortality of ADRD among adults aged \u226565 years increased by",
    "entities": [
      {
        "text": "ADRD",
        "label": "ORG"
      },
      {
        "text": "\u226565 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "115%, from 6.5 (95% UI 1.5-18) per 100,000 population in 1991 to 14 (95% UI",
    "entities": [
      {
        "text": "115%",
        "label": "PERCENT"
      },
      {
        "text": "6.5",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "1.5-18",
        "label": "CARDINAL"
      },
      {
        "text": "100,000",
        "label": "CARDINAL"
      },
      {
        "text": "1991",
        "label": "DATE"
      },
      {
        "text": "14",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "3.5-37) per 100,000 population in 2021, with an Average Annual Percentage Change",
    "entities": [
      {
        "text": "3.5",
        "label": "CARDINAL"
      },
      {
        "text": "100,000",
        "label": "CARDINAL"
      },
      {
        "text": "2021",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(AAPC) of 1.10% (95%CI 0.45%-1.76%). The prevalence of ADRD in adults aged \u226565",
    "entities": [
      {
        "text": "1.10%",
        "label": "PERCENT"
      },
      {
        "text": "95%CI 0.45%-1.76%",
        "label": "PERCENT"
      },
      {
        "text": "ADRD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "years increased by 160% between 1991 and 2021, from 18.7 (95%UI 14.9-23.2)",
    "entities": [
      {
        "text": "160%",
        "label": "PERCENT"
      },
      {
        "text": "between 1991",
        "label": "DATE"
      },
      {
        "text": "2021",
        "label": "DATE"
      },
      {
        "text": "18.7",
        "label": "CARDINAL"
      },
      {
        "text": "14.9",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "million to 49 (95%UI 38.6-61.2) million. The aged \u226565 years age-standardized",
    "entities": [
      {
        "text": "million to 49",
        "label": "CARDINAL"
      },
      {
        "text": "38.6",
        "label": "CARDINAL"
      },
      {
        "text": "years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "prevalence of ADRD in this age group increased from 11,977 (95%UI 9,438-14,935)",
    "entities": [
      {
        "text": "ADRD",
        "label": "ORG"
      },
      {
        "text": "11,977",
        "label": "CARDINAL"
      },
      {
        "text": "95%UI",
        "label": "CARDINAL"
      },
      {
        "text": "9,438-14,935",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "per 100,000 population in 1991 to 12,124 (95%UI 9,489-15,204) per 100,000",
    "entities": [
      {
        "text": "100,000",
        "label": "CARDINAL"
      },
      {
        "text": "1991",
        "label": "DATE"
      },
      {
        "text": "12,124",
        "label": "CARDINAL"
      },
      {
        "text": "9,489-15,204",
        "label": "CARDINAL"
      },
      {
        "text": "100,000",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "population in 2021. The aged \u226565 years the number of prevalent persons was more",
    "entities": [
      {
        "text": "2021",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "significant among females than among males (males: from 6.2 (95%UI 4.8-7.8)",
    "entities": [
      {
        "text": "6.2",
        "label": "CARDINAL"
      },
      {
        "text": "95%UI",
        "label": "CARDINAL"
      },
      {
        "text": "4.8-7.8",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "million in 1991 to 17.2 (95%UI 13.4-21.6) million in 2021; women: from 12.5",
    "entities": [
      {
        "text": "1991",
        "label": "DATE"
      },
      {
        "text": "17.2",
        "label": "CARDINAL"
      },
      {
        "text": "13.4",
        "label": "CARDINAL"
      },
      {
        "text": "2021",
        "label": "DATE"
      },
      {
        "text": "12.5",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(95%UI 10.0-15.4) million in 1991 to 31.7 (95%UI 25.1-39.6) million in 2021). In",
    "entities": [
      {
        "text": "10.0",
        "label": "CARDINAL"
      },
      {
        "text": "1991",
        "label": "DATE"
      },
      {
        "text": "31.7",
        "label": "CARDINAL"
      },
      {
        "text": "25.1",
        "label": "CARDINAL"
      },
      {
        "text": "2021",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "2021, ADRD in adults aged \u226565 years caused 8.02 (95%UI 1.34-22.19) million",
    "entities": [
      {
        "text": "2021",
        "label": "DATE"
      },
      {
        "text": "ADRD",
        "label": "ORG"
      },
      {
        "text": "\u226565 years",
        "label": "DATE"
      },
      {
        "text": "8.02",
        "label": "CARDINAL"
      },
      {
        "text": "1.34-22.19",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "deaths and 25.38 (95%UI 23.18-71.20) million DALYs attributable to dementia, and",
    "entities": [
      {
        "text": "25.38",
        "label": "CARDINAL"
      },
      {
        "text": "23.18-71.20",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "high BMI, high fasting glucose, and smoking remained modifiable risk factors in",
    "entities": [
      {
        "text": "BMI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CONCLUSIONS: From 1991 to 2021, the worldwide prevalence of Alzheimer's disease",
    "entities": [
      {
        "text": "1991",
        "label": "DATE"
      },
      {
        "text": "2021",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "and other dementias among adults aged 65 and above has increased by 1.6 times,",
    "entities": [
      {
        "text": "aged 65",
        "label": "DATE"
      },
      {
        "text": "1.6",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "largely driven by the expanding older adults. This escalating trend poses",
    "entities": []
  },
  {
    "text": "significant challenges to the global healthcare system in terms of both",
    "entities": []
  },
  {
    "text": "mortality rates and disability-adjusted life years. We recommend that",
    "entities": [
      {
        "text": "years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "standardized screening programmes be promoted globally, especially in high-risk",
    "entities": []
  },
  {
    "text": "areas and among high-risk populations, for early detection and intervention of",
    "entities": []
  },
  {
    "text": "the disease. Secondly, we recommend strengthening the management of risk factor",
    "entities": [
      {
        "text": "Secondly",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "DOI: 10.3389/fpubh.2025.1585711",
    "entities": [
      {
        "text": "10.3389",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "PMID: 40666154 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40666154",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "From frailty to resilience: exploring adaptive capacity and reserve in older",
    "entities": []
  },
  {
    "text": "adults-a narrative review.",
    "entities": []
  },
  {
    "text": "(1)Johns Hopkins University School of Medicine, Division of Geriatric Medicine",
    "entities": [
      {
        "text": "1)Johns Hopkins University School of Medicine, Division of Geriatric Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and Gerontology, Baltimore, MD, United States.",
    "entities": [
      {
        "text": "Gerontology",
        "label": "PERSON"
      },
      {
        "text": "Baltimore",
        "label": "GPE"
      },
      {
        "text": "MD",
        "label": "GPE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Resilience, the capacity to adapt and recover from adversity, plays a critical",
    "entities": []
  },
  {
    "text": "role in the health and wellbeing of older adults. In geriatric populations,",
    "entities": []
  },
  {
    "text": "resilience encompasses physical, cognitive, and psychosocial domains and is",
    "entities": []
  },
  {
    "text": "essential for maintaining functional independence and quality of life amidst the",
    "entities": []
  },
  {
    "text": "challenges of aging. This review explores the concept of resilience within",
    "entities": []
  },
  {
    "text": "geriatric medicine across physical, cognitive, and psychosocial domains,",
    "entities": []
  },
  {
    "text": "highlights the differences from frailty and reserve, underscores importance of",
    "entities": []
  },
  {
    "text": "stressors, summarizes key biomarkers that predict resilience, and evaluates",
    "entities": []
  },
  {
    "text": "interventions designed to enhance resilience in older adults.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 Cosarderelioglu, Walston and Abadir.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Cosarderelioglu",
        "label": "GPE"
      },
      {
        "text": "Walston",
        "label": "GPE"
      },
      {
        "text": "Abadir",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "10.1177/13872877251360004. Online ahead of print.",
    "entities": [
      {
        "text": "10.1177/13872877251360004",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Exploring causal gut-brain axes in Alzheimer's disease using mediation Mendelian",
    "entities": [
      {
        "text": "Mendelian",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "randomization analysis.",
    "entities": []
  },
  {
    "text": "(1)Department of Traditional Chinese Medicine, The Second Hospital of Shandong",
    "entities": [
      {
        "text": "Traditional Chinese Medicine",
        "label": "ORG"
      },
      {
        "text": "The Second Hospital of",
        "label": "ORG"
      },
      {
        "text": "Shandong",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "University, Jinan, China.",
    "entities": [
      {
        "text": "Jinan",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BackgroundAlzheimer's disease (AD) is a progressive neurodegenerative condition",
    "entities": [
      {
        "text": "BackgroundAlzheimer",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "with unclear etiology. Recent studies suggest gut microbiota may be involved in",
    "entities": []
  },
  {
    "text": "AD pathogenesis through imbalances that increase intestinal permeability, affect",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "blood-brain barrier function, and promote neuroinflammation. However,",
    "entities": []
  },
  {
    "text": "observational studies are susceptible to confounding biases and reverse",
    "entities": []
  },
  {
    "text": "causality.ObjectiveThis study aimed to explore causal relationships between gut",
    "entities": []
  },
  {
    "text": "microbiota, brain imaging-derived phenotypes (IDPs), and AD using mediation",
    "entities": []
  },
  {
    "text": "Mendelian randomization analysis to identify specific gut-brain axes involved in",
    "entities": [
      {
        "text": "Mendelian",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "AD mechanisms.MethodsWe conducted a three-phase Mendelian randomization analysis",
    "entities": [
      {
        "text": "AD mechanisms",
        "label": "DATE"
      },
      {
        "text": "MethodsWe",
        "label": "ORG"
      },
      {
        "text": "three",
        "label": "CARDINAL"
      },
      {
        "text": "Mendelian",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "using large-scale genome-wide association study (GWAS) data. Phase 1 analyzed",
    "entities": []
  },
  {
    "text": "causal effects of 412 gut microbiota on AD. Phase 2 examined causal effects of",
    "entities": [
      {
        "text": "412",
        "label": "CARDINAL"
      },
      {
        "text": "AD",
        "label": "DATE"
      },
      {
        "text": "Phase 2",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "920 IDPs on AD. Phase 3 performed mediation analysis to understand the role of",
    "entities": [
      {
        "text": "920",
        "label": "CARDINAL"
      },
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "IDPs in the gut microbiota-AD pathway. Data sources included Dutch population",
    "entities": [
      {
        "text": "Dutch",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "study (7738 individuals), MiBioGen consortium (18,340 individuals), UK Biobank",
    "entities": [
      {
        "text": "7738",
        "label": "CARDINAL"
      },
      {
        "text": "MiBioGen",
        "label": "GPE"
      },
      {
        "text": "18,340",
        "label": "CARDINAL"
      },
      {
        "text": "UK",
        "label": "GPE"
      },
      {
        "text": "Biobank",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "brain imaging (8428 samples), and AD GWAS dataset (487,511 participants).",
    "entities": [
      {
        "text": "8428",
        "label": "DATE"
      },
      {
        "text": "AD GWAS",
        "label": "ORG"
      },
      {
        "text": "487,511",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Inverse variance weighted method was the primary analysis approach.ResultsWe",
    "entities": []
  },
  {
    "text": "identified 12 gut microbiota metabolic pathways and 32 gut microbiota species",
    "entities": [
      {
        "text": "12",
        "label": "CARDINAL"
      },
      {
        "text": "32",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "causally related to AD, plus 29 IDPs with potential causal relationships to AD.",
    "entities": [
      {
        "text": "29",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Mediation analysis revealed four distinct gut-brain axes: genus",
    "entities": [
      {
        "text": "four",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Butyrivibrio-brain stem-AD, genus Lachnospiraceae-brain stem-AD,",
    "entities": [
      {
        "text": "Lachnospiraceae",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "PEPTIDOGLYCANSYN pathway-L1 External capsule Left-AD, and TCA cycle pathway-L1",
    "entities": [
      {
        "text": "Left-AD",
        "label": "PERSON"
      },
      {
        "text": "TCA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "External capsule Left-AD.ConclusionsThis study identified four specific gut",
    "entities": [
      {
        "text": "Left-AD.ConclusionsThis",
        "label": "PERSON"
      },
      {
        "text": "four",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "microbiota-brain structure axes causally involved in AD mechanisms, providing",
    "entities": [
      {
        "text": "AD mechanisms",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "novel insights for understanding the gut-brain axis role in AD pathogenesis and",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "potential therapeutic targets.",
    "entities": []
  },
  {
    "text": "10.1177/13872877251359638. Online ahead of print.",
    "entities": [
      {
        "text": "10.1177/13872877251359638",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Brain amyloid-\u03b2 deposition, severity of subjective cognitive decline and gait",
    "entities": []
  },
  {
    "text": "speed in cognitively unimpaired oldest-old.",
    "entities": []
  },
  {
    "text": "(1)Department of Medicine, Division of Geriatric Medicine, University of",
    "entities": [
      {
        "text": "Medicine, Division of Geriatric Medicine, University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.",
    "entities": [
      {
        "text": "Neurology, University of Pittsburgh",
        "label": "ORG"
      },
      {
        "text": "Pittsburgh",
        "label": "GPE"
      },
      {
        "text": "PA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA.",
    "entities": [
      {
        "text": "Biostatistics, University of Pittsburgh",
        "label": "ORG"
      },
      {
        "text": "Pittsburgh",
        "label": "GPE"
      },
      {
        "text": "PA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.",
    "entities": [
      {
        "text": "Radiology, University of Pittsburgh",
        "label": "ORG"
      },
      {
        "text": "Pittsburgh",
        "label": "GPE"
      },
      {
        "text": "PA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Psychiatry, University of Pittsburgh",
        "label": "ORG"
      },
      {
        "text": "Pittsburgh",
        "label": "GPE"
      },
      {
        "text": "PA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BackgroundGait speed slows prior to cognitive decline in clinical Alzheimer's",
    "entities": []
  },
  {
    "text": "disease (AD), and is associated with cognitive performance and biomarkers of",
    "entities": []
  },
  {
    "text": "amyloid-\u03b2 (A\u03b2) pathology in cognitively unimpaired (CU) older adults. However,",
    "entities": [
      {
        "text": "CU",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the influence of subjective cognitive decline (SCD) severity on the association",
    "entities": [
      {
        "text": "SCD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "between A\u03b2 and gait speed is not known.ObjectiveWe examined the relationship",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "among gait speed, SCD severity and A\u03b2 deposition in CU older adults.MethodsGait",
    "entities": [
      {
        "text": "SCD",
        "label": "ORG"
      },
      {
        "text": "A\u03b2",
        "label": "PERSON"
      },
      {
        "text": "CU",
        "label": "ORG"
      },
      {
        "text": "MethodsGait",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "speed was measured over 15-feet. A\u03b2 deposition was quantified using Pittsburgh-B",
    "entities": [
      {
        "text": "over 15-feet",
        "label": "QUANTITY"
      },
      {
        "text": "Pittsburgh",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(PiB) PET, expressed in Centiloid units (CL). Severity of SCD was quantified on",
    "entities": [
      {
        "text": "PET",
        "label": "ORG"
      },
      {
        "text": "Centiloid",
        "label": "PERSON"
      },
      {
        "text": "SCD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the Memory Functioning Questionnaire (MFQ) on measures of seriousness and",
    "entities": [
      {
        "text": "the Memory Functioning Questionnaire",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "frequency of forgetting, mnemonic usage and retrospective functioning. We fitted",
    "entities": []
  },
  {
    "text": "a series of linear models with gait speed as the dependent variable; and each",
    "entities": [
      {
        "text": "linear",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "dichotomized sub-scale of the MFQ and A\u03b2 as independent variables, adjusting for",
    "entities": [
      {
        "text": "MFQ",
        "label": "ORG"
      },
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "depression, white matter hyperintensity volume and executive function.ResultsIn",
    "entities": []
  },
  {
    "text": "58 CU individuals (mean age 85, 35% female), mean gait speed was 0.91 m/s and A\u03b2",
    "entities": [
      {
        "text": "58",
        "label": "CARDINAL"
      },
      {
        "text": "CU",
        "label": "ORG"
      },
      {
        "text": "age 85",
        "label": "DATE"
      },
      {
        "text": "35%",
        "label": "PERCENT"
      },
      {
        "text": "0.91 m/s",
        "label": "QUANTITY"
      },
      {
        "text": "A\u03b2\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "deposition was 36 CL. The relationship between slower gait and greater A\u03b2",
    "entities": [
      {
        "text": "36",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "deposition showed a stronger association in those with more frequent mnemonic",
    "entities": []
  },
  {
    "text": "use (r = -0.36, p = 0.05) and with greater seriousness of forgetting (r = -0.33,",
    "entities": [
      {
        "text": "-0.36",
        "label": "FAC"
      },
      {
        "text": "0.05",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "p = 0.08) compared to those with lesser severity of subjective cognitive",
    "entities": [
      {
        "text": "0.08",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "concerns (r = 0.02, p = 0.9 and r = -0.08, p = 0.7 respectively).ConclusionsThe",
    "entities": [
      {
        "text": "0.02",
        "label": "CARDINAL"
      },
      {
        "text": "0.9",
        "label": "CARDINAL"
      },
      {
        "text": "-0.08",
        "label": "CARDINAL"
      },
      {
        "text": "0.7 respectively).ConclusionsThe",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "findings indicate that in those with greater severity of SCD, association",
    "entities": [
      {
        "text": "SCD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "between slower gait and greater A\u03b2 deposition is stronger, warranting",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "longitudinal assessments of SCD severity and gait changes in preclinical AD.",
    "entities": [
      {
        "text": "SCD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "30. Ann Clin Transl Neurol. 2025 Jul 15. doi: 10.1002/acn3.70143. Online ahead of",
    "entities": [
      {
        "text": "30",
        "label": "CARDINAL"
      },
      {
        "text": "Ann Clin Transl Neurol",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1002",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Cognitive Resilience in Apolipoprotein \u03b54 Carrier Women Predicted by",
    "entities": [
      {
        "text": "Apolipoprotein",
        "label": "GPE"
      },
      {
        "text": "Carrier Women Predicted",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Neuron-Derived Extracellular Vesicles.",
    "entities": [
      {
        "text": "Neuron-Derived Extracellular",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Pucha KA(1), Yao PJ(1), Blommer J(1), Vreones MP(1), York W(1), Knight DL(1),",
    "entities": [
      {
        "text": "Pucha KA(1",
        "label": "PERSON"
      },
      {
        "text": "Yao PJ(1",
        "label": "PERSON"
      },
      {
        "text": "Vreones MP(1",
        "label": "PERSON"
      },
      {
        "text": "York W(1",
        "label": "LOC"
      },
      {
        "text": "Knight DL(1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Rapp SR(2), Shadyab AH(3), Manson JE(4), Casanova R(5), Wallace RB(6), Ferrucci",
    "entities": [
      {
        "text": "Shadyab AH(3",
        "label": "PERSON"
      },
      {
        "text": "Manson JE(4",
        "label": "PERSON"
      },
      {
        "text": "Casanova",
        "label": "PERSON"
      },
      {
        "text": "Wallace",
        "label": "PERSON"
      },
      {
        "text": "Ferrucci",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "L(7), Resnick SM(8), Kapogiannis D(1).",
    "entities": [
      {
        "text": "Resnick SM(8",
        "label": "PERSON"
      },
      {
        "text": "Kapogiannis",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Laboratory of Clinical Investigation, Intramural Research Program, National",
    "entities": [
      {
        "text": "Clinical Investigation",
        "label": "ORG"
      },
      {
        "text": "Intramural Research Program",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Institute on Aging, Baltimore, Maryland, USA.",
    "entities": [
      {
        "text": "Institute on Aging,",
        "label": "ORG"
      },
      {
        "text": "Baltimore",
        "label": "GPE"
      },
      {
        "text": "Maryland",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Psychiatry and Behavioral Medicine, Wake Forest University",
    "entities": [
      {
        "text": "Psychiatry",
        "label": "ORG"
      },
      {
        "text": "Behavioral Medicine",
        "label": "ORG"
      },
      {
        "text": "Wake Forest University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "School of Medicine, Winston-Salem, North Carolina, USA.",
    "entities": [
      {
        "text": "School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Winston-Salem",
        "label": "GPE"
      },
      {
        "text": "North Carolina",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Herbert Wertheim School of Public Health and Human Longevity Science and",
    "entities": [
      {
        "text": "Wertheim School of Public Health and Human Longevity Science",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Division of Geriatrics, Gerontology and Palliative Care, Department of Medicine,",
    "entities": [
      {
        "text": "Division of Geriatrics, Gerontology and Palliative Care, Department of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of California San Diego, La Jolla, California, USA.",
    "entities": [
      {
        "text": "University of California San Diego",
        "label": "ORG"
      },
      {
        "text": "La Jolla",
        "label": "GPE"
      },
      {
        "text": "California",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Medicine, Brigham and Women's Hospital, Harvard Medical School,",
    "entities": [
      {
        "text": "Medicine, Brigham and Women's Hospital",
        "label": "ORG"
      },
      {
        "text": "Harvard Medical School",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Boston, Massachusetts, USA.",
    "entities": [
      {
        "text": "Boston",
        "label": "GPE"
      },
      {
        "text": "Massachusetts",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Department of Biostatistics and Data Sciences, Wake Forest University School",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Biostatistics and Data Sciences",
        "label": "ORG"
      },
      {
        "text": "Wake Forest University School",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Medicine, Winston-Salem, North Carolina, USA.",
    "entities": [
      {
        "text": "Winston-Salem",
        "label": "GPE"
      },
      {
        "text": "North Carolina",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Department of Epidemiology, College of Public Health, University of Iowa,",
    "entities": [
      {
        "text": "Epidemiology, College of Public Health, University of Iowa",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(7)Longitudinal Studies Section, Intramural Research Program, National Institute",
    "entities": [
      {
        "text": "Intramural Research Program",
        "label": "ORG"
      },
      {
        "text": "National Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "on Aging, Baltimore, Maryland, USA.",
    "entities": [
      {
        "text": "Aging,",
        "label": "ORG"
      },
      {
        "text": "Baltimore",
        "label": "GPE"
      },
      {
        "text": "Maryland",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Laboratory of Behavioral Neuroscience, National Institute on Aging,",
    "entities": [
      {
        "text": "Behavioral Neuroscience",
        "label": "ORG"
      },
      {
        "text": "National Institute on Aging",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Baltimore, Maryland, USA.",
    "entities": [
      {
        "text": "Baltimore",
        "label": "GPE"
      },
      {
        "text": "Maryland",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "OBJECTIVE: The Apolipoprotein (APOE) \u03b54 allele is the strongest genetic risk",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      },
      {
        "text": "\u03b54 allele",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "factor for late-onset Alzheimer's disease (AD); however, many \u03b54 carriers remain",
    "entities": [
      {
        "text": "\u03b54",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cognitively intact into old age. Leveraging plasma neuron-derived extracellular",
    "entities": []
  },
  {
    "text": "vesicles (NDEVs), we sought to identify biomarkers of cognitive resilience and",
    "entities": []
  },
  {
    "text": "their interplay with APOE genotype.",
    "entities": []
  },
  {
    "text": "METHODS: In this case-control study nested within the Women's Health Initiative",
    "entities": [
      {
        "text": "the Women's Health Initiative\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(WHI), we analyzed 1130 plasma samples from 676 women in the WHI Memory Study",
    "entities": [
      {
        "text": "1130",
        "label": "DATE"
      },
      {
        "text": "676",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(WHIMS)/Long Life Study (LLS), with APOE \u03b54 or \u03b53/\u03b53 genotypes. At baseline, all",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "participants were cognitively intact and at LLS visit, 13-17 years later, were",
    "entities": [
      {
        "text": "13-17 years later",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "classified as still cognitively intact (resilient) or having become impaired at",
    "entities": []
  },
  {
    "text": "age > 80 or \u2264 80 years. We isolated NDEVs using immunoaffinity capture for the",
    "entities": [
      {
        "text": "80",
        "label": "CARDINAL"
      },
      {
        "text": "80 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "neuronal marker L1CAM and quantified AD pathogenic proteins (A\u03b242, total Tau,",
    "entities": [
      {
        "text": "AD",
        "label": "ORG"
      },
      {
        "text": "Tau",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "p181-Tau), insulin signaling (pSer312-IRS-1), TNFR1/NF\u03baB pathway mediators and",
    "entities": [
      {
        "text": "p181-Tau",
        "label": "PERSON"
      },
      {
        "text": "TNFR1/NF\u03baB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "targets, and mitochondrial Complex V. Linear mixed models assessed group",
    "entities": [
      {
        "text": "Complex V. Linear",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "differences, adjusting for NDEV yield, age, and education, with FDR correction.",
    "entities": [
      {
        "text": "NDEV",
        "label": "ORG"
      },
      {
        "text": "FDR",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "RESULTS: No group differences were found for A\u03b242, Tau proteins, or pS312-IRS-1.",
    "entities": []
  },
  {
    "text": "Resilient \u03b54 carriers had higher baseline levels of phosphorylated TNFR1, NF\u03baB,",
    "entities": [
      {
        "text": "TNFR1",
        "label": "GPE"
      },
      {
        "text": "NF\u03baB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "c-Myc, and FADD than \u03b54 carriers who eventually developed impairment at > 80 or",
    "entities": [
      {
        "text": "FADD",
        "label": "ORG"
      },
      {
        "text": "80",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "\u2264 80 years. Additionally, resilient \u03b54 carriers had higher baseline Complex V",
    "entities": [
      {
        "text": "80 years",
        "label": "DATE"
      },
      {
        "text": "\u03b54",
        "label": "ORG"
      },
      {
        "text": "Complex V\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "levels than \u03b54 carriers impaired at age > 80.",
    "entities": [
      {
        "text": "\u03b54",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "INTERPRETATION: Augmented neuronal TNFR1/NF\u03baB signaling and Complex V levels may",
    "entities": [
      {
        "text": "TNFR1/NF\u03baB",
        "label": "ORG"
      },
      {
        "text": "Complex V",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "promote cognitive resilience in \u03b54 carrier women. Boosting these mechanisms may",
    "entities": [
      {
        "text": "\u03b54",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "have preventive and therapeutic potential against cognitive decline in this",
    "entities": []
  },
  {
    "text": "high-risk population.",
    "entities": []
  },
  {
    "text": "\u00a9 2025 The Author(s). Annals of Clinical and Translational Neurology published",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "by Wiley Periodicals LLC on behalf of American Neurological Association. This",
    "entities": [
      {
        "text": "Wiley Periodicals",
        "label": "ORG"
      },
      {
        "text": "American Neurological Association",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "article has been contributed to by U.S. Government employees and their work is",
    "entities": [
      {
        "text": "U.S. Government",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "in the public domain in the USA.",
    "entities": [
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Pittsburgh plasma p-tau217: Classification accuracies for autosomal dominant and",
    "entities": [
      {
        "text": "Pittsburgh",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "sporadic Alzheimer's disease in the community.",
    "entities": []
  },
  {
    "text": "(1)Department of Psychiatry, School of Medicine, University of Pittsburgh,",
    "entities": [
      {
        "text": "Psychiatry, School of Medicine, University of Pittsburgh",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Geriatric Research Education and Clinical Center, VA Pittsburgh HS,",
    "entities": [
      {
        "text": "Research Education",
        "label": "ORG"
      },
      {
        "text": "Clinical Center",
        "label": "FAC"
      },
      {
        "text": "VA Pittsburgh HS",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "(3)Department of Biostatistics and Health Data Science, School of Public Health,",
    "entities": [
      {
        "text": "Biostatistics and Health Data Science, School of Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of Pittsburgh, Pittsburgh, Pennsylvania, USA.",
    "entities": [
      {
        "text": "University of Pittsburgh",
        "label": "ORG"
      },
      {
        "text": "Pittsburgh",
        "label": "GPE"
      },
      {
        "text": "Pennsylvania",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Radiology, School of Medicine, University of Pittsburgh,",
    "entities": [
      {
        "text": "Radiology, School of Medicine, University of Pittsburgh",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Department of Human Genetics, School of Public Health, University of",
    "entities": [
      {
        "text": "Human Genetics, School of Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Department of Neurology, School of Medicine, University of Pittsburgh,",
    "entities": [
      {
        "text": "Neurology, School of Medicine, University of Pittsburgh",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "INTRODUCTION: Most available phosphorylated tau (p-tau)217 immunoassays have",
    "entities": []
  },
  {
    "text": "similar performance. It is unclear if this is due to the use of the same",
    "entities": []
  },
  {
    "text": "antibody (the \"ALZpath antibody\"). We established and evaluated a novel p-tau217",
    "entities": [
      {
        "text": "ALZpath",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "assay that uses an alternative antibody and benchmarked the results against",
    "entities": []
  },
  {
    "text": "METHODS: After development and analytical validation of the University of",
    "entities": [
      {
        "text": "the University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Pittsburgh (\"Pitt-p-tau217\") method, clinical verification was performed in",
    "entities": [
      {
        "text": "Pittsburgh",
        "label": "GPE"
      },
      {
        "text": "Pitt-p-tau217",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "three independent cohorts (n = 363).",
    "entities": [
      {
        "text": "three",
        "label": "CARDINAL"
      },
      {
        "text": "363",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "RESULTS: Pitt-p-tau217 demonstrated high between-run stability, linearity, and",
    "entities": []
  },
  {
    "text": "specificity. Clinically, Pitt-p-tau217 differentiated neuropathologically",
    "entities": [
      {
        "text": "Pitt-p-tau217",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "confirmed PSEN1 mutation carriers from controls with area under the curve",
    "entities": [
      {
        "text": "PSEN1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(AUC) = 0.94, and amyloid beta (A\u03b2) positron emission tomography (PET)-positive",
    "entities": [
      {
        "text": "0.94",
        "label": "CARDINAL"
      },
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "from A\u03b2 PET-negative cognitively normal older adults with AUC up to 0.84,",
    "entities": [
      {
        "text": "A\u03b2 PET-negative",
        "label": "PERSON"
      },
      {
        "text": "AUC",
        "label": "ORG"
      },
      {
        "text": "up to 0.84",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "equivalent to ALZpath-p-tau217 results. Both Pitt-p-tau217 and ALZpath-p-tau217",
    "entities": [
      {
        "text": "ALZpath-p-tau217",
        "label": "ORG"
      },
      {
        "text": "Pitt-p-tau217",
        "label": "ORG"
      },
      {
        "text": "ALZpath-p-tau217\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "were slightly elevated in tau PET-positive versus tau PET-negative participants.",
    "entities": [
      {
        "text": "PET",
        "label": "ORG"
      },
      {
        "text": "PET",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Between-assay correlations were up to 0.93.",
    "entities": [
      {
        "text": "0.93",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "DISCUSSION: The new Pitt-p-tau217 assay exhibits high and reproducible",
    "entities": [
      {
        "text": "Pitt-p-tau217",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "classification accuracies for identifying individuals with biological evidence",
    "entities": []
  },
  {
    "text": "of Alzheimer's disease, equivalent to the widely used ALZpath-p-tau217.",
    "entities": [
      {
        "text": "ALZpath-p-tau217",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "HIGHLIGHTS: We designed and developed an alternative assay to quantify plasma",
    "entities": []
  },
  {
    "text": "phosphorylated tau (p-tau)217, aiming to enhance accuracy and enable early",
    "entities": []
  },
  {
    "text": "detection of Alzheimer's disease (AD). Comprehensive analytical and clinical",
    "entities": []
  },
  {
    "text": "validation demonstrated that the new p-tau217 assay is a valuable and affordable",
    "entities": []
  },
  {
    "text": "resource for investigating AD pathophysiology. The new p-tau217 assay showed",
    "entities": []
  },
  {
    "text": "similar performance to the established ALZpath assay in staging and monitoring",
    "entities": [
      {
        "text": "ALZpath",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "early AD.",
    "entities": [
      {
        "text": "early AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "\u00a9 2025 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Wiley Periodicals",
        "label": "ORG"
      },
      {
        "text": "LLC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "on behalf of Alzheimer's Association.",
    "entities": []
  },
  {
    "text": "PMID: 40665482 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40665482",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Alzheimer's disease and its co-pathologies: Implications for hippocampal",
    "entities": []
  },
  {
    "text": "degeneration, cognitive decline, and the role of APOE \u03b54.",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Imaging and Pathology, Laboratory of Neuropathology, KU Leuven,",
    "entities": [
      {
        "text": "Imaging",
        "label": "GPE"
      },
      {
        "text": "Pathology, Laboratory of Neuropathology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Department of Neuroscience, Laboratory of Neurobiology, KU Leuven, Leuven,",
    "entities": [
      {
        "text": "Neuroscience, Laboratory of Neurobiology",
        "label": "ORG"
      },
      {
        "text": "Leuven",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(3)Department of Human Genetics, Laboratory of Multi-omic Integrative",
    "entities": [
      {
        "text": "Human Genetics, Laboratory",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Laboratory of Neuropathology, Institute of Pathology, Ulm University, Ulm,",
    "entities": [
      {
        "text": "4)Laboratory",
        "label": "CARDINAL"
      },
      {
        "text": "Neuropathology, Institute of Pathology",
        "label": "ORG"
      },
      {
        "text": "Ulm University",
        "label": "ORG"
      },
      {
        "text": "Ulm",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Germany.",
    "entities": [
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Complex Genetics of Alzheimer's Disease Group, VIB Center for Molecular",
    "entities": [
      {
        "text": "5)Complex",
        "label": "CARDINAL"
      },
      {
        "text": "Disease Group",
        "label": "ORG"
      },
      {
        "text": "VIB Center for Molecular",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.",
    "entities": [
      {
        "text": "Biomedical Sciences",
        "label": "ORG"
      },
      {
        "text": "University of Antwerp",
        "label": "ORG"
      },
      {
        "text": "Antwerp",
        "label": "GPE"
      },
      {
        "text": "Belgium",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Department of Neuroscience, Laboratory for Translational Neuropsychiatry, KU",
    "entities": [
      {
        "text": "Neuroscience, Laboratory for Translational Neuropsychiatry",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(8)Department of Neurology, Ulm University, Ulm, Germany.",
    "entities": [
      {
        "text": "Neurology, Ulm University",
        "label": "ORG"
      },
      {
        "text": "Ulm",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)Department of Neurology, University of Halle, Halle, Germany.",
    "entities": [
      {
        "text": "Neurology, University of Halle",
        "label": "ORG"
      },
      {
        "text": "Halle",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(10)Department of Geriatrics, University Medical Center G\u00f6ttingen, G\u00f6ttingen,",
    "entities": [
      {
        "text": "10)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Geriatrics, University Medical Center G\u00f6ttingen",
        "label": "ORG"
      },
      {
        "text": "G\u00f6ttingen",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(11)Institute of Anatomy, Johann Wolfgang Goethe University, Frankfurt, Germany.",
    "entities": [
      {
        "text": "11)Institute",
        "label": "CARDINAL"
      },
      {
        "text": "Johann Wolfgang Goethe University",
        "label": "ORG"
      },
      {
        "text": "Frankfurt",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(14)Department of Neurosciences, Laboratory for Cognitive Neurology, KU Leuven,",
    "entities": [
      {
        "text": "Neurosciences, Laboratory for Cognitive Neurology",
        "label": "ORG"
      },
      {
        "text": "KU Leuven",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(15)Department of Electrical Engineering, Processing Speech and Images, KU",
    "entities": [
      {
        "text": "15)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Electrical Engineering",
        "label": "ORG"
      },
      {
        "text": "Processing Speech",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "INTRODUCTION: In neurodegenerative dementias, the co-occurrence and interaction",
    "entities": []
  },
  {
    "text": "of amyloid \u03b2 peptide (A\u03b2), tau pathology, and other pathological lesions",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "confound their individual contributions to neurodegeneration and their",
    "entities": []
  },
  {
    "text": "modulation by risk factors.",
    "entities": []
  },
  {
    "text": "METHODS: We analyzed 480 post mortem human brains (ages 50-99) using regression",
    "entities": [
      {
        "text": "480",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "and structural equation models to assess the relationships among A\u03b2, tau,",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "limbic-predominant age-related TDP-43 encephalopathy neuropathological changes",
    "entities": []
  },
  {
    "text": "(LATE-NC), \u03b1-synuclein, other age-related lesions, and apolipoprotein E (APOE)",
    "entities": []
  },
  {
    "text": "\u03b54, as well as their effects on CA1 neuronal density, brain weight, and",
    "entities": [
      {
        "text": "\u03b54",
        "label": "ORG"
      },
      {
        "text": "CA1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "RESULTS: A\u03b2, tau, LATE-NC, and amygdala-predominant \u03b1-synuclein pathology were",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "mutually interdependent. Tau was the strongest predictor of global",
    "entities": []
  },
  {
    "text": "neurodegeneration, while LATE-NC primarily, but not exclusively, affected",
    "entities": []
  },
  {
    "text": "hippocampal neuron loss. Small vessel disease correlated with both LATE-NC and",
    "entities": []
  },
  {
    "text": "\u03b1-synuclein, while APOE \u03b54 was mainly associated with extracellular parenchymal",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and capillary A\u03b2 pathology.",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "DISCUSSION: Although Alzheimer's disease pathology plays a central role in brain",
    "entities": []
  },
  {
    "text": "degeneration, coexisting pathologies can both exacerbate and independently",
    "entities": []
  },
  {
    "text": "contribute to it. These factors should be considered in patient stratification.",
    "entities": []
  },
  {
    "text": "HIGHLIGHTS: In aging individuals, amyloid \u03b2 peptide (A\u03b2), tau pathology,",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(LATE-NC), and amygdala-predominant \u03b1-synuclein pathology were interrelated but",
    "entities": []
  },
  {
    "text": "contributed independently to neurodegeneration. LATE-NC was the strongest driver",
    "entities": [
      {
        "text": "NC",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "of CA1 neuronal loss, while tau burden was the strongest predictor of global",
    "entities": [
      {
        "text": "CA1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "brain degeneration. Apolipoprotein E \u03b54 was associated with both extracellular",
    "entities": []
  },
  {
    "text": "and capillary A\u03b2 deposits, but not with tau burden. Temporal lobe small vessel",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "disease was associated with both LATE-NC and amygdala-predominant \u03b1-synuclein",
    "entities": []
  },
  {
    "text": "pathology. Neural network models can reliably identify hippocampal pyramidal",
    "entities": []
  },
  {
    "text": "neurons on hematoxylin-stained histological slides.",
    "entities": [
      {
        "text": "hematoxylin",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "PMID: 40665478 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40665478",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Focused ultrasound-mediated APOE4 knockdown in mouse brain.",
    "entities": [
      {
        "text": "APOE4",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Biomedical Engineering, Columbia University, New York, New",
    "entities": [
      {
        "text": "Biomedical Engineering",
        "label": "ORG"
      },
      {
        "text": "Columbia University",
        "label": "ORG"
      },
      {
        "text": "New York",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "York, USA.",
    "entities": [
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Pathology and Cell Biology, Columbia University Irving Medical",
    "entities": [
      {
        "text": "2)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Cell Biology",
        "label": "ORG"
      },
      {
        "text": "Columbia University Irving Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Center, New York, New York, USA.",
    "entities": [
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Taub Institute for Research on Alzheimer's Disease and the Aging Brain,",
    "entities": [
      {
        "text": "3)Taub Institute for Research on Alzheimer's",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Columbia University Irving Medical Center, New York, New York, USA.",
    "entities": [
      {
        "text": "Columbia University Irving Medical Center",
        "label": "ORG"
      },
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Radiology, Columbia University Medical Center, New York, New",
    "entities": [
      {
        "text": "Radiology, Columbia University Medical Center",
        "label": "ORG"
      },
      {
        "text": "New York",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Department of Systems Biology, Columbia University Medical Center, New York,",
    "entities": [
      {
        "text": "Systems Biology",
        "label": "ORG"
      },
      {
        "text": "Columbia University Medical Center",
        "label": "ORG"
      },
      {
        "text": "New York",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "New York, USA.",
    "entities": [
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "INTRODUCTION: The apolipoprotein E (APOE) \u03b54 allele is widely recognized as the",
    "entities": [
      {
        "text": "\u03b54 allele",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "strongest genetic risk factor for late-onset Alzheimer's disease. Therapeutic",
    "entities": []
  },
  {
    "text": "strategies to reduce apoE4 expression in APOE \u03b54 carriers hold promise to",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "mitigate neuroinflammatory and neurodegenerative processes driving disease",
    "entities": []
  },
  {
    "text": "METHODS: Focused ultrasound (FUS) was employed to transiently open the",
    "entities": []
  },
  {
    "text": "blood-brain barrier (BBB) for efficient knockdown of humanized APOE \u03b54 in the",
    "entities": [
      {
        "text": "BBB",
        "label": "ORG"
      },
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "mouse brain via gene editing. The all-in-one clustered regularly interspaced",
    "entities": [
      {
        "text": "mouse",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "short palindromic repeats (CRISPR)-based adeno-associated virus (AAV) vectors",
    "entities": [
      {
        "text": "AAV",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "were administered intravenously at a dose of 1.5\u00d71012 vg per mouse to determine",
    "entities": [
      {
        "text": "1.5\u00d71012",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "the gene-editing efficacy within the hippocampus.",
    "entities": []
  },
  {
    "text": "RESULTS: FUS-enhanced delivery of AAV resulted in a 12.6% knockdown of APOE \u03b54",
    "entities": [
      {
        "text": "AAV",
        "label": "PRODUCT"
      },
      {
        "text": "12.6%",
        "label": "PERCENT"
      },
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "gene expression in the targeted hippocampus, accompanied by an over 20% decrease",
    "entities": [
      {
        "text": "an over 20%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "in apoE4 protein levels and significant reductions in astrocyte and microglia",
    "entities": [
      {
        "text": "astrocyte",
        "label": "ORG"
      },
      {
        "text": "microglia\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "DISCUSSION: Our findings demonstrate a noninvasive, targeted approach for APOE",
    "entities": []
  },
  {
    "text": "\u03b54 knockdown, highlighting FUS-mediated brain-directed interventions as a",
    "entities": [
      {
        "text": "\u03b54 knockdown",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "promising therapeutic strategy for Alzheimer's disease.",
    "entities": []
  },
  {
    "text": "HIGHLIGHTS: Focused ultrasound (FUS) enables noninvasive, transient blood-brain",
    "entities": []
  },
  {
    "text": "barrier (BBB) opening for enhanced adeno-associated virus (AAV) delivery.",
    "entities": [
      {
        "text": "BBB",
        "label": "ORG"
      },
      {
        "text": "adeno",
        "label": "GPE"
      },
      {
        "text": "AAV",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "FUS-mediated gene editing achieves a 12.6% knockdown in APOE \u03b54 expression",
    "entities": [
      {
        "text": "12.6%",
        "label": "PERCENT"
      },
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "within the hippocampus of mouse brain. APOE \u03b54 knockdown significantly reduces",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "apoE4 protein levels and astrocyte and microglia levels. No detectable gross",
    "entities": [
      {
        "text": "astrocyte",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "toxicity was observed following the FUS-mediated gene editing.",
    "entities": [
      {
        "text": "FUS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PMID: 40665471 [Indexed for MEDLINE]",
    "entities": []
  },
  {
    "text": "34. Alzheimers Res Ther. 2025 Jul 15;17(1):160. doi: 10.1186/s13195-025-01804-9.",
    "entities": [
      {
        "text": "34",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.1186",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Combinatorial targeting of NMDARs and 5-HT(4)Rs exerts beneficial effects in a",
    "entities": [
      {
        "text": "5",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "mouse model of Alzheimer's disease.",
    "entities": [
      {
        "text": "mouse",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Doctoral Program in Neurobiology and Behavior (NB&B), Columbia University,",
    "entities": [
      {
        "text": "1)Doctoral",
        "label": "CARDINAL"
      },
      {
        "text": "NB&B",
        "label": "ORG"
      },
      {
        "text": "Columbia University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "New York, NY, 10027, USA.",
    "entities": [
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "ORG"
      },
      {
        "text": "10027",
        "label": "DATE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Psychiatry, Columbia University Irving Medical Center (CUIMC),",
    "entities": [
      {
        "text": "Psychiatry",
        "label": "ORG"
      },
      {
        "text": "Columbia University Irving Medical Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "NYSPI Kolb Research Annex, 1051 Riverside Drive, Unit 87, New York, NY, 10032,",
    "entities": [
      {
        "text": "Kolb Research",
        "label": "ORG"
      },
      {
        "text": "1051",
        "label": "DATE"
      },
      {
        "text": "Riverside Drive",
        "label": "WORK_OF_ART"
      },
      {
        "text": "Unit 87",
        "label": "DATE"
      },
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "ORG"
      },
      {
        "text": "10032",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(3)Division of Systems Neuroscience, Research Foundation for Mental Hygiene,",
    "entities": [
      {
        "text": "Research Foundation for Mental Hygiene",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Inc. (RFMH)/New York State Psychiatric Institute (NYSPI), New York, NY, 10032,",
    "entities": [
      {
        "text": "RFMH)/New York State Psychiatric Institute",
        "label": "ORG"
      },
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "ORG"
      },
      {
        "text": "10032",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(4)Present address: Center for Neurodegenerative Diseases and Therapeutics,",
    "entities": []
  },
  {
    "text": "Rosalind Franklin University of Medicine and Science / Foundational Sciences and",
    "entities": [
      {
        "text": "Franklin University of Medicine and Science / Foundational Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Humanities, The Chicago Medical School, North Chicago, IL, USA.",
    "entities": [
      {
        "text": "The Chicago Medical School",
        "label": "ORG"
      },
      {
        "text": "North Chicago",
        "label": "GPE"
      },
      {
        "text": "IL",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Present address: Weil Cornell Medical College, New York, NY, USA.",
    "entities": [
      {
        "text": "5)Present",
        "label": "CARDINAL"
      },
      {
        "text": "Cornell Medical College",
        "label": "ORG"
      },
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Present address: University of Cambridge, Cambridge, UK.",
    "entities": [
      {
        "text": "University of Cambridge",
        "label": "ORG"
      },
      {
        "text": "Cambridge",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Medical Scientist Training Program (MSTP), Columbia University Irving Medical",
    "entities": [
      {
        "text": "Scientist Training Program",
        "label": "ORG"
      },
      {
        "text": "Columbia University Irving Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Center (CUIMC), New York, NY, 10032, USA.",
    "entities": [
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "ORG"
      },
      {
        "text": "10032",
        "label": "DATE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Department of Psychiatry and Behavioral Sciences, University of Massachusetts",
    "entities": [
      {
        "text": "Psychiatry",
        "label": "ORG"
      },
      {
        "text": "Behavioral Sciences",
        "label": "ORG"
      },
      {
        "text": "University of Massachusetts",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Chan Medical School, Worcester, MA, 01605, USA.",
    "entities": [
      {
        "text": "Chan Medical School",
        "label": "ORG"
      },
      {
        "text": "Worcester",
        "label": "GPE"
      },
      {
        "text": "MA",
        "label": "GPE"
      },
      {
        "text": "01605",
        "label": "DATE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(10)Department of Psychiatry, Columbia University Irving Medical Center (CUIMC),",
    "entities": [
      {
        "text": "10)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Psychiatry",
        "label": "ORG"
      },
      {
        "text": "Columbia University Irving Medical Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(11)Division of Systems Neuroscience, Research Foundation for Mental Hygiene,",
    "entities": [
      {
        "text": "11)Division",
        "label": "CARDINAL"
      },
      {
        "text": "Research Foundation for Mental Hygiene",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BACKGROUND: Alzheimer's disease (AD) is the leading cause of dementia. There are",
    "entities": []
  },
  {
    "text": "limited approved medications that delay cognitive decline or lessen",
    "entities": []
  },
  {
    "text": "neuropsychiatric symptoms. Numerous clinical trials for AD using a single drug",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "administration have failed to meet therapeutic endpoints, which is most likely",
    "entities": []
  },
  {
    "text": "due to the complexity of AD. A multimodal therapeutic intervention is more",
    "entities": []
  },
  {
    "text": "likely to improve symptoms by targeting multiple targets implicated in AD. Here,",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "we investigated if targeting both N-Methyl-D-aspartic acid receptors (NMDARs)",
    "entities": [
      {
        "text": "N-Methyl-D-aspartic",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and serotonin type 4 receptors (5-HT4R) may have beneficial effects in a mouse",
    "entities": [
      {
        "text": "4",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "model of AD, as they have separately been shown to improve cognition and/or",
    "entities": []
  },
  {
    "text": "METHODS: Male and female control (Ctrl) or APP/PS1 mice were administered",
    "entities": [
      {
        "text": "APP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "single, intermittent, or chronic administration of 1) saline; 2) (R,S)-ketamine,",
    "entities": [
      {
        "text": "1",
        "label": "CARDINAL"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "an NMDAR antagonist; 3) prucalopride, a 5-HT4R agonist; or 4)",
    "entities": [
      {
        "text": "NMDAR",
        "label": "ORG"
      },
      {
        "text": "3",
        "label": "CARDINAL"
      },
      {
        "text": "5",
        "label": "CARDINAL"
      },
      {
        "text": "4",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "neuropsychiatric and cognitive deficits. Behavioral assays were then",
    "entities": []
  },
  {
    "text": "administered to measure cognition, perseverative behavior, hyponeophagia, and/or",
    "entities": [
      {
        "text": "hyponeophagia",
        "label": "GPE"
      },
      {
        "text": "and/or\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "sleep. Brains were processed for glial fibrillary acidic protein (GFAP)",
    "entities": [
      {
        "text": "GFAP",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "RESULTS: Single and chronic administration of (R,S)-ketamine + prucalopride",
    "entities": []
  },
  {
    "text": "administration improved cognitive decline by increasing memory retrieval in a",
    "entities": []
  },
  {
    "text": "contextual fear conditioning (CFC) paradigm in APP/PS1 mice. Drug efficacy was",
    "entities": [
      {
        "text": "APP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "less effective in females than in males and was age dependent. Hippocampal GFAP",
    "entities": []
  },
  {
    "text": "immunoreactivity was decreased by chronic (R,S)-ketamine + prucalopride",
    "entities": []
  },
  {
    "text": "treatment in females.",
    "entities": []
  },
  {
    "text": "CONCLUSIONS: Our results indicate that combined administration of",
    "entities": []
  },
  {
    "text": "(R,S)-ketamine + prucalopride is a novel multimodal therapeutic strategy to",
    "entities": []
  },
  {
    "text": "treat cognitive decline in AD. Future work will further characterize these",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "interactions with the goal of clinical development.",
    "entities": []
  },
  {
    "text": "\u00a9 2025. The Author(s).",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "DOI: 10.1186/s13195-025-01804-9",
    "entities": [
      {
        "text": "10.1186",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "PMID: 40665449 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40665449",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declarations. Ethics approval and consent to",
    "entities": []
  },
  {
    "text": "participate: All procedures were conducted in accordance with the National",
    "entities": [
      {
        "text": "the National\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Institutes of Health (NIH) regulations and by the Institutional Animal Care and",
    "entities": [
      {
        "text": "Institutes of Health",
        "label": "ORG"
      },
      {
        "text": "NIH",
        "label": "ORG"
      },
      {
        "text": "the Institutional Animal Care",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Use Committees (IACUCs) of Columbia University Irving Medical Center (CUIMC) and",
    "entities": [
      {
        "text": "Columbia University Irving Medical Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the Research Foundation for Mental Hygiene, Inc. (RFMH) at the New York State",
    "entities": [
      {
        "text": "the Research Foundation for Mental Hygiene, Inc.",
        "label": "ORG"
      },
      {
        "text": "New York State",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Psychiatric Institute (NYSPI). Competing interests: BKC, HCH, and CAD are named",
    "entities": [
      {
        "text": "Psychiatric Institute",
        "label": "ORG"
      },
      {
        "text": "BKC",
        "label": "ORG"
      },
      {
        "text": "HCH",
        "label": "ORG"
      },
      {
        "text": "CAD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "on provisional patent applications for the prophylactic use of (R,S)-ketamine,",
    "entities": []
  },
  {
    "text": "5-HT4R agonists, and other compounds against stress-related psychiatric",
    "entities": [
      {
        "text": "5",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "disorders and Alzheimer\u2019s disease. SJ is employed by Silo Pharma, and EW is",
    "entities": [
      {
        "text": "Silo Pharma",
        "label": "ORG"
      },
      {
        "text": "EW",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "founder and Chief Executive Officer of Silo Pharma. AW, LCM, AY, MJW, and RL",
    "entities": [
      {
        "text": "LCM",
        "label": "ORG"
      },
      {
        "text": "MJW",
        "label": "ORG"
      },
      {
        "text": "RL",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "have no conflicts of interest to disclose.",
    "entities": []
  },
  {
    "text": "35. Alzheimers Res Ther. 2025 Jul 15;17(1):159. doi: 10.1186/s13195-025-01808-5.",
    "entities": [
      {
        "text": "35",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "10.1186",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Cardiovascular risk factors are associated with lower posterior-medial network",
    "entities": []
  },
  {
    "text": "functional connectivity in older adults.",
    "entities": []
  },
  {
    "text": "Medit-Ageing Research Group.",
    "entities": [
      {
        "text": "Medit-Ageing Research Group",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Normandy University, UNICAEN, INSERM, U1237, PhIND \"Physiopathology and",
    "entities": [
      {
        "text": "1)Normandy University",
        "label": "ORG"
      },
      {
        "text": "UNICAEN",
        "label": "ORG"
      },
      {
        "text": "INSERM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Imaging of Neurological Disorders\", Neuropresage Team; GIP Cyceron, Bd Henri",
    "entities": [
      {
        "text": "Neuropresage Team",
        "label": "ORG"
      },
      {
        "text": "Cyceron",
        "label": "PRODUCT"
      },
      {
        "text": "Bd Henri",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(2)Clinical and Research Memory Centre of Lyon, Department of Geriatric",
    "entities": [
      {
        "text": "Research Memory Centre of Lyon",
        "label": "ORG"
      },
      {
        "text": "Department of Geriatric",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, Lyon Institute for Aging, Clinical Research Center",
    "entities": []
  },
  {
    "text": "Ageing-Brain-Frailty, Charpennes Hospital, University Claude Bernard Lyon 1,",
    "entities": [
      {
        "text": "Ageing-Brain-Frailty",
        "label": "ORG"
      },
      {
        "text": "Charpennes Hospital",
        "label": "ORG"
      },
      {
        "text": "Bernard Lyon 1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(4)PhIND Physiopathology and Imaging of Neurological Disorders, Normandy",
    "entities": [
      {
        "text": "4)PhIND",
        "label": "CARDINAL"
      },
      {
        "text": "Physiopathology and Imaging of Neurological Disorders",
        "label": "ORG"
      },
      {
        "text": "Normandy\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "University, UNICAEN, INSERM, U1237, Institut Blood and Brain @ Caen-Normandie",
    "entities": [
      {
        "text": "UNICAEN",
        "label": "ORG"
      },
      {
        "text": "INSERM",
        "label": "ORG"
      },
      {
        "text": "Institut Blood",
        "label": "ORG"
      },
      {
        "text": "Brain @ Caen-Normandie",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(6)Normandy University, UNICAEN, INSERM, U1237, PhIND \"Physiopathology and",
    "entities": [
      {
        "text": "6)Normandy University",
        "label": "ORG"
      },
      {
        "text": "UNICAEN",
        "label": "ORG"
      },
      {
        "text": "INSERM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BACKGROUND: Cortico-hippocampal functional networks, specifically the",
    "entities": []
  },
  {
    "text": "anterior-temporal (AT) and posterior-medial (PM) systems, are crucial for memory",
    "entities": []
  },
  {
    "text": "and highly vulnerable to aging and Alzheimer's disease (AD). While modifiable",
    "entities": []
  },
  {
    "text": "cardiovascular risk factors may offer prevention opportunities to preserve brain",
    "entities": []
  },
  {
    "text": "aging, their effects on AT/PM functional connectivity remain unknown. This study",
    "entities": [
      {
        "text": "AT/PM",
        "label": "EVENT"
      }
    ]
  },
  {
    "text": "aims to investigate these associations in older adults, considering major risk",
    "entities": []
  },
  {
    "text": "categories and exploring potential interactions with protective lifestyle habits",
    "entities": []
  },
  {
    "text": "and AD risk factors.",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "METHODS: One hundred thirty-one community-dwelling cognitively unimpaired adults",
    "entities": [
      {
        "text": "One hundred thirty-one",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "aged 65 + were selected from the Age-Well trial, a French monocentric",
    "entities": [
      {
        "text": "65 +",
        "label": "DATE"
      },
      {
        "text": "French",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "population-based study conducted from 2016 to 2020. Resting-state fMRI and",
    "entities": [
      {
        "text": "2016",
        "label": "DATE"
      },
      {
        "text": "2020",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "cardiovascular risk assessments were performed at baseline and 18-month",
    "entities": [
      {
        "text": "18-month",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "follow-up. Functional connectivity within the AT and PM networks was derived",
    "entities": [
      {
        "text": "AT",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "from seed-based analyses using the perirhinal and parahippocampal cortices as",
    "entities": []
  },
  {
    "text": "individual seeds, respectively. Generalized additive and linear mixed models",
    "entities": [
      {
        "text": "linear",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "assessed the effects of cardiovascular risk factors on AT/PM functional",
    "entities": [
      {
        "text": "AT/PM",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "connectivity, including interactions with protective lifestyle habits and AD",
    "entities": []
  },
  {
    "text": "RESULTS: Baseline mean age was 69 (65-84) years, with 63.5% women. Higher",
    "entities": [
      {
        "text": "69",
        "label": "DATE"
      },
      {
        "text": "65-84",
        "label": "DATE"
      },
      {
        "text": "63.5%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "abdominal fat (95% CI: -0.00118, -0.00005; F = 5.39; P =.02), higher LDL",
    "entities": [
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "PERSON"
      },
      {
        "text": "F =",
        "label": "PRODUCT"
      },
      {
        "text": "5.39",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "cholesterol (95% CI: -0.01642, -0.00345; F = 10.40; P =.001), longer smoking",
    "entities": [
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "PERSON"
      },
      {
        "text": "F =",
        "label": "PRODUCT"
      },
      {
        "text": "10.40",
        "label": "CARDINAL"
      },
      {
        "text": "P =",
        "label": "ORG"
      },
      {
        "text": ".001",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "duration (95% CI: NA; F = 3.89; P =.03) and greater alcohol consumption (95% CI:",
    "entities": [
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "NA",
        "label": "ORG"
      },
      {
        "text": "F =",
        "label": "PRODUCT"
      },
      {
        "text": "3.89",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "-0.01134, -0.00045; F = 4.66; P =.02) were consistently associated with lower PM",
    "entities": [
      {
        "text": "F =",
        "label": "PRODUCT"
      },
      {
        "text": "4.66",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "connectivity, collectively explaining 11.4% of the variance. However, only LDL",
    "entities": [
      {
        "text": "11.4%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "cholesterol survived multiple comparisons, possibly reflecting a more direct",
    "entities": []
  },
  {
    "text": "involvement in cardiovascular mechanisms affecting functional connectivity. No",
    "entities": []
  },
  {
    "text": "association was found with AT connectivity. Exploratory analyses showed that",
    "entities": [
      {
        "text": "Exploratory",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "these relationships were independent of cerebral A\u03b2-positivity or APOE-\u03b54",
    "entities": [
      {
        "text": "A\u03b2-positivity",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "carrier status and were unaffected by physical activity and Mediterranean diet",
    "entities": [
      {
        "text": "Mediterranean",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "when considered separately.",
    "entities": []
  },
  {
    "text": "DISCUSSION: This study highlights converging associations between higher",
    "entities": []
  },
  {
    "text": "cardiovascular risk factors and lower functional connectivity in cognitively",
    "entities": []
  },
  {
    "text": "unimpaired older adults, specifically affecting the PM-but not AT-network, and",
    "entities": []
  },
  {
    "text": "independent of AD risk. Targeting these specific modifiable factors may prevent",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "age-related network alterations to promote cognitive health in aging.",
    "entities": []
  },
  {
    "text": "TRIAL REGISTRATION INFORMATION: The Age-Well trial was registered with",
    "entities": []
  },
  {
    "text": "ClinicalTrials.gov on November 25, 2016 (identifier: NCT02977819).",
    "entities": [
      {
        "text": "November 25, 2016",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "DOI: 10.1186/s13195-025-01808-5",
    "entities": [
      {
        "text": "10.1186",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "PMID: 40665410 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40665410",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "participate: All participants provided written informed consent prior to",
    "entities": []
  },
  {
    "text": "participation. The Age-Well trial was approved by the Nord Ouest III ethics",
    "entities": [
      {
        "text": "the Nord Ouest III",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "committee (Caen, France) and sponsored by the Institut National de la Sant\u00e9 et",
    "entities": [
      {
        "text": "Caen",
        "label": "ORG"
      },
      {
        "text": "France",
        "label": "GPE"
      },
      {
        "text": "the Institut National de la Sant\u00e9",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "registration number: EudraCT: 2016\u2013002441-36; IDRCB: 2016-A01767-44;",
    "entities": [
      {
        "text": "2016\u2013002441-36",
        "label": "CARDINAL"
      },
      {
        "text": "IDRCB",
        "label": "ORG"
      },
      {
        "text": "2016-A01767-44",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "registration date: 2016\u201311\u201325). Competing interests: The authors declare no",
    "entities": [
      {
        "text": "2016\u201311\u201325",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "competing interests.",
    "entities": []
  },
  {
    "text": "36. Alzheimers Res Ther. 2025 Jul 15;17(1):162. doi: 10.1186/s13195-025-01814-7.",
    "entities": [
      {
        "text": "36",
        "label": "CARDINAL"
      },
      {
        "text": "Alzheimers Res Ther",
        "label": "PERSON"
      },
      {
        "text": "10.1186",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Dual risk of anticholinergic burden and CSF alzheimer's biomarkers in older",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "patients: a mortality follow-up study from daily medical practice.",
    "entities": [
      {
        "text": "daily",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Mouton-Liger F(6), Hugon J(6)(4), Bouaziz-Amar E(6)(8), Lilamand M(9)(6), Paquet",
    "entities": [
      {
        "text": "Mouton-Liger F(6",
        "label": "ORG"
      },
      {
        "text": "Hugon J(6)(4",
        "label": "GPE"
      },
      {
        "text": "Bouaziz-Amar E(6)(8",
        "label": "PERSON"
      },
      {
        "text": "Lilamand",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(1)Geriatrics Department, Fernand Widal Lariboisi\u00e8re University Hospital, GHU",
    "entities": [
      {
        "text": "1)Geriatrics Department",
        "label": "ORG"
      },
      {
        "text": "Fernand Widal Lariboisi\u00e8re University Hospital",
        "label": "ORG"
      },
      {
        "text": "GHU",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Paris-Cit\u00e9 University, Inserm U1144, Paris, France. theodore.decaix@aphp.fr.",
    "entities": [
      {
        "text": "2)Paris-Cit\u00e9 University",
        "label": "ORG"
      },
      {
        "text": "U1144",
        "label": "GPE"
      },
      {
        "text": "Paris",
        "label": "GPE"
      },
      {
        "text": "France",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Cognitive Neurology Center, Fernand Widal Lariboisi\u00e8re University Hospital,",
    "entities": [
      {
        "text": "Fernand Widal Lariboisi\u00e8re University Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "GHU APHP.Nord, Paris, France.",
    "entities": [
      {
        "text": "GHU APHP.Nord",
        "label": "PERSON"
      },
      {
        "text": "Paris",
        "label": "GPE"
      },
      {
        "text": "France",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Paris-Cit\u00e9 University, Inserm U1153, Paris, France.",
    "entities": [
      {
        "text": "5)Paris-Cit\u00e9 University",
        "label": "ORG"
      },
      {
        "text": "Paris",
        "label": "GPE"
      },
      {
        "text": "France",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Paris-Cit\u00e9 University, Inserm U1144, Paris, France.",
    "entities": [
      {
        "text": "6)Paris-Cit\u00e9 University",
        "label": "ORG"
      },
      {
        "text": "U1144",
        "label": "GPE"
      },
      {
        "text": "Paris",
        "label": "GPE"
      },
      {
        "text": "France",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Geriatrics Department, Bichat University Hospital, GHU AP-HP.Nord, Paris,",
    "entities": [
      {
        "text": "7)Geriatrics Department",
        "label": "ORG"
      },
      {
        "text": "Bichat University Hospital",
        "label": "ORG"
      },
      {
        "text": "GHU AP-HP.Nord",
        "label": "ORG"
      },
      {
        "text": "Paris",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Biochemistry Department, Fernand Widal Lariboisi\u00e8re University Hospital, GHU",
    "entities": [
      {
        "text": "8)Biochemistry Department",
        "label": "ORG"
      },
      {
        "text": "Fernand Widal Lariboisi\u00e8re University Hospital",
        "label": "ORG"
      },
      {
        "text": "GHU",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(9)Geriatrics Department, Fernand Widal Lariboisi\u00e8re University Hospital, GHU",
    "entities": [
      {
        "text": "9)Geriatrics Department",
        "label": "ORG"
      },
      {
        "text": "Fernand Widal Lariboisi\u00e8re University Hospital",
        "label": "ORG"
      },
      {
        "text": "GHU",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BACKGROUND: Anticholinergic medications are widely prescribed to older adults",
    "entities": [
      {
        "text": "Anticholinergic",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "and are linked to increased mortality and cognitive decline. Cerebrospinal fluid",
    "entities": []
  },
  {
    "text": "(CSF) biomarkers of Alzheimer's disease (AD)-amyloid and tau-are strong",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "prognostic indicators in neurocognitive disorders (NCD). However, it remains",
    "entities": []
  },
  {
    "text": "unclear whether anticholinergic burden amplifies mortality risk depending on CSF",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "biomarker profiles in cognitively impaired individuals.",
    "entities": []
  },
  {
    "text": "METHODS: We conducted a retrospective monocentric study of 927 patients",
    "entities": [
      {
        "text": "927",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "aged \u2265 65 years with mild or major NCD from a tertiary memory clinic in Paris,",
    "entities": [
      {
        "text": "\u2265",
        "label": "PERSON"
      },
      {
        "text": "65 years",
        "label": "DATE"
      },
      {
        "text": "NCD",
        "label": "ORG"
      },
      {
        "text": "tertiary",
        "label": "ORDINAL"
      },
      {
        "text": "Paris",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "France. Participants underwent CSF biomarker assessment for amyloid (A),",
    "entities": [
      {
        "text": "France",
        "label": "GPE"
      },
      {
        "text": "CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "phosphorylated tau (T), and total tau (N), and were classified into ATN",
    "entities": [
      {
        "text": "ATN",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "profiles. Anticholinergic burden was evaluated at baseline using the",
    "entities": []
  },
  {
    "text": "Anticholinergic Cognitive Burden (ACB) scale: none (ACB = 0), low-moderate",
    "entities": [
      {
        "text": "0",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(ACB = 1-2), or high (ACB \u2265 3). The primary outcome was all-cause mortality.",
    "entities": [
      {
        "text": "1-2",
        "label": "CARDINAL"
      },
      {
        "text": "\u2265",
        "label": "PERSON"
      },
      {
        "text": "3",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Proportional hazards regression assessed associations between ACB, ATN profiles,",
    "entities": [
      {
        "text": "ACB",
        "label": "ORG"
      },
      {
        "text": "ATN",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and mortality, adjusting for demographic, clinical, and genetic covariates.",
    "entities": []
  },
  {
    "text": "RESULTS: High ACB was associated with increased mortality in model 1 (HR = 1.30,",
    "entities": [
      {
        "text": "ACB",
        "label": "ORG"
      },
      {
        "text": "1",
        "label": "CARDINAL"
      },
      {
        "text": "1.30",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "95% CI: 1.03-1.64, p = 0.02), but not after full adjustment (HR = 1.26, 95% CI:",
    "entities": [
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "1.03-1.64",
        "label": "CARDINAL"
      },
      {
        "text": "0.02",
        "label": "CARDINAL"
      },
      {
        "text": "1.26",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "0.96-1.66, p = 0.09). ATN profiles remained strong independent predictors of",
    "entities": [
      {
        "text": "0.96-1.66",
        "label": "DATE"
      },
      {
        "text": "0.09",
        "label": "CARDINAL"
      },
      {
        "text": "ATN",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "mortality, with highest risks for A-T-N + and A + T + Nx profiles. Combined high",
    "entities": []
  },
  {
    "text": "ACB and abnormal biomarkers conferred greater risk than either alone (e.g.,",
    "entities": [
      {
        "text": "ACB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "HR = 2.24 for A + T + Nx and high ACB).",
    "entities": [
      {
        "text": "2.24",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "CONCLUSION: Anticholinergic burden may increase vulnerability to mortality in",
    "entities": []
  },
  {
    "text": "older adults with an AD biomarker profile. These results support integrating",
    "entities": [
      {
        "text": "AD",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "DOI: 10.1186/s13195-025-01814-7",
    "entities": [
      {
        "text": "10.1186",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "PMID: 40665403 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40665403",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "participate: All participants received both oral and written information",
    "entities": []
  },
  {
    "text": "regarding the opportunity to provide additional blood and CSF samples for",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "further research, as outlined in the BioCogBank\u00a9 protocol. Additionally, all",
    "entities": []
  },
  {
    "text": "participants consented to the anonymous use of their clinical data and the",
    "entities": []
  },
  {
    "text": "results of their CSF analyses. The study was approved by the local Ethics",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      },
      {
        "text": "Ethics",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Institutional Review Board 00006477, ref 16 \u2212 004) and the Commission Nationale",
    "entities": [
      {
        "text": "Institutional Review Board 00006477",
        "label": "ORG"
      },
      {
        "text": "16",
        "label": "CARDINAL"
      },
      {
        "text": "004",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Informatique et Libert\u00e9s. This study was conducted in accordance with the",
    "entities": []
  },
  {
    "text": "principles of the Declaration of Helsinki. Consent for publication: not",
    "entities": [
      {
        "text": "the Declaration of Helsinki",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "applicable. Competing interests: The authors declare no competing interests.",
    "entities": []
  },
  {
    "text": "Ethanol consumption aggravates amyloid pathology and neuroinflammation in",
    "entities": []
  },
  {
    "text": "Alzheimer's disease associated with inflammasome activation and ASC speck",
    "entities": [
      {
        "text": "ASC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Medicine, Beth Israel Deaconess Medical Center and Harvard",
    "entities": [
      {
        "text": "Beth Israel Deaconess Medical Center",
        "label": "ORG"
      },
      {
        "text": "Harvard",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medical School, Boston, MA, USA.",
    "entities": [
      {
        "text": "Medical School",
        "label": "ORG"
      },
      {
        "text": "Boston",
        "label": "GPE"
      },
      {
        "text": "MA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Medicine, University of Massachusetts Chan Medical School,",
    "entities": [
      {
        "text": "Medicine, University of Massachusetts Chan Medical School",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Worcester, MA, USA.",
    "entities": [
      {
        "text": "MA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Medicine, Beth Israel Deaconess Medical Center and Harvard",
    "entities": [
      {
        "text": "Beth Israel Deaconess Medical Center",
        "label": "ORG"
      },
      {
        "text": "Harvard",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medical School, Boston, MA, USA. gszabo1@bidmc.harvard.edu.",
    "entities": [
      {
        "text": "Medical School",
        "label": "ORG"
      },
      {
        "text": "Boston",
        "label": "GPE"
      },
      {
        "text": "MA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      },
      {
        "text": "gszabo1@bidmc.harvard.edu",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Broad Institute of MIT and Harvard, Cambridge, MA, USA.",
    "entities": [
      {
        "text": "Institute of MIT",
        "label": "ORG"
      },
      {
        "text": "Harvard",
        "label": "ORG"
      },
      {
        "text": "Cambridge",
        "label": "GPE"
      },
      {
        "text": "MA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Alcohol use disorder (AUD) has been associated with Alzheimer's",
    "entities": [
      {
        "text": "AUD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "disease (AD) and dementia, yet the underlying mechanisms and specific role of",
    "entities": []
  },
  {
    "text": "ethanol in AD progression remain poorly understood. Neuroinflammation has",
    "entities": [
      {
        "text": "AD",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "emerged as a key contributor to both AD pathogenesis and ethanol-induced brain",
    "entities": []
  },
  {
    "text": "damage. Activation of innate immune cells and signaling pathways, in particular",
    "entities": []
  },
  {
    "text": "NLRP3 inflammasome, plays a pivotal role in both AD and ethanol-induced",
    "entities": [
      {
        "text": "NLRP3",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "inflammation. Thus, we postulated that excessive ethanol consumption could",
    "entities": []
  },
  {
    "text": "METHODS: The 12-15-month-old WT and APP/PS1 mice received water or ethanol (3.5",
    "entities": [
      {
        "text": "12",
        "label": "CARDINAL"
      },
      {
        "text": "15-month-old",
        "label": "DATE"
      },
      {
        "text": "WT",
        "label": "ORG"
      },
      {
        "text": "APP",
        "label": "ORG"
      },
      {
        "text": "3.5",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "g/kg) binge every alternate day for a period of one month. The effects of",
    "entities": [
      {
        "text": "g/kg",
        "label": "ORG"
      },
      {
        "text": "one month",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "ethanol on amyloid pathology, microglia and astrocyte activation, and NLRP3",
    "entities": [
      {
        "text": "microglia",
        "label": "PERSON"
      },
      {
        "text": "astrocyte",
        "label": "ORG"
      },
      {
        "text": "NLRP3",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "inflammasome activation were evaluated in the mouse brains. The effect of",
    "entities": []
  },
  {
    "text": "ethanol and amyloid \u03b2 on NLRP3 inflammasome signaling was further studied in",
    "entities": [
      {
        "text": "NLRP3",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "RESULTS: In this study, we show that repeated ethanol binges aggravate the",
    "entities": []
  },
  {
    "text": "amyloid pathology and plaque burden in the hippocampus of APP/PS1 mice.",
    "entities": [
      {
        "text": "APP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Furthermore, we demonstrate the additive effect of ethanol administration on",
    "entities": []
  },
  {
    "text": "NLRP3 inflammasome activation, IL-1\u03b2 release, and ASC aggregation in the brains",
    "entities": [
      {
        "text": "NLRP3",
        "label": "PRODUCT"
      },
      {
        "text": "IL-1\u03b2",
        "label": "ORG"
      },
      {
        "text": "ASC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of APP/PS1 mice and primary glia cultures. Our study also reveals a strong",
    "entities": [
      {
        "text": "APP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "astrocyte activation by ethanol in the hippocampus of APP/PS1 mice as",
    "entities": [
      {
        "text": "astrocyte",
        "label": "ORG"
      },
      {
        "text": "APP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "demonstrated by significantly increased GFAP and ALDH1L1 protein levels. Further",
    "entities": [
      {
        "text": "GFAP",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "in vitro analysis revealed that ethanol potentiates the effect of amyloid \u03b2 to",
    "entities": []
  },
  {
    "text": "increase the NLRP3 inflammasome activation in both primary astrocytes and",
    "entities": [
      {
        "text": "NLRP3",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "microglia. Lastly, we demonstrate that glia-produced ASC specks induce IL-1\u03b2 in",
    "entities": [
      {
        "text": "IL-1\u03b2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "microglia and astrocytes and induce ROS in SH-SY5Y neurons, contributing to",
    "entities": [
      {
        "text": "ROS",
        "label": "ORG"
      },
      {
        "text": "SH-SY5Y",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "sustained neuroinflammation in AD.",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "CONCLUSION: Collectively, our results demonstrate that ethanol consumption",
    "entities": []
  },
  {
    "text": "exacerbates features of AD pathology associated with amplified neuroinflammation",
    "entities": [
      {
        "text": "AD",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "and NLRP3/ASC inflammasome activation, which may play an important role in the",
    "entities": [
      {
        "text": "NLRP3/ASC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "disease progression and severity.",
    "entities": []
  },
  {
    "text": "DOI: 10.1186/s12974-025-03501-8",
    "entities": [
      {
        "text": "10.1186",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "PMID: 40665351 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40665351",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "participate: All the mice breeding, experimental protocols, and euthanasia were",
    "entities": []
  },
  {
    "text": "conducted as per the institutional ethics and Institutional Animal Care and Use",
    "entities": [
      {
        "text": "Institutional Animal Care",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Committee (IACUC) approved protocols No. 019\u20132019, 030\u20132022, and 051\u20132024.",
    "entities": [
      {
        "text": "030\u20132022",
        "label": "ORG"
      },
      {
        "text": "051\u20132024",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Competing interests: G.S. is scientific consultant for Cyta Therapeutics,",
    "entities": [
      {
        "text": "G.S.",
        "label": "GPE"
      },
      {
        "text": "Cyta Therapeutics",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Novo Nordisk, Resolution therapeutics and also holds equity in Glympse Bio,",
    "entities": [
      {
        "text": "Novo Nordisk",
        "label": "PERSON"
      },
      {
        "text": "Glympse Bio",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Zomagen and Satellite Bio. She received royalties from UptoDate and Springer.",
    "entities": [
      {
        "text": "Zomagen",
        "label": "ORG"
      },
      {
        "text": "UptoDate",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "The remaining authors have no competing interests to report.",
    "entities": []
  },
  {
    "text": "38. Mol Neurobiol. 2025 Jul 15. doi: 10.1007/s12035-025-05162-3. Online ahead of",
    "entities": [
      {
        "text": "38",
        "label": "CARDINAL"
      },
      {
        "text": "Mol Neurobiol",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.1007",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Multiple Mechanisms and Therapeutic Strategies for the Involvement of AMPK in",
    "entities": [
      {
        "text": "Multiple Mechanisms and Therapeutic Strategies for the Involvement of AMPK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the Development of Alzheimer's Disease.",
    "entities": [
      {
        "text": "the Development of Alzheimer's Disease",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Key Laboratory of Basic Pharmacology of Ministry of Education and Joint",
    "entities": [
      {
        "text": "Basic Pharmacology of Ministry of Education",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "International Research Laboratory of Ethnomedicine of Ministry of Education,",
    "entities": [
      {
        "text": "International Research Laboratory of Ethnomedicine of Ministry of Education",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Zunyi Medical University, Zunyi, Guizhou Province, China.",
    "entities": [
      {
        "text": "Zunyi Medical University",
        "label": "ORG"
      },
      {
        "text": "Zunyi",
        "label": "GPE"
      },
      {
        "text": "Guizhou Province",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Key Laboratory of Basic Pharmacology of Ministry of Education and Joint",
    "entities": [
      {
        "text": "2)Key Laboratory of Basic Pharmacology of Ministry of Education",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Zunyi Medical University, Zunyi, Guizhou Province, China. szhou@zmu.edu.cn.",
    "entities": [
      {
        "text": "Zunyi Medical University",
        "label": "ORG"
      },
      {
        "text": "Zunyi",
        "label": "GPE"
      },
      {
        "text": "Guizhou Province",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Key Laboratory of Basic Pharmacology of Ministry of Education and Joint",
    "entities": [
      {
        "text": "3)Key Laboratory of Basic Pharmacology of Ministry of Education",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Alzheimer's disease (AD) is a major cause of dementia, a life-threatening",
    "entities": []
  },
  {
    "text": "condition for which there is currently no cure. Currently, the treatment of AD",
    "entities": []
  },
  {
    "text": "focuses on reducing the accumulation of amyloid \u03b2-protein (A\u03b2) and the",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "phosphorylation of Tau proteins (Tau). However, simply reducing pathological",
    "entities": []
  },
  {
    "text": "features does not completely improve AD. Therefore, there is an urgent need to",
    "entities": []
  },
  {
    "text": "explore a target that regulates AD-related pathologies and highlights its",
    "entities": []
  },
  {
    "text": "potential as a novel therapeutic target. Recent studies suggest that oxidative",
    "entities": []
  },
  {
    "text": "stress, neuroinflammation, autophagy dysfunction, and energy metabolism",
    "entities": []
  },
  {
    "text": "alterations are associated with the development of AD. Reviewing previous data,",
    "entities": []
  },
  {
    "text": "we found that AMP-activated protein kinase (AMPK) not only acts as a cellular",
    "entities": []
  },
  {
    "text": "energy sensor to influence the progression of AD, but also activation of AMPK",
    "entities": [
      {
        "text": "AMPK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "affects the pathologic processes above. In this review, we provide an update on",
    "entities": []
  },
  {
    "text": "activating the AMPK pathway with targeting in AD therapy. Finally, research has",
    "entities": [
      {
        "text": "AMPK",
        "label": "ORG"
      },
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "shown that compounds can activate the AMPK pathway to affect a series of",
    "entities": [
      {
        "text": "AMPK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cellular processes and improve AD. We propose that AMPK activation represents a",
    "entities": [
      {
        "text": "AMPK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "paradigm-shifting strategy for AD therapy by simultaneously targeting multiple",
    "entities": []
  },
  {
    "text": "pathological cascades, although challenges in isoform-specific activation and",
    "entities": []
  },
  {
    "text": "brain delivery warrant further investigation.",
    "entities": []
  },
  {
    "text": "\u00a9 2025. The Author(s), under exclusive licence to Springer Science+Business",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Springer Science+Business\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Media, LLC, part of Springer Nature.",
    "entities": [
      {
        "text": "LLC",
        "label": "ORG"
      },
      {
        "text": "Springer Nature",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "DOI: 10.1007/s12035-025-05162-3",
    "entities": [
      {
        "text": "10.1007",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declarations. Competing interests: The authors",
    "entities": []
  },
  {
    "text": "39. Nat Med. 2025 Jul 15. doi: 10.1038/s41591-025-03833-1. Online ahead of print.",
    "entities": [
      {
        "text": "39",
        "label": "CARDINAL"
      },
      {
        "text": "Nat Med",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Shared and disease-specific pathways in frontotemporal dementia and Alzheimer's",
    "entities": []
  },
  {
    "text": "and Parkinson's diseases.",
    "entities": []
  },
  {
    "text": "Neurodegeneration Proteomics Consortium (GNPC); Hansson O(4)(9), Winchester",
    "entities": [
      {
        "text": "Neurodegeneration Proteomics Consortium",
        "label": "ORG"
      },
      {
        "text": "GNPC",
        "label": "ORG"
      },
      {
        "text": "Hansson",
        "label": "ORG"
      },
      {
        "text": "Winchester",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Department of Psychiatry, Washington University School of Medicine, St.",
    "entities": [
      {
        "text": "Psychiatry",
        "label": "ORG"
      },
      {
        "text": "Washington University School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)NeuroGenomics and Informatics Center, Washington University School of",
    "entities": [
      {
        "text": "2)NeuroGenomics",
        "label": "CARDINAL"
      },
      {
        "text": "Informatics Center",
        "label": "ORG"
      },
      {
        "text": "Washington University School of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, St. Louis, MO, USA.",
    "entities": [
      {
        "text": "St. Louis",
        "label": "GPE"
      },
      {
        "text": "MO",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Psychiatry, University of Oxford, Oxford, UK.",
    "entities": [
      {
        "text": "Psychiatry, University of Oxford",
        "label": "ORG"
      },
      {
        "text": "Oxford",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Clinical Memory Research Unit, Department of Clinical Sciences Malm\u00f6, Lund",
    "entities": [
      {
        "text": "Memory Research Unit",
        "label": "ORG"
      },
      {
        "text": "Department of Clinical Sciences Malm\u00f6",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University, Lund, Sweden.",
    "entities": [
      {
        "text": "Lund",
        "label": "GPE"
      },
      {
        "text": "Sweden",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Department of Clinical Sciences Malm\u00f6, SciLifeLab, Lund University, Lund,",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Clinical Sciences Malm\u00f6",
        "label": "ORG"
      },
      {
        "text": "Lund University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Amsterdam UMC location VUmc, Amsterdam, The Netherlands.",
    "entities": [
      {
        "text": "Amsterdam",
        "label": "GPE"
      },
      {
        "text": "VUmc",
        "label": "PERSON"
      },
      {
        "text": "Amsterdam",
        "label": "GPE"
      },
      {
        "text": "The Netherlands",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Gates Ventures, Seattle, WA, USA.",
    "entities": [
      {
        "text": "Ventures",
        "label": "ORG"
      },
      {
        "text": "Seattle",
        "label": "GPE"
      },
      {
        "text": "WA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(10)Department of Psychiatry, Washington University School of Medicine, St.",
    "entities": [
      {
        "text": "10)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Psychiatry",
        "label": "ORG"
      },
      {
        "text": "Washington University School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(11)NeuroGenomics and Informatics Center, Washington University School of",
    "entities": [
      {
        "text": "Informatics Center",
        "label": "ORG"
      },
      {
        "text": "Washington University School of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, St. Louis, MO, USA. cruchagac@wustl.edu.",
    "entities": [
      {
        "text": "St. Louis",
        "label": "GPE"
      },
      {
        "text": "MO",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(12)Department of Neurology, Washington University School of Medicine, St.",
    "entities": [
      {
        "text": "Neurology",
        "label": "ORG"
      },
      {
        "text": "Washington University School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(13)Hope Center for Neurological Disorders, Washington University, St. Louis,",
    "entities": [
      {
        "text": "Center for Neurological Disorders",
        "label": "ORG"
      },
      {
        "text": "Washington University",
        "label": "ORG"
      },
      {
        "text": "St. Louis",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(14)Department of Genetics, Washington University School of Medicine, St. Louis,",
    "entities": [
      {
        "text": "14)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Genetics",
        "label": "ORG"
      },
      {
        "text": "Washington University School of Medicine",
        "label": "ORG"
      },
      {
        "text": "St. Louis",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Neurodegenerative diseases (NDs), such as Alzheimer's disease (AD), Parkinson's",
    "entities": []
  },
  {
    "text": "disease (PD) and frontotemporal dementia (FTD), exhibit distinct yet overlapping",
    "entities": []
  },
  {
    "text": "pathological mechanisms. Leveraging large-scale plasma proteomics data from the",
    "entities": []
  },
  {
    "text": "Global Neurodegeneration Proteomics Consortium, we analyzed 10,527 plasma",
    "entities": [
      {
        "text": "Global Neurodegeneration Proteomics Consortium",
        "label": "ORG"
      },
      {
        "text": "10,527",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "samples (1,936 AD, 525 PD, 163 FTD, 1,638 dementia and 6,265 controls) to",
    "entities": [
      {
        "text": "1,936 AD",
        "label": "DATE"
      },
      {
        "text": "525",
        "label": "CARDINAL"
      },
      {
        "text": "163",
        "label": "CARDINAL"
      },
      {
        "text": "1,638",
        "label": "CARDINAL"
      },
      {
        "text": "6,265",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "identify disease-specific and shared proteins across NDs. We identified 5,187",
    "entities": [
      {
        "text": "5,187",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "proteins significantly associated with AD, 3,748 with PD and 2,380 with FTD that",
    "entities": [
      {
        "text": "3,748",
        "label": "CARDINAL"
      },
      {
        "text": "PD",
        "label": "LOC"
      },
      {
        "text": "2,380",
        "label": "CARDINAL"
      },
      {
        "text": "FTD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "revealed both common and divergent proteomic signatures, which were confirmed by",
    "entities": []
  },
  {
    "text": "multiple analytical approaches and orthogonal validation. PD and FTD showed the",
    "entities": [
      {
        "text": "FTD",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "highest overlap (r2 = 0.44) and AD and PD the least (r2 = 0.04). Immune system,",
    "entities": [
      {
        "text": "0.44",
        "label": "CARDINAL"
      },
      {
        "text": "0.04",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "glycolysis, and matrisome-related pathways were enriched across all NDs, while",
    "entities": []
  },
  {
    "text": "disease-specific pathways included apoptotic processes in AD, endoplasmic",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "reticulum-phagosome impairment in PD and platelet dysregulation in FTD. Network",
    "entities": [
      {
        "text": "PD",
        "label": "GPE"
      },
      {
        "text": "FTD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "analysis identified key upstream regulators (RPS27A in AD, IRAK4 in PD and MAPK1",
    "entities": [
      {
        "text": "IRAK4",
        "label": "GPE"
      },
      {
        "text": "PD",
        "label": "GPE"
      },
      {
        "text": "MAPK1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "in FTD) potentially driving these proteomic changes. These findings reveal",
    "entities": [
      {
        "text": "FTD",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "distinct and shared mechanisms across NDs, highlighting potential regulatory",
    "entities": []
  },
  {
    "text": "proteins and pathways for diagnostic and therapeutic strategies in",
    "entities": []
  },
  {
    "text": "\u00a9 2025. The Author(s), under exclusive licence to Springer Nature America, Inc.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Springer Nature America, Inc.",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Competing interests: C.C. has received research",
    "entities": [
      {
        "text": "C.C.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "support from GlaxoSmithKline and EISAI. C.C. is a member of the scientific",
    "entities": [
      {
        "text": "GlaxoSmithKline",
        "label": "ORG"
      },
      {
        "text": "EISAI",
        "label": "ORG"
      },
      {
        "text": "C.C.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "advisory board of Circular Genomics and owns stocks. C.C. is a member of the",
    "entities": [
      {
        "text": "advisory board of Circular Genomics",
        "label": "ORG"
      },
      {
        "text": "C.C.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "scientific advisory board of ADmit. There is an invention disclosure for the",
    "entities": []
  },
  {
    "text": "prediction models, including protein IDs, alternative proteins and weights,",
    "entities": []
  },
  {
    "text": "cutoff and algorithms. O.H. is an employee of Eli Lilly and Lund University.",
    "entities": [
      {
        "text": "O.H.",
        "label": "GPE"
      },
      {
        "text": "Eli Lilly",
        "label": "ORG"
      },
      {
        "text": "Lund University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "M.A., B.E., Y.C., Y.X., K.G., M.L., A.P.B., J.T., D.W., C.Y., G.H., J.W.V.,",
    "entities": [
      {
        "text": "M.A.",
        "label": "GPE"
      },
      {
        "text": "B.E.",
        "label": "GPE"
      },
      {
        "text": "Y.C.",
        "label": "GPE"
      },
      {
        "text": "Y.X.",
        "label": "GPE"
      },
      {
        "text": "K.G.",
        "label": "GPE"
      },
      {
        "text": "M.L.",
        "label": "GPE"
      },
      {
        "text": "A.P.B.",
        "label": "ORG"
      },
      {
        "text": "J.T.",
        "label": "GPE"
      },
      {
        "text": "D.W.",
        "label": "GPE"
      },
      {
        "text": "C.Y.",
        "label": "GPE"
      },
      {
        "text": "G.H.",
        "label": "GPE"
      },
      {
        "text": "J.W.V.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "B.M.T., V.K., F.I. and L.W. declare no competing interests.",
    "entities": [
      {
        "text": "B.M.T.",
        "label": "ORG"
      },
      {
        "text": "V.K.",
        "label": "GPE"
      },
      {
        "text": "F.I.",
        "label": "GPE"
      },
      {
        "text": "L.W.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "40. Nat Med. 2025 Jul 15. doi: 10.1038/s41591-025-03831-3. Online ahead of print.",
    "entities": [
      {
        "text": "40",
        "label": "CARDINAL"
      },
      {
        "text": "Nat Med",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Disruption of the cerebrospinal fluid-plasma protein balance in cognitive",
    "entities": []
  },
  {
    "text": "impairment and aging.",
    "entities": []
  },
  {
    "text": "Farinas A(1)(2)(3), Rutledge J(2)(3), Bot VA(2)(3)(4), Western D(5)(6)(7), Ying",
    "entities": [
      {
        "text": "Farinas",
        "label": "PERSON"
      },
      {
        "text": "Rutledge",
        "label": "GPE"
      },
      {
        "text": "Ying\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "K(2)(3)(8)(9), Lawrence KA(10), Oh HS(2)(3)(11)(12)(13)(14), Yoon S(2)(3), Ding",
    "entities": [
      {
        "text": "Lawrence KA(10",
        "label": "PERSON"
      },
      {
        "text": "Yoon",
        "label": "PERSON"
      },
      {
        "text": "Ding",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Global Neurodegeneration Proteomics Consortium (GNPC); Montgomery",
    "entities": [
      {
        "text": "Global Neurodegeneration Proteomics Consortium",
        "label": "ORG"
      },
      {
        "text": "GNPC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Mormino E(19), Cruchaga C(5)(6)(21)(22)(23)(24), Wyss-Coray T(25)(26)(27).",
    "entities": [
      {
        "text": "Mormino E(19",
        "label": "PERSON"
      },
      {
        "text": "Cruchaga",
        "label": "PERSON"
      },
      {
        "text": "Wyss-Coray",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Graduate Program in Neuroscience, Stanford University, Stanford, CA, USA.",
    "entities": [
      {
        "text": "Neuroscience",
        "label": "GPE"
      },
      {
        "text": "Stanford University",
        "label": "ORG"
      },
      {
        "text": "Stanford",
        "label": "ORG"
      },
      {
        "text": "CA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)The Phil and Penny Knight Initiative for Brain Resilience, Stanford",
    "entities": [
      {
        "text": "2)The",
        "label": "CARDINAL"
      },
      {
        "text": "Penny Knight",
        "label": "PERSON"
      },
      {
        "text": "Stanford",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University, Stanford, CA, USA.",
    "entities": [
      {
        "text": "Stanford",
        "label": "ORG"
      },
      {
        "text": "CA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.",
    "entities": [
      {
        "text": "3)Wu Tsai Neurosciences Institute",
        "label": "ORG"
      },
      {
        "text": "Stanford University",
        "label": "ORG"
      },
      {
        "text": "Stanford",
        "label": "ORG"
      },
      {
        "text": "CA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Graduate Program in Biomedical Engineering, Stanford University, Stanford,",
    "entities": [
      {
        "text": "4)Graduate Program in Biomedical Engineering",
        "label": "ORG"
      },
      {
        "text": "Stanford University",
        "label": "ORG"
      },
      {
        "text": "Stanford",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Department of Psychiatry, Washington University School of Medicine, St.",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Psychiatry",
        "label": "ORG"
      },
      {
        "text": "Washington University School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)NeuroGenomics and Informatics Center, Washington University School of",
    "entities": [
      {
        "text": "6)NeuroGenomics",
        "label": "CARDINAL"
      },
      {
        "text": "Informatics Center",
        "label": "ORG"
      },
      {
        "text": "Washington University School of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(7)Division of Biology and Biomedical Sciences, Washington University School of",
    "entities": [
      {
        "text": "Biology and Biomedical Sciences",
        "label": "ORG"
      },
      {
        "text": "Washington University School of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(8)Department of Biochemistry, University of Washington, Seattle, WA, USA.",
    "entities": [
      {
        "text": "Biochemistry, University of Washington",
        "label": "ORG"
      },
      {
        "text": "Seattle",
        "label": "GPE"
      },
      {
        "text": "WA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)Institute for Protein Design, University of Washington, Seattle, WA, USA.",
    "entities": [
      {
        "text": "Protein Design, University of Washington",
        "label": "ORG"
      },
      {
        "text": "Seattle",
        "label": "GPE"
      },
      {
        "text": "WA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(10)Department of Genetics, Stanford University School of Medicine, Stanford,",
    "entities": [
      {
        "text": "10)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Genetics",
        "label": "ORG"
      },
      {
        "text": "Stanford University School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Stanford",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(11)Nash Family Department of Neuroscience, Icahn School of Medicine at Mount",
    "entities": [
      {
        "text": "Family Department of Neuroscience",
        "label": "ORG"
      },
      {
        "text": "Icahn School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Mount\n",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "Sinai, New York, NY, USA.",
    "entities": [
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(12)Brain and Body Research Center of the Friedman Brain Institute, Icahn School",
    "entities": [
      {
        "text": "12)Brain",
        "label": "CARDINAL"
      },
      {
        "text": "Body Research Center",
        "label": "ORG"
      },
      {
        "text": "the Friedman Brain Institute",
        "label": "ORG"
      },
      {
        "text": "Icahn School",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Medicine at Mount Sinai, New York, NY, USA.",
    "entities": [
      {
        "text": "Mount Sinai",
        "label": "FAC"
      },
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(13)Department of Genetics and Genomic Sciences, Icahn School of Medicine at",
    "entities": [
      {
        "text": "13)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Genetics and Genomic Sciences",
        "label": "ORG"
      },
      {
        "text": "Icahn School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Mount Sinai, New York, NY, USA.",
    "entities": [
      {
        "text": "Mount Sinai",
        "label": "GPE"
      },
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(14)Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at",
    "entities": [
      {
        "text": "14)Ronald",
        "label": "CARDINAL"
      },
      {
        "text": "Icahn School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(15)Quantitative Services Unit, Department of Medicine, Stanford University",
    "entities": [
      {
        "text": "15)Quantitative Services Unit",
        "label": "ORG"
      },
      {
        "text": "Department of Medicine",
        "label": "ORG"
      },
      {
        "text": "Stanford University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "School of Medicine, Stanford, CA, USA.",
    "entities": [
      {
        "text": "School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Stanford",
        "label": "ORG"
      },
      {
        "text": "CA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(16)Department of Pathology, Stanford University School of Medicine, Stanford,",
    "entities": [
      {
        "text": "16)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Stanford University School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Stanford",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(17)Department of Biomedical Data Science, Stanford University School of",
    "entities": [
      {
        "text": "17)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Biomedical Data Science",
        "label": "ORG"
      },
      {
        "text": "Stanford University School",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, Stanford, CA, USA.",
    "entities": [
      {
        "text": "Stanford",
        "label": "ORG"
      },
      {
        "text": "CA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(18)Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.",
    "entities": [
      {
        "text": "18)Howard",
        "label": "CARDINAL"
      },
      {
        "text": "Hughes Medical Institute",
        "label": "ORG"
      },
      {
        "text": "University of Washington",
        "label": "ORG"
      },
      {
        "text": "Seattle",
        "label": "GPE"
      },
      {
        "text": "WA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(19)Department of Neurology and Neurological Sciences, Stanford University",
    "entities": [
      {
        "text": "Stanford University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(20)Department of Psychology, Stanford University, Stanford, CA, USA.",
    "entities": [
      {
        "text": "20)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Stanford University",
        "label": "ORG"
      },
      {
        "text": "Stanford",
        "label": "ORG"
      },
      {
        "text": "CA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(21)Department of Neurology, Washington University School of Medicine, St.",
    "entities": [
      {
        "text": "21)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Neurology",
        "label": "ORG"
      },
      {
        "text": "Washington University School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(22)Department of Genetics, Washington University School of Medicine, St. Louis,",
    "entities": [
      {
        "text": "22)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Genetics",
        "label": "ORG"
      },
      {
        "text": "Washington University School of Medicine",
        "label": "ORG"
      },
      {
        "text": "St. Louis",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(23)Hope Center for Neurologic Diseases, Washington University, St. Louis, MO,",
    "entities": [
      {
        "text": "Center for Neurologic Diseases",
        "label": "WORK_OF_ART"
      },
      {
        "text": "Washington University",
        "label": "ORG"
      },
      {
        "text": "St. Louis",
        "label": "GPE"
      },
      {
        "text": "MO",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(24)Knight Alzheimer Disease Research Center, Washington University School of",
    "entities": [
      {
        "text": "24)Knight",
        "label": "CARDINAL"
      },
      {
        "text": "Alzheimer Disease Research Center",
        "label": "ORG"
      },
      {
        "text": "Washington University School of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(25)The Phil and Penny Knight Initiative for Brain Resilience, Stanford",
    "entities": [
      {
        "text": "25)The",
        "label": "CARDINAL"
      },
      {
        "text": "Penny Knight",
        "label": "PERSON"
      },
      {
        "text": "Stanford",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University, Stanford, CA, USA. twc@stanford.edu.",
    "entities": [
      {
        "text": "Stanford",
        "label": "ORG"
      },
      {
        "text": "CA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(26)Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.",
    "entities": [
      {
        "text": "26)Wu",
        "label": "CARDINAL"
      },
      {
        "text": "Tsai Neurosciences Institute",
        "label": "ORG"
      },
      {
        "text": "Stanford University",
        "label": "ORG"
      },
      {
        "text": "Stanford",
        "label": "ORG"
      },
      {
        "text": "CA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(27)Department of Neurology and Neurological Sciences, Stanford University",
    "entities": [
      {
        "text": "27)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Stanford University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "School of Medicine, Stanford, CA, USA. twc@stanford.edu.",
    "entities": [
      {
        "text": "School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Stanford",
        "label": "ORG"
      },
      {
        "text": "CA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "The brain barrier system, including the choroid plexus, meninges and brain",
    "entities": []
  },
  {
    "text": "concentrations between blood and cerebrospinal fluid (CSF). Aging and",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "neurodegeneration disrupt brain barrier function, but proteomic studies of the",
    "entities": []
  },
  {
    "text": "effects on blood-CSF protein balance are limited. Here we used SomaScan",
    "entities": [
      {
        "text": "SomaScan",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "proteomics to characterize paired CSF and plasma samples from 2,171 healthy or",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      },
      {
        "text": "2,171",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "cognitively impaired older individuals from multiple cohorts, including the",
    "entities": []
  },
  {
    "text": "Global Neurodegeneration Proteomics Consortium. We identified proteins with",
    "entities": [
      {
        "text": "Global Neurodegeneration Proteomics Consortium",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "correlated CSF and plasma levels that are produced primarily outside the brain",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and are enriched for structural domains that may enable their transport across",
    "entities": []
  },
  {
    "text": "brain barriers. CSF to plasma ratios of 848 proteins increased with aging in",
    "entities": [
      {
        "text": "848",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "healthy control individuals, including complement and coagulation proteins,",
    "entities": []
  },
  {
    "text": "chemokines and proteins linked to neurodegeneration, whereas 64 protein ratios",
    "entities": [
      {
        "text": "64",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "decreased with age, suggesting substrate-specific barrier regulation. Notably,",
    "entities": []
  },
  {
    "text": "elevated CSF to plasma ratios of peripherally derived or vascular-associated",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "proteins, including DCUN1D1, MFGE8 and VEGFA, were associated with preserved",
    "entities": [
      {
        "text": "MFGE8",
        "label": "PERSON"
      },
      {
        "text": "VEGFA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cognitive function. Genome-wide association studies identified genetic loci",
    "entities": []
  },
  {
    "text": "associated with CSF to plasma ratios of 241 proteins, many of which have known",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      },
      {
        "text": "241",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "disease associations, including FCN2, the collagen-like domain of which may",
    "entities": [
      {
        "text": "FCN2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "facilitate blood-CSF transport. Overall, this work provides molecular insight",
    "entities": []
  },
  {
    "text": "into the human brain barrier system and its disruption with age and disease,",
    "entities": []
  },
  {
    "text": "with implications for the development of brain-permeable therapeutics.",
    "entities": []
  },
  {
    "text": "DOI: 10.1038/s41591-025-03831-3",
    "entities": [
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Competing interests: T.W.-C., J.R. and H.S.O.",
    "entities": [
      {
        "text": "J.R.",
        "label": "PERSON"
      },
      {
        "text": "H.S.O.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "are co-founders and scientific advisors of Teal Omics Inc. and have received",
    "entities": [
      {
        "text": "Teal Omics Inc.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "equity stakes. T.W.-C. is a co-founder and scientific advisor of Alkahest Inc.",
    "entities": [
      {
        "text": "T.W.-C.",
        "label": "PERSON"
      },
      {
        "text": "Alkahest Inc.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and Qinotto Inc. and has received equity stakes in these companies. C.C. has",
    "entities": [
      {
        "text": "Qinotto Inc.",
        "label": "ORG"
      },
      {
        "text": "C.C.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "received research support from GSK and EISAI. C.C. is a member of the scientific",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "EISAI",
        "label": "ORG"
      },
      {
        "text": "C.C.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "advisory board of Circular Genomics and owns stock and a member of the",
    "entities": [
      {
        "text": "advisory board of Circular Genomics",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Scientific Advisory Board of ADmit. K.L.P. is on the Scientific Advisory Board",
    "entities": [
      {
        "text": "Scientific Advisory Board of ADmit",
        "label": "ORG"
      },
      {
        "text": "K.L.P.",
        "label": "ORG"
      },
      {
        "text": "the Scientific Advisory Board",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "for Amprion and is a consultant for Novartis, Biohaven, Curasen and Neuron23,",
    "entities": [
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "Biohaven",
        "label": "PERSON"
      },
      {
        "text": "Curasen",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "where she receives consulting fees. S.B.M. is an advisor to MyOme, PhiTech and",
    "entities": [
      {
        "text": "S.B.M.",
        "label": "ORG"
      },
      {
        "text": "MyOme",
        "label": "ORG"
      },
      {
        "text": "PhiTech",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Valinor Discovery. The remaining authors declare no competing interests.",
    "entities": [
      {
        "text": "Valinor Discovery",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "41. Nat Med. 2025 Jul 15. doi: 10.1038/s41591-025-03835-z. Online ahead of print.",
    "entities": [
      {
        "text": "41",
        "label": "CARDINAL"
      },
      {
        "text": "Nat Med",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "APOE \u03b54 carriers share immune-related proteomic changes across neurodegenerative",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Shvetcov A(1)(2), Johnson ECB(3)(4), Winchester LM(5), Walker KA(6), Wilkins",
    "entities": [
      {
        "text": "Johnson",
        "label": "PERSON"
      },
      {
        "text": "Winchester LM(5",
        "label": "PERSON"
      },
      {
        "text": "Walker KA(6",
        "label": "PERSON"
      },
      {
        "text": "Wilkins",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Global Neurodegeneration Proteomics Consortium (GNPC); Burns JM(7)(8), Swerdlow",
    "entities": [
      {
        "text": "Global Neurodegeneration Proteomics Consortium",
        "label": "ORG"
      },
      {
        "text": "GNPC",
        "label": "ORG"
      },
      {
        "text": "Burns JM(7)(8",
        "label": "PERSON"
      },
      {
        "text": "Swerdlow",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RH(7)(8)(9)(14), Slawson C(7)(9)(15), Finney CA(16)(17).",
    "entities": [
      {
        "text": "Slawson C(7)(9)(15",
        "label": "PERSON"
      },
      {
        "text": "Finney CA(16)(17",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Neurodegeneration and Disease Modelling Research Group, Westmead Institute",
    "entities": [
      {
        "text": "Disease Modelling Research Group",
        "label": "ORG"
      },
      {
        "text": "Westmead Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "for Medical Research, The University of Sydney, Westmead, New South Wales,",
    "entities": [
      {
        "text": "Medical Research",
        "label": "ORG"
      },
      {
        "text": "The University of Sydney, Westmead",
        "label": "ORG"
      },
      {
        "text": "New South Wales",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)School of Medical Sciences, Faculty of Medicine and Health, The University of",
    "entities": [
      {
        "text": "Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Faculty of Medicine and Health",
        "label": "ORG"
      },
      {
        "text": "The University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sydney, Sydney, New South Wales, Australia. artur.shvetcov@wimr.org.au.",
    "entities": [
      {
        "text": "Sydney",
        "label": "GPE"
      },
      {
        "text": "Sydney",
        "label": "GPE"
      },
      {
        "text": "New South Wales",
        "label": "GPE"
      },
      {
        "text": "Australia",
        "label": "GPE"
      },
      {
        "text": "artur.shvetcov@wimr.org.au",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Department of Neurology, Emory University, Atlanta, GA, USA.",
    "entities": [
      {
        "text": "Neurology, Emory University",
        "label": "ORG"
      },
      {
        "text": "Atlanta",
        "label": "GPE"
      },
      {
        "text": "GA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Goizueta Alzheimer's Disease Research Centre, Emory University, Atlanta, GA,",
    "entities": [
      {
        "text": "Disease Research Centre",
        "label": "ORG"
      },
      {
        "text": "Emory University",
        "label": "ORG"
      },
      {
        "text": "Atlanta",
        "label": "GPE"
      },
      {
        "text": "GA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Department of Psychiatry, University of Oxford, Oxford, UK.",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Psychiatry",
        "label": "ORG"
      },
      {
        "text": "University of Oxford",
        "label": "ORG"
      },
      {
        "text": "Oxford",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Laboratory of Behavioral Neuroscience, National Institute on Aging,",
    "entities": [
      {
        "text": "Behavioral Neuroscience",
        "label": "ORG"
      },
      {
        "text": "National Institute on Aging",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Intramural Research Program, Baltimore, MD, USA.",
    "entities": [
      {
        "text": "Intramural Research Program",
        "label": "ORG"
      },
      {
        "text": "Baltimore",
        "label": "GPE"
      },
      {
        "text": "MD",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)University of Kansas Alzheimer's Disease Research Centre, University of",
    "entities": [
      {
        "text": "Kansas Alzheimer's Disease Research Centre",
        "label": "ORG"
      },
      {
        "text": "University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Kansas Medical Center, Kansas City, KS, USA.",
    "entities": [
      {
        "text": "Kansas Medical Center",
        "label": "ORG"
      },
      {
        "text": "Kansas City",
        "label": "GPE"
      },
      {
        "text": "KS",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Department of Neurology, University of Kansas School of Medicine, Kansas",
    "entities": [
      {
        "text": "Neurology, University of Kansas School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Kansas",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "City, KS, USA.",
    "entities": [
      {
        "text": "KS",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)Department of Biochemistry and Molecular Biology, University of Kansas",
    "entities": [
      {
        "text": "Biochemistry and Molecular Biology",
        "label": "ORG"
      },
      {
        "text": "University of Kansas",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medical Center, Kansas City, KS, USA.",
    "entities": [
      {
        "text": "Medical Center",
        "label": "ORG"
      },
      {
        "text": "Kansas City",
        "label": "GPE"
      },
      {
        "text": "KS",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(10)OnPoint Scientific, Inc., San Diego, CA, USA.",
    "entities": [
      {
        "text": "10)OnPoint",
        "label": "CARDINAL"
      },
      {
        "text": "San Diego",
        "label": "GPE"
      },
      {
        "text": "CA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(11)Brain Science Institute, Johns Hopkins University School of Medicine,",
    "entities": [
      {
        "text": "11)Brain",
        "label": "CARDINAL"
      },
      {
        "text": "Science Institute",
        "label": "ORG"
      },
      {
        "text": "Johns Hopkins University School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(12)Department of Neurology, Johns Hopkins University School of Medicine,",
    "entities": [
      {
        "text": "Johns Hopkins University School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(13)Gates Ventures, Seattle, WA, USA.",
    "entities": [
      {
        "text": "13)Gates",
        "label": "CARDINAL"
      },
      {
        "text": "Ventures",
        "label": "GPE"
      },
      {
        "text": "Seattle",
        "label": "GPE"
      },
      {
        "text": "WA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(14)Department of Cell Biology and Physiology, University of Kansas Medical",
    "entities": [
      {
        "text": "Cell Biology and Physiology, University of Kansas Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Center, Kansas City, KS, USA.",
    "entities": [
      {
        "text": "Center",
        "label": "GPE"
      },
      {
        "text": "Kansas City",
        "label": "GPE"
      },
      {
        "text": "KS",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(15)University of Kansas Cancer Center, University of Kansas Medical Center,",
    "entities": [
      {
        "text": "15)University",
        "label": "CARDINAL"
      },
      {
        "text": "Kansas Cancer Center,",
        "label": "ORG"
      },
      {
        "text": "University of Kansas Medical Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(16)Neurodegeneration and Disease Modelling Research Group, Westmead Institute",
    "entities": [
      {
        "text": "16)Neurodegeneration",
        "label": "CARDINAL"
      },
      {
        "text": "Disease Modelling Research Group",
        "label": "ORG"
      },
      {
        "text": "Westmead Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(17)School of Medical Sciences, Faculty of Medicine and Health, The University",
    "entities": [
      {
        "text": "17)School",
        "label": "CARDINAL"
      },
      {
        "text": "Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Faculty of Medicine and Health",
        "label": "ORG"
      },
      {
        "text": "The University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Sydney, Sydney, New South Wales, Australia. caitlin.finney@wimr.org.au.",
    "entities": [
      {
        "text": "Sydney",
        "label": "GPE"
      },
      {
        "text": "Sydney",
        "label": "GPE"
      },
      {
        "text": "New South Wales",
        "label": "GPE"
      },
      {
        "text": "Australia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "The APOE \u03b54 genetic variant is the strongest genetic risk factor for late-onset",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Alzheimer's disease (AD) and is increasingly being implicated in other",
    "entities": []
  },
  {
    "text": "neurodegenerative diseases. Using the Global Neurodegeneration Proteomics",
    "entities": [
      {
        "text": "the Global Neurodegeneration Proteomics",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Consortium SomaScan dataset covering 1,346 cerebrospinal fluid (CSF) and 9,924",
    "entities": [
      {
        "text": "1,346 cerebrospinal fluid",
        "label": "QUANTITY"
      },
      {
        "text": "CSF",
        "label": "ORG"
      },
      {
        "text": "9,924",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "plasma samples, we used machine learning-based proteome profiling to identify an",
    "entities": [
      {
        "text": "plasma samples",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "APOE \u03b54 proteomic signature shared across individuals with AD, frontotemporal",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "dementia (FTD), Parkinson's disease dementia (PDD), Parkinson's disease (PD),",
    "entities": []
  },
  {
    "text": "amyotrophic lateral sclerosis (ALS) and nonimpaired controls. This signature was",
    "entities": [
      {
        "text": "ALS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "enriched in pro-inflammatory immune and infection pathways as well as immune",
    "entities": []
  },
  {
    "text": "cells, including monocytes, T cells and natural killer cells. Analysis of the",
    "entities": []
  },
  {
    "text": "dorsolateral prefrontal cortex proteome for 262 donors from the Accelerating",
    "entities": [
      {
        "text": "262",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Medicines Partnership for AD UPenn Proteomics Study revealed a consistent APOE",
    "entities": []
  },
  {
    "text": "\u03b54 phenotype, independent of neurodegenerative pathology, including amyloid-\u03b2",
    "entities": [
      {
        "text": "\u03b54 phenotype",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "tau and gliosis for all diseases, as well as TDP-43 in ALS and FTD cases, and",
    "entities": [
      {
        "text": "ALS",
        "label": "ORG"
      },
      {
        "text": "FTD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "\u03b1-synuclein in PD and PDD cases. While systemic proteomic changes were",
    "entities": [
      {
        "text": "PD",
        "label": "GPE"
      },
      {
        "text": "PDD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "consistent across APOE \u03b54 carriers, their relationship with clinical and",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "lifestyle factors, such as hypertension and smoking, varied by disease. These",
    "entities": []
  },
  {
    "text": "findings suggest APOE \u03b54 confers a systemic biological vulnerability that is",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "necessary but not sufficient for neurodegeneration, emphasizing the need to",
    "entities": []
  },
  {
    "text": "consider gene-environment interactions. Overall, our study reveals a conserved",
    "entities": []
  },
  {
    "text": "APOE \u03b54-associated pro-inflammatory immune signature persistent across the",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "brain, CSF and plasma irrespective of neurodegenerative disease, highlighting a",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "This work reframes APOE \u03b54 as a pleiotropic immune modulator rather than an",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "AD-specific risk gene, providing a foundation for precision biomarker",
    "entities": [
      {
        "text": "AD",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "development and early intervention strategies across neurodegenerative diseases.",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: Competing interests: The authors declare no",
    "entities": []
  },
  {
    "text": "42. Nat Med. 2025 Jul 15. doi: 10.1038/s41591-025-03834-0. Online ahead of print.",
    "entities": [
      {
        "text": "42",
        "label": "CARDINAL"
      },
      {
        "text": "Nat Med",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "The Global Neurodegeneration Proteomics Consortium: biomarker and drug target",
    "entities": [
      {
        "text": "The Global Neurodegeneration Proteomics Consortium",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "discovery for common neurodegenerative diseases and aging.",
    "entities": []
  },
  {
    "text": "JL(18)(19), Farinas A(20)(21)(22), Ferrucci L(23), Finney CA(24)(25), Frasier",
    "entities": [
      {
        "text": "Farinas A(20)(21)(22",
        "label": "PERSON"
      },
      {
        "text": "Ferrucci L(23",
        "label": "PERSON"
      },
      {
        "text": "Finney CA(24)(25",
        "label": "PERSON"
      },
      {
        "text": "Frasier",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "O(33)(45), Rothstein JD(46), Saykin AJ(18)(19), Shvetcov A(24)(25), Slawson",
    "entities": [
      {
        "text": "Rothstein JD(46",
        "label": "PERSON"
      },
      {
        "text": "Saykin AJ(18)(19",
        "label": "PERSON"
      },
      {
        "text": "Slawson",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "KA(55), Winchester LM(56), Wyss-Coray T(21)(22)(57), Yang C(6)(7), Bose N(4),",
    "entities": [
      {
        "text": "KA(55",
        "label": "PERSON"
      },
      {
        "text": "Winchester LM(56",
        "label": "PERSON"
      },
      {
        "text": "Wyss-Coray T(21)(22)(57",
        "label": "PERSON"
      },
      {
        "text": "Yang",
        "label": "PERSON"
      },
      {
        "text": "N(4",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Lovestone S(58); Global Neurodegeneration Proteomics Consortium (GNPC).",
    "entities": [
      {
        "text": "Global Neurodegeneration Proteomics Consortium",
        "label": "ORG"
      },
      {
        "text": "GNPC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Gates Ventures, Seattle, WA, USA. farhad.imam@gatesventures.com.",
    "entities": [
      {
        "text": "1)Gates",
        "label": "CARDINAL"
      },
      {
        "text": "Ventures",
        "label": "ORG"
      },
      {
        "text": "Seattle",
        "label": "GPE"
      },
      {
        "text": "WA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Neurology, University of California, San Francisco, San",
    "entities": [
      {
        "text": "Neurology, University of California,",
        "label": "ORG"
      },
      {
        "text": "San Francisco",
        "label": "GPE"
      },
      {
        "text": "San\n",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Clinical Sciences Malm\u00f6, SciLifeLab, Lund University, Lund,",
    "entities": [
      {
        "text": "Clinical Sciences Malm\u00f6",
        "label": "ORG"
      },
      {
        "text": "Lund University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Gates Ventures, Seattle, WA, USA.",
    "entities": [
      {
        "text": "Ventures",
        "label": "GPE"
      },
      {
        "text": "Seattle",
        "label": "GPE"
      },
      {
        "text": "WA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Johnson & Johnson, Spring House, PA, USA.",
    "entities": [
      {
        "text": "5)Johnson & Johnson",
        "label": "ORG"
      },
      {
        "text": "Spring House",
        "label": "ORG"
      },
      {
        "text": "PA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Department of Psychiatry, Washington University School of Medicine, St.",
    "entities": [
      {
        "text": "Psychiatry",
        "label": "ORG"
      },
      {
        "text": "Washington University School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(7)NeuroGenomics and Informatics Center, Washington University School of",
    "entities": [
      {
        "text": "7)NeuroGenomics",
        "label": "DATE"
      },
      {
        "text": "Informatics Center",
        "label": "ORG"
      },
      {
        "text": "Washington University School of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(8)Barcelona\u03b2eta Brain Research Center (BBRC), Pasqual Maragall Foundation,",
    "entities": [
      {
        "text": "Brain Research Center",
        "label": "ORG"
      },
      {
        "text": "Pasqual Maragall Foundation",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Barcelona, Spain.",
    "entities": [
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)Hospital del Mar Research Institute, Barcelona, Spain.",
    "entities": [
      {
        "text": "9)Hospital del Mar Research Institute",
        "label": "ORG"
      },
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(10)Centre for Genomic Regulation (CRG), Barcelona Institute of Science and",
    "entities": [
      {
        "text": "10)Centre",
        "label": "CARDINAL"
      },
      {
        "text": "Genomic Regulation",
        "label": "ORG"
      },
      {
        "text": "CRG",
        "label": "ORG"
      },
      {
        "text": "Barcelona Institute of Science",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Technology (BIST), Barcelona, Spain.",
    "entities": [
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(11)Department of Neurological Sciences, Rush Alzheimer's Disease Center,",
    "entities": [
      {
        "text": "11)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Neurological Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Chicago, IL, USA.",
    "entities": [
      {
        "text": "Chicago",
        "label": "GPE"
      },
      {
        "text": "IL",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(12)Clinical Memory Research Unit, Department of Clinical Sciences Malm\u00f6, Lund",
    "entities": [
      {
        "text": "12)Clinical",
        "label": "CARDINAL"
      },
      {
        "text": "Memory Research Unit",
        "label": "ORG"
      },
      {
        "text": "Department of Clinical Sciences Malm\u00f6",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(13)Department of Physiology and Pharmacology, Universit\u00e9 de Montr\u00e9al, Montreal,",
    "entities": [
      {
        "text": "13)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Physiology and Pharmacology",
        "label": "ORG"
      },
      {
        "text": "Universit\u00e9 de Montr\u00e9al",
        "label": "PERSON"
      },
      {
        "text": "Montreal",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(14)Montreal Geriatrics Institute Research Center, Montreal, Quebec, Canada.",
    "entities": [
      {
        "text": "14)Montreal",
        "label": "CARDINAL"
      },
      {
        "text": "Geriatrics Institute Research Center",
        "label": "ORG"
      },
      {
        "text": "Montreal",
        "label": "GPE"
      },
      {
        "text": "Quebec",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(15)University of Kansas Alzheimer's Disease Research Center, Kansas City, KS,",
    "entities": [
      {
        "text": "15)University",
        "label": "CARDINAL"
      },
      {
        "text": "Disease Research Center",
        "label": "ORG"
      },
      {
        "text": "Kansas City",
        "label": "GPE"
      },
      {
        "text": "KS",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(16)Department of Neurology, University of Kansas Medical Center, Kansas City,",
    "entities": [
      {
        "text": "University of Kansas Medical Center",
        "label": "ORG"
      },
      {
        "text": "Kansas City",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(17)Department of Neurology, Washington University School of Medicine, St.",
    "entities": [
      {
        "text": "17)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Neurology",
        "label": "ORG"
      },
      {
        "text": "Washington University School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(18)Indiana Alzheimer's Disease Research Center, Indianapolis, IN, USA.",
    "entities": [
      {
        "text": "18)Indiana Alzheimer's",
        "label": "ORG"
      },
      {
        "text": "Disease Research Center",
        "label": "ORG"
      },
      {
        "text": "Indianapolis",
        "label": "GPE"
      },
      {
        "text": "IN",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(19)Department of Neurology, Indiana University School of Medicine,",
    "entities": [
      {
        "text": "Indiana University School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(20)Graduate Program in Neuroscience, Stanford University, Stanford, CA, USA.",
    "entities": [
      {
        "text": "20)Graduate",
        "label": "CARDINAL"
      },
      {
        "text": "Neuroscience",
        "label": "GPE"
      },
      {
        "text": "Stanford University",
        "label": "ORG"
      },
      {
        "text": "Stanford",
        "label": "ORG"
      },
      {
        "text": "CA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(21)The Phil and Penny Knight Initiative for Brain Resilience, Stanford",
    "entities": [
      {
        "text": "Penny Knight",
        "label": "PERSON"
      },
      {
        "text": "Stanford",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(22)Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.",
    "entities": [
      {
        "text": "22)Wu",
        "label": "CARDINAL"
      },
      {
        "text": "Tsai Neurosciences Institute",
        "label": "ORG"
      },
      {
        "text": "Stanford University",
        "label": "ORG"
      },
      {
        "text": "Stanford",
        "label": "ORG"
      },
      {
        "text": "CA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(23)Translational Gerontology Branch, National Institute on Aging, Bethesda, MD,",
    "entities": [
      {
        "text": "23)Translational Gerontology Branch",
        "label": "TIME"
      },
      {
        "text": "National Institute on Aging",
        "label": "ORG"
      },
      {
        "text": "Bethesda",
        "label": "GPE"
      },
      {
        "text": "MD",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(24)Neurodegeneration and Precision Medicine Research Group, Westmead Institute",
    "entities": [
      {
        "text": "24)Neurodegeneration",
        "label": "CARDINAL"
      },
      {
        "text": "Precision Medicine Research Group",
        "label": "ORG"
      },
      {
        "text": "Westmead Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "for Medical Research, Westmead, New South Wales, Australia.",
    "entities": [
      {
        "text": "Medical Research",
        "label": "ORG"
      },
      {
        "text": "Westmead",
        "label": "ORG"
      },
      {
        "text": "New South Wales",
        "label": "GPE"
      },
      {
        "text": "Australia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(25)Faculty of Medicine and Health, University of Sydney School of Medical",
    "entities": [
      {
        "text": "25)Faculty",
        "label": "CARDINAL"
      },
      {
        "text": "Medicine and Health, University of Sydney School of Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sciences, Westmead, New South Wales, Australia.",
    "entities": [
      {
        "text": "Westmead",
        "label": "ORG"
      },
      {
        "text": "New South Wales",
        "label": "GPE"
      },
      {
        "text": "Australia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(26)Michael J. Fox Foundation, New York, NY, USA.",
    "entities": [
      {
        "text": "26)Michael",
        "label": "CARDINAL"
      },
      {
        "text": "J. Fox Foundation",
        "label": "ORG"
      },
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(27)Vanderbilt Memory & Alzheimer's Disease, Department of Neurology, Vanderbilt",
    "entities": [
      {
        "text": "27)Vanderbilt",
        "label": "CARDINAL"
      },
      {
        "text": "Memory & Alzheimer's",
        "label": "ORG"
      },
      {
        "text": "Disease, Department of Neurology",
        "label": "ORG"
      },
      {
        "text": "Vanderbilt",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "University Medical Center, Nashville, TN, USA.",
    "entities": [
      {
        "text": "University Medical Center",
        "label": "ORG"
      },
      {
        "text": "Nashville",
        "label": "GPE"
      },
      {
        "text": "TN",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(29)Emory University School of Medicine, Atlanta, GA, USA.",
    "entities": [
      {
        "text": "29)Emory University School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Atlanta",
        "label": "GPE"
      },
      {
        "text": "GA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(30)Department of Neurology, Emory University School of Medicine, Atlanta, GA,",
    "entities": [
      {
        "text": "30)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Emory University School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Atlanta",
        "label": "GPE"
      },
      {
        "text": "GA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(31)UCL Brain Sciences, University College London, London, UK.",
    "entities": [
      {
        "text": "Brain Sciences",
        "label": "ORG"
      },
      {
        "text": "University College London",
        "label": "ORG"
      },
      {
        "text": "London",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(32)University of Helsinki, Clinicum, Helsinki, Finland.",
    "entities": [
      {
        "text": "32)University",
        "label": "CARDINAL"
      },
      {
        "text": "Helsinki",
        "label": "GPE"
      },
      {
        "text": "Clinicum",
        "label": "GPE"
      },
      {
        "text": "Helsinki",
        "label": "GPE"
      },
      {
        "text": "Finland",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(33)Ageing & Epidemiology (AGE) Research Unit, School of Public Health, Imperial",
    "entities": [
      {
        "text": "33)Ageing & Epidemiology",
        "label": "ORG"
      },
      {
        "text": "Research Unit",
        "label": "ORG"
      },
      {
        "text": "School of Public Health",
        "label": "ORG"
      },
      {
        "text": "Imperial",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "College London, London, UK.",
    "entities": [
      {
        "text": "London",
        "label": "GPE"
      },
      {
        "text": "London",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(35)Biomedical Research Networking Centre in Neurodegenerative Diseases",
    "entities": [
      {
        "text": "Neurodegenerative Diseases",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "(CIBERNED), National Institute of Health Carlos III, Madrid, Spain.",
    "entities": [
      {
        "text": "National Institute of Health Carlos III",
        "label": "ORG"
      },
      {
        "text": "Madrid",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Department of Microbiology, Immunology and Molecular Genetics, Long School of",
    "entities": [
      {
        "text": "Department of Microbiology, Immunology and Molecular Genetics",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, The University of Texas Health Science Center, San Antonio, TX, USA.",
    "entities": [
      {
        "text": "The University of Texas Health Science Center",
        "label": "ORG"
      },
      {
        "text": "San Antonio",
        "label": "GPE"
      },
      {
        "text": "TX",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(37)Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research,",
    "entities": [
      {
        "text": "37)Neurodegenerative Diseases",
        "label": "ORG"
      },
      {
        "text": "Hertie Institute for Clinical Brain Research",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(38)Department of Neurodegenerative Diseases, German Center of Neurodegenerative",
    "entities": [
      {
        "text": "38)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Neurodegenerative Diseases",
        "label": "ORG"
      },
      {
        "text": "German Center of Neurodegenerative",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Diseases, T\u00fcbingen, Germany.",
    "entities": [
      {
        "text": "T\u00fcbingen",
        "label": "ORG"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(40)Memory Clinic, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden.",
    "entities": [
      {
        "text": "40)Memory Clinic",
        "label": "ORG"
      },
      {
        "text": "Sk\u00e5ne University Hospital",
        "label": "ORG"
      },
      {
        "text": "Malm\u00f6",
        "label": "GPE"
      },
      {
        "text": "Sweden",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(41)Department of Radiology & Imaging Sciences, Indiana University School of",
    "entities": [
      {
        "text": "41)Department of Radiology & Imaging Sciences",
        "label": "MONEY"
      },
      {
        "text": "Indiana University School of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(42)Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, USA.",
    "entities": [
      {
        "text": "42)Mount Sinai",
        "label": "ORG"
      },
      {
        "text": "Icahn School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Mount Sinai",
        "label": "FAC"
      },
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(43)Department of Neurology, Mayo Clinic, Rochester, MN, USA.",
    "entities": [
      {
        "text": "Neurology",
        "label": "ORG"
      },
      {
        "text": "Mayo Clinic",
        "label": "ORG"
      },
      {
        "text": "Rochester",
        "label": "GPE"
      },
      {
        "text": "MN,",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(45)Department of Epidemiology and Biostatistics, School of Public Health,",
    "entities": [
      {
        "text": "45)Department",
        "label": "CARDINAL"
      },
      {
        "text": "School of Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(46)Robert Packard Center for ALS Research, Johns Hopkins University, Baltimore,",
    "entities": [
      {
        "text": "46)Robert Packard Center",
        "label": "ORG"
      },
      {
        "text": "ALS Research",
        "label": "ORG"
      },
      {
        "text": "Johns Hopkins University",
        "label": "ORG"
      },
      {
        "text": "Baltimore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(47)Department of Biochemistry and Molecular Biology, University of Kansas",
    "entities": [
      {
        "text": "47)Department of Biochemistry and Molecular Biology",
        "label": "ORG"
      },
      {
        "text": "University of Kansas",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(49)Department of Neurology, Hospital del Mar, Barcelona, Spain.",
    "entities": [
      {
        "text": "49)Department of Neurology",
        "label": "MONEY"
      },
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(52)ALS Therapy Development Institute, Cambridge, MA, USA.",
    "entities": [
      {
        "text": "52)ALS",
        "label": "CARDINAL"
      },
      {
        "text": "Therapy Development Institute",
        "label": "ORG"
      },
      {
        "text": "Cambridge",
        "label": "GPE"
      },
      {
        "text": "MA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(53)Department of Human Genetics, Radboud University Medical Center, Nijmegen,",
    "entities": [
      {
        "text": "Radboud University Medical Center",
        "label": "ORG"
      },
      {
        "text": "Nijmegen",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "The Netherlands.",
    "entities": [
      {
        "text": "Netherlands",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(54)Alzheimer Center Limburg, School for Mental Health and Neuroscience,",
    "entities": [
      {
        "text": "Center Limburg",
        "label": "GPE"
      },
      {
        "text": "School for Mental Health and Neuroscience",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Maastricht University, Maastricht, The Netherlands.",
    "entities": [
      {
        "text": "Maastricht University",
        "label": "ORG"
      },
      {
        "text": "Maastricht",
        "label": "GPE"
      },
      {
        "text": "The Netherlands",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(55)Laboratory of Behavioral Neuroscience, National Institute on Aging,",
    "entities": [
      {
        "text": "55)Laboratory",
        "label": "CARDINAL"
      },
      {
        "text": "National Institute on Aging",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Bethesda, MD, USA.",
    "entities": [
      {
        "text": "Bethesda",
        "label": "GPE"
      },
      {
        "text": "MD",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(56)Department of Psychiatry, Oxford University, Oxford, UK.",
    "entities": [
      {
        "text": "56)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Psychiatry",
        "label": "ORG"
      },
      {
        "text": "Oxford University",
        "label": "ORG"
      },
      {
        "text": "Oxford",
        "label": "ORG"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(57)Department of Neurology and Neurological Sciences, Stanford University",
    "entities": [
      {
        "text": "Stanford University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "School of Medicine, Standford, CA, USA.",
    "entities": [
      {
        "text": "School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Standford",
        "label": "GPE"
      },
      {
        "text": "CA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(58)Johnson & Johnson, London, UK.",
    "entities": [
      {
        "text": "58)Johnson & Johnson",
        "label": "ORG"
      },
      {
        "text": "London",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "More than 57 million people globally suffer from neurodegenerative diseases, a",
    "entities": [
      {
        "text": "More than 57 million",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "figure expected to double every 20 years. Despite this growing burden, there are",
    "entities": [
      {
        "text": "every 20 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "currently no cures, and treatment options remain limited due to disease",
    "entities": []
  },
  {
    "text": "heterogeneity, prolonged preclinical and prodromal phases, poor understanding of",
    "entities": []
  },
  {
    "text": "disease mechanisms, and diagnostic challenges. Identifying novel biomarkers is",
    "entities": []
  },
  {
    "text": "crucial for improving early detection, prognosis, staging and subtyping of these",
    "entities": []
  },
  {
    "text": "conditions. High-dimensional molecular studies in biofluids ('omics') offer",
    "entities": []
  },
  {
    "text": "promise for scalable biomarker discovery, but challenges in assembling large,",
    "entities": []
  },
  {
    "text": "diverse datasets hinder progress. To address this, the Global Neurodegeneration",
    "entities": [
      {
        "text": "the Global Neurodegeneration",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Proteomics Consortium (GNPC)-a public-private partnership-established one of the",
    "entities": [
      {
        "text": "Proteomics Consortium",
        "label": "ORG"
      },
      {
        "text": "GNPC)-a",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "world's largest harmonized proteomic datasets. It includes approximately 250",
    "entities": [
      {
        "text": "approximately 250",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "35,000 biofluid samples (plasma, serum and cerebrospinal fluid) contributed by",
    "entities": [
      {
        "text": "35,000",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "23 partners, alongside associated clinical data spanning Alzheimer's disease",
    "entities": [
      {
        "text": "23",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(AD), Parkinson's disease (PD), frontotemporal dementia (FTD) and amyotrophic",
    "entities": [
      {
        "text": "FTD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "lateral sclerosis (ALS). This dataset is accessible to GNPC members via the",
    "entities": [
      {
        "text": "ALS",
        "label": "ORG"
      },
      {
        "text": "GNPC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Alzheimer's Disease Data Initiative's AD Workbench, a secure cloud-based",
    "entities": [
      {
        "text": "AD Workbench",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "environment, and will be available to the wider research community on 15 July",
    "entities": [
      {
        "text": "15 July",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "2025. Here we present summary analyses of the plasma proteome revealing",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "signatures of clinical severity. Furthermore, we describe a robust plasma",
    "entities": []
  },
  {
    "text": "proteomic signature of APOE \u03b54 carriership, reproducible across AD, PD, FTD and",
    "entities": [
      {
        "text": "APOE",
        "label": "ORG"
      },
      {
        "text": "AD, PD",
        "label": "DATE"
      },
      {
        "text": "FTD",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "ALS, as well as distinct patterns of organ aging across these conditions. This",
    "entities": [
      {
        "text": "ALS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "work demonstrates the power of international collaboration, data sharing and",
    "entities": []
  },
  {
    "text": "DOI: 10.1038/s41591-025-03834-0",
    "entities": [
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Competing interests: A.L.B. receives research",
    "entities": [
      {
        "text": "A.L.B.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "support from the NIH, the Tau Research Consortium, the Association for",
    "entities": [
      {
        "text": "NIH",
        "label": "ORG"
      },
      {
        "text": "the Tau Research Consortium",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Frontotemporal Degeneration, Bluefield Project to Cure Frontotemporal Dementia,",
    "entities": [
      {
        "text": "Cure Frontotemporal Dementia",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the GHR Foundation and the Alzheimer\u2019s Association. He has been a consultant for",
    "entities": [
      {
        "text": "the GHR Foundation",
        "label": "ORG"
      },
      {
        "text": "the Alzheimer\u2019s Association",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Alchemab, Alector, Alexion, Amylyx, Arrowhead, Arvinas, Eli Lilly, Muna,",
    "entities": [
      {
        "text": "Alchemab, Alector, Alexion, Amylyx",
        "label": "ORG"
      },
      {
        "text": "Arrowhead",
        "label": "ORG"
      },
      {
        "text": "Arvinas",
        "label": "ORG"
      },
      {
        "text": "Eli Lilly",
        "label": "ORG"
      },
      {
        "text": "Muna",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Neurocrine, Ono, Oscotec, Pfizer, Switch, Transposon and UnlearnAI. C.C. has",
    "entities": [
      {
        "text": "Ono",
        "label": "GPE"
      },
      {
        "text": "Pfizer",
        "label": "PERSON"
      },
      {
        "text": "Switch",
        "label": "PERSON"
      },
      {
        "text": "Transposon",
        "label": "PERSON"
      },
      {
        "text": "C.C.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "received research support from GSK and Eisai. C.C. is a member of the scientific",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Eisai",
        "label": "GPE"
      },
      {
        "text": "C.C.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "scientific advisory board of ADmit. J.L.D. has a patent pending for compounds",
    "entities": [
      {
        "text": "ADmit",
        "label": "ORG"
      },
      {
        "text": "J.L.D.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and methods targeting human tau. L.F. has given unpaid seminars and/or webinars",
    "entities": [
      {
        "text": "L.F.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "sponsored or co-sponsored by SomaLogic. O.H. has received nonfinancial support",
    "entities": [
      {
        "text": "SomaLogic",
        "label": "ORG"
      },
      {
        "text": "O.H.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "from Roache and Lilly and is currently employed by Lilly. E.M.R. has received",
    "entities": [
      {
        "text": "Roache",
        "label": "ORG"
      },
      {
        "text": "Lilly",
        "label": "ORG"
      },
      {
        "text": "Lilly",
        "label": "ORG"
      },
      {
        "text": "E.M.R.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "grants from National Institute on Aging and the state of Arizona; receives",
    "entities": [
      {
        "text": "National Institute on Aging",
        "label": "ORG"
      },
      {
        "text": "Arizona",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "philanthropic funding from the Banner Alzheimer\u2019s Foundation, Sun Health",
    "entities": [
      {
        "text": "the Banner Alzheimer\u2019s Foundation",
        "label": "ORG"
      },
      {
        "text": "Sun Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Foundation and Roche/Roche Diagnostics; receives personal fees from Alkahest,",
    "entities": [
      {
        "text": "Roche/Roche Diagnostics",
        "label": "ORG"
      },
      {
        "text": "Alkahest",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "Alzheon, Aural Analytics, Denali, Green Valley, MagQ, Takeda/Zinfandel and",
    "entities": [
      {
        "text": "MagQ",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "United Neuroscience; has since submission of manuscript become a cofounder of",
    "entities": [
      {
        "text": "United Neuroscience",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "ALZpath, which aims to further develop P-tau217 and fluid biomarkers and advance",
    "entities": [
      {
        "text": "ALZpath",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "their use in research, drug development and clinical settings; holds a patent",
    "entities": []
  },
  {
    "text": "owned by Banner Health for a strategy to use biomarkers to accelerate evaluation",
    "entities": [
      {
        "text": "Banner Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Alzheimer prevention therapies; and is a principal investigator of prevention",
    "entities": []
  },
  {
    "text": "trials that include research agreements with Genentech/Roche and Novartis/Amgen,",
    "entities": [
      {
        "text": "Genentech/Roche",
        "label": "ORG"
      },
      {
        "text": "Novartis/Amgen",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PET studies that include research agreements with Avid/Lilly and several NIH and",
    "entities": [
      {
        "text": "PET",
        "label": "ORG"
      },
      {
        "text": "Avid/Lilly",
        "label": "ORG"
      },
      {
        "text": "NIH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Foundation-supported research studies. T.W.-C. and H.S.-H.O. are co-founders and",
    "entities": [
      {
        "text": "H.S.-H.O.",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "scientific advisors of Teal Omics Inc. and have received equity stakes. T.W.-C.",
    "entities": [
      {
        "text": "Teal Omics Inc.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "is a co-founder and scientific advisor of Alkahest Inc. and Qinotto Inc. and has",
    "entities": [
      {
        "text": "Alkahest Inc.",
        "label": "ORG"
      },
      {
        "text": "Qinotto Inc.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "received equity stakes in these companies. The other authors declare no",
    "entities": []
  },
  {
    "text": "43. Nat Med. 2025 Jul 15. doi: 10.1038/d41591-022-00044-w. Online ahead of print.",
    "entities": [
      {
        "text": "43",
        "label": "CARDINAL"
      },
      {
        "text": "Nat Med",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Global collaboration is key to decoding Alzheimer's disease.",
    "entities": []
  },
  {
    "text": "Retained introns in phototransduction genes of 5xFAD mouse retina suggest vision",
    "entities": [
      {
        "text": "5xFAD",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "impairment as an early diagnostic marker for Alzheimer's disease.",
    "entities": []
  },
  {
    "text": "(1)Department of Life Science, Chung-Ang University, 84 Heukseok-Ro, Dongjak-Gu,",
    "entities": [
      {
        "text": "Life Science",
        "label": "FAC"
      },
      {
        "text": "Chung-Ang University",
        "label": "ORG"
      },
      {
        "text": "84",
        "label": "CARDINAL"
      },
      {
        "text": "Heukseok-Ro",
        "label": "PERSON"
      },
      {
        "text": "Dongjak-Gu",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Seoul, 06974, Republic of Korea.",
    "entities": [
      {
        "text": "Seoul",
        "label": "GPE"
      },
      {
        "text": "06974",
        "label": "DATE"
      },
      {
        "text": "Republic of Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Gwangju Alzheimer's & Related Dementia Cohort Research Center, Chosun",
    "entities": [
      {
        "text": "2)Gwangju Alzheimer's & Related Dementia Cohort Research Center",
        "label": "ORG"
      },
      {
        "text": "Chosun",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "University, Gwangju, 61452, Republic of Korea.",
    "entities": [
      {
        "text": "University, Gwangju",
        "label": "ORG"
      },
      {
        "text": "61452",
        "label": "DATE"
      },
      {
        "text": "Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Biomedical Science, Chosun University, Gwangju, 61452, Republic",
    "entities": [
      {
        "text": "Biomedical Science, Chosun University, Gwangju",
        "label": "ORG"
      },
      {
        "text": "61452",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "of Korea.",
    "entities": [
      {
        "text": "Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Life Science, Chung-Ang University, 84 Heukseok-Ro, Dongjak-Gu,",
    "entities": [
      {
        "text": "Life Science",
        "label": "FAC"
      },
      {
        "text": "Chung-Ang University",
        "label": "ORG"
      },
      {
        "text": "84",
        "label": "CARDINAL"
      },
      {
        "text": "Heukseok-Ro",
        "label": "PERSON"
      },
      {
        "text": "Dongjak-Gu",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Seoul, 06974, Republic of Korea. jungkim@cau.ac.kr.",
    "entities": [
      {
        "text": "Seoul",
        "label": "GPE"
      },
      {
        "text": "06974",
        "label": "DATE"
      },
      {
        "text": "Republic of Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Alzheimer's disease (AD) is an age-related neurodegenerative disorder",
    "entities": []
  },
  {
    "text": "characterized by neuronal and synaptic loss in the brain, which leads to",
    "entities": []
  },
  {
    "text": "cognitive impairment and dementia. Therefore, early diagnosis by employing",
    "entities": []
  },
  {
    "text": "various biomarkers is crucial for preventing and treating AD. Although retinal",
    "entities": []
  },
  {
    "text": "pathology is an emerging biomarker associated with AD, detailed molecular",
    "entities": [
      {
        "text": "AD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "mechanisms of retinal impairments remain unclear. Herein, we identified",
    "entities": []
  },
  {
    "text": "genome-wide dysfunction of alternative splicing in the early stage of 5xFAD",
    "entities": [
      {
        "text": "5xFAD",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "transgenic mouse retina by performing RNA sequencing analysis. Notably, retained",
    "entities": [
      {
        "text": "transgenic mouse",
        "label": "PERSON"
      },
      {
        "text": "RNA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "introns, highly enriched in phototransduction and retinal genes in the",
    "entities": []
  },
  {
    "text": "1.5-month-old 5xFAD mouse retina, was significantly associated with",
    "entities": [
      {
        "text": "1.5-month-old",
        "label": "DATE"
      },
      {
        "text": "5xFAD",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "physiological impairment of rod photoreceptors in the retina, as evidenced by",
    "entities": []
  },
  {
    "text": "electroretinogram (ERG) analysis. These results indicate that the abnormal",
    "entities": [
      {
        "text": "ERG",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "scotopic ERG associated with global splicing impairment may be valuable as an",
    "entities": [
      {
        "text": "ERG",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "early-detection biomarker for AD.",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "PMID: 40664927 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40664927",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "declare no competing interests. Ethics approval: The animal study protocol was",
    "entities": []
  },
  {
    "text": "approved by the Institutional Review Board of Chung-Ang University (2020-00061),",
    "entities": [
      {
        "text": "the Institutional Review Board",
        "label": "ORG"
      },
      {
        "text": "Chung-Ang University",
        "label": "ORG"
      },
      {
        "text": "2020-00061",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "and the approval date is July 27, 2020. Consent for publication: All authors",
    "entities": [
      {
        "text": "July 27, 2020",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "agree to the publication of this manuscript.",
    "entities": []
  },
  {
    "text": "45. Nat Chem Biol. 2025 Jul 15. doi: 10.1038/s41589-025-01975-4. Online ahead of",
    "entities": [
      {
        "text": "45",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "A genetically encoded selection for amyloid-\u03b2 oligomer binders.",
    "entities": []
  },
  {
    "text": "Lee B(1), Mannone JA(1), Wang T(2).",
    "entities": [
      {
        "text": "Lee B(1",
        "label": "PERSON"
      },
      {
        "text": "Mannone JA(1",
        "label": "ORG"
      },
      {
        "text": "Wang T(2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Chemistry, University of Wisconsin-Madison, Madison, WI, USA.",
    "entities": [
      {
        "text": "Chemistry, University of Wisconsin-Madison",
        "label": "ORG"
      },
      {
        "text": "Madison",
        "label": "PERSON"
      },
      {
        "text": "WI",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Chemistry, University of Wisconsin-Madison, Madison, WI, USA.",
    "entities": [
      {
        "text": "Chemistry, University of Wisconsin-Madison",
        "label": "ORG"
      },
      {
        "text": "Madison",
        "label": "PERSON"
      },
      {
        "text": "WI",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Soluble amyloid-\u03b2 oligomers (A\u03b2Os) are a hypothesized source of neurotoxicity in",
    "entities": [
      {
        "text": "A\u03b2Os",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "Alzheimer disease. Binding proteins that recognize these species may have high",
    "entities": []
  },
  {
    "text": "utility in diagnostic and therapeutic applications. However, identifying binders",
    "entities": []
  },
  {
    "text": "to A\u03b2Os directly generated from the aggregation cascade is challenging because",
    "entities": [
      {
        "text": "A\u03b2Os",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "of the short lifetime and low concentrations of oligomer populations. We report",
    "entities": []
  },
  {
    "text": "a strategy to detect binding to A\u03b2Os formed during A\u03b242 aggregation using a",
    "entities": [
      {
        "text": "A\u03b2Os",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "genetically encoded biosensor. We show that our method enables rapid, highly",
    "entities": []
  },
  {
    "text": "reproducible measurement of the activity of existing A\u03b2O binders and can be used",
    "entities": [
      {
        "text": "A\u03b2O",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "to select for new binders with improved potency. We uncover hits that are",
    "entities": []
  },
  {
    "text": ">20-fold more effective than reported binders at delaying secondary nucleation,",
    "entities": [
      {
        "text": "20-fold",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "the step in A\u03b2 aggregation thought to generate the highest number of toxic",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "oligomers. Our approach may greatly accelerate the discovery and",
    "entities": []
  },
  {
    "text": "characterization of binding proteins that target A\u03b2Os.",
    "entities": [
      {
        "text": "A\u03b2Os",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "DOI: 10.1038/s41589-025-01975-4",
    "entities": [
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Competing interests: A provisional patent",
    "entities": []
  },
  {
    "text": "application (application no. 63/657,564) on the cCadC\u2013A\u03b242 method for detecting",
    "entities": []
  },
  {
    "text": "oligomer binders has been filed by the University of Wisconsin, with B.L. and",
    "entities": [
      {
        "text": "the University of Wisconsin",
        "label": "ORG"
      },
      {
        "text": "B.L.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "T.W. as coinventors. The other author declares no competing interests.",
    "entities": []
  },
  {
    "text": "Potential utility of salivary gland amyloid uptake as a surrogate marker for",
    "entities": []
  },
  {
    "text": "adipose tissue and amyloid-beta dynamics based on its association with BMI and",
    "entities": [
      {
        "text": "BMI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Ewha Womans University College of Medicine, 25, Magokdong-ro 2-gil,",
    "entities": [
      {
        "text": "Womans University College of Medicine",
        "label": "ORG"
      },
      {
        "text": "25",
        "label": "DATE"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Gangseo-gu, Seoul, 07804, Republic of Korea.",
    "entities": [
      {
        "text": "Gangseo-gu",
        "label": "PERSON"
      },
      {
        "text": "Seoul",
        "label": "GPE"
      },
      {
        "text": "07804",
        "label": "DATE"
      },
      {
        "text": "Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Nuclear Medicine, Ewha Womans University College of Medicine,",
    "entities": []
  },
  {
    "text": "Seoul, 07804, Republic of Korea.",
    "entities": [
      {
        "text": "Seoul",
        "label": "GPE"
      },
      {
        "text": "07804",
        "label": "DATE"
      },
      {
        "text": "Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Nuclear Medicine, Ewha Womans University College of Medicine,",
    "entities": []
  },
  {
    "text": "Recent studies have noted an unexpected inverse correlation between body mass",
    "entities": []
  },
  {
    "text": "index (BMI) and cerebral amyloid-beta (A\u03b2) deposition, suggesting a potential",
    "entities": [
      {
        "text": "BMI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "involvement of adipose tissue in AD pathology. Given the adipose-rich nature of",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "salivary glands, we investigated whether A\u03b2 uptake in the salivary glands is",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "associated with the link between BMI and cerebral A\u03b2 deposition",
    "entities": [
      {
        "text": "BMI",
        "label": "ORG"
      },
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "using18F-Florbetaben PET/CT. We analyzed data from 187 participants, classified",
    "entities": [
      {
        "text": "using18F-Florbetaben PET/CT",
        "label": "ORG"
      },
      {
        "text": "187",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "into A\u03b2-cognitively normal (A\u03b2-CN), A\u03b2+ mild cognitive impairment (A\u03b2+MCI), and",
    "entities": [
      {
        "text": "A\u03b2-CN",
        "label": "PERSON"
      },
      {
        "text": "A\u03b2+MCI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "A\u03b2+ AD dementia (A\u03b2+D) groups. BMI, standardized uptake value ratio of salivary",
    "entities": [
      {
        "text": "BMI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "glands (SUVRSG), and brain (SUVRB) were quantified, and their associations were",
    "entities": [
      {
        "text": "SUVRB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "examined using Pearson correlation and multiple regression analyses. Higher BMI",
    "entities": [
      {
        "text": "Pearson",
        "label": "PRODUCT"
      },
      {
        "text": "BMI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "was correlated with increased SUVRSG (r = 0.231, p = 0.0019) and decreased SUVRB",
    "entities": [
      {
        "text": "0.231",
        "label": "CARDINAL"
      },
      {
        "text": "0.0019",
        "label": "CARDINAL"
      },
      {
        "text": "SUVRB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(r = -0.247, p = 0.0009). SUVRSG and SUVRB were negatively correlated (r =",
    "entities": [
      {
        "text": "0.0009",
        "label": "CARDINAL"
      },
      {
        "text": "SUVRB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "-0.188, p = 0.0102). Multiple regression analysis identified BMI as an",
    "entities": [
      {
        "text": "0.0102",
        "label": "CARDINAL"
      },
      {
        "text": "BMI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "independent predictor of composite brain SUVR (\u03b2 = -0.0168, p = 0.0046), while",
    "entities": [
      {
        "text": "SUVR",
        "label": "ORG"
      },
      {
        "text": "0.0046",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "SUVRSG was marginally significant (\u03b2 = -0.0714, p = 0.0701). Regionally, both",
    "entities": [
      {
        "text": "SUVRSG",
        "label": "ORG"
      },
      {
        "text": "0.0701",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "BMI and SUVRSG were significantly associated with lower SUVRB in the striatum,",
    "entities": [
      {
        "text": "BMI",
        "label": "ORG"
      },
      {
        "text": "SUVRSG",
        "label": "ORG"
      },
      {
        "text": "SUVRB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "precuneus, and cingulate cortex. Consistent with previous studies, BMI exhibited",
    "entities": [
      {
        "text": "BMI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "an inverse correlation with SUVRB. Notably, SUVRSG was negatively associated",
    "entities": [
      {
        "text": "SUVRB",
        "label": "ORG"
      },
      {
        "text": "SUVRSG",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "with SUVRB while demonstrating a positive correlation with BMI. Interpreting",
    "entities": [
      {
        "text": "SUVRB",
        "label": "ORG"
      },
      {
        "text": "BMI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "SUVRSG as a fat-related marker, these findings suggest that A\u03b2 sequestration in",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "adipose tissue may contribute to lower cerebral A\u03b2 accumulation. Additional",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "research is necessary to elucidate the underlying mechanism.",
    "entities": []
  },
  {
    "text": "DOI: 10.1038/s41598-025-11731-2",
    "entities": [
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "PMID: 40664695 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40664695",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Online ahead of print.",
    "entities": []
  },
  {
    "text": "A multimodal lifestyle intervention complemented with epigallocatechin gallate",
    "entities": []
  },
  {
    "text": "to prevent cognitive decline in APOE- \u025b4 carriers with Subjective Cognitive",
    "entities": [
      {
        "text": "APOE- \u025b4",
        "label": "ORG"
      },
      {
        "text": "Subjective Cognitive",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Decline: a randomized, double-blinded clinical trial (PENSA study).",
    "entities": []
  },
  {
    "text": "Forcano L(1), Soldevila-Domenech N(2), Boronat A(3), S\u00e1nchez-Benavides G(4),",
    "entities": [
      {
        "text": "Soldevila-Domenech",
        "label": "PERSON"
      },
      {
        "text": "Boronat A(3",
        "label": "PERSON"
      },
      {
        "text": "S\u00e1nchez",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(1)Integrative Pharmacology and Systems Neuroscience Research Group,",
    "entities": [
      {
        "text": "1)Integrative",
        "label": "CARDINAL"
      },
      {
        "text": "Pharmacology and Systems Neuroscience Research Group",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Neuroscience Research Program, Hospital del Mar Research Institute, Barcelona,",
    "entities": [
      {
        "text": "Neuroscience Research Program",
        "label": "ORG"
      },
      {
        "text": "Hospital del Mar Research Institute",
        "label": "ORG"
      },
      {
        "text": "Barcelona",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Carlos III, Madrid, Spain.",
    "entities": [
      {
        "text": "Carlos III",
        "label": "PERSON"
      },
      {
        "text": "Madrid",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Integrative Pharmacology and Systems Neuroscience Research Group,",
    "entities": [
      {
        "text": "2)Integrative",
        "label": "CARDINAL"
      },
      {
        "text": "Pharmacology and Systems Neuroscience Research Group",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Spain; Barcelona\u03b2eta Brain Research Center (BBRC), Pasqual Maragall Foundation,",
    "entities": [
      {
        "text": "Spain",
        "label": "GPE"
      },
      {
        "text": "Barcelona\u03b2eta Brain Research Center",
        "label": "ORG"
      },
      {
        "text": "Pasqual Maragall Foundation",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Integrative Pharmacology and Systems Neuroscience Research Group,",
    "entities": [
      {
        "text": "Pharmacology and Systems Neuroscience Research Group",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Spain; Department of Medicine and Life Sciences, Universitat Pompeu Fabra,",
    "entities": [
      {
        "text": "Spain",
        "label": "GPE"
      },
      {
        "text": "Department of Medicine and Life Sciences",
        "label": "ORG"
      },
      {
        "text": "Universitat Pompeu Fabra",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Barcelona\u03b2eta Brain Research Center (BBRC), Pasqual Maragall Foundation,",
    "entities": [
      {
        "text": "Brain Research Center",
        "label": "ORG"
      },
      {
        "text": "Pasqual Maragall Foundation",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Barcelona, Spain; Clinical and Risk Factors for Neurodegenerative Diseases",
    "entities": [
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      },
      {
        "text": "Clinical and Risk Factors for Neurodegenerative Diseases",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Research Group, Neuroscience Research Program, Hospital del Mar Research",
    "entities": [
      {
        "text": "Research Group",
        "label": "ORG"
      },
      {
        "text": "Neuroscience Research Program",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Integrative Pharmacology and Systems Neuroscience Research Group,",
    "entities": [
      {
        "text": "Pharmacology and Systems Neuroscience Research Group",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Spain; Cognition and Behavior Unit, Department of Neurology, Hospital Del Mar,",
    "entities": [
      {
        "text": "Spain",
        "label": "GPE"
      },
      {
        "text": "Cognition and Behavior Unit",
        "label": "ORG"
      },
      {
        "text": "Department of Neurology",
        "label": "ORG"
      },
      {
        "text": "Del Mar",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Barcelona, Spain; ERA-Net on Cardiovascular Diseases (ERA-CVD) Consortium,",
    "entities": [
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      },
      {
        "text": "ERA-Net on Cardiovascular Diseases",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Integrative Pharmacology and Systems Neuroscience Research Group,",
    "entities": [
      {
        "text": "Pharmacology and Systems Neuroscience Research Group",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Barcelona, Spain; Department of Medicine and Life Sciences, Universitat Pompeu",
    "entities": [
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      },
      {
        "text": "Department of Medicine and Life Sciences",
        "label": "ORG"
      },
      {
        "text": "Universitat Pompeu",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Fabra, Barcelona, Spain; Neuroimaging of neurodegenerative disease and healthy",
    "entities": [
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "aging Research Group, Neuroscience Research Program, Hospital del Mar Research",
    "entities": [
      {
        "text": "Research Group",
        "label": "ORG"
      },
      {
        "text": "Neuroscience Research Program",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(7)Integrative Pharmacology and Systems Neuroscience Research Group,",
    "entities": [
      {
        "text": "Pharmacology and Systems Neuroscience Research Group",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Barcelona, Spain; Clinical Research Unit, Neuroscience Research Program,",
    "entities": [
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      },
      {
        "text": "Clinical Research Unit",
        "label": "ORG"
      },
      {
        "text": "Neuroscience Research Program",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Hospital del Mar Research Institute, Barcelona, Spain.",
    "entities": [
      {
        "text": "Hospital del Mar Research Institute",
        "label": "ORG"
      },
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(CIBER-FES), Instituto de Salud Carlos III, Madrid, Spain; Cognition and",
    "entities": [
      {
        "text": "Madrid",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Behavior Unit, Department of Neurology, Hospital Del Mar, Barcelona, Spain.",
    "entities": [
      {
        "text": "Behavior Unit",
        "label": "ORG"
      },
      {
        "text": "Department of Neurology",
        "label": "ORG"
      },
      {
        "text": "Del Mar",
        "label": "GPE"
      },
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)Barcelona\u03b2eta Brain Research Center (BBRC), Pasqual Maragall Foundation,",
    "entities": [
      {
        "text": "Brain Research Center",
        "label": "ORG"
      },
      {
        "text": "Pasqual Maragall Foundation",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Institute, Barcelona, Spain; Clinical Research Unit, Neuroscience Research",
    "entities": [
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      },
      {
        "text": "Clinical Research Unit",
        "label": "ORG"
      },
      {
        "text": "Neuroscience Research",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Program, Hospital del Mar Research Institute, Barcelona, Spain; CIBER en",
    "entities": [
      {
        "text": "Mar Research Institute",
        "label": "ORG"
      },
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      },
      {
        "text": "CIBER",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(10)Integrative Pharmacology and Systems Neuroscience Research Group,",
    "entities": [
      {
        "text": "10)Integrative",
        "label": "CARDINAL"
      },
      {
        "text": "Pharmacology and Systems Neuroscience Research Group",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Spain.",
    "entities": [
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(11)Clinical Research Unit, Neuroscience Research Program, Hospital del Mar",
    "entities": [
      {
        "text": "11)Clinical Research Unit",
        "label": "ORG"
      },
      {
        "text": "Neuroscience Research Program",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Research Institute, Barcelona, Spain.",
    "entities": [
      {
        "text": "Research Institute",
        "label": "ORG"
      },
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(12)Barcelona\u03b2eta Brain Research Center (BBRC), Pasqual Maragall Foundation,",
    "entities": [
      {
        "text": "Brain Research Center",
        "label": "ORG"
      },
      {
        "text": "Pasqual Maragall Foundation",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(13)Integrative Pharmacology and Systems Neuroscience Research Group,",
    "entities": [
      {
        "text": "13)Integrative Pharmacology and Systems Neuroscience Research Group",
        "label": "MONEY"
      }
    ]
  },
  {
    "text": "(14)Integrative Pharmacology and Systems Neuroscience Research Group,",
    "entities": [
      {
        "text": "14)Integrative Pharmacology and Systems Neuroscience Research Group",
        "label": "MONEY"
      }
    ]
  },
  {
    "text": "Spain; Department of Statistics and Operations Research, Universitat Polit\u00e8cnica",
    "entities": [
      {
        "text": "Spain",
        "label": "GPE"
      },
      {
        "text": "Department of Statistics and Operations Research",
        "label": "ORG"
      },
      {
        "text": "Universitat Polit\u00e8cnica",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(15)Integrative Pharmacology and Systems Neuroscience Research Group,",
    "entities": [
      {
        "text": "15)Integrative Pharmacology and Systems Neuroscience Research Group",
        "label": "MONEY"
      }
    ]
  },
  {
    "text": "Barcelona, Spain; Centre for Genomic Regulation (CRG), The Barcelona Institute",
    "entities": [
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      },
      {
        "text": "Centre for Genomic Regulation",
        "label": "ORG"
      },
      {
        "text": "CRG",
        "label": "ORG"
      },
      {
        "text": "The Barcelona Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Science and Technology, Barcelona, Spain; CIBER de Enfermedades Raras",
    "entities": [
      {
        "text": "Science and Technology",
        "label": "ORG"
      },
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      },
      {
        "text": "CIBER de Enfermedades Raras",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(16)Attention to Chronicity and Innovation in Health (GRACIS), Escola Superior",
    "entities": [
      {
        "text": "16)Attention",
        "label": "CARDINAL"
      },
      {
        "text": "Chronicity and Innovation in Health",
        "label": "ORG"
      },
      {
        "text": "Escola Superior\n",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "(17)Barcelona\u03b2eta Brain Research Center (BBRC), Pasqual Maragall Foundation,",
    "entities": [
      {
        "text": "Brain Research Center",
        "label": "ORG"
      },
      {
        "text": "Pasqual Maragall Foundation",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(18)Integrative Pharmacology and Systems Neuroscience Research Group,",
    "entities": [
      {
        "text": "18)Integrative Pharmacology and Systems Neuroscience Research Group",
        "label": "MONEY"
      }
    ]
  },
  {
    "text": "Carlos III, Madrid, Spain; Department of Medicine and Life Sciences, Universitat",
    "entities": [
      {
        "text": "Carlos III",
        "label": "PERSON"
      },
      {
        "text": "Madrid",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      },
      {
        "text": "Department of Medicine and Life Sciences",
        "label": "ORG"
      },
      {
        "text": "Universitat",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BACKGROUND: The potential of dietary compounds to enhance the effects of",
    "entities": []
  },
  {
    "text": "multimodal lifestyle interventions (MLIs) on cognition in individuals at high",
    "entities": []
  },
  {
    "text": "risk of cognitive impairment remains unclear.",
    "entities": []
  },
  {
    "text": "OBJECTIVES: To assess whether the addition of a green tea extract enriched with",
    "entities": [
      {
        "text": "OBJECTIVES",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "epigallocatechin-3-gallate (EGCG) enhances the effects of an MLI.",
    "entities": [
      {
        "text": "MLI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "DESIGN: Double-blind, randomized, two-arm, and placebo-controlled trial.",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Exploratory comparisons were made with a non-randomized group (NRG) receiving",
    "entities": [
      {
        "text": "NRG",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "healthy lifestyle recommendations.",
    "entities": []
  },
  {
    "text": "SETTING: Population-based study conducted in Barcelona, Spain PARTICIPANTS:",
    "entities": [
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "APOE-\u025b4 carriers aged 60-80 with subjective cognitive decline INTERVENTION: A",
    "entities": [
      {
        "text": "60-80",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "12-month intensive MLI including dietary counseling, guided physical activity,",
    "entities": [
      {
        "text": "12-month",
        "label": "DATE"
      },
      {
        "text": "MLI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and cognitive stimulation, combined with EGCG (5-6 mg/kg) or placebo, followed",
    "entities": [
      {
        "text": "EGCG",
        "label": "ORG"
      },
      {
        "text": "5-6",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "by a 3-month washout.",
    "entities": [
      {
        "text": "3-month",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "MEASUREMENTS: Primary endpoint was change in the modified Preclinical Alzheimer",
    "entities": [
      {
        "text": "Preclinical Alzheimer\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RESULTS: 129 participants (65.1% 84 women, aged 66.7\u00b15.5 years) were enrolled",
    "entities": [
      {
        "text": "129",
        "label": "CARDINAL"
      },
      {
        "text": "65.1%",
        "label": "PERCENT"
      },
      {
        "text": "84",
        "label": "CARDINAL"
      },
      {
        "text": "66.7\u00b15.5 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(52 MLI+EGCG, 52 MLI+placebo and 25 NRG), with126 (97.7%) included in the",
    "entities": [
      {
        "text": "52 MLI+EGCG",
        "label": "QUANTITY"
      },
      {
        "text": "52",
        "label": "CARDINAL"
      },
      {
        "text": "25",
        "label": "CARDINAL"
      },
      {
        "text": "97.7%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "modified intention-to-treat analysis. After 12 months, no statistically",
    "entities": [
      {
        "text": "12 months",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "significant difference was observed between MLI+EGCG and MLI+placebo in the",
    "entities": [
      {
        "text": "MLI+placebo",
        "label": "LANGUAGE"
      }
    ]
  },
  {
    "text": "PACC-exe (adjusted mean difference [AMD]: 0.12; 95%CI: -0.01, 0.24; p=0.061).",
    "entities": [
      {
        "text": "0.12",
        "label": "CARDINAL"
      },
      {
        "text": "0.24",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "However, participants in the MLI+EGCG group were 2.6 times more likely to show a",
    "entities": [
      {
        "text": "MLI+EGCG",
        "label": "NORP"
      },
      {
        "text": "2.6",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "reliable cognitive improvement. In exploratory analyses following a 3-month",
    "entities": [
      {
        "text": "3-month",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "washout, the MLI+EGCG group showed significant cognitive benefits compared to",
    "entities": [
      {
        "text": "MLI+EGCG",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "the MLI+placebo (AMD: 0.19; 95%CI: 0.06, 0.32; p=0.005). Exploratory comparisons",
    "entities": [
      {
        "text": "MLI+placebo",
        "label": "PRODUCT"
      },
      {
        "text": "AMD",
        "label": "ORG"
      },
      {
        "text": "0.19",
        "label": "CARDINAL"
      },
      {
        "text": "0.06",
        "label": "CARDINAL"
      },
      {
        "text": "0.32",
        "label": "CARDINAL"
      },
      {
        "text": "p=0.005",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "with the NRG also suggested greater gains in cognition and dementia risk",
    "entities": [
      {
        "text": "NRG",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "reduction in both MLI groups, particularly with EGCG.",
    "entities": [
      {
        "text": "MLI",
        "label": "ORG"
      },
      {
        "text": "EGCG",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CONCLUSIONS: While the primary outcome was not met, this proof-of-concept trial",
    "entities": []
  },
  {
    "text": "suggests that combining MLIs with EGCG warrants further investigation in larger,",
    "entities": []
  },
  {
    "text": "confirmatory studies.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025. Published by Elsevier Masson SAS.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Elsevier Masson SAS",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declaration of Competing interests The authors",
    "entities": []
  },
  {
    "text": "declare the following financial interests/personal relationships which may be",
    "entities": []
  },
  {
    "text": "considered as potential competing interests: Jose Luis Molinuevo reports a",
    "entities": [
      {
        "text": "Jose Luis Molinuevo",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "relationship with H Lundbeck that includes: employment. If there are other",
    "entities": [
      {
        "text": "H Lundbeck",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "authors, they declare that they have no known competing financial interests or",
    "entities": []
  },
  {
    "text": "personal relationships that could have appeared to influence the work reported",
    "entities": []
  },
  {
    "text": "in this paper.",
    "entities": []
  },
  {
    "text": "10.1016/j.compbiomed.2025.110762. Online ahead of print.",
    "entities": [
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "ML-based prediction to experimental validation: Development of",
    "entities": [
      {
        "text": "ML",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "dihydroquinazoline based multi-potent ligands as anti-Alzheimer's agents.",
    "entities": []
  },
  {
    "text": "(1)Laboratory of Organic and Medicinal Chemistry, Department of Chemistry,",
    "entities": [
      {
        "text": "Organic and Medicinal Chemistry",
        "label": "ORG"
      },
      {
        "text": "Department of Chemistry",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Central University of Punjab, Bathinda, 151401, India; Department of",
    "entities": [
      {
        "text": "Central University of Punjab",
        "label": "ORG"
      },
      {
        "text": "Bathinda",
        "label": "ORG"
      },
      {
        "text": "151401",
        "label": "DATE"
      },
      {
        "text": "India",
        "label": "GPE"
      },
      {
        "text": "Department of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Pharmaceutical Sciences and Natural Products, Central University of Punjab,",
    "entities": [
      {
        "text": "Pharmaceutical Sciences",
        "label": "ORG"
      },
      {
        "text": "Natural Products",
        "label": "ORG"
      },
      {
        "text": "Central University of Punjab",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Laboratory of Organic and Medicinal Chemistry, Department of Chemistry,",
    "entities": [
      {
        "text": "2)Laboratory",
        "label": "CARDINAL"
      },
      {
        "text": "Organic and Medicinal Chemistry",
        "label": "ORG"
      },
      {
        "text": "Department of Chemistry",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Central University of Punjab, Bathinda, 151401, India.",
    "entities": [
      {
        "text": "Central University of Punjab",
        "label": "ORG"
      },
      {
        "text": "Bathinda",
        "label": "ORG"
      },
      {
        "text": "151401",
        "label": "DATE"
      },
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Pharmacology, Central University of Punjab, Bathinda, 151401,",
    "entities": [
      {
        "text": "Pharmacology, Central University of Punjab",
        "label": "ORG"
      },
      {
        "text": "Bathinda",
        "label": "ORG"
      },
      {
        "text": "151401",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(4)Department of Pharmaceutical Sciences and Natural Products, Central",
    "entities": [
      {
        "text": "Pharmaceutical Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of Punjab, Bathinda, 151401, India.",
    "entities": [
      {
        "text": "University of Punjab",
        "label": "ORG"
      },
      {
        "text": "Bathinda",
        "label": "ORG"
      },
      {
        "text": "151401",
        "label": "DATE"
      },
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Laboratory of Organic and Medicinal Chemistry, Department of Chemistry,",
    "entities": [
      {
        "text": "Organic and Medicinal Chemistry",
        "label": "ORG"
      },
      {
        "text": "Department of Chemistry",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Central University of Punjab, Bathinda, 151401, India. Electronic address:",
    "entities": [
      {
        "text": "Central University of Punjab",
        "label": "ORG"
      },
      {
        "text": "Bathinda",
        "label": "ORG"
      },
      {
        "text": "151401",
        "label": "DATE"
      },
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Alzheimer's disease (AD) is a multifactorial neurological disorder accounting",
    "entities": []
  },
  {
    "text": "for the cognitive decline in the patients. The disease is linked to numerous",
    "entities": []
  },
  {
    "text": "pathological factors including hyperactivation of acetylcholinesterase (AChE)",
    "entities": []
  },
  {
    "text": "and monoamine oxidase B (MAO-B), accumulation of amyloid-beta (A\u03b2) plaques and",
    "entities": []
  },
  {
    "text": "neurofibrillary tangles in the brain etc. The single-target medications already",
    "entities": []
  },
  {
    "text": "available in the market are found to be ineffective and the research focus is",
    "entities": []
  },
  {
    "text": "shifting towards the development of multitargeting agents. In order to find a",
    "entities": []
  },
  {
    "text": "multi-potent inhibitor against AChE, MAO-B and A\u03b21-42, in the present study we",
    "entities": [
      {
        "text": "AChE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "employed a machine learning-based tool, PyRMD, to screen an in-house generated",
    "entities": []
  },
  {
    "text": "library of dihydroquinazoline derivatives. This screening process identified six",
    "entities": [
      {
        "text": "six",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "promising compounds, KV-271, KV-832, KV-968, KV-1131, KV-1159, KV-1234 with dual",
    "entities": [
      {
        "text": "KV-1131",
        "label": "GPE"
      },
      {
        "text": "KV-1159",
        "label": "DATE"
      },
      {
        "text": "KV-1234",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "inhibition potential against AChE and MAO-B enzymes. In the docking studies,",
    "entities": [
      {
        "text": "AChE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "these compounds showed good interactions at the active cavity of the AChE and",
    "entities": [
      {
        "text": "AChE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "MAO-B comparable to the standard inhibitors donepezil (AChE) and pargyline",
    "entities": []
  },
  {
    "text": "(MAO-B). To validate these predictions, the six identified compounds were",
    "entities": [
      {
        "text": "six",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "synthesized and subjected to in vitro enzymatic assays. All the six compounds",
    "entities": [
      {
        "text": "six",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "displayed significant inhibitory activity, with IC50 values below 5 \u03bcM for both",
    "entities": [
      {
        "text": "5",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "AChE and MAO-B. Amongst these compounds, KV-1131 and KV-1234 were found to be",
    "entities": [
      {
        "text": "MAO-B. Amongst",
        "label": "PERSON"
      },
      {
        "text": "KV-1131",
        "label": "GPE"
      },
      {
        "text": "KV-1234",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "the most potent inhibitors with IC50 values of 0.93 \u03bcM and 0.85 \u03bcM against AChE",
    "entities": [
      {
        "text": "0.93",
        "label": "CARDINAL"
      },
      {
        "text": "0.85",
        "label": "CARDINAL"
      },
      {
        "text": "AChE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and IC50 values of 1.17 \u03bcM and 0.79 \u03bcM against MAO-B, respectively. In addition,",
    "entities": [
      {
        "text": "1.17",
        "label": "CARDINAL"
      },
      {
        "text": "0.79",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "KV-1131 and KV-1234 exhibited inhibitory activity against A\u03b21-42",
    "entities": [
      {
        "text": "KV-1131",
        "label": "GPE"
      },
      {
        "text": "KV-1234",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "self-aggregation inhibition of 34.79 % and 45.70 %, respectively, after 48 h of",
    "entities": [
      {
        "text": "34.79 %",
        "label": "PERCENT"
      },
      {
        "text": "45.70 %",
        "label": "PERCENT"
      },
      {
        "text": "48",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "incubation. Both KV-1131 and KV-1234 were found to be non-toxic up to 10 \u03bcM",
    "entities": [
      {
        "text": "KV-1131",
        "label": "GPE"
      },
      {
        "text": "KV-1234",
        "label": "PERSON"
      },
      {
        "text": "up to",
        "label": "CARDINAL"
      },
      {
        "text": "10",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "concentration and showed neuroprotective potential against 6-hydroxydopamine",
    "entities": [
      {
        "text": "6",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "induced neurotoxicity in the SHSY-5Y cells. Thus, KV-1131 and KV-1234 were",
    "entities": [
      {
        "text": "SHSY-5Y",
        "label": "PRODUCT"
      },
      {
        "text": "KV-1131",
        "label": "GPE"
      },
      {
        "text": "KV-1234",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "identified as potent leads that can be developed as drug candidates for the",
    "entities": []
  },
  {
    "text": "treatment of Alzheimer's disease.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025. Published by Elsevier Ltd.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Elsevier Ltd.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "DOI: 10.1016/j.compbiomed.2025.110762",
    "entities": [
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declaration of competing interest The authors",
    "entities": []
  },
  {
    "text": "declare that they have no known competing financial interests or personal",
    "entities": []
  },
  {
    "text": "relationships that could have appeared to influence the work reported in this",
    "entities": []
  },
  {
    "text": "A hydrogen bond-triggered excimer probe for dynamic monitoring of aspartic acid",
    "entities": []
  },
  {
    "text": "(1)School of Chemistry and Chemical Engineering, Southeast University, Nanjing,",
    "entities": [
      {
        "text": "1)School of",
        "label": "ORG"
      },
      {
        "text": "Chemistry and Chemical Engineering",
        "label": "ORG"
      },
      {
        "text": "Southeast University",
        "label": "ORG"
      },
      {
        "text": "Nanjing",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)School of Chemistry and Chemical Engineering, Southeast University, Nanjing,",
    "entities": [
      {
        "text": "Chemistry and Chemical Engineering",
        "label": "ORG"
      },
      {
        "text": "Southeast University",
        "label": "ORG"
      },
      {
        "text": "Nanjing",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Jiangsu 211189, PR China. Electronic address: qizhengjian@seu.edu.cn.",
    "entities": [
      {
        "text": "211189",
        "label": "DATE"
      },
      {
        "text": "PR China",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "exhibit concentration abnormalities closely associated with epilepsy,",
    "entities": []
  },
  {
    "text": "Alzheimer's disease, and other neurological disorders. However, current",
    "entities": []
  },
  {
    "text": "detection methods face limitations in selectivity, sensitivity, and",
    "entities": []
  },
  {
    "text": "practicality. In this study, we developed a series of novel D-\u03c0-A structured",
    "entities": []
  },
  {
    "text": "fluorescent probes (PM-1, PM-2, PM-3, and PM-4), Among which PM-4 demonstrates",
    "entities": []
  },
  {
    "text": "weak monomer emission (540 nm) in aqueous solution. The pyridine side chain of",
    "entities": [
      {
        "text": "540",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "PM-4 forms hydrogen bonds with the dual carboxylate groups of Asp/Glu,",
    "entities": [
      {
        "text": "Asp/Glu",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "triggering the formation of emissive excimers. This process generates a new,",
    "entities": []
  },
  {
    "text": "enhanced red-shifted emission peak at 630 nm, enabling specific detection. The",
    "entities": [
      {
        "text": "630",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "detection limits reached 1.26 \u03bcM (Asp) and 1.29 \u03bcM (Glu), with high selectivity.",
    "entities": [
      {
        "text": "1.26",
        "label": "CARDINAL"
      },
      {
        "text": "1.29",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "The formation mechanism of the probe-analyte complex was confirmed by NMR",
    "entities": [
      {
        "text": "NMR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "titration experiments. PM-4 successfully monitored diurnal fluctuations of",
    "entities": []
  },
  {
    "text": "Asp/Glu in saliva samples from healthy volunteers and concentration variations",
    "entities": [
      {
        "text": "Asp/Glu",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "after smoking, revealing a correlation with emotional states (e.g., peak",
    "entities": []
  },
  {
    "text": "concentrations observed 10 min after smoking). The developed PM-4 probe",
    "entities": [
      {
        "text": "10",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "integrates high sensitivity, selectivity, providing a powerful analytical tool",
    "entities": []
  },
  {
    "text": "for neurometabolic studies and disease biomarker detection. Its demonstrated",
    "entities": []
  },
  {
    "text": "performance highlights promising potential for both fundamental research and",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 Elsevier B.V. All rights reserved.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "50. IEEE Trans Med Imaging. 2025 Jul 15;PP. doi: 10.1109/TMI.2025.3588859. Online",
    "entities": [
      {
        "text": "50",
        "label": "CARDINAL"
      },
      {
        "text": "Trans Med Imaging",
        "label": "ORG"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.1109",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "ahead of print.",
    "entities": []
  },
  {
    "text": "Bayesian Posterior Distribution Estimation of Kinetic Parameters in Dynamic",
    "entities": [
      {
        "text": "Bayesian Posterior Distribution Estimation of Kinetic Parameters",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Brain PET Using Generative Deep Learning Models.",
    "entities": [
      {
        "text": "Brain PET Using Generative Deep Learning Models",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Positron Emission Tomography (PET) is a valuable imaging method for studying",
    "entities": [
      {
        "text": "PET",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "molecular-level processes in the body, such as hyperphosphorylated tau (p-tau)",
    "entities": []
  },
  {
    "text": "protein aggregates, a hallmark of several neurodegenerative diseases including",
    "entities": []
  },
  {
    "text": "Alzheimer's disease. P-tau density and cerebral perfusion can be quantified from",
    "entities": []
  },
  {
    "text": "dynamic PET images using tracer kinetic modeling techniques. However, noise in",
    "entities": [
      {
        "text": "PET",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PET images leads to uncertainty in the estimated kinetic parameters, which can",
    "entities": [
      {
        "text": "PET",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "be quantified by estimating the posterior distribution of kinetic parameters",
    "entities": []
  },
  {
    "text": "using Bayesian inference (BI). Markov Chain Monte Carlo (MCMC) techniques are",
    "entities": [
      {
        "text": "Bayesian",
        "label": "NORP"
      },
      {
        "text": "BI",
        "label": "ORG"
      },
      {
        "text": "Markov Chain Monte Carlo",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "commonly used for posterior estimation but with significant computational needs.",
    "entities": []
  },
  {
    "text": "This work proposes an Improved Denoising Diffusion Probabilistic Model",
    "entities": []
  },
  {
    "text": "(iDDPM)-based method to estimate the posterior distribution of kinetic",
    "entities": []
  },
  {
    "text": "parameters in dynamic PET, leveraging the high computational efficiency of deep",
    "entities": [
      {
        "text": "PET",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "learning. The performance of the proposed method was evaluated on a [18F]MK6240",
    "entities": [
      {
        "text": "18F]MK6240",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "study and compared to a Conditional Variational Autoencoder with dual decoder",
    "entities": []
  },
  {
    "text": "(CVAE-DD)-based method and a Wasserstein GAN with gradient penalty",
    "entities": [
      {
        "text": "Wasserstein",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(WGAN-GP)-based method. Posterior distributions inferred from Metropolis-Hasting",
    "entities": [
      {
        "text": "Metropolis-Hasting",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "MCMC were used as reference. Our approach consistently outperformed the CVAE-DD",
    "entities": []
  },
  {
    "text": "and WGAN-GP methods and offered significant reduction in computation time than",
    "entities": [
      {
        "text": "WGAN",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the MCMC method (over 230 times faster), inferring accurate (< 0.67% mean error)",
    "entities": [
      {
        "text": "MCMC",
        "label": "ORG"
      },
      {
        "text": "over 230",
        "label": "CARDINAL"
      },
      {
        "text": "0.67%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "and precise (< 7.23% standard deviation error) posterior distributions.",
    "entities": [
      {
        "text": "7.23%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "51. IEEE J Biomed Health Inform. 2025 Jul 15;PP. doi: 10.1109/JBHI.2025.3589290.",
    "entities": [
      {
        "text": "51",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.1109",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "A Hierarchical Attention-based Negative Sampling Method for Drug Repositioning",
    "entities": [
      {
        "text": "Negative Sampling Method for Drug Repositioning\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Using Neighborhood Interaction Fusion.",
    "entities": [
      {
        "text": "Using Neighborhood Interaction Fusion",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Accurate prediction of drug-disease associations (DDAs) is essential for drug",
    "entities": []
  },
  {
    "text": "repositioning and the development of novel therapeutic strategies. However,",
    "entities": []
  },
  {
    "text": "existing methods often suffer from limited prior knowledge and the use of",
    "entities": []
  },
  {
    "text": "oversimplified negative sampling techniques, which hinder their ability to",
    "entities": []
  },
  {
    "text": "capture the complex relationships between drugs and diseases. To break through",
    "entities": []
  },
  {
    "text": "these limitations, we propose a new model, Hierarchical Attention",
    "entities": [
      {
        "text": "Hierarchical Attention",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Mechanism-Based Negative Sampling (HA-NegS), which aims to enhance the",
    "entities": [
      {
        "text": "Mechanism-Based Negative Sampling",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "prediction of potential DDAs. In this study, HA-NegS further computes the",
    "entities": []
  },
  {
    "text": "similarity information between drugs and diseases and constructs heterogeneous",
    "entities": []
  },
  {
    "text": "and homogeneous networks based on it. For the similarity network, HA-NegS fuses",
    "entities": []
  },
  {
    "text": "Graph Convolutional Network (GCN) and Graph Attention Network (GAT) to",
    "entities": [
      {
        "text": "Graph Convolutional Network",
        "label": "ORG"
      },
      {
        "text": "GCN",
        "label": "ORG"
      },
      {
        "text": "Graph Attention Network",
        "label": "ORG"
      },
      {
        "text": "GAT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "effectively capture the neighborhood features of the target nodes. Subsequently,",
    "entities": []
  },
  {
    "text": "the model incorporates a hierarchical sampling strategy using the PageRank",
    "entities": [
      {
        "text": "PageRank",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "algorithm to rank nodes in descending order of global importance. The attention",
    "entities": []
  },
  {
    "text": "mechanism is then used to calculate the attention score and re-rank the nodes",
    "entities": []
  },
  {
    "text": "accordingly. This approach ensures the reliability of the negative sample",
    "entities": []
  },
  {
    "text": "selection. In order to obtain optimized representations, we use graph",
    "entities": []
  },
  {
    "text": "contrastive learning methods to refine drug and disease features with",
    "entities": []
  },
  {
    "text": "homogeneous and heterogeneous neighborhood information. Experimental results on",
    "entities": []
  },
  {
    "text": "a benchmark dataset show that HA-NegS outperforms existing baseline methods in",
    "entities": []
  },
  {
    "text": "predicting DDA. In addition, case studies for Alzheimer's disease and",
    "entities": []
  },
  {
    "text": "Parkinson's disease highlight the effectiveness of HA-NegS in discovering new",
    "entities": [
      {
        "text": "HA-NegS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "therapeutic applications for existing drugs.",
    "entities": []
  },
  {
    "text": "Peripheral administration of blood from tau transgenic animals exacerbates brain",
    "entities": []
  },
  {
    "text": "tau-associated pathology.",
    "entities": []
  },
  {
    "text": "(1)Department of Cell Biology, Genetics and Physiology, Instituto de",
    "entities": [
      {
        "text": "Cell Biology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Investigacion Biomedica de Malaga - IBIMA-Plataforma Bionand, Faculty of",
    "entities": [
      {
        "text": "Investigacion Biomedica de Malaga - IBIMA-Plataforma Bionand",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Sciences, Malaga University, Malaga, Spain.",
    "entities": [
      {
        "text": "Malaga University",
        "label": "ORG"
      },
      {
        "text": "Malaga",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibanez,",
    "entities": [
      {
        "text": "2)Latin",
        "label": "CARDINAL"
      },
      {
        "text": "American Brain Health Institute",
        "label": "ORG"
      },
      {
        "text": "BrainLat",
        "label": "ORG"
      },
      {
        "text": "Ibanez",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Center for Social and Cognitive Neuroscience (CSCN), School of Psychology,",
    "entities": [
      {
        "text": "Social and Cognitive Neuroscience",
        "label": "ORG"
      },
      {
        "text": "CSCN",
        "label": "ORG"
      },
      {
        "text": "School of Psychology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(8)Department of Neurology, The University of Texas Health Science Center at",
    "entities": [
      {
        "text": "Neurology",
        "label": "ORG"
      },
      {
        "text": "The University of Texas Health Science Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Houston, Houston, Texas, United States of America.",
    "entities": [
      {
        "text": "Houston",
        "label": "GPE"
      },
      {
        "text": "Houston",
        "label": "GPE"
      },
      {
        "text": "Texas",
        "label": "GPE"
      },
      {
        "text": "United States of America",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Bernardo O'Higgins, Santiago, Chile.",
    "entities": [
      {
        "text": "Bernardo O'Higgins",
        "label": "PERSON"
      },
      {
        "text": "Santiago",
        "label": "GPE"
      },
      {
        "text": "Chile",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "The accumulation of amyloid plaques and neurofibrillary tangles are pathological",
    "entities": []
  },
  {
    "text": "hallmarks of Alzheimer's disease (AD). While amyloid-beta propagation through",
    "entities": []
  },
  {
    "text": "prion-like mechanisms has been extensively studied in both central and",
    "entities": []
  },
  {
    "text": "peripheral pathways, the potential spreading of tau aggregates in the periphery",
    "entities": []
  },
  {
    "text": "remains largely unexplored. Emerging evidence suggests that hyperphosphorylated",
    "entities": []
  },
  {
    "text": "tau (ptau) aggregates may propagate beyond the central nervous system, as they",
    "entities": []
  },
  {
    "text": "have been detected in peripheral tissues and biological fluids from humans and",
    "entities": []
  },
  {
    "text": "mouse models of tauopathies. However, whether peripheral ptau aggregates or",
    "entities": [
      {
        "text": "mouse",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "other factors associated to its accumulation contribute to brain pathology",
    "entities": []
  },
  {
    "text": "remains unclear. In this study, we investigate the contribution of peripheral",
    "entities": []
  },
  {
    "text": "blood from aged P301S tau transgenic mice to tau-associated brain pathology.",
    "entities": []
  },
  {
    "text": "Blood was administered via intraperitoneal and intravenous routes to assess",
    "entities": []
  },
  {
    "text": "their effect on cognitive and motor impairment, ptau accumulation, and glial",
    "entities": []
  },
  {
    "text": "response. Our findings reveal that inoculation of blood from aged P301S mice",
    "entities": []
  },
  {
    "text": "increases tau pathology in the hippocampus, exacerbates motor and cognitive",
    "entities": []
  },
  {
    "text": "impairment, and elevates glial response. These results underscore the potential",
    "entities": []
  },
  {
    "text": "role of peripheral factors in driving brain pathology, supporting the hypothesis",
    "entities": []
  },
  {
    "text": "that blood from affected individuals contributes to the progression of",
    "entities": []
  },
  {
    "text": "tau-related neurodegeneration. Elucidating the mechanisms of tau dissemination",
    "entities": []
  },
  {
    "text": "could provide critical insights into disease progression and strengthen the",
    "entities": []
  },
  {
    "text": "rationale for targeting tau as a therapeutic strategy in AD and other",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "tauopathies.",
    "entities": []
  },
  {
    "text": "Copyright: \u00a9 2025 Vegas-Gomez et al. This is an open access article distributed",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Vegas-Gomez",
        "label": "PERSON"
      },
      {
        "text": "al",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "under the terms of the Creative Commons Attribution License, which permits",
    "entities": [
      {
        "text": "the Creative Commons Attribution License",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "unrestricted use, distribution, and reproduction in any medium, provided the",
    "entities": []
  },
  {
    "text": "original author and source are credited.",
    "entities": []
  },
  {
    "text": "PMID: 40663569 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40663569",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: The authors have no competing interests to",
    "entities": []
  },
  {
    "text": "53. J Nat Prod. 2025 Jul 15. doi: 10.1021/acs.jnatprod.5c00486. Online ahead of",
    "entities": [
      {
        "text": "53",
        "label": "CARDINAL"
      },
      {
        "text": "10.1021",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Bletistrosides M-X, Anti-Alzheimer's Disease Compounds from the Tubers of",
    "entities": [
      {
        "text": "Bletistrosides M-X",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)School of Pharmacy, Lanzhou University, Lanzhou, Gansu 730000, P. R. China.",
    "entities": [
      {
        "text": "1)School of Pharmacy",
        "label": "ORG"
      },
      {
        "text": "Lanzhou University",
        "label": "ORG"
      },
      {
        "text": "Lanzhou",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Chemistry Department, Faculty of Science, University of Malaya, 50603 Kuala",
    "entities": [
      {
        "text": "Department, Faculty of Science, University of Malaya",
        "label": "ORG"
      },
      {
        "text": "50603",
        "label": "CARDINAL"
      },
      {
        "text": "Kuala",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Institute of Natural Medicine and Health Products, School of Pharmaceutical",
    "entities": [
      {
        "text": "Natural Medicine and Health Products, School of Pharmaceutical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sciences, Zhejiang Provincial Key Laboratory of Plant Evolutionary Ecology and",
    "entities": [
      {
        "text": "Zhejiang Provincial Key Laboratory",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Conservation, Taizhou University, Taizhou Zhejiang 318000, PR China.",
    "entities": [
      {
        "text": "Taizhou University",
        "label": "ORG"
      },
      {
        "text": "Taizhou Zhejiang 318000",
        "label": "GPE"
      },
      {
        "text": "PR China",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Glasgow International College, University of Glasgow, Glasgow, G11 6NU,",
    "entities": [
      {
        "text": "4)Glasgow International College",
        "label": "ORG"
      },
      {
        "text": "University of Glasgow",
        "label": "ORG"
      },
      {
        "text": "Glasgow",
        "label": "GPE"
      },
      {
        "text": "G11 6NU",
        "label": "EVENT"
      }
    ]
  },
  {
    "text": "Scotland United Kingdom.",
    "entities": [
      {
        "text": "Scotland",
        "label": "GPE"
      },
      {
        "text": "United Kingdom",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Drug Discovery, Biomedical Sciences and Public Health, Medical University of",
    "entities": [
      {
        "text": "Discovery",
        "label": "PRODUCT"
      },
      {
        "text": "Biomedical Sciences",
        "label": "ORG"
      },
      {
        "text": "Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "South Carolina, Charleston, South Carolina 29425, United States.",
    "entities": [
      {
        "text": "South Carolina",
        "label": "GPE"
      },
      {
        "text": "Charleston",
        "label": "GPE"
      },
      {
        "text": "South Carolina",
        "label": "GPE"
      },
      {
        "text": "29425",
        "label": "DATE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Twelve new compounds, bletistrosides M-X (1-12), including five",
    "entities": [
      {
        "text": "Twelve",
        "label": "CARDINAL"
      },
      {
        "text": "1-12",
        "label": "CARDINAL"
      },
      {
        "text": "five",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "glucosyloxybenzyl 2-isobutylmalates (1-5), along with four neolignan glycosides",
    "entities": [
      {
        "text": "glucosyloxybenzyl",
        "label": "ORG"
      },
      {
        "text": "2-isobutylmalates",
        "label": "QUANTITY"
      },
      {
        "text": "four",
        "label": "CARDINAL"
      },
      {
        "text": "neolignan",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6-9), two phenanthrene derivatives (10-11), and one bibenzyl derivative (12),",
    "entities": [
      {
        "text": "6-9",
        "label": "DATE"
      },
      {
        "text": "two",
        "label": "CARDINAL"
      },
      {
        "text": "10-11",
        "label": "DATE"
      },
      {
        "text": "one",
        "label": "CARDINAL"
      },
      {
        "text": "12",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "were isolated from the tubers of Bletilla striata (B. striata). The structures",
    "entities": [
      {
        "text": "Bletilla",
        "label": "ORG"
      },
      {
        "text": "B.",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "and absolute configurations of the undescribed compounds were elucidated on the",
    "entities": []
  },
  {
    "text": "basis of spectroscopic data analysis, experimental and calculated electronic",
    "entities": []
  },
  {
    "text": "circular dichroism data, chiroptical analysis, and chemical derivatizations. In",
    "entities": []
  },
  {
    "text": "silico, compounds 2, 3, and 12 bound well to A\u03b21-42. Compounds 2, 3, and 12",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "3",
        "label": "DATE"
      },
      {
        "text": "12",
        "label": "CARDINAL"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "3",
        "label": "DATE"
      },
      {
        "text": "12",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "significantly delayed the paralysis phenotype in CL4176 worms compared to",
    "entities": [
      {
        "text": "CL4176",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "controls. Higher nonparalysis rates were observed in these treatment groups (5",
    "entities": [
      {
        "text": "5",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "\u03bcM for compound 2; 25, 50 \u03bcM for compounds 2, 3 and 12), suggesting their",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "25",
        "label": "DATE"
      },
      {
        "text": "50",
        "label": "CARDINAL"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "3",
        "label": "CARDINAL"
      },
      {
        "text": "12",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "potential role in anti-Alzheimer's disease.",
    "entities": []
  },
  {
    "text": "54. Am J Chin Med. 2025 Jul 15:1-23. doi: 10.1142/S0192415X25500569. Online ahead",
    "entities": [
      {
        "text": "54",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.1142",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "of print.",
    "entities": []
  },
  {
    "text": "Quercetin Ameliorates Learning and Memory in OVX/D-gal-Induced Alzheimer's",
    "entities": [
      {
        "text": "Quercetin Ameliorates Learning",
        "label": "PERSON"
      },
      {
        "text": "OVX",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Disease in Rats by Inhibiting Neuroinflammation via cGAS-STING Signal Pathway.",
    "entities": [
      {
        "text": "Inhibiting Neuroinflammation",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Pharmacy, Hebei North University, Zhangjiakou, Hebei 075000,",
    "entities": [
      {
        "text": "Hebei North University",
        "label": "ORG"
      },
      {
        "text": "Zhangjiakou",
        "label": "GPE"
      },
      {
        "text": "Hebei 075000",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Hebei Key Laboratory of Neuropharmacology, Zhangjiakou, Hebei 075000, China.",
    "entities": [
      {
        "text": "Key Laboratory of Neuropharmacology",
        "label": "ORG"
      },
      {
        "text": "Zhangjiakou",
        "label": "GPE"
      },
      {
        "text": "Hebei 075000",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Alzheimer's disease (AD) is an age-related degenerative disorder of the central",
    "entities": []
  },
  {
    "text": "nervous system. Neuroinflammation is considered a key factor in its etiology and",
    "entities": []
  },
  {
    "text": "progression. AD is more prevalent in women than men and may be related to",
    "entities": [
      {
        "text": "AD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "postmenopausal hormone deficiency. This study constructed an AD rat model by",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "bilateral ovariectomy (OVX) and intraperitoneal injection of D-galactose (D-gal)",
    "entities": [
      {
        "text": "OVX",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and an in vitro AD cell model was induced in PC12 cells using lipopolysaccharide",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(LPS). The Morris water maze test was employed to assess the impact of quercetin",
    "entities": [
      {
        "text": "LPS",
        "label": "ORG"
      },
      {
        "text": "Morris",
        "label": "PERSON"
      },
      {
        "text": "quercetin\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(Que) on learning and memory in OVX/D-gal rats. Immunohistochemistry was",
    "entities": [
      {
        "text": "Que",
        "label": "PERSON"
      },
      {
        "text": "OVX",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "utilized to assess the impact of Que on the expression of A\u03b2 protein, p-tau",
    "entities": [
      {
        "text": "Que",
        "label": "PERSON"
      },
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "protein, GFAP, and Iba1 in the hippocampus of OVX/D-gal rats. Nissl staining was",
    "entities": [
      {
        "text": "GFAP",
        "label": "GPE"
      },
      {
        "text": "OVX",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "performed to examine hippocampal pathological damage. ELISA was conducted to",
    "entities": [
      {
        "text": "ELISA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "measure serum estrogen levels and the release of inflammatory cytokines,",
    "entities": []
  },
  {
    "text": "specifically TNF-\u03b1 and IL-1\u03b2, in the hippocampus of OVX/D-gal rats. HE staining",
    "entities": [
      {
        "text": "TNF",
        "label": "ORG"
      },
      {
        "text": "IL-1\u03b2",
        "label": "ORG"
      },
      {
        "text": "OVX",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "was utilized to evaluate uterine pathological alterations in OVX/D-gal rats.",
    "entities": [
      {
        "text": "OVX",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Cell viability was assessed using the CCK-8 assay to determine the protective",
    "entities": [
      {
        "text": "CCK-8",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "effect of quercetin on LPS-induced PC12 cells. Western Blot analysis was",
    "entities": [
      {
        "text": "quercetin",
        "label": "GPE"
      },
      {
        "text": "LPS",
        "label": "ORG"
      },
      {
        "text": "Western Blot",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "conducted to evaluate the expression levels of estrogen receptors and the",
    "entities": [
      {
        "text": "estrogen",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "proteins associated with the cGAS-STING pathway in both in vitro and in vivo",
    "entities": []
  },
  {
    "text": "models. Protein-protein docking studies were performed to investigate the",
    "entities": []
  },
  {
    "text": "binding affinity between the estrogen receptor and proteins involved in the",
    "entities": [
      {
        "text": "estrogen",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "cGAS-STING signaling pathway. Results demonstrated that Que enhanced learning",
    "entities": [
      {
        "text": "Que",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "and memory capabilities in OVX/D-gal rats, alleviated hippocampal pathological",
    "entities": [
      {
        "text": "OVX",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "damage, reduced the expression of A\u03b2, p-tau, GFAP, and Iba1, and inhibited the",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      },
      {
        "text": "GFAP",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "release of inflammatory factors. Additionally, Que activated estrogen receptor",
    "entities": [
      {
        "text": "Que",
        "label": "PERSON"
      },
      {
        "text": "estrogen",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "expression and increased serum estrogen levels without exacerbating uterine",
    "entities": []
  },
  {
    "text": "lesions. Furthermore, Que activated the estrogen receptor in LPS-induced PC12",
    "entities": [
      {
        "text": "Que",
        "label": "PERSON"
      },
      {
        "text": "estrogen",
        "label": "ORDINAL"
      },
      {
        "text": "LPS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cells, which inhibited the release of IL-6 and exerted neuroprotective effects.",
    "entities": [
      {
        "text": "IL-6",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Que also suppressed the expression of proteins associated with the cGAS-STING",
    "entities": [
      {
        "text": "Que",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "pathway both in vitro and in vivo. Estrogen receptors exhibited strong binding",
    "entities": []
  },
  {
    "text": "affinity with cGAS-STING pathway proteins. In conclusion, Que can inhibit",
    "entities": [
      {
        "text": "Que",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "neuroinflammation in vitro and in vivo, enhance learning and memory in OVX/D-gal",
    "entities": [
      {
        "text": "OVX",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "rats, and exert neuroprotective effects. The underlying mechanism may involve",
    "entities": []
  },
  {
    "text": "the inhibition of the cGAS-STING signaling pathway, and the estrogen receptor",
    "entities": [
      {
        "text": "estrogen",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "potentially influences this pathway directly or indirectly.",
    "entities": []
  },
  {
    "text": "55. J Clin Invest. 2025 Jul 15:e182702. doi: 10.1172/JCI182702. Online ahead of",
    "entities": [
      {
        "text": "55",
        "label": "CARDINAL"
      },
      {
        "text": "Clin Invest",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1172/JCI182702",
        "label": "MONEY"
      }
    ]
  },
  {
    "text": "Efficacy and safety of a therapeutic humanized FSH-blocking antibody in obesity",
    "entities": [
      {
        "text": "FSH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and Alzheimer's disease models.",
    "entities": []
  },
  {
    "text": "(1)Mount Sinai Center for Translational Medicine, Icahn School of Medicine at",
    "entities": [
      {
        "text": "1)Mount",
        "label": "TIME"
      },
      {
        "text": "Sinai Center for Translational Medicine",
        "label": "ORG"
      },
      {
        "text": "Icahn School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Mount Sinai, New York, United States of America.",
    "entities": [
      {
        "text": "Mount Sinai",
        "label": "GPE"
      },
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "United States of America",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Greehey Children's Cancer Research Institute, University of Texas Health",
    "entities": [
      {
        "text": "Cancer Research Institute",
        "label": "ORG"
      },
      {
        "text": "University of Texas Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Science Center at San Antonio, San Antonio, United States of America.",
    "entities": [
      {
        "text": "San Antonio",
        "label": "GPE"
      },
      {
        "text": "San Antonio",
        "label": "GPE"
      },
      {
        "text": "United States of America",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Northeastern Collaborative Access Team, Department of Chemistry and Chemica,",
    "entities": [
      {
        "text": "Collaborative Access Team,",
        "label": "ORG"
      },
      {
        "text": "Department of Chemistry",
        "label": "ORG"
      },
      {
        "text": "Chemica",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Cornell University, Ithaca, United States of America.",
    "entities": [
      {
        "text": "Cornell University",
        "label": "ORG"
      },
      {
        "text": "Ithaca",
        "label": "GPE"
      },
      {
        "text": "United States of America",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)BioMedical Engineering and Imaging Institute, Icahn School of Medicine at",
    "entities": [
      {
        "text": "Imaging Institute",
        "label": "ORG"
      },
      {
        "text": "Icahn School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Department of Pathology-Comparative Medicine, Wake Forest University School",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Pathology-Comparative Medicine",
        "label": "ORG"
      },
      {
        "text": "Wake Forest University School",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Medicine, Winston-Salem, United States of America.",
    "entities": [
      {
        "text": "Winston-Salem",
        "label": "GPE"
      },
      {
        "text": "United States of America",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's",
    "entities": []
  },
  {
    "text": "Hospital, Harvard Medical School, Boston, United States of America.",
    "entities": [
      {
        "text": "Harvard Medical School",
        "label": "ORG"
      },
      {
        "text": "Boston",
        "label": "GPE"
      },
      {
        "text": "United States of America",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Institute of Systems, Molecular and Integrative Biology, University of",
    "entities": [
      {
        "text": "Integrative Biology, University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Liverpool, Liverpool, United Kingdom.",
    "entities": [
      {
        "text": "Liverpool",
        "label": "GPE"
      },
      {
        "text": "Liverpool",
        "label": "GPE"
      },
      {
        "text": "United Kingdom",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)School of Pharmacy, University College, London, United Kingdom.",
    "entities": [
      {
        "text": "Pharmacy, University College",
        "label": "ORG"
      },
      {
        "text": "London",
        "label": "GPE"
      },
      {
        "text": "United Kingdom",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)5MaineHealth Institute for Research, Scarborough, United States of America.",
    "entities": [
      {
        "text": "Institute for Research",
        "label": "ORG"
      },
      {
        "text": "Scarborough",
        "label": "GPE"
      },
      {
        "text": "United States of America",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "There is growing evidence for direct actions of follicle-stimulating hormone",
    "entities": []
  },
  {
    "text": "(FSH) on tissues other than the ovaries and testes. Blocking FSH action, either",
    "entities": [
      {
        "text": "FSH",
        "label": "ORG"
      },
      {
        "text": "FSH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "genetically or pharmacologically, protects against bone loss, fat gain, and",
    "entities": []
  },
  {
    "text": "memory loss in mice. We thus developed a humanized FSH-blocking",
    "entities": [
      {
        "text": "FSH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "antibody--MS-Hu6--as a lead therapeutic for three diseases of public health",
    "entities": [
      {
        "text": "three",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "magnitude--osteoporosis, obesity and Alzheimer's disease (AD) that track",
    "entities": []
  },
  {
    "text": "together in post-menopausal women. Here, we report the crystal structure of",
    "entities": [
      {
        "text": "crystal",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "MS-Hu6 and its interaction with FSH in atomistic detail. Using our",
    "entities": [
      {
        "text": "FSH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Good-Laboratory-Practice-Compliant platform (21CFR58), we formulated MS-Hu6 and",
    "entities": [
      {
        "text": "Good-Laboratory-Practice-Compliant",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the murine equivalent Hf2 at an ultra-high concentration; both formulated",
    "entities": []
  },
  {
    "text": "antibodies displayed enhanced thermal and colloidal stability. A single",
    "entities": []
  },
  {
    "text": "injection of 89Zr-labelled MS-Hu6 revealed a beta-phase t\u00bd of 89 and 131 hours",
    "entities": [
      {
        "text": "89 and 131 hours",
        "label": "TIME"
      }
    ]
  },
  {
    "text": "for female and male mice, respectively, with retention in regions of interest.",
    "entities": []
  },
  {
    "text": "Female mice injected subcutaneously with Hf2 displayed a dose-dependent",
    "entities": []
  },
  {
    "text": "reduction in body weight and body fat. Hf2 also rescued recognition memory and",
    "entities": []
  },
  {
    "text": "spatial learning loss in a context- and time-dependent manner in AD-prone 3xTg",
    "entities": [
      {
        "text": "AD-prone 3xTg",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "and APP/PS1 mice. MS-Hu6 injected into African green monkeys (8 mg/kg)",
    "entities": [
      {
        "text": "APP",
        "label": "ORG"
      },
      {
        "text": "African",
        "label": "NORP"
      },
      {
        "text": "8 mg/kg",
        "label": "QUANTITY"
      }
    ]
  },
  {
    "text": "intravenously, and then subcutaneously at monthly intervals, was safe, and",
    "entities": [
      {
        "text": "monthly",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "without effects on vitals, blood chemistries or blood counts. There was a",
    "entities": []
  },
  {
    "text": "notable ~4% weight loss in all four monkeys after the first injection, which",
    "entities": [
      {
        "text": "~4",
        "label": "GPE"
      },
      {
        "text": "four",
        "label": "CARDINAL"
      },
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "continued in two of four monkeys. We thus provide IND-enabling data towards an",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      },
      {
        "text": "four",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "upcoming first-in-human study.",
    "entities": [
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "Preparation of \u03bcSPOT Lactam-Cyclized Peptides for Ligand Optimization.",
    "entities": [
      {
        "text": "Lactam-Cyclized Peptides",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Center for Biopharmaceuticals, Department of Drug Design and Pharmacology,",
    "entities": [
      {
        "text": "1)Center",
        "label": "CARDINAL"
      },
      {
        "text": "Biopharmaceuticals, Department of Drug Design and Pharmacology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Chemistry, Gubra A/S, H\u00f8rsholm, Denmark. christian.bartling@sund.ku.dk.",
    "entities": [
      {
        "text": "Gubra A/S, H\u00f8rsholm",
        "label": "WORK_OF_ART"
      },
      {
        "text": "Denmark",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Center for Biopharmaceuticals, Department of Drug Design and Pharmacology,",
    "entities": [
      {
        "text": "Biopharmaceuticals, Department of Drug Design and Pharmacology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Cyclic peptides have emerged as promising therapeutic agents for targeting",
    "entities": []
  },
  {
    "text": "challenging protein-protein interactions (PPIs), combining high affinity,",
    "entities": []
  },
  {
    "text": "specificity, stability, and potential for improved drug-like properties. The",
    "entities": []
  },
  {
    "text": "outlined protocol describes a streamlined method for side chain-to-side chain",
    "entities": []
  },
  {
    "text": "lactam cyclization in a peptide array format based on the \u03bcSPOT method. The",
    "entities": [
      {
        "text": "\u03bcSPOT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "approach enables efficient synthesis and screening of cyclic peptide libraries",
    "entities": []
  },
  {
    "text": "with minimal synthetic effort, focusing on exploring cyclization positions and",
    "entities": []
  },
  {
    "text": "linker topology. The method is exemplified by developing cyclic peptide",
    "entities": []
  },
  {
    "text": "modulators of the APP/Mint2 PPI, a target implicated in Alzheimer's disease. The",
    "entities": [
      {
        "text": "APP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "workflow integrates orthogonal protection strategies, analytical controls, and",
    "entities": []
  },
  {
    "text": "array-based binding assays, enabling the identification of binding-optimized",
    "entities": []
  },
  {
    "text": "cyclic peptides. Follow-up validation through fluorescence polarization assays",
    "entities": []
  },
  {
    "text": "demonstrated a strong correlation with array-based relative binding data",
    "entities": []
  },
  {
    "text": "(r2 = 0.88). The described approach is versatile and scalable, offering a robust",
    "entities": [
      {
        "text": "0.88",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "platform for discovering novel cyclic peptides with enhanced stability,",
    "entities": []
  },
  {
    "text": "affinity, and permeability, paving the way for advanced therapeutic applications",
    "entities": []
  },
  {
    "text": "in PPI modulation.",
    "entities": []
  },
  {
    "text": "\u00a9 2025. The Author(s), under exclusive license to Springer Science+Business",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Springer Science+Business\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "PMID: 40663323 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40663323",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "57. Mol Neurobiol. 2025 Jul 15. doi: 10.1007/s12035-025-05220-w. Online ahead of",
    "entities": [
      {
        "text": "57",
        "label": "CARDINAL"
      },
      {
        "text": "Mol Neurobiol",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.1007",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Ubiquitination in the Nervous System: From Molecular Mechanisms to Disease",
    "entities": [
      {
        "text": "Molecular Mechanisms",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Implications.",
    "entities": []
  },
  {
    "text": "(1)School of Pharmacy, Hubei Key Laboratory of Diabetes and Angiopathy, Xianning",
    "entities": [
      {
        "text": "1)School of Pharmacy, Hubei Key Laboratory",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medical College, Hubei University of Science and Technology, Xianning , Hubei,",
    "entities": [
      {
        "text": "Medical College",
        "label": "ORG"
      },
      {
        "text": "Hubei University of Science and Technology",
        "label": "ORG"
      },
      {
        "text": "Xianning",
        "label": "GPE"
      },
      {
        "text": "Hubei",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)School of Resource and Environmental Sciences and Engineering, Hubei",
    "entities": [
      {
        "text": "Resource and Environmental Sciences",
        "label": "ORG"
      },
      {
        "text": "Engineering",
        "label": "GPE"
      },
      {
        "text": "Hubei",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "University of Science and Technology, Xianning , Hubei, 437000, China.",
    "entities": [
      {
        "text": "University of Science and Technology",
        "label": "ORG"
      },
      {
        "text": "Xianning",
        "label": "GPE"
      },
      {
        "text": "Hubei",
        "label": "GPE"
      },
      {
        "text": "437000",
        "label": "DATE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)School of Basic Medical Sciences, Xianning Medical College, Hubei University",
    "entities": [
      {
        "text": "Basic Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Xianning Medical College",
        "label": "ORG"
      },
      {
        "text": "Hubei University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Science and Technology, No. 88 Xianning Avenue, Xianning , Hubei, 437000,",
    "entities": [
      {
        "text": "Science and Technology",
        "label": "ORG"
      },
      {
        "text": "Xianning Avenue",
        "label": "FAC"
      },
      {
        "text": "Xianning",
        "label": "GPE"
      },
      {
        "text": "Hubei",
        "label": "GPE"
      },
      {
        "text": "437000",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "the proteasome, which are collectively responsible for selectively regulating",
    "entities": []
  },
  {
    "text": "protein degradation within the human body. Ubiquitination plays a crucial role",
    "entities": []
  },
  {
    "text": "in various physiological and pathological processes of the nervous system. In",
    "entities": []
  },
  {
    "text": "formation, and mitochondrial homeostasis. E3 ubiquitin ligases (E3s) such as",
    "entities": [
      {
        "text": "E3",
        "label": "CARDINAL"
      },
      {
        "text": "E3s",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "ubiquitin-protein ligase E3A (UBE3A), HUWE1, and Parkin, along with",
    "entities": [
      {
        "text": "HUWE1",
        "label": "GPE"
      },
      {
        "text": "Parkin",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "X-linked) and OTUD5, are vital for neural development and functional",
    "entities": [
      {
        "text": "OTUD5",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "maintenance. The dysregulation of ubiquitination is closely associated with",
    "entities": []
  },
  {
    "text": "neurodegenerative diseases such as Parkinson's disease (PD) and Alzheimer's",
    "entities": []
  },
  {
    "text": "disease (AD). A comprehensive understanding of the functions of ubiquitination",
    "entities": []
  },
  {
    "text": "in the nervous system and an in-depth exploration of its mechanisms in neural",
    "entities": []
  },
  {
    "text": "development and disease progression may reveal potential targets and therapeutic",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: Declarations. Ethics Approval and consent to",
    "entities": [
      {
        "text": "Ethics Approval",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "participate: Not applicable. Consent for publication: All authors agree to",
    "entities": []
  },
  {
    "text": "publish this review. Competing interests: The authors declare no competing",
    "entities": []
  },
  {
    "text": "interests.",
    "entities": []
  },
  {
    "text": "58. Mol Neurobiol. 2025 Jul 15. doi: 10.1007/s12035-025-05191-y. Online ahead of",
    "entities": [
      {
        "text": "58",
        "label": "CARDINAL"
      },
      {
        "text": "Mol Neurobiol",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.1007",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Fermented Soybean Pulp Alleviates Disease Progression of 5\u00d7FAD Model Mice.",
    "entities": [
      {
        "text": "Fermented Soybean Pulp Alleviates Disease Progression",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Life Sciences, National Taiwan Normal University, Taipei,",
    "entities": [
      {
        "text": "Life Sciences",
        "label": "ORG"
      },
      {
        "text": "National Taiwan Normal University",
        "label": "ORG"
      },
      {
        "text": "Taipei",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Neurology, Chang Gung Memorial Hospital, Chang Gung University",
    "entities": [
      {
        "text": "Neurology",
        "label": "PERSON"
      },
      {
        "text": "Chang Gung Memorial Hospital",
        "label": "PERSON"
      },
      {
        "text": "Chang Gung University",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "College of Medicine, Taoyuan, Taiwan.",
    "entities": [
      {
        "text": "College of Medicine, Taoyuan",
        "label": "ORG"
      },
      {
        "text": "Taiwan",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Life Sciences, National Taiwan Normal University, Taipei,",
    "entities": [
      {
        "text": "Life Sciences",
        "label": "ORG"
      },
      {
        "text": "National Taiwan Normal University",
        "label": "ORG"
      },
      {
        "text": "Taipei",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Alzheimer's disease (AD) is the most common neurodegenerative disorder of the",
    "entities": []
  },
  {
    "text": "central nervous system, characterized by memory loss and cognitive decline. The",
    "entities": []
  },
  {
    "text": "two main hypotheses regarding AD involve the accumulation of amyloid-\u03b2 (A\u03b2)",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      },
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "forming plaques and the intracellular hyperphosphorylation of tau protein,",
    "entities": []
  },
  {
    "text": "leading to the formation of neurofibrillary tangles (NFT). These processes are",
    "entities": [
      {
        "text": "NFT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "accompanied by neuroinflammation and oxidative stress, and eventual neuronal",
    "entities": []
  },
  {
    "text": "death. While soy foods are widely recognized for their nutritional benefits,",
    "entities": []
  },
  {
    "text": "soybean pulp (okara), the residue left over from making tofu or soybean milk, is",
    "entities": []
  },
  {
    "text": "mostly discarded as kitchen waste, despite being rich in nutrients such as",
    "entities": []
  },
  {
    "text": "dietary fiber, protein, and isoflavones. This underutilized byproduct may serve",
    "entities": []
  },
  {
    "text": "as a valuable resource for functional food development and sustainable resource",
    "entities": []
  },
  {
    "text": "use. In this study, fermented soybean pulp (FS) demonstrated neuroprotective",
    "entities": [
      {
        "text": "FS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "effects. In vitro, FS at concentrations of 0.001 \u00b5g/mL and 0.01 \u00b5g/mL",
    "entities": [
      {
        "text": "FS",
        "label": "ORG"
      },
      {
        "text": "0.001",
        "label": "CARDINAL"
      },
      {
        "text": "0.01",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "significantly improved cell viability in A\u03b2-induced HT-22 cells and reduced",
    "entities": [
      {
        "text": "HT-22",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "lipid peroxidation. Further, in vivo oral administration of FS attenuated the",
    "entities": [
      {
        "text": "FS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cognitive deficits of 5 \u00d7 FAD mice, enhancing both short and long-term memory",
    "entities": [
      {
        "text": "5",
        "label": "CARDINAL"
      },
      {
        "text": "\u00d7 FAD",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "and reducing anxiety-like behaviors. Immunohistochemical analysis revealed that",
    "entities": []
  },
  {
    "text": "the FS-treated 5 \u00d7 FAD mice group significantly reduced hippocampal amyloid",
    "entities": [
      {
        "text": "FS",
        "label": "ORG"
      },
      {
        "text": "5",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "plaque accumulation and gliosis. FS also upregulated the expression levels of",
    "entities": [
      {
        "text": "FS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "brain-derived neurotrophic factor (BDNF), PSD95, and synaptophysin, while",
    "entities": []
  },
  {
    "text": "preventing hippocampal neuronal loss. Mechanistically, FS may activate the Nrf2",
    "entities": [
      {
        "text": "FS",
        "label": "ORG"
      },
      {
        "text": "Nrf2",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "antioxidant pathway and NF-\u03baB-mediated inflammation through the modulation of",
    "entities": [
      {
        "text": "antioxidant pathway",
        "label": "PERSON"
      },
      {
        "text": "NF-\u03baB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the Akt/GSK3\u03b2 signaling axis in the hippocampus. These molecular actions likely",
    "entities": [
      {
        "text": "Akt",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "contribute to increased antioxidant enzymes and suppressed neuroinflammatory",
    "entities": []
  },
  {
    "text": "responses. Overall, this study suggests that FS has therapeutic potential for",
    "entities": [
      {
        "text": "FS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "alleviating cognitive and behavioral impairments in AD. Moreover, the",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "repurposing of soybean pulp, which would otherwise be discarded, enhances its",
    "entities": []
  },
  {
    "text": "utilization value and supports sustainable green recycling.",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: Declarations. Ethics Approval: All of the animal",
    "entities": []
  },
  {
    "text": "experiments were conducted according to the Institutional Animal Care and Use",
    "entities": [
      {
        "text": "the Institutional Animal Care",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Committee (IACUC) of the National Taiwan Normal University, Taipei, Taiwan",
    "entities": [
      {
        "text": "the National Taiwan Normal University",
        "label": "ORG"
      },
      {
        "text": "Taipei",
        "label": "GPE"
      },
      {
        "text": "Taiwan",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(Permit Number: NTNU112017). Consent to Participate: Not applicable. Consent to",
    "entities": []
  },
  {
    "text": "Publish: Authors approve for submitting the publication. Competing interests:",
    "entities": []
  },
  {
    "text": "The authors declare no competing interests.",
    "entities": []
  },
  {
    "text": "59. J Sports Med Phys Fitness. 2025 Jul 15. doi: 10.23736/S0022-4707.25.16503-1.",
    "entities": [
      {
        "text": "59",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.23736",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Do exercise interventions improve functional mobility and balance in Alzheimer's",
    "entities": []
  },
  {
    "text": "patients? A systematic review.",
    "entities": []
  },
  {
    "text": "(1)Clinical Exercise and Rehabilitation Research Center, University of Derby,",
    "entities": [
      {
        "text": "Rehabilitation Research Center",
        "label": "ORG"
      },
      {
        "text": "University of Derby",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)University of Naples Parthenope, Naples, Italy.",
    "entities": [
      {
        "text": "2)University",
        "label": "CARDINAL"
      },
      {
        "text": "Naples Parthenope",
        "label": "PERSON"
      },
      {
        "text": "Naples",
        "label": "GPE"
      },
      {
        "text": "Italy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Clinical Exercise and Rehabilitation Research Center, University of Derby,",
    "entities": [
      {
        "text": "Rehabilitation Research Center",
        "label": "ORG"
      },
      {
        "text": "University of Derby",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Derby, UK - f.ferraro@derby.ac.uk.",
    "entities": [
      {
        "text": "Derby",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "INTRODUCTION: Alzheimer's Disease (AD) is a form of dementia defined as a",
    "entities": []
  },
  {
    "text": "degenerative neurological condition associated with cognitive and functional",
    "entities": []
  },
  {
    "text": "decline above the natural and irreversible structural changes in body tissues",
    "entities": []
  },
  {
    "text": "caused by ageing. AD is the most common form of cognitive impairment in the",
    "entities": []
  },
  {
    "text": "population over 65 years old, also associated with poor functional mobility (FM)",
    "entities": [
      {
        "text": "65 years old",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "and balance, which can lead to falls in elderly populations.",
    "entities": []
  },
  {
    "text": "EVIDENCE ACQUISITION: This systematic review, conducted according to the PRISMA",
    "entities": [
      {
        "text": "PRISMA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and PROSPERO guidelines, assesses the effectiveness of various physical exercise",
    "entities": [
      {
        "text": "PROSPERO",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "interventions in improving functional mobility, balance and reducing the risk of",
    "entities": []
  },
  {
    "text": "falls in patients with Alzheimer's older than 65 years. A search has been",
    "entities": [
      {
        "text": "older than 65 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "conducted in PubMed, PEDro and Cochrane Library databases to identify relevant",
    "entities": [
      {
        "text": "PubMed",
        "label": "ORG"
      },
      {
        "text": "PEDro",
        "label": "PERSON"
      },
      {
        "text": "Cochrane Library",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Randomized Controlled Trial studies. Only studies published in English focusing",
    "entities": [
      {
        "text": "English",
        "label": "LANGUAGE"
      }
    ]
  },
  {
    "text": "on Exercise, Exercise Intervention, Alzheimer's, Alzheimer's Disease, Functional",
    "entities": []
  },
  {
    "text": "Mobility, Mobility, Risk of Falling, Balance, Over 65, and combinations were",
    "entities": [
      {
        "text": "65",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "included. The Cochrane RoB2 tool was used to assess the quality of the",
    "entities": [
      {
        "text": "Cochrane",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "identified RCTs. Seven out of 5432 studies were included in the analysis.",
    "entities": [
      {
        "text": "Seven",
        "label": "CARDINAL"
      },
      {
        "text": "5432",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "EVIDENCE SYNTHESIS: A moderate level of evidence suggests that interventions",
    "entities": []
  },
  {
    "text": "involving strength exercises, FM and balance are effective in improving mobility",
    "entities": []
  },
  {
    "text": "and balance in older Alzheimer's patients. Limited evidence indicates that this",
    "entities": []
  },
  {
    "text": "type of activity could also reduce the risk of falls.",
    "entities": []
  },
  {
    "text": "CONCLUSIONS: Further recommendations concerning exercises, including walking",
    "entities": []
  },
  {
    "text": "activities, and suggestions for future studies on more comprehensive AD cohorts",
    "entities": []
  },
  {
    "text": "Evaluating administrative measures of school quality as mediators of the",
    "entities": []
  },
  {
    "text": "relationship between attending a segregated school and cognitive function among",
    "entities": []
  },
  {
    "text": "older Black individuals: The STAR Study.",
    "entities": [
      {
        "text": "The STAR Study",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Epidemiology and Biostatistics, University of California San",
    "entities": [
      {
        "text": "Epidemiology and Biostatistics, University of California San\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Francisco, San Francisco, California, United States.",
    "entities": [
      {
        "text": "Francisco",
        "label": "GPE"
      },
      {
        "text": "San Francisco",
        "label": "GPE"
      },
      {
        "text": "California",
        "label": "GPE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Alzheimer's Disease Center, University of California Davis, Sacramento,",
    "entities": [
      {
        "text": "2)Alzheimer",
        "label": "ORG"
      },
      {
        "text": "Disease Center, University of California Davis",
        "label": "ORG"
      },
      {
        "text": "Sacramento",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "California, United States.",
    "entities": [
      {
        "text": "California",
        "label": "GPE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Public Health Sciences, University of California Davis, Davis,",
    "entities": [
      {
        "text": "Public Health Sciences",
        "label": "ORG"
      },
      {
        "text": "University of California Davis",
        "label": "ORG"
      },
      {
        "text": "Davis",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(4)Division of Research, Kaiser Permanente Northern California, Pleasanton,",
    "entities": [
      {
        "text": "Research",
        "label": "ORG"
      },
      {
        "text": "Kaiser Permanente Northern California",
        "label": "ORG"
      },
      {
        "text": "Pleasanton",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Department of Medicine, University of California San Francisco, San",
    "entities": [
      {
        "text": "Medicine, University of California San Francisco",
        "label": "ORG"
      },
      {
        "text": "San\n",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Francisco, California, United States.",
    "entities": [
      {
        "text": "Francisco",
        "label": "GPE"
      },
      {
        "text": "California",
        "label": "GPE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)School of Public and Community Health Sciences, University of Montana,",
    "entities": [
      {
        "text": "Public and Community Health Sciences",
        "label": "ORG"
      },
      {
        "text": "University of Montana",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Missoula, Montana, United States.",
    "entities": [
      {
        "text": "Missoula",
        "label": "GPE"
      },
      {
        "text": "Montana",
        "label": "GPE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago,",
    "entities": [
      {
        "text": "Disease Center, Rush University Medical Center",
        "label": "ORG"
      },
      {
        "text": "Chicago",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Illinois, United States.",
    "entities": [
      {
        "text": "Illinois",
        "label": "GPE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Department of Epidemiology, Boston University School of Public Health,",
    "entities": [
      {
        "text": "Epidemiology",
        "label": "ORG"
      },
      {
        "text": "Boston University School of Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Boston, Massachusetts, United States.",
    "entities": [
      {
        "text": "Boston",
        "label": "GPE"
      },
      {
        "text": "Massachusetts",
        "label": "GPE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Research highlights school segregation's impact on cognitive aging for older",
    "entities": []
  },
  {
    "text": "Black adults, yet the mediating role of school quality-reflecting systemic",
    "entities": []
  },
  {
    "text": "(dis)investment in segregated schools-remains unexplored. This study included",
    "entities": []
  },
  {
    "text": "726 community-dwelling Black adults from the Study of Healthy Aging in African",
    "entities": [
      {
        "text": "726",
        "label": "CARDINAL"
      },
      {
        "text": "the Study of Healthy Aging",
        "label": "WORK_OF_ART"
      },
      {
        "text": "African",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Americans. Participants self-reported segregated school attendance, while",
    "entities": [
      {
        "text": "Americans",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "administrative measures of state-level school quality (term length, percent",
    "entities": []
  },
  {
    "text": "attendance, student-teacher ratio, composite z-score) were linked to their",
    "entities": []
  },
  {
    "text": "grade-specific state of residence. We estimated the extent to which associations",
    "entities": []
  },
  {
    "text": "between segregated schooling and domain-specific cognition were mediated by",
    "entities": []
  },
  {
    "text": "school quality. Sensitivity analyses examined grade-specific effects. Attending",
    "entities": []
  },
  {
    "text": "a segregated school was associated with poorer school quality (e.g.,",
    "entities": []
  },
  {
    "text": "\u03b2term-length= -1.71 [-2.52,-0.91]) and lower semantic memory (\u03b2= -0.17",
    "entities": []
  },
  {
    "text": "[-0.32,-0.02]). The school quality composite measure mediated 30% of the overall",
    "entities": [
      {
        "text": "30%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "association with semantic memory (natural indirect effect: \u03b2= -0.05",
    "entities": []
  },
  {
    "text": "were imprecise for executive function and verbal episodic memory. Our results",
    "entities": []
  },
  {
    "text": "suggest that state-level (dis)investments in school quality may be an important",
    "entities": []
  },
  {
    "text": "mechanism by which school-based segregation contributes to late-life cognitive",
    "entities": []
  },
  {
    "text": "function. Interventions that target the upstream, structural drivers of",
    "entities": []
  },
  {
    "text": "school-based segregation and related disinvestments may be important strategies",
    "entities": []
  },
  {
    "text": "for reducing cognitive aging inequities.",
    "entities": []
  },
  {
    "text": "\u00a9 The Author(s) 2025. Published by Oxford University Press on behalf of the",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Oxford University Press",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Johns Hopkins Bloomberg School of Public Health.",
    "entities": [
      {
        "text": "Johns Hopkins Bloomberg School of Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "A Latent-Class Model for Time-To-Event Outcomes and High-Dimensional Imaging",
    "entities": []
  },
  {
    "text": "(1)Department of Statistics and Actuarial Science, Simon Fraser University,",
    "entities": [
      {
        "text": "Statistics",
        "label": "ORG"
      },
      {
        "text": "Simon Fraser University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Burnaby, British Columbia, Canada.",
    "entities": [
      {
        "text": "Burnaby",
        "label": "ORG"
      },
      {
        "text": "British Columbia",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)School of Medicine, Wake Forest University, Winston-Salem, North Carolina,",
    "entities": [
      {
        "text": "Medicine, Wake Forest University",
        "label": "ORG"
      },
      {
        "text": "Winston-Salem",
        "label": "GPE"
      },
      {
        "text": "North Carolina",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)School of Engineering, Simon Fraser University, Burnaby, British Columbia,",
    "entities": [
      {
        "text": "Engineering",
        "label": "GPE"
      },
      {
        "text": "Simon Fraser University",
        "label": "ORG"
      },
      {
        "text": "Burnaby",
        "label": "ORG"
      },
      {
        "text": "British Columbia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Structural magnetic resonance imaging (MRI) is one of the primary predictors of",
    "entities": []
  },
  {
    "text": "Alzheimer's disease risk, enabling the identification of patients with similar",
    "entities": []
  },
  {
    "text": "risk profiles for precision medicine treatment. Motivated by the need for",
    "entities": []
  },
  {
    "text": "flexible modeling in AD research, we propose a latent-class model that addresses",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "the heterogeneity within study populations. This model allows for varying",
    "entities": []
  },
  {
    "text": "relationships between covariates and survival outcomes, accommodating the",
    "entities": []
  },
  {
    "text": "dynamics of AD progression. The imaging predictors are characterized by",
    "entities": [
      {
        "text": "AD",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "bivariate splines over triangulation to accommodate the irregular domain of the",
    "entities": []
  },
  {
    "text": "brain images. We develop a generalized expectation-maximization (EM) algorithm",
    "entities": [
      {
        "text": "EM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "that combines the computational methods for logistic regression and penalized",
    "entities": []
  },
  {
    "text": "proportional hazards models to implement the proposed approach. We demonstrate",
    "entities": []
  },
  {
    "text": "the advantages of the proposed method through extensive simulation studies and",
    "entities": []
  },
  {
    "text": "provide an application to the Alzheimer's Disease Neuroimaging Initiative (ADNI)",
    "entities": []
  },
  {
    "text": "study, which helps to reveal different subtypes or stages of the disease process",
    "entities": []
  },
  {
    "text": "\u00a9 2025 The Author(s). Statistics in Medicine published by John Wiley & Sons Ltd.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "John Wiley & Sons Ltd.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PMID: 40662861 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40662861",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "10.1093/bioinformatics/btaf257.",
    "entities": [
      {
        "text": "10.1093",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Trustworthy causal biomarker discovery: a multiomics brain imaging",
    "entities": [
      {
        "text": "Trustworthy causal",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "genetics-based approach.",
    "entities": [
      {
        "text": "genetics",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Alzheimer\u2019s Disease Neuroimaging Initiative.",
    "entities": []
  },
  {
    "text": "(1)Department of Intelligent Science and Technology, Northwestern Polytechnical",
    "entities": [
      {
        "text": "Intelligent Science and Technology",
        "label": "ORG"
      },
      {
        "text": "Northwestern Polytechnical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University School of Automation, Shaanxi 710072, China.",
    "entities": [
      {
        "text": "University School of Automation, Shaanxi 710072",
        "label": "ORG"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)School of Artificial Intelligence, Nanjing University of Aeronautics and",
    "entities": [
      {
        "text": "Artificial Intelligence",
        "label": "ORG"
      },
      {
        "text": "Nanjing University of Aeronautics",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Astronautics, Nanjing 210000, China.",
    "entities": [
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "MOTIVATION: Discovering genetic variations underpinning brain disorders is",
    "entities": []
  },
  {
    "text": "important to understand their pathogenesis. Indirect associations or spurious",
    "entities": []
  },
  {
    "text": "causal relationships pose a threat to the reliability of biomarker discovery for",
    "entities": []
  },
  {
    "text": "brain disorders, potentially misleading or incurring bias in subsequent",
    "entities": []
  },
  {
    "text": "decision-making. Unfortunately, the stringent selection of reliable biomarker",
    "entities": []
  },
  {
    "text": "candidates for brain disorders remains a predominantly unexplored challenge.",
    "entities": []
  },
  {
    "text": "RESULTS: In this article, to fill this gap, we propose a fresh and powerful",
    "entities": []
  },
  {
    "text": "scheme, referred to as the Causality-aware Genotype intermediate Phenotype",
    "entities": [
      {
        "text": "Genotype",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Correlation Approach (Ca-GPCA). Specifically, we design a bidirectional",
    "entities": [
      {
        "text": "Ca-GPCA",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "association learning framework, integrated with a parallel causal variable",
    "entities": []
  },
  {
    "text": "trustworthy causal biomarkers. A disease diagnosis module is further",
    "entities": [
      {
        "text": "trustworthy causal biomarkers",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "incorporated to ensure accurate diagnosis and identification of causal effects",
    "entities": []
  },
  {
    "text": "for pathogenesis. Additionally, considering the large computational burden",
    "entities": []
  },
  {
    "text": "incurred by high-dimensional genotype-phenotype covariances, we develop a fast",
    "entities": []
  },
  {
    "text": "and efficient strategy to reduce the runtime and prompt practical availability",
    "entities": []
  },
  {
    "text": "and applicability. Extensive experimental results on four simulation data and",
    "entities": [
      {
        "text": "four",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "real neuroimaging genetic data clearly show that Ca-GPCA outperforms",
    "entities": [
      {
        "text": "Ca-GPCA",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "state-of-the-art methods with excellent built-in interpretability. This can",
    "entities": []
  },
  {
    "text": "provide novel and reliable insights into the underlying pathogenic mechanisms of",
    "entities": []
  },
  {
    "text": "AVAILABILITY AND IMPLEMENTATION: The software is publicly available at",
    "entities": [
      {
        "text": "AVAILABILITY",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "\u00a9 The Author(s) 2025. Published by Oxford University Press.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Oxford University Press",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "DOI: 10.1093/bioinformatics/btaf257",
    "entities": [
      {
        "text": "10.1093",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "PMID: 40662843 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40662843",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Optimal Linear Combination of Biomarkers by Weighted Youden Index Maximization.",
    "entities": [
      {
        "text": "Optimal Linear Combination of Biomarkers",
        "label": "ORG"
      },
      {
        "text": "Weighted",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Key Laboratory of Advanced Theory and Application in Statistics and Data",
    "entities": [
      {
        "text": "Laboratory of Advanced Theory and Application in Statistics",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Science - MOE, School of Statistics, East China Normal University, Shanghai,",
    "entities": [
      {
        "text": "Science - MOE",
        "label": "ORG"
      },
      {
        "text": "School of Statistics",
        "label": "ORG"
      },
      {
        "text": "East China Normal University",
        "label": "ORG"
      },
      {
        "text": "Shanghai",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Statistics and Data Science, National University of Singapore,",
    "entities": [
      {
        "text": "2)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Statistics",
        "label": "ORG"
      },
      {
        "text": "Data Science",
        "label": "ORG"
      },
      {
        "text": "National University of Singapore",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Duke University-NUS Graduate Medical School, Singapore, Singapore.",
    "entities": [
      {
        "text": "University-NUS Graduate Medical School",
        "label": "ORG"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "In medical research, it is common practice to combine various biomarkers to",
    "entities": []
  },
  {
    "text": "improve the accuracy of disease diagnosis. The weighted Youden index (WYI),",
    "entities": [
      {
        "text": "Youden",
        "label": "PERSON"
      },
      {
        "text": "WYI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "which assigns unequal weights to sensitivity and specificity based on their",
    "entities": []
  },
  {
    "text": "relative importance, serves as an important and flexible evaluation metric of",
    "entities": []
  },
  {
    "text": "diagnostic tests. However, no existing methods have been designed specifically",
    "entities": []
  },
  {
    "text": "to identify the optimal linear combination of biomarkers that maximizes the WYI.",
    "entities": [
      {
        "text": "WYI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "In this paper, we propose a novel method to construct an optimal diagnosis score",
    "entities": []
  },
  {
    "text": "and determine the best cut-off point at the same time. The estimated combination",
    "entities": []
  },
  {
    "text": "coefficients and cut-off point are shown to have cube root asymptotics, and",
    "entities": []
  },
  {
    "text": "their joint limiting distribution is established rigorously. Further, the",
    "entities": []
  },
  {
    "text": "asymptotic normality of the optimal in-sample WYI is established, and",
    "entities": [
      {
        "text": "WYI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "out-of-sample inference for score distribution and comparison is investigated.",
    "entities": []
  },
  {
    "text": "These results provide deep theoretical insights for methods of Youden index",
    "entities": [
      {
        "text": "Youden",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "maximization for the first time. Computationally, an iterative marginal",
    "entities": [
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "optimization algorithm, different from the existing literature, is adopted to",
    "entities": []
  },
  {
    "text": "deal with the objective function that is neither continuous nor smooth.",
    "entities": []
  },
  {
    "text": "Simulation studies support the theoretical results and demonstrate the",
    "entities": []
  },
  {
    "text": "superiority of the proposed method. Two real-world examples-coronary disease and",
    "entities": [
      {
        "text": "Two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Alzheimer's disease diagnosis-are presented for illustration.",
    "entities": []
  },
  {
    "text": "\u00a9 2025 John Wiley & Sons Ltd.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "John Wiley & Sons Ltd.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PMID: 40662748 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40662748",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "64. J Osteopath Med. 2025 Jul 16. doi: 10.1515/jom-2025-0065. Online ahead of",
    "entities": [
      {
        "text": "64",
        "label": "CARDINAL"
      },
      {
        "text": "Osteopath Med",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.1515/jom-2025-0065",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "Minimum physical activities protective against Alzheimer's disease in late life:",
    "entities": []
  },
  {
    "text": "a systematic review.",
    "entities": []
  },
  {
    "text": "(1)Department of Foundational Biomedical Sciences, College of Osteopathic",
    "entities": [
      {
        "text": "Foundational Biomedical Sciences",
        "label": "ORG"
      },
      {
        "text": "College of Osteopathic\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, Touro University California, Vallejo, CA, USA.",
    "entities": [
      {
        "text": "Touro University",
        "label": "ORG"
      },
      {
        "text": "California",
        "label": "GPE"
      },
      {
        "text": "Vallejo",
        "label": "ORG"
      },
      {
        "text": "CA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "CONTEXT: Previous studies indicate an inverse relationship between physical",
    "entities": []
  },
  {
    "text": "activity (PA) and the risk of Alzheimer's disease (AD). Although they",
    "entities": []
  },
  {
    "text": "highlighted the health benefits of PA, the specific effects of PA in late life",
    "entities": [
      {
        "text": "PA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "remain unclear, and intense PA may be challenging for older adults. Moreover,",
    "entities": []
  },
  {
    "text": "there is significant variation in how PA is assessed, including the timing and",
    "entities": []
  },
  {
    "text": "types of activities considered.",
    "entities": []
  },
  {
    "text": "OBJECTIVES: This review aimed to evaluate existing literature to determine the",
    "entities": []
  },
  {
    "text": "effects of PA with an emphasis on late-life PA and the minimum levels of PA for",
    "entities": []
  },
  {
    "text": "METHODS: We conducted a systematic review via the Preferred Reporting Items for",
    "entities": [
      {
        "text": "the Preferred Reporting Items for\n",
        "label": "LAW"
      }
    ]
  },
  {
    "text": "Systematic Reviews and Meta-Analyses (PRISMA) protocol utilizing the MEDLINE and",
    "entities": [
      {
        "text": "Meta-Analyses",
        "label": "ORG"
      },
      {
        "text": "MEDLINE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases,",
    "entities": [
      {
        "text": "Allied Health Literature (CINAHL",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "last assessed in July 2023. Studies that met the inclusion criteria were",
    "entities": [
      {
        "text": "July 2023",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "prospective cohort or interventional studies, that are written in English, and",
    "entities": [
      {
        "text": "English",
        "label": "LANGUAGE"
      }
    ]
  },
  {
    "text": "that measured PA in a cohort who did not have dementia, AD, or cognitive decline",
    "entities": [
      {
        "text": "AD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "at baseline. Retrospective cohort, cross-sectional, case reports, and studies",
    "entities": []
  },
  {
    "text": "not meeting the inclusion criteria were excluded. Each study was evaluated in",
    "entities": []
  },
  {
    "text": "seven domains of bias utilizing the Risk Of Bias In Non-randomized Studies of",
    "entities": [
      {
        "text": "seven",
        "label": "CARDINAL"
      },
      {
        "text": "the Risk Of Bias In Non-randomized Studies of\n",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "Exposures (ROBINS-E) tool.",
    "entities": []
  },
  {
    "text": "RESULTS: Out of 2,322 studies screened, 17 met the inclusion criteria, including",
    "entities": [
      {
        "text": "2,322",
        "label": "CARDINAL"
      },
      {
        "text": "17",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "six new studies not included in the previous systematic review. This resulted in",
    "entities": [
      {
        "text": "six",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "206,463 participants from North America (United States and Canada) and Europe",
    "entities": [
      {
        "text": "206,463",
        "label": "CARDINAL"
      },
      {
        "text": "North America",
        "label": "LOC"
      },
      {
        "text": "United States",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      },
      {
        "text": "Europe",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "(Denmark, Finland, Italy, Sweden, and the United Kingdom). Our method",
    "entities": [
      {
        "text": "Denmark",
        "label": "GPE"
      },
      {
        "text": "Finland",
        "label": "GPE"
      },
      {
        "text": "Italy",
        "label": "GPE"
      },
      {
        "text": "Sweden",
        "label": "GPE"
      },
      {
        "text": "the United Kingdom",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "effectively reduced the number of duplicated studies during screenings,",
    "entities": []
  },
  {
    "text": "resulting in 92 duplications compared to 3,580 in the previous review. The risk",
    "entities": [
      {
        "text": "92",
        "label": "CARDINAL"
      },
      {
        "text": "3,580",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "of bias assessment in the quality of evidence was \"low risk\" in 13 studies and",
    "entities": [
      {
        "text": "13",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "\"some concerns\" in four studies. Four studies assessed PA at midlife (average",
    "entities": [
      {
        "text": "four",
        "label": "CARDINAL"
      },
      {
        "text": "Four",
        "label": "CARDINAL"
      },
      {
        "text": "PA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "age, 49 years; average follow-up time, 29.2 years), 11 studies assessed PA in",
    "entities": [
      {
        "text": "49 years",
        "label": "DATE"
      },
      {
        "text": "29.2 years",
        "label": "DATE"
      },
      {
        "text": "11",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "late life (average age, 75.9 years; average follow-up time, 5.9 years), and two",
    "entities": [
      {
        "text": "75.9 years",
        "label": "DATE"
      },
      {
        "text": "5.9 years",
        "label": "DATE"
      },
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "assessed PA in adulthood without specification. For studies that assessed PA at",
    "entities": []
  },
  {
    "text": "midlife, 2 out of 4 (50 %) had statistically significant findings (p<0.05) for",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "4 (50 %",
        "label": "PERCENT"
      },
      {
        "text": "p<0.05",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "studies that assessed PA during late life, 8 out of 11 (75 %) had significant",
    "entities": [
      {
        "text": "8",
        "label": "CARDINAL"
      },
      {
        "text": "11",
        "label": "CARDINAL"
      },
      {
        "text": "75 %",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "findings (p<0.05), and 2 out of 2 (100 %) of unspecified timing had significant",
    "entities": [
      {
        "text": "p<0.05",
        "label": "ORG"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "100 %",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "findings (p<0.05). Our review indicated that engaging in PA at least three times",
    "entities": [
      {
        "text": "p<0.05",
        "label": "ORG"
      },
      {
        "text": "PA",
        "label": "GPE"
      },
      {
        "text": "at least three",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "per week, for at least 15 min per session, was judged to be the minimum",
    "entities": [
      {
        "text": "at least 15",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "requirement tested for protective effects against AD in late life. Potential",
    "entities": []
  },
  {
    "text": "biological mechanisms were also discussed.",
    "entities": []
  },
  {
    "text": "CONCLUSIONS: Our current review supports existing evidence that PA provides",
    "entities": [
      {
        "text": "PA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "significant protection against the development of AD and found that the",
    "entities": []
  },
  {
    "text": "requirement of PA may be less than the current guidelines for sufficient and",
    "entities": []
  },
  {
    "text": "meaningful protection in late life. Excitingly, any form of PA tested can be",
    "entities": []
  },
  {
    "text": "protective against the development of AD, including household activities,",
    "entities": []
  },
  {
    "text": "suggesting that a wider variety of PA can be more appropriate for late life.",
    "entities": []
  },
  {
    "text": "More standardized and detailed studies are needed to update the benefits of PA,",
    "entities": [
      {
        "text": "PA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "particularly in the areas of occupational, household/transportation, and",
    "entities": []
  },
  {
    "text": "age-group activities. Further research is needed to determine the optimal PA",
    "entities": []
  },
  {
    "text": "thresholds in these groups.",
    "entities": []
  },
  {
    "text": "\u00a9 2025 the author(s), published by De Gruyter, Berlin/Boston.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "De Gruyter",
        "label": "PERSON"
      },
      {
        "text": "Berlin/Boston",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "65. Cent Nerv Syst Agents Med Chem. 2025 Jul 14. doi:",
    "entities": [
      {
        "text": "65",
        "label": "CARDINAL"
      },
      {
        "text": "Cent Nerv",
        "label": "ORG"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "14",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "10.2174/0118715249385792250709073502. Online ahead of print.",
    "entities": [
      {
        "text": "10.2174/0118715249385792250709073502",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Computational Design of Drugs for Epilepsy using a Novel Guided Evolutionary",
    "entities": [
      {
        "text": "Epilepsy",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Algorithm for Enhanced Blood Brain Barrier Permeability.",
    "entities": []
  },
  {
    "text": "(1)Department of Biotechnology, GITAM School of Technology, GITAM,",
    "entities": [
      {
        "text": "Biotechnology, GITAM School of Technology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "INTRODUCTION: Epilepsy is a common disorder of the Central Nervous System (CNS).",
    "entities": [
      {
        "text": "Epilepsy",
        "label": "PERSON"
      },
      {
        "text": "the Central Nervous System",
        "label": "ORG"
      },
      {
        "text": "CNS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "The rational design of small-molecule drugs for disorders of the CNS is a",
    "entities": [
      {
        "text": "CNS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "difficult process because the majority of small molecules are unable to cross",
    "entities": []
  },
  {
    "text": "the Blood-Brain-Barrier. An efficient method for the design of inhibitors that",
    "entities": [
      {
        "text": "the Blood-Brain-Barrier",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "have high permeability through the Blood-Brain-Barrier has the potential for",
    "entities": [
      {
        "text": "the Blood-Brain-Barrier",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "application in drug design for CNS disorders such as Addiction, Alzheimer's",
    "entities": [
      {
        "text": "CNS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "disease, Bipolar disorder, Depression, Epilepsy, Gliomas, and Tuberculous",
    "entities": [
      {
        "text": "Epilepsy",
        "label": "PERSON"
      },
      {
        "text": "Gliomas",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "METHOD: Supervised learning was used to model the Blood-Brain-Barrier",
    "entities": [
      {
        "text": "METHOD",
        "label": "ORG"
      },
      {
        "text": "the Blood-Brain-Barrier",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "permeability of drugs like small organic molecules. This information was",
    "entities": []
  },
  {
    "text": "utilized to guide an evolutionary algorithm for the design of inhibitors with",
    "entities": []
  },
  {
    "text": "increased affinity for the target as well as higher Blood-Brain-Barrier",
    "entities": [
      {
        "text": "Blood-Brain-Barrier",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "permeability.",
    "entities": []
  },
  {
    "text": "RESULTS: The ligands designed with guided evolution were predicted to have",
    "entities": []
  },
  {
    "text": "higher binding affinity for the target as well as higher permeability across the",
    "entities": []
  },
  {
    "text": "Blood-Brain-Barrier compared to an evolutionary algorithm without the guidance.",
    "entities": [
      {
        "text": "Blood-Brain-Barrier",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "The guided evolutionary method was applied to design a set of drug-like ligands",
    "entities": []
  },
  {
    "text": "that were predicted to bind to GABA-T with high affinity, to be BBB permeable,",
    "entities": [
      {
        "text": "GABA",
        "label": "ORG"
      },
      {
        "text": "BBB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and to be chemically synthesizable.",
    "entities": []
  },
  {
    "text": "DISCUSSION: Despite the availability of several drugs that are approved for the",
    "entities": []
  },
  {
    "text": "treatment of epilepsy, there are many cases that do not respond to available",
    "entities": []
  },
  {
    "text": "drugs or experience adverse effects. The novel ligands designed as part of this",
    "entities": []
  },
  {
    "text": "work have the potential to address the limitations of available drugs.",
    "entities": []
  },
  {
    "text": "CONCLUSION: Guided evolution is an efficient computational approach for the",
    "entities": []
  },
  {
    "text": "design of CNS drugs. The de novo design of drugs by application of the guided",
    "entities": [
      {
        "text": "CNS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "evolution algorithm, developed as part of this work, has resulted in the",
    "entities": [
      {
        "text": "evolution algorithm",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "generation of ligands that are potential drugs for the cure of epilepsy.",
    "entities": []
  },
  {
    "text": "However, the effectiveness of these drugs for the cure of epilepsy has to be",
    "entities": []
  },
  {
    "text": "validated experimentally.",
    "entities": []
  },
  {
    "text": "Copyright\u00a9 Bentham Science Publishers; For any queries, please email at",
    "entities": [
      {
        "text": "Bentham Science Publishers",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Identification of MicroRNA Drug Targets for Alzheimer's and Diabetes Mellitus",
    "entities": [
      {
        "text": "Identification of MicroRNA Drug Targets for Alzheimer's",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Using Network Medicine.",
    "entities": []
  },
  {
    "text": "(5)Division of Population Health & Biostatistics, School of Medicine, The",
    "entities": [
      {
        "text": "Population Health & Biostatistics",
        "label": "ORG"
      },
      {
        "text": "School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of Texas Rio Grande Valley, Texas, Edinburg, United States of",
    "entities": [
      {
        "text": "University of Texas Rio Grande Valley",
        "label": "ORG"
      },
      {
        "text": "Texas",
        "label": "GPE"
      },
      {
        "text": "Edinburg",
        "label": "GPE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "America.",
    "entities": [
      {
        "text": "America",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "INTRODUCTION: Type 2 diabetes mellitus (T2D) is a known risk factor for",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "T2D",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "developing Alzheimer's disease (AD). Recent research shows that both diseases",
    "entities": []
  },
  {
    "text": "share complex and related pathophysiological processes. Network medicine",
    "entities": []
  },
  {
    "text": "approaches can help to elucidate common dysregulated processes among different",
    "entities": []
  },
  {
    "text": "diseases, such as AD and T2D. Thus, the aim of this work was to determine",
    "entities": [
      {
        "text": "T2D. Thus",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "differentially expressed genes (DEGs) in AD and T2D and to apply a network",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "medicine approach to identify the microRNAs (miRNAs) involved in the AD-T2D",
    "entities": []
  },
  {
    "text": "association.",
    "entities": []
  },
  {
    "text": "METHODS: Gene expression microarray data sets consisting of 384 control samples",
    "entities": [
      {
        "text": "384",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "and 399 samples belonging to AD and T2D disease were analyzed to obtain DEGs",
    "entities": [
      {
        "text": "399",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "shared by both diseases; the miRNAs associated with these DEGs were predicted",
    "entities": []
  },
  {
    "text": "using a network medicine approach. Finally, potential small molecules targeting",
    "entities": []
  },
  {
    "text": "these potentially deregulated miRNAs were identified.",
    "entities": []
  },
  {
    "text": "RESULTS: AD and T2D shared a small subset of 82 downregulated DEGs. These genes",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      },
      {
        "text": "T2D",
        "label": "ORG"
      },
      {
        "text": "82",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "were significantly associated (p < 0.01) with the ontology terms of chemical",
    "entities": []
  },
  {
    "text": "synaptic deregulation. DEGs were associated with 12 miRNAs expressed in specific",
    "entities": [
      {
        "text": "12",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "tissues for AD and T2D. Such miRNAs were also primarily associated with the",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      },
      {
        "text": "T2D. Such miRNAs",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "ontology terms related to synaptic deregulation and cancer, and AKT signaling",
    "entities": [
      {
        "text": "AKT",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "pathways. Steroid anti-inflammatory drugs, antineoplastics, and glucose",
    "entities": []
  },
  {
    "text": "metabolites were predicted to be potential regulators of the 12 shared miRNAs.",
    "entities": [
      {
        "text": "12",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "DISCUSSION: The network medicine approach integrating DEGs and miRNAs enabled",
    "entities": []
  },
  {
    "text": "the identification of shared, potentially deregulated biological processes and",
    "entities": []
  },
  {
    "text": "pathways underlying the pathophysiology of AD and T2D. These common molecular",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      },
      {
        "text": "T2D. These",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "mechanisms were also linked to drugs currently used in clinical practice,",
    "entities": []
  },
  {
    "text": "suggesting that this strategy may inform future drug repurposing efforts.",
    "entities": []
  },
  {
    "text": "Nonetheless, further in-depth biological validation is required to confirm these",
    "entities": []
  },
  {
    "text": "CONCLUSION: Network medicine allowed identifying 12 miRNAs involved in the",
    "entities": [
      {
        "text": "12",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "AD-T2D association, and these could be drug targets for the design of new",
    "entities": [
      {
        "text": "AD-T2D association",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "treatments; however, the identified miRNAs need further experimental",
    "entities": []
  },
  {
    "text": "confirmation.",
    "entities": []
  },
  {
    "text": "Neural Networks of Knowledge: Ontologies Pioneering Precision Medicine In",
    "entities": [
      {
        "text": "Neural Networks of Knowledge:",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)GITAM School of Pharmacy, GITAM (Deemed to be) University, Rudraram,",
    "entities": [
      {
        "text": "1)GITAM School of Pharmacy",
        "label": "ORG"
      },
      {
        "text": "Rudraram",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Department of Pharmacology, Indore Institute of Pharmacy, IIST Campus, Rau,",
    "entities": [
      {
        "text": "Pharmacology, Indore Institute of Pharmacy",
        "label": "ORG"
      },
      {
        "text": "Rau",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(3)Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.",
    "entities": [
      {
        "text": "3)Chitkara College of Pharmacy",
        "label": "ORG"
      },
      {
        "text": "Chitkara University",
        "label": "ORG"
      },
      {
        "text": "Rajpura",
        "label": "PERSON"
      },
      {
        "text": "Punjab",
        "label": "GPE"
      },
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University),",
    "entities": [
      {
        "text": "4)MM College of Pharmacy",
        "label": "ORG"
      },
      {
        "text": "Maharishi Markandeshwar",
        "label": "ORG"
      },
      {
        "text": "Deemed",
        "label": "PERSON"
      },
      {
        "text": "University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Bristol Myers Squibb, Hyderabad, India.",
    "entities": [
      {
        "text": "5)Bristol Myers Squibb",
        "label": "ORG"
      },
      {
        "text": "Hyderabad",
        "label": "GPE"
      },
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Department of Pharm Chemistry, Manipal College of Pharmaceutical Sciences,",
    "entities": [
      {
        "text": "Pharm Chemistry",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Manipal Academy of Higher Education Manipal, 576104, Karnataka, India.",
    "entities": [
      {
        "text": "Manipal Academy of Higher Education Manipal",
        "label": "ORG"
      },
      {
        "text": "576104",
        "label": "DATE"
      },
      {
        "text": "Karnataka",
        "label": "GPE"
      },
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Department of Entomology and Nematology, UC Davis Comprehensive Cancer",
    "entities": [
      {
        "text": "Entomology and Nematology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Center, University of California Davis, One Shields Avenue, Davis, CA 95616,",
    "entities": [
      {
        "text": "Center, University of California Davis",
        "label": "ORG"
      },
      {
        "text": "One",
        "label": "CARDINAL"
      },
      {
        "text": "Shields Avenue",
        "label": "FAC"
      },
      {
        "text": "Davis",
        "label": "PERSON"
      },
      {
        "text": "CA 95616",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(8)Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah",
    "entities": [
      {
        "text": "Pharmaceutical Sciences",
        "label": "ORG"
      },
      {
        "text": "College of Pharmacy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(9)Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil",
    "entities": [
      {
        "text": "Pharmacy, Faculty of Allied Health Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "International University, Dhaka, Bangladesh.",
    "entities": [
      {
        "text": "International University",
        "label": "ORG"
      },
      {
        "text": "Dhaka",
        "label": "GPE"
      },
      {
        "text": "Bangladesh",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(10)Centre for Global Health Research, Saveetha Medical College and Hospital,",
    "entities": [
      {
        "text": "10)Centre",
        "label": "CARDINAL"
      },
      {
        "text": "Global Health Research",
        "label": "ORG"
      },
      {
        "text": "Saveetha Medical College and Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu,",
    "entities": [
      {
        "text": "Saveetha Institute of Medical and Technical Sciences",
        "label": "ORG"
      },
      {
        "text": "Chennai",
        "label": "ORG"
      },
      {
        "text": "Tamil Nadu",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(11)Department of Health Sciences, Faculty of Science, Novel Global Community",
    "entities": [
      {
        "text": "11)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Health Sciences, Faculty of Science, Novel Global Community",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Educational Foundation, Australia.",
    "entities": [
      {
        "text": "Educational Foundation",
        "label": "ORG"
      },
      {
        "text": "Australia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(12)Department of Nursing, Research and Scientific Studies Unit, College of",
    "entities": [
      {
        "text": "Nursing, Research and Scientific Studies Unit",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Nursing and Allied Health Sciences, Jazan University, Jazan, 45142, Saudi",
    "entities": [
      {
        "text": "Allied Health Sciences",
        "label": "ORG"
      },
      {
        "text": "Jazan University",
        "label": "ORG"
      },
      {
        "text": "Jazan",
        "label": "GPE"
      },
      {
        "text": "45142",
        "label": "DATE"
      },
      {
        "text": "Saudi",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "(13)School of Medicine, Universidad Espiritu Santo, Samborondon, 091952,",
    "entities": [
      {
        "text": "Universidad Espiritu Santo",
        "label": "PERSON"
      },
      {
        "text": "Samborondon",
        "label": "GPE"
      },
      {
        "text": "091952",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(14)Department of Pharmaceutical Analysis, GITAM School of Pharmacy, GITAM",
    "entities": [
      {
        "text": "14)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Pharmaceutical Analysis",
        "label": "ORG"
      },
      {
        "text": "GITAM School of Pharmacy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(Deemed to be) University, Visakhapatnam, Andhra Pradesh, 53004, Rushikonda,",
    "entities": [
      {
        "text": "University",
        "label": "GPE"
      },
      {
        "text": "Visakhapatnam",
        "label": "GPE"
      },
      {
        "text": "Andhra Pradesh",
        "label": "PERSON"
      },
      {
        "text": "53004",
        "label": "DATE"
      },
      {
        "text": "Rushikonda",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "The review focuses on the ways that ontologies are revolutionising precision",
    "entities": []
  },
  {
    "text": "medicine in their effort to understand neurodegenerative illnesses. Ontologies,",
    "entities": []
  },
  {
    "text": "which are structured frameworks that outline the relationships between concepts",
    "entities": []
  },
  {
    "text": "in a certain field, offer a crucial foundation for combining different",
    "entities": []
  },
  {
    "text": "biological data. Novel insights into the construction of a precision medicine",
    "entities": []
  },
  {
    "text": "approach to treat neurodegenerative diseases (NDDs) are given by growing",
    "entities": []
  },
  {
    "text": "advancements in the area of pharmacogenomics. Affected parts of the central",
    "entities": []
  },
  {
    "text": "nervous system may develop neurological disorders, including Alzheimer's,",
    "entities": []
  },
  {
    "text": "Parkinson's, autism spectrum, and attention-deficit/hyperactivity disorder.",
    "entities": []
  },
  {
    "text": "These models allow for standard and helpful data marking, which is needed for",
    "entities": []
  },
  {
    "text": "crossdisciplinary study and teamwork. With case studies, you can see how",
    "entities": []
  },
  {
    "text": "ontologies have been used to find biomarkers, understand how sicknesses work,",
    "entities": []
  },
  {
    "text": "and make models for predicting how drugs will work and how the disease will get",
    "entities": []
  },
  {
    "text": "worse. For example, problems with data quality, meaning variety, and the need",
    "entities": []
  },
  {
    "text": "for constant changes to reflect the growing body of scientific knowledge are",
    "entities": []
  },
  {
    "text": "discussed in this review. It also looks at how semantic data can be mixed with",
    "entities": []
  },
  {
    "text": "cutting-edge computer methods such as artificial intelligence and machine",
    "entities": []
  },
  {
    "text": "learning to make brain disease diagnostic and prediction models more exact and",
    "entities": []
  },
  {
    "text": "accurate. These collaborative networks aim to identify patients at risk,",
    "entities": []
  },
  {
    "text": "identify patients in the preclinical or early stages of illness, and develop",
    "entities": []
  },
  {
    "text": "tailored preventative interventions to enhance patient quality of life and",
    "entities": []
  },
  {
    "text": "prognosis. They also seek to identify new, robust, and effective methods for",
    "entities": []
  },
  {
    "text": "these patient identification tasks. To this end, the current study has been",
    "entities": []
  },
  {
    "text": "considered to examine the essential components that may be part of precise and",
    "entities": []
  },
  {
    "text": "tailored therapy plans used for neurodegenerative illnesses.",
    "entities": []
  },
  {
    "text": "Integrating Misclassified EHR Outcomes With Validated Outcomes From a",
    "entities": []
  },
  {
    "text": "Non-Probability Sample.",
    "entities": [
      {
        "text": "Non-Probability Sample",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Biostatistics, Epidemiology, and Informatics, Perelman School",
    "entities": [
      {
        "text": "Biostatistics, Epidemiology",
        "label": "ORG"
      },
      {
        "text": "Informatics",
        "label": "ORG"
      },
      {
        "text": "Perelman School",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.",
    "entities": [
      {
        "text": "Medicine, University of Pennsylvania",
        "label": "ORG"
      },
      {
        "text": "Philadelphia",
        "label": "GPE"
      },
      {
        "text": "Pennsylvania",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Biostatistics, Brown University School of Public Health,",
    "entities": [
      {
        "text": "2)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Biostatistics, Brown University School of Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Providence, Rhode Island, USA.",
    "entities": [
      {
        "text": "Providence",
        "label": "GPE"
      },
      {
        "text": "Rhode Island",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Although increasingly used for research, electronic health records (EHR) often",
    "entities": []
  },
  {
    "text": "lack a gold-standard assessment of key data elements. Linking EHRs to other data",
    "entities": []
  },
  {
    "text": "sources with higher-quality measurements can improve statistical inference, but",
    "entities": []
  },
  {
    "text": "such analyses must account for selection bias if the linked data source arises",
    "entities": []
  },
  {
    "text": "from a non-probability sample. We propose a set of novel estimators targeting",
    "entities": []
  },
  {
    "text": "the average treatment effect (ATE) that combine information from binary outcomes",
    "entities": [
      {
        "text": "ATE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "measured with error in a large, population-representative EHR database with",
    "entities": []
  },
  {
    "text": "gold-standard outcomes obtained from a smaller validation sample subject to",
    "entities": []
  },
  {
    "text": "selection bias. We evaluate our approach in extensive simulations and an",
    "entities": []
  },
  {
    "text": "analysis of data from the Adult Changes in Thought (ACT) study, a longitudinal",
    "entities": [
      {
        "text": "the Adult Changes",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "study of incident dementia in a cohort of Kaiser Permanente Washington members",
    "entities": [
      {
        "text": "Kaiser Permanente",
        "label": "ORG"
      },
      {
        "text": "Washington",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "with linked EHR data. For a subset of deceased ACT participants who consented to",
    "entities": []
  },
  {
    "text": "brain autopsy prior to death, gold-standard measures of Alzheimer's disease",
    "entities": []
  },
  {
    "text": "neuropathology are available. Our proposed estimators reduced bias and improved",
    "entities": []
  },
  {
    "text": "efficiency for the ATE, facilitating valid inference with EHR data when key data",
    "entities": [
      {
        "text": "ATE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "elements are ascertained with error.",
    "entities": []
  },
  {
    "text": "PMID: 40662425 [Indexed for MEDLINE]",
    "entities": []
  },
  {
    "text": "10.1177/13872877251359642. Online ahead of print.",
    "entities": []
  },
  {
    "text": "New Alzheimer's association workgroup criteria underestimate syndromes in",
    "entities": []
  },
  {
    "text": "The biological definition of Alzheimer's disease promoted by the Alzheimer's",
    "entities": []
  },
  {
    "text": "Association Working Group's new criteria relegates cognitive impairment to the",
    "entities": [
      {
        "text": "Association Working Group's",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "background when defining the disease. However, cognitive syndromes, as plaques",
    "entities": []
  },
  {
    "text": "and tangles, are important biological phenomena, are part of the disease and not",
    "entities": []
  },
  {
    "text": "of the illness, and are objectively investigable. When well delineated, they",
    "entities": []
  },
  {
    "text": "show a close correlation with brain anatomy and neuropathology and are also few,",
    "entities": []
  },
  {
    "text": "relatively invariable, well-defined and well distinguishable from each other.",
    "entities": []
  },
  {
    "text": "Therefore, their detection retains a high value in suggesting the presence of",
    "entities": []
  },
  {
    "text": "the disease, which still must be confirmed by principle of exclusion.",
    "entities": []
  },
  {
    "text": "10.1177/13872877251359637. Online ahead of print.",
    "entities": [
      {
        "text": "10.1177/13872877251359637",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "The gap between amyloid pathology and cognition.",
    "entities": []
  },
  {
    "text": "(1)Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical",
    "entities": [
      {
        "text": "1)Board",
        "label": "CARDINAL"
      },
      {
        "text": "Governors Regenerative Medicine Institute",
        "label": "ORG"
      },
      {
        "text": "Cedars-Sinai Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Nrf2 is a transcription factor critical for protecting the brain against",
    "entities": [
      {
        "text": "transcription",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "oxidative stress and is decreased in Alzheimer's disease (AD) patients, making",
    "entities": []
  },
  {
    "text": "it a potential therapeutic target. The Curran lab previously identified a novel",
    "entities": [
      {
        "text": "Curran",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "regulator, WDR23. Now, in a new study by Liu et al., they demonstrate that",
    "entities": [
      {
        "text": "Liu et al.",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "knocking out WDR23 in the 3xTg-AD mouse improves spatial working memory,",
    "entities": [
      {
        "text": "3xTg-AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "interestingly, while increasing a measure of AD-like pathology. Their work",
    "entities": []
  },
  {
    "text": "brings up several interesting new questions and adds to a growing body of",
    "entities": []
  },
  {
    "text": "literature that highlights how the relationship between cognition and amyloid",
    "entities": []
  },
  {
    "text": "pathology is not as clearcut as once thought.",
    "entities": []
  },
  {
    "text": "Intermittent supplementation with Akkermansia muciniphila and",
    "entities": [
      {
        "text": "Akkermansia muciniphila",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "galactooligosaccharides modulates Alzheimer's disease progression, gut",
    "entities": []
  },
  {
    "text": "microbiota, and colon short-chain fatty acid profiles in mice.",
    "entities": []
  },
  {
    "text": "(1)Department of Biological Models, Institute of Biochemistry, Life Sciences",
    "entities": [
      {
        "text": "Biological Models",
        "label": "ORG"
      },
      {
        "text": "Institute of Biochemistry, Life Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Department of Molecular Microbiology and Biotechnology, Institute of",
    "entities": [
      {
        "text": "Molecular Microbiology and Biotechnology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Biochemistry, Life Sciences Center, Vilnius University, Vilnius, Lithuania.",
    "entities": [
      {
        "text": "Biochemistry, Life Sciences Center",
        "label": "ORG"
      },
      {
        "text": "Vilnius University",
        "label": "ORG"
      },
      {
        "text": "Vilnius",
        "label": "GPE"
      },
      {
        "text": "Lithuania",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Microbiology and Biochemistry of Dairy Products, Dairy Research",
    "entities": [
      {
        "text": "Dairy Research",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Institute IPLA-CSIC, Oviedo, Spain.",
    "entities": [
      {
        "text": "Institute IPLA-CSIC",
        "label": "GPE"
      },
      {
        "text": "Oviedo",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Bidirectional communication and mutual regulation between the",
    "entities": []
  },
  {
    "text": "gastrointestinal tract and the CNS is facilitated through the gut-brain axis.",
    "entities": [
      {
        "text": "CNS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Recent studies have found reduced diversity of the gut microbiota in Alzheimer's",
    "entities": []
  },
  {
    "text": "disease (AD) patients, and animal models suggest microbial involvement in",
    "entities": []
  },
  {
    "text": "amyloid beta peptide (A\u03b2) accumulation. Modulation of the gut microbiota by",
    "entities": []
  },
  {
    "text": "new-generation probiotics represents a novel treatment strategy to alleviate the",
    "entities": []
  },
  {
    "text": "symptoms and slow the progression of AD.",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "METHODS: In this study, the therapeutic effect of the probiotic Akkermansia",
    "entities": [
      {
        "text": "Akkermansia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "muciniphila and the prebiotic galactooligosaccharides (GOS) was investigated in",
    "entities": [
      {
        "text": "muciniphila",
        "label": "ORG"
      },
      {
        "text": "GOS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the APP/PS1 mouse model. After 7 months of triweekly administration, we",
    "entities": [
      {
        "text": "APP",
        "label": "ORG"
      },
      {
        "text": "7 months",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "evaluated physiological parameters, glucose metabolism, and behavioral outcomes.",
    "entities": []
  },
  {
    "text": "Additionally, we assessed gut microbiota diversity and composition, short-chain",
    "entities": []
  },
  {
    "text": "fatty acid (SCFA) concentrations in the cecum, A\u03b2 load in the hippocampus and",
    "entities": [
      {
        "text": "SCFA",
        "label": "ORG"
      },
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "prefrontal cortex, and microglial abundance in the hippocampus.",
    "entities": [
      {
        "text": "prefrontal cortex",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RESULTS: A. muciniphila and GOS administration normalized fasting glucose",
    "entities": [
      {
        "text": "GOS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "levels, glucose metabolism, and intestinal transit time to wild-type levels.",
    "entities": []
  },
  {
    "text": "Furthermore, supplementation reduced anxiety, improved long-and short-term",
    "entities": []
  },
  {
    "text": "memory, and partially restored activity levels. It also regulated SCFA",
    "entities": [
      {
        "text": "SCFA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "concentrations in the cecum, improved the richness of the gut microbiota, and",
    "entities": []
  },
  {
    "text": "normalized abundance of microglia in the hippocampus, indicating reduced",
    "entities": []
  },
  {
    "text": "CONCLUSION: These findings suggest that long-term administration of A.",
    "entities": [
      {
        "text": "A.",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "muciniphila and GOS effectively improves metabolic health and modulates symptoms",
    "entities": [
      {
        "text": "muciniphila",
        "label": "ORG"
      },
      {
        "text": "GOS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of AD in the APP/PS1 mouse model.",
    "entities": [
      {
        "text": "APP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Perianesthetic Management in a Patient With Alzheimer's Disease Complicated With",
    "entities": [
      {
        "text": "Perianesthetic Management",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Pulmonary Infection Who Underwent Emergency Right Artificial Femoral Head",
    "entities": [
      {
        "text": "Pulmonary Infection Who Underwent Emergency",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Replacement Surgery: A Case Report and Review of the Literature.",
    "entities": []
  },
  {
    "text": "(1)Department of Anesthesiology, Shaanxi Provincial Hospital, Xi'an 710068,",
    "entities": [
      {
        "text": "Anesthesiology, Shaanxi Provincial Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Xi'an Medical University, Xi'an 710068, China.",
    "entities": [
      {
        "text": "2)Xi'an",
        "label": "CARDINAL"
      },
      {
        "text": "Medical University",
        "label": "ORG"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Background: Choosing the appropriate timing for surgery is a common clinical",
    "entities": []
  },
  {
    "text": "problem when hip fracture occurs in elderly patients with a variety of",
    "entities": []
  },
  {
    "text": "complications. Case Presentation: We present a fatal case involving an",
    "entities": []
  },
  {
    "text": "84-year-old male patient with bradycardia who underwent cardiac pacemaker",
    "entities": [
      {
        "text": "84-year-old",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "implantation and presented with cognitive impairment, Alzheimer's disease, and",
    "entities": []
  },
  {
    "text": "pulmonary infection and had an American Society of Anesthesiologists (ASA) IV",
    "entities": []
  },
  {
    "text": "status; this patient underwent emergency right artificial femoral head",
    "entities": []
  },
  {
    "text": "replacement surgery. We strengthened our perioperative evaluation and",
    "entities": []
  },
  {
    "text": "monitoring, but the patient's condition did not improve after the operation.",
    "entities": []
  },
  {
    "text": "Conclusion: We utilized multidisciplinary consultation before the operation,",
    "entities": []
  },
  {
    "text": "attempted to improve the state of the patient before the operation, chose an",
    "entities": []
  },
  {
    "text": "appropriate anesthetic scheme during the operation, strengthened cardiopulmonary",
    "entities": []
  },
  {
    "text": "protections, and returned the patient to the ward safely after the operation;",
    "entities": []
  },
  {
    "text": "however, the patient did not recover well post operation.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 Wenying Song et al. Case Reports in Infectious Diseases",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Wenying Song",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "published by John Wiley & Sons Ltd.",
    "entities": [
      {
        "text": "John Wiley & Sons Ltd.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: The authors declare no conflicts of interest.",
    "entities": []
  },
  {
    "text": "Inhibition of Acyl-CoA: Cholesterol Acyltransferase 1 Promotes Shedding of",
    "entities": []
  },
  {
    "text": "Soluble TREM2 and LRP1-Dependent Phagocytosis of Amyloid \u03b2 Protein in Microglia.",
    "entities": [
      {
        "text": "LRP1-Dependent Phagocytosis of Amyloid \u03b2 Protein",
        "label": "LAW"
      },
      {
        "text": "Microglia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Lipid regulation plays a major role in the pathogenesis of Alzheimer's disease",
    "entities": []
  },
  {
    "text": "(AD). In AD patients and transgenic mice, microglia exhibit increased expression",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "of SOAT1 , encoding Acyl-CoA: Cholesterol Acyltransferase 1 (ACAT1), which",
    "entities": [
      {
        "text": "SOAT1",
        "label": "PERSON"
      },
      {
        "text": "Acyl-CoA",
        "label": "PERSON"
      },
      {
        "text": "ACAT1",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "catalyzes the production of cholesteryl esters in lipid droplets. ACAT1",
    "entities": [
      {
        "text": "ACAT1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Inhibition has been reported to reduce \u03b2-amyloid pathology. However, the",
    "entities": []
  },
  {
    "text": "molecular mechanism underlying this effect remains unknown. Here, we show ACAT1",
    "entities": [
      {
        "text": "ACAT1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "inhibition in mouse and human iPSC- derived microglia upregulates LRP1 levels",
    "entities": []
  },
  {
    "text": "and shedding of soluble TREM2 (sTREM2) owing to enhanced cleavage of TREM2 by",
    "entities": [
      {
        "text": "TREM2",
        "label": "PRODUCT"
      },
      {
        "text": "TREM2",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "ADAM10/17. Knocking out TREM2 or preventing sTREM2 release abrogated the ability",
    "entities": [
      {
        "text": "TREM2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of ACAT1 inhibition to enhance microglial uptake of amyloid \u03b2 (A\u03b2). This could",
    "entities": [
      {
        "text": "ACAT1",
        "label": "FAC"
      },
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "be rescued by the addition of recombinant sTREM2, but only in the presence of",
    "entities": []
  },
  {
    "text": "LRP1. Collectively, these data indicate ACAT1 inhibition increases microglial",
    "entities": [
      {
        "text": "ACAT1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "uptake of A\u03b2 in a sTREM2- and LRP1-dependent manner suggesting new avenues for",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      },
      {
        "text": "sTREM2-",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "treating and preventing AD.",
    "entities": []
  },
  {
    "text": "Viral Infection Induces Alzheimer's Disease-Related Pathways and Senescence in",
    "entities": [
      {
        "text": "Viral Infection Induces Alzheimer's",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "INTRODUCTION: The Pathogen Infection Hypothesis proposes that \u03b2-Amyloid (A\u03b2)",
    "entities": [
      {
        "text": "Pathogen Infection Hypothesis",
        "label": "ORG"
      },
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "functions as an antimicrobial peptide, with pathogen-induced aggregation",
    "entities": []
  },
  {
    "text": "potentially contributing to Alzheimer's disease (AD) pathology.",
    "entities": []
  },
  {
    "text": "METHODS: We used human iPSC-derived 2D neurons and 3D cerebral organoids from",
    "entities": []
  },
  {
    "text": "wild-type and familial AD ( PSEN1/2 mutant) lines to model acute infections with",
    "entities": []
  },
  {
    "text": "HSV-1 and TBEV and A\u03b2 aggregation. Transcriptomic and proteomic analyses were",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "conducted to assess molecular responses.",
    "entities": []
  },
  {
    "text": "RESULTS: HSV-1, but not TBEV, induced robust A\u03b2 clustering, which was, however,",
    "entities": [
      {
        "text": "HSV-1",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "widespread HSV-1-induced changes, including activation of",
    "entities": []
  },
  {
    "text": "neurodegeneration-related pathways. Proteomic profiling confirmed enrichment of",
    "entities": []
  },
  {
    "text": "mutations did not alter the acute infection response. Reanalysis of independent",
    "entities": []
  },
  {
    "text": "datasets confirmed our findings and revealed a limited protective effect of",
    "entities": []
  },
  {
    "text": "acyclovir.",
    "entities": []
  },
  {
    "text": "DISCUSSION: Results directly support the Pathogen Infection Hypothesis and",
    "entities": [
      {
        "text": "Pathogen Infection Hypothesis",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "suggest that preventing viral infections via vaccinations may represent a",
    "entities": []
  },
  {
    "text": "feasible approach to reducing AD risk.",
    "entities": []
  },
  {
    "text": "A spatial long-read approach at near-single-cell resolution reveals",
    "entities": []
  },
  {
    "text": "developmental regulation of splicing and polyadenylation sites in distinct",
    "entities": []
  },
  {
    "text": "cortical layers and cell types.",
    "entities": []
  },
  {
    "text": "J, Belchikov N, Jarroux J, He Y, Elizabeth Ross M, Hajirasouliha I, Tartaglia",
    "entities": [
      {
        "text": "Belchikov N",
        "label": "PERSON"
      },
      {
        "text": "Jarroux",
        "label": "ORG"
      },
      {
        "text": "Elizabeth Ross M",
        "label": "PERSON"
      },
      {
        "text": "Hajirasouliha",
        "label": "PERSON"
      },
      {
        "text": "Tartaglia",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Genome-wide single-cell and spatial long-read approaches have gained traction,",
    "entities": []
  },
  {
    "text": "but mostly lack single-cell resolution - and yield limited read lengths. Here,",
    "entities": []
  },
  {
    "text": "we introduce spatial ISOform sequencing (Spl-ISO-Seq), which reveals exons and",
    "entities": [
      {
        "text": "ISOform",
        "label": "ORG"
      },
      {
        "text": "Spl-ISO-Seq",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "polyadenylation sites from long reads with near-single-cell resolution.",
    "entities": []
  },
  {
    "text": "Spl-ISO-Seq selects long cDNAs and doubles to triples read lengths compared to",
    "entities": [
      {
        "text": "Spl-ISO-Seq",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "standard preparations. Adding a highly specific software tool (Spl-ISOquant) and",
    "entities": []
  },
  {
    "text": "comparing human post-mortem pre-puberty samples of the visual cortex (8-11",
    "entities": [
      {
        "text": "8",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "years) to post-puberty samples (16-19 years), we find that cortical layers",
    "entities": [
      {
        "text": "16-19 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "harbor stronger splicing and poly(A)-site regulation than the adjacent white",
    "entities": []
  },
  {
    "text": "matter, with enrichment of multiple protein-domain types. For oligodendrocytes",
    "entities": []
  },
  {
    "text": "however, developmental splicing changes are stronger in white matter. Among",
    "entities": []
  },
  {
    "text": "cortical layers, layer 4 has the most developmental changes in alternative-exon",
    "entities": [
      {
        "text": "4",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "inclusion in excitatory neurons and in poly(A) sites. We also find many repeat",
    "entities": []
  },
  {
    "text": "elements, especially ERV1 long terminal repeats downstream of",
    "entities": []
  },
  {
    "text": "developmentally-regulated layer 4 exons. Overall, alternative splicing changes",
    "entities": [
      {
        "text": "4",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "are linked to synapses - specifically at the post-synapse. Age-linked splicing",
    "entities": []
  },
  {
    "text": "changes in layers 1-3 and 4 are associated with autism spectrum disorder but not",
    "entities": [
      {
        "text": "1-3",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "with schizophrenia, amyotrophic lateral sclerosis and Alzheimer's disease. These",
    "entities": []
  },
  {
    "text": "results root developmental splicing changes during puberty and the resulting",
    "entities": []
  },
  {
    "text": "protein changes in specific layers and cell types. More generally, our new",
    "entities": []
  },
  {
    "text": "technologies enable new observations for any complex tissue.",
    "entities": []
  },
  {
    "text": "Accumulation of LRRK2-associated phospho-Rab12 degenerative lysosomes in",
    "entities": []
  },
  {
    "text": "Parkinson's disease (PD) pathogenic mutations in leucine-rich repeat kinase 2 (",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "LRRK2 ) are associated with endolysosomal dysfunction across cell types, and",
    "entities": [
      {
        "text": "LRRK2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "carriers of LRRK2 mutations variably present with phosphorylated tau and",
    "entities": [
      {
        "text": "LRRK2",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "\u03b1-synuclein deposits in post-mortem analysis. LRRK2 mutations increase the",
    "entities": [
      {
        "text": "LRRK2",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "phosphorylation of Rab substrates including Rab12. Rab12 is expressed in",
    "entities": [
      {
        "text": "Rab12",
        "label": "GPE"
      },
      {
        "text": "Rab12",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "neuronal and non-neuronal cells with localization to membranes in the",
    "entities": []
  },
  {
    "text": "endolysosomal compartment. Under lysosomal stress, LRRK2 interaction with Rab12",
    "entities": [
      {
        "text": "LRRK2",
        "label": "ORG"
      },
      {
        "text": "Rab12",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "upregulates LRRK2 kinase activity. In this study, using a recently developed",
    "entities": [
      {
        "text": "LRRK2",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "monoclonal antibody directed to the LRRK2-mediated phosphorylation site on Rab12",
    "entities": [
      {
        "text": "LRRK2",
        "label": "GPE"
      },
      {
        "text": "Rab12",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "at amino acid Ser106 (pS106-Rab12), we test whether aberrant LRRK2",
    "entities": [
      {
        "text": "LRRK2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "phosphorylation is associated with tau and/or \u03b1-synuclein pathology across",
    "entities": []
  },
  {
    "text": "clinically distinct neurodegenerative diseases. Analysis of brain tissue lysates",
    "entities": []
  },
  {
    "text": "and immunohistochemistry of pathology-susceptible brain regions demonstrate that",
    "entities": []
  },
  {
    "text": "pS106-Rab12 levels are increased in Dementia with Lewy bodies (DLB), Alzheimer's",
    "entities": [
      {
        "text": "Dementia",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "disease (AD), and PD, and in LRRK2 mutation carriers. In early pathological",
    "entities": [
      {
        "text": "PD",
        "label": "GPE"
      },
      {
        "text": "LRRK2",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "stages, phosphorylated Rab12 localizes to granulovacuolar degeneration bodies",
    "entities": [
      {
        "text": "Rab12",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(GVBs), which are thought to be active lysosomal-like structures, in neurons.",
    "entities": []
  },
  {
    "text": "pS106-Rab12-positive GVBs accumulate with pathological tau across brain tissues",
    "entities": [
      {
        "text": "Rab12",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "in DLB, AD, and PD, and in LRRK2 mutation carriers. In a mouse model of",
    "entities": [
      {
        "text": "DLB",
        "label": "GPE"
      },
      {
        "text": "AD",
        "label": "DATE"
      },
      {
        "text": "PD",
        "label": "GPE"
      },
      {
        "text": "LRRK2",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "tauopathy, pS106-Rab12 localizes to GVBs during early tau deposition in an",
    "entities": []
  },
  {
    "text": "age-dependent manner. While GVBs are largely absent in neurons with mature",
    "entities": []
  },
  {
    "text": "protein pathology, subsets of both tau and \u03b1-synuclein inclusions appear to",
    "entities": [
      {
        "text": "protein pathology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "incorporate pS106-Rab12 at later pathological stages. Finally, pS106-Rab12",
    "entities": []
  },
  {
    "text": "labels GVBs in neurons and shows widespread co-pathology with tau inclusions in",
    "entities": []
  },
  {
    "text": "primary tauopathies including Pick's disease, progressive supranuclear palsy and",
    "entities": [
      {
        "text": "Pick",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "corticobasal degeneration. These results implicate LRRK2 kinase activity and Rab",
    "entities": [
      {
        "text": "LRRK2",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "phosphorylation in endolysosomal dysfunction in both tau and",
    "entities": []
  },
  {
    "text": "\u03b1-synuclein-associated neurodegenerative diseases.",
    "entities": []
  },
  {
    "text": "Assessing the Suitability of Deubiquitylases As Substrates For Targeted Protein",
    "entities": []
  },
  {
    "text": "Deubiquitylases (DUBs) are a family of specialized proteases that hydrolyze the",
    "entities": []
  },
  {
    "text": "isopeptide bond between a lysine and the C-terminal carboxylate of Ubiquitin.",
    "entities": [
      {
        "text": "Ubiquitin",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "DUBs are involved in a myriad of cellular processes and many are attractive drug",
    "entities": []
  },
  {
    "text": "targets. However, it has proven extremely difficult to develop selective",
    "entities": []
  },
  {
    "text": "inhibitors due to the high degree of homology between DUB active sites. Targeted",
    "entities": [
      {
        "text": "DUB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "protein degradation using a proteolysis-targeting chimera (PROTAC) that",
    "entities": []
  },
  {
    "text": "recognizes the DUB in a less conserved region outside of the catalytic domain",
    "entities": [
      {
        "text": "DUB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "constitutes an attractive alternative strategy for selectively inhibiting a",
    "entities": []
  },
  {
    "text": "given DUB. Such ligands are unlikely to block the catalytic activity of the",
    "entities": []
  },
  {
    "text": "enzyme, raising the concern that auto-deubiqtuiylation will make DUBs inherently",
    "entities": []
  },
  {
    "text": "poor substrates for PROTACs of this type. Since drug-like ligands that engage",
    "entities": []
  },
  {
    "text": "DUBs outside of the active site are extremely rare, this issue is difficult to",
    "entities": []
  },
  {
    "text": "address in a straightforward fashion. In this study we establish a generally",
    "entities": []
  },
  {
    "text": "applicable chemical genetics workflow to evaluate the degradability of DUBs by a",
    "entities": []
  },
  {
    "text": "PROTAC. The data indicate that some DUBs are readily degradable and some are",
    "entities": []
  },
  {
    "text": "not. In particular, USP11, an attractive drug target in various cancers and",
    "entities": []
  },
  {
    "text": "Alzheimer's disease, is shown to be rapidly degradable, while its paralogs, USP4",
    "entities": [
      {
        "text": "USP4",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "and USP15 resist degradation through auto-deubiquitylation.",
    "entities": [
      {
        "text": "USP15",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "SIGNIFICANCE: The development of selective inhibitors of Deubiquitylase enzymes",
    "entities": []
  },
  {
    "text": "(DUBs) is difficult due to a high level of homology in the active sites of the \u2248",
    "entities": []
  },
  {
    "text": "100 such enzymes in the human proteome. A potentially attractive strategy to",
    "entities": [
      {
        "text": "100",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "achieve this goal would be to develop PROTACs or molecular glues that engage the",
    "entities": []
  },
  {
    "text": "target DUB in a less conserved region outside of the catalytic domain. However,",
    "entities": [
      {
        "text": "DUB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "this raises the concern that auto-deubiquitylation would make DUBs poor",
    "entities": []
  },
  {
    "text": "substrates for this modality. Here we describe a chemical genetics system to",
    "entities": []
  },
  {
    "text": "evaluate this issue. We find that some Dubs are readily degradable via the",
    "entities": [
      {
        "text": "Dubs",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Ubiquitin-proteasome pathway and some are not. Of the latter category, some",
    "entities": [
      {
        "text": "Ubiquitin",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "resist turnover through auto-deubiquitylation and some are simply poor",
    "entities": []
  },
  {
    "text": "proteasome substrates.",
    "entities": []
  },
  {
    "text": "HIGHLIGHTS: Some active DUBs, including USP11 are vulnerable to targeted protein",
    "entities": []
  },
  {
    "text": "degradation by a PROTAC.Other DUBs, including USP4 and USP15, resist",
    "entities": [
      {
        "text": "USP4",
        "label": "GPE"
      },
      {
        "text": "USP15",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "PROTAC-mediated degradation via auto-deubiquitylation.Some DUBs are poor",
    "entities": []
  },
  {
    "text": "substrates for targeted degradation because they are processed inefficiently by",
    "entities": []
  },
  {
    "text": "the proteasome.",
    "entities": []
  },
  {
    "text": "Age and Alzheimer's disease affect functional connectivity along separate axes",
    "entities": []
  },
  {
    "text": "of functional brain organization.",
    "entities": []
  },
  {
    "text": "Aging and Alzheimer's disease (AD) are associated with alterations in functional",
    "entities": []
  },
  {
    "text": "connectivity (FC), yet their spatial and temporal characteristics remain",
    "entities": [
      {
        "text": "FC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "debated. Whole-cortex functional gradients, which organize regions along axes of",
    "entities": []
  },
  {
    "text": "functional similarity, are positioned here as a framework for understanding such",
    "entities": []
  },
  {
    "text": "alterations. Across two independent cohorts (BioFINDER-2, N=973; ADNI, N=129),",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      },
      {
        "text": "ADNI",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "we demonstrate that hyper- and hypoconnectivity in both healthy aging and",
    "entities": []
  },
  {
    "text": "biomarker-confirmed AD progression coexist systematically, forming consistent",
    "entities": [
      {
        "text": "biomarker-confirmed",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "spatial patterns that align with two distinct axes of brain organization. Using",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "a combination of longitudinal and non-linear analyses, we show that the early",
    "entities": []
  },
  {
    "text": "(but not late) stages of AD pathology accumulation is associated with functional",
    "entities": [
      {
        "text": "AD",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "alteration along the sensory-association axis, a pattern that vanishes in later",
    "entities": []
  },
  {
    "text": "stages of AD. However, functional alteration along the sensory-association axis",
    "entities": []
  },
  {
    "text": "is associated with worse cognition throughout the AD spectrum, and even in older",
    "entities": []
  },
  {
    "text": "adults without AD pathology, suggesting that these FC patterns may reflect a",
    "entities": [
      {
        "text": "FC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "general neural response to cognitive strain. Independently of AD, older age was",
    "entities": []
  },
  {
    "text": "associated with alterations instead along the executive-nonexecutive axis, a",
    "entities": []
  },
  {
    "text": "finding that was consistent throughout the adult lifespan. These findings",
    "entities": []
  },
  {
    "text": "highlight the fundamental role of intrinsic functional organization in shaping",
    "entities": []
  },
  {
    "text": "how the brain responds to aging and to AD, helping to resolve previously",
    "entities": []
  },
  {
    "text": "Smelling the Risk: Early Olfactory Deficits, Brain Networks, and Blood Markers",
    "entities": [
      {
        "text": "Brain Networks",
        "label": "ORG"
      },
      {
        "text": "Blood Markers",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "of Alzheimer's Disease Risk in Humanized APOE Mice.",
    "entities": []
  },
  {
    "text": "Moon HS, Han ZY, Anderson RJ, Mahzarnia A, Stout J, Niculescu A, Tremblay J,",
    "entities": [
      {
        "text": "Moon HS",
        "label": "PERSON"
      },
      {
        "text": "Han ZY",
        "label": "ORG"
      },
      {
        "text": "Anderson RJ",
        "label": "PERSON"
      },
      {
        "text": "Mahzarnia A",
        "label": "ORG"
      },
      {
        "text": "Niculescu A",
        "label": "PERSON"
      },
      {
        "text": "Tremblay J",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Olfactory impairment is a hallmark of early Alzheimer's disease (AD), but the",
    "entities": []
  },
  {
    "text": "underlying mechanisms connecting sensory decline to genetic and environmental",
    "entities": []
  },
  {
    "text": "risk factors remain unclear. Our integrative analysis combines ethologically",
    "entities": []
  },
  {
    "text": "relevant olfactory behavior assays, high-resolution diffusion MRI connectomics,",
    "entities": []
  },
  {
    "text": "and blood transcriptomics in a large cohort of humanized APOE mice stratified by",
    "entities": []
  },
  {
    "text": "APOE genotype (APOE2, APOE3, APOE4), age, sex, high-fat diet, and immune",
    "entities": [
      {
        "text": "APOE2",
        "label": "LOC"
      },
      {
        "text": "APOE3",
        "label": "ORG"
      },
      {
        "text": "APOE4",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "background (HN). Behaviorally, APOE4 mice exhibited accelerated deficits in odor",
    "entities": [
      {
        "text": "APOE4",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "salience, novelty detection, and memory, especially when exposed to a high-fat",
    "entities": []
  },
  {
    "text": "diet, whereas APOE2 mice showed resilience (ANOVA: APOE x HN, F(2,1669)=77.25,",
    "entities": [
      {
        "text": "diet",
        "label": "ORG"
      },
      {
        "text": "APOE2",
        "label": "LOC"
      },
      {
        "text": "F(2,1669)=77.25",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "p<0.001, eta squared effect size = 0.08). Notably, age and diet exerted",
    "entities": [
      {
        "text": "0.08",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "compounding effects, with older and HFD-fed mice displaying reduced odor-guided",
    "entities": [
      {
        "text": "HFD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "0.01). Memory analyses revealed robust genotype- and age-dependent impairments:",
    "entities": [
      {
        "text": "0.01",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "at 24- and 48-hour delays, recognition indices were significantly lower in APOE4",
    "entities": [
      {
        "text": "48-hour",
        "label": "TIME"
      },
      {
        "text": "APOE4",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "mice compared to APOE2 (long-term memory: APOE x HN, F(2,395)=5.6, p=0.004).",
    "entities": [
      {
        "text": "APOE2",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "Elastic Net-regularized multi-set canonical correlation analysis (MCCA) linked",
    "entities": []
  },
  {
    "text": "behavior to brain network substrates, revealing subnetworks whose connectivity",
    "entities": []
  },
  {
    "text": "explained up to 24 percent of behavioral variance (sum of canonical",
    "entities": [
      {
        "text": "24 percent",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "correlations: 1.27, 95% CI [1.18, 1.85], p<0.0001). High-weighted connections",
    "entities": [
      {
        "text": "1.27",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "1.18",
        "label": "CARDINAL"
      },
      {
        "text": "1.85",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "between the ventral orbital cortex, somatosensory cortex, and",
    "entities": []
  },
  {
    "text": "cerebellar-brainstem pathways were identified as critical nodes for risk or",
    "entities": []
  },
  {
    "text": "compensation. Integrative blood transcriptomics revealed eigengene modules",
    "entities": []
  },
  {
    "text": "strongly correlated with imaging changes in olfactory-memory circuits (for",
    "entities": []
  },
  {
    "text": "example, eigengene 2 vs. subiculum diffusivity: r = -0.5, p < 1e-30, explaining",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "up to 24 percent of variance). Gene ontology analysis pinpointed shared pathways",
    "entities": [
      {
        "text": "up to 24 percent",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "in synaptic signaling, translation, and metabolic regulation across brain and",
    "entities": []
  },
  {
    "text": "blood. Notably, glutamatergic and synaptic pathways were enriched among genes",
    "entities": []
  },
  {
    "text": "linking peripheral and central compartments. Collectively, these results",
    "entities": []
  },
  {
    "text": "demonstrate that olfactory behavior, quantitatively shaped by genotype, age,",
    "entities": []
  },
  {
    "text": "diet, and immune status, serves as a sensitive and translatable early biomarker",
    "entities": [
      {
        "text": "diet",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Alzheimer's disease risk. Our systems-level approach identifies specific",
    "entities": []
  },
  {
    "text": "brain networks and peripheral molecular signatures underlying sensory-cognitive",
    "entities": []
  },
  {
    "text": "vulnerability, providing a robust framework for early detection and targeted",
    "entities": []
  },
  {
    "text": "intervention in AD.",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Bisdemethoxycurcumin mitigates Alzheimer disease pathology through",
    "entities": []
  },
  {
    "text": "autophagy-mediated reduction of senescence and amyloid beta.",
    "entities": []
  },
  {
    "text": "Bharate S, Ahmed Z, Kumar A.",
    "entities": [
      {
        "text": "Bharate S",
        "label": "PERSON"
      },
      {
        "text": "Ahmed Z",
        "label": "PERSON"
      },
      {
        "text": "Kumar A.\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "AD pathology is accompanied by increased senescence and reduced levels of",
    "entities": [
      {
        "text": "AD",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "autophagy in the brain. We investigated whether pharmacologically inducing",
    "entities": []
  },
  {
    "text": "autophagy could alter the senescent phenotype and help ameliorate AD pathology.",
    "entities": []
  },
  {
    "text": "We discovered that Bisdemethoxycurcumin (BDMC), a natural compound found in",
    "entities": [
      {
        "text": "Bisdemethoxycurcumin",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Curcuma longa , stimulates autophagy in primary astrocytes. We found that",
    "entities": []
  },
  {
    "text": "autophagy and senescence exhibit an inverse relationship in aging astrocytes,",
    "entities": []
  },
  {
    "text": "with increased expression of senescent proteins and downregulation of autophagic",
    "entities": []
  },
  {
    "text": "proteins. However, treatment of aged astrocytes with BDMC reversed the senescent",
    "entities": [
      {
        "text": "BDMC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "phenotype by ameliorating the impaired autophagy. Interestingly, the senescent",
    "entities": []
  },
  {
    "text": "phenotype persisted when autophagy was downregulated by knockdown of AMPK .",
    "entities": [
      {
        "text": "AMPK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Additionally, BDMC-induced autophagy aided in the removal of amyloid beta that",
    "entities": []
  },
  {
    "text": "was administered externally to the astrocytes. Further, to validate these",
    "entities": []
  },
  {
    "text": "results in a mouse model of AD, we confirmed that BDMC can significantly",
    "entities": [
      {
        "text": "BDMC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "penetrate the blood-brain barrier (BBB) in mice. Therefore, we administered 50",
    "entities": [
      {
        "text": "BBB",
        "label": "ORG"
      },
      {
        "text": "50",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "and 100 mg/kg b.w. of BDMC to transgenic 3xTg-AD mice for two months. In their",
    "entities": [
      {
        "text": "100 mg/kg b.w",
        "label": "QUANTITY"
      },
      {
        "text": "BDMC",
        "label": "ORG"
      },
      {
        "text": "3xTg-AD",
        "label": "DATE"
      },
      {
        "text": "two months",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "hippocampus, the Control 3xTg-AD animals showed more senescent cells and lower",
    "entities": []
  },
  {
    "text": "autophagy levels. In contrast, autophagic proteins were significantly",
    "entities": []
  },
  {
    "text": "upregulated while senescence indicators, such as senescence-associated secretory",
    "entities": []
  },
  {
    "text": "phenotype (SASP) proteins, were sharply downregulated in the brain of treated",
    "entities": []
  },
  {
    "text": "animals. Additionally, we discovered that the treated mice's hippocampus had a",
    "entities": []
  },
  {
    "text": "significantly lower amyloid beta load. These molecular changes in the brain were",
    "entities": []
  },
  {
    "text": "ultimately reflected in the improved working memory and neuromuscular",
    "entities": []
  },
  {
    "text": "coordination behavior of mice treated with BDMC. This study warrants further",
    "entities": [
      {
        "text": "BDMC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "evaluation of BDMC for the management of AD.",
    "entities": [
      {
        "text": "BDMC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "DCPS modulates TDP-43 mediated neurodegeneration through P-body regulation.",
    "entities": []
  },
  {
    "text": "The proteinopathy of the RNA-binding protein TDP-43, characterized by nuclear",
    "entities": [
      {
        "text": "RNA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "clearance and cytoplasmic inclusion, is a hallmark of multiple neurodegenerative",
    "entities": []
  },
  {
    "text": "diseases, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia",
    "entities": [
      {
        "text": "ALS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(FTD), and Alzheimer's disease (AD). Through CRISPR interference (CRISPRi)",
    "entities": []
  },
  {
    "text": "screening in human neurons, we identified the decapping enzyme scavenger (DCPS)",
    "entities": []
  },
  {
    "text": "as a novel genetic modifier of TDP-43 loss-of-function (LOF)-mediated",
    "entities": []
  },
  {
    "text": "neurotoxicity. Our findings reveal that TDP-43 LOF leads to aberrant mRNA",
    "entities": [
      {
        "text": "LOF",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "degradation, via disrupting the properties and function of processing bodies",
    "entities": []
  },
  {
    "text": "(P-bodies). TDP-43 interacts with P-body component proteins, potentially",
    "entities": []
  },
  {
    "text": "influencing their dynamic equilibrium and assembly into ribonucleoprotein (RNP)",
    "entities": [
      {
        "text": "RNP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "granules. Reducing DCPS restores P-body integrity and RNA turnover, ultimately",
    "entities": [
      {
        "text": "RNA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "improving neuronal survival. Overall, this study highlights a novel role of",
    "entities": []
  },
  {
    "text": "TDP-43 in RNA processing through P-body regulation and identifies DCPS as a",
    "entities": [
      {
        "text": "RNA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "potential therapeutic target for TDP-43 proteinopathy-related neurodegenerative",
    "entities": []
  },
  {
    "text": "The cholinergic drug galantamine ameliorates acute and subacute peripheral and",
    "entities": []
  },
  {
    "text": "brain manifestations of acute respiratory distress syndrome in mice.",
    "entities": []
  },
  {
    "text": "Falvey A, Palandira SP, Chaudhry S, Tynan A, Consolim-Colombo FM, Metz CN,",
    "entities": [
      {
        "text": "Falvey A",
        "label": "PERSON"
      },
      {
        "text": "Palandira SP",
        "label": "PERSON"
      },
      {
        "text": "Chaudhry S",
        "label": "PERSON"
      },
      {
        "text": "Tynan A",
        "label": "PERSON"
      },
      {
        "text": "Consolim-Colombo FM",
        "label": "ORG"
      },
      {
        "text": "Metz CN",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Brines M, Chang EH, Chavan SS, Tracey KJ, Pavlov VA.",
    "entities": [
      {
        "text": "Brines M",
        "label": "ORG"
      },
      {
        "text": "Chang EH",
        "label": "PERSON"
      },
      {
        "text": "Chavan SS",
        "label": "ORG"
      },
      {
        "text": "Tracey KJ",
        "label": "PERSON"
      },
      {
        "text": "Pavlov VA",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Acute respiratory distress syndrome (ARDS) is a life-threatening form of acute",
    "entities": []
  },
  {
    "text": "lung injury (ALI), which is a common cause of respiratory failure and high",
    "entities": [
      {
        "text": "ALI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "mortality in critically ill patients. Long-term mortality and brain dysfunction",
    "entities": []
  },
  {
    "text": "have been documented in ARDS patients after hospital discharge. Inflammation",
    "entities": []
  },
  {
    "text": "plays a key role in ALI/ARDS pathogenesis. Neural cholinergic signaling",
    "entities": [
      {
        "text": "ALI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "regulates cytokine responses and inflammation. Here, we studied the effects of",
    "entities": []
  },
  {
    "text": "galantamine, an approved cholinergic drug (for Alzheimer's disease) on ALI/ARDS",
    "entities": [
      {
        "text": "ALI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "severity and inflammation in mice, using a clinically relevant mouse model",
    "entities": []
  },
  {
    "text": "induced by intratracheal administration of hydrochloric acid and",
    "entities": []
  },
  {
    "text": "lipopolysaccharide. Mice were treated 30 mins prior to each insult with vehicle",
    "entities": [
      {
        "text": "30",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "or galantamine (4 mg/kg, i.p.). Galantamine treatment significantly decreased",
    "entities": [
      {
        "text": "4 mg/kg",
        "label": "QUANTITY"
      },
      {
        "text": "i.p.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "bronchoalveolar lavage (BAL) and serum TNF, IL-1\u03b2, and IL-6 levels, as well as",
    "entities": [
      {
        "text": "BAL",
        "label": "ORG"
      },
      {
        "text": "TNF",
        "label": "ORG"
      },
      {
        "text": "IL-1\u03b2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BAL total protein and myeloperoxidase and lung histopathology in ALI/ARDS mice.",
    "entities": [
      {
        "text": "BAL",
        "label": "ORG"
      },
      {
        "text": "ALI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "In addition, galantamine improved the functional state of mice with ALI/ARDS",
    "entities": [
      {
        "text": "ALI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "during a 10-day monitoring and attenuated lung injury and indices of brain",
    "entities": [
      {
        "text": "10-day",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "inflammation at 10 days. These findings support further studies utilizing this",
    "entities": [
      {
        "text": "10 days",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "approved cholinergic drug in therapeutic strategies for ARDS and its subacute",
    "entities": []
  },
  {
    "text": "Canagliflozin reprograms the aging hippocampus in genetically diverse UM-HET3",
    "entities": []
  },
  {
    "text": "mice and attenuates Alzheimer's-like pathology.",
    "entities": []
  },
  {
    "text": "Aging is the strongest risk factor for cognitive decline and Alzheimer's disease",
    "entities": []
  },
  {
    "text": "(AD), yet the mechanisms underlying brain aging and their modulation by",
    "entities": []
  },
  {
    "text": "pharmacological interventions remain poorly defined. The hippocampus, essential",
    "entities": []
  },
  {
    "text": "for learning and memory, is particularly vulnerable to metabolic stress and",
    "entities": []
  },
  {
    "text": "co-transporter 2 inhibitor (SGLT2i) for type 2 diabetes, extends lifespan in",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "SGLT2i",
        "label": "ORG"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "male but not female mice, but its impact on brain aging is unknown. Here, we",
    "entities": []
  },
  {
    "text": "used a multi-omics strategy integrating transcriptomics, proteomics, and",
    "entities": []
  },
  {
    "text": "metabolomics to investigate how chronic Cana treatment reprograms brain aging in",
    "entities": [
      {
        "text": "Cana",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "genetically diverse UM-HET3 mice. In males, Cana induced mitochondrial function,",
    "entities": [
      {
        "text": "Cana",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "insulin and cGMP-PKG signaling, and suppressed neuroinflammatory networks across",
    "entities": []
  },
  {
    "text": "all molecular layers, resulting in improved hippocampal-dependent learning and",
    "entities": []
  },
  {
    "text": "memory. In females, transcriptional activation of neuroprotective pathways did",
    "entities": []
  },
  {
    "text": "not translate to protein or metabolite-level changes and failed to rescue",
    "entities": []
  },
  {
    "text": "cognition. In the 5xFAD AD model, Cana reduced amyloid plaque burden,",
    "entities": [
      {
        "text": "Cana",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "microgliosis, and memory deficits in males only, despite comparable peripheral",
    "entities": []
  },
  {
    "text": "glucose improvements in both sexes. Our study reveals sex-specific remodeling of",
    "entities": []
  },
  {
    "text": "hippocampal aging by a clinically available SGLT2i, with implications for AD",
    "entities": [
      {
        "text": "SGLT2i",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "pathology and lifespan extension, and highlights Cana's potential to combat",
    "entities": [
      {
        "text": "Cana",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "brain aging and AD through sex-specific mechanisms.",
    "entities": []
  },
  {
    "text": "\"Glutaminolysis Fuels Reactive Astrocytes, Exacerbating Amyloid Pathology in",
    "entities": [
      {
        "text": "Glutaminolysis Fuels Reactive Astrocytes",
        "label": "WORK_OF_ART"
      },
      {
        "text": "Exacerbating Amyloid Pathology",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Amyloid-\u03b2 (A\u03b2) plaques with progressively increasing reactive astrocytes",
    "entities": [
      {
        "text": "Amyloid-\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "characterize Alzheimer's disease (AD). Reactive astrocytes are regulated by",
    "entities": []
  },
  {
    "text": "cellular and molecular mechanisms that are known to progress A\u03b2 pathology.",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "However, the metabolic adaptation and metabolites required to fuel these",
    "entities": []
  },
  {
    "text": "molecular changes in reactive astrocytes remain unknown. Using human AD samples,",
    "entities": []
  },
  {
    "text": "in vivo amyloid mouse models, and in vitro approaches, we demonstrate that",
    "entities": []
  },
  {
    "text": "reactive astrocytes utilize glutamine to fuel anaplerosis and meet their",
    "entities": []
  },
  {
    "text": "metabolic demands, thereby progressing amyloidosis. We show that reactive",
    "entities": []
  },
  {
    "text": "astrocytes increase Na + -coupled neutral amino acid transporters for glutamine",
    "entities": []
  },
  {
    "text": "uptake that are interdependent on Na + /K + ATPase. Furthermore, increasing",
    "entities": []
  },
  {
    "text": "brain-glutamine levels with a high-glutamine diet exacerbated reactive",
    "entities": []
  },
  {
    "text": "astrocytes, increasing A\u03b2 burden in an amyloid mouse model. We demonstrate that",
    "entities": [
      {
        "text": "A\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "enzymes to be incorporated into TCA metabolites for anaplerosis.",
    "entities": [
      {
        "text": "TCA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Pharmacologically or genetically blocking glutaminolysis reduces reactive",
    "entities": []
  },
  {
    "text": "astrocytes and decreases A\u03b2 pathology in an amyloid mouse. Our findings reveal",
    "entities": [
      {
        "text": "A\u03b2 pathology",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "the first glutamine-dependent metabolic adaptation of reactive astrocytes",
    "entities": [
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "affecting A\u03b2 pathology, which may be harnessed for AD therapeutic strategies.",
    "entities": [
      {
        "text": "A\u03b2 pathology",
        "label": "PERSON"
      },
      {
        "text": "AD",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Nociceptin receptor and ligand in Alzheimer's disease: Implications for",
    "entities": [
      {
        "text": "Nociceptin",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "psychiatric symptoms and circadian regulation.",
    "entities": []
  },
  {
    "text": "BACKGROUND: Nociceptin (N/OFQ) and its receptor OPRL1 play crucial roles in",
    "entities": [
      {
        "text": "Nociceptin",
        "label": "ORG"
      },
      {
        "text": "OPRL1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "emotional processing, reward-related behaviors, learning, and neurotransmitter",
    "entities": []
  },
  {
    "text": "regulation, but their involvement in Alzheimer's disease (AD) pathology remains",
    "entities": []
  },
  {
    "text": "poorly understood. This study investigated possible relationships between",
    "entities": []
  },
  {
    "text": "prepronociceptin ( PNOC ) and OPRL1 expression and psychiatric symptoms in AD,",
    "entities": [
      {
        "text": "prepronociceptin ( PNOC )",
        "label": "ORG"
      },
      {
        "text": "OPRL1",
        "label": "ORG"
      },
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "utilizing Natural Language Processing (NLP) to assess Research Domain Criteria",
    "entities": [
      {
        "text": "Natural Language Processing (",
        "label": "WORK_OF_ART"
      },
      {
        "text": "NLP",
        "label": "ORG"
      },
      {
        "text": "Domain Criteria",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "METHODS: Post-mortem brain tissue from the dorsal anterior cingulate gyrus",
    "entities": []
  },
  {
    "text": "(BA32) was analyzed in 61 donors across different Braak and Braak (B&B) stages.",
    "entities": [
      {
        "text": "61",
        "label": "CARDINAL"
      },
      {
        "text": "Braak",
        "label": "ORG"
      },
      {
        "text": "Braak",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RNA expression of PNOC and OPRL1 was quantified and correlated with RDoC scores",
    "entities": [
      {
        "text": "RNA",
        "label": "ORG"
      },
      {
        "text": "PNOC",
        "label": "ORG"
      },
      {
        "text": "OPRL1",
        "label": "GPE"
      },
      {
        "text": "RDoC",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "derived from medical records using NLP. Sex-stratified analyses, circadian",
    "entities": [
      {
        "text": "NLP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "rhythmicity analysis, and cell-type specific expression patterns were examined.",
    "entities": []
  },
  {
    "text": "RESULTS: Both genes showed significant downregulation in AD cases ( PNOC : p =",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "0.024; OPRL1 : p < 0.001), with notable sex differences. Men displayed higher",
    "entities": [
      {
        "text": "0.024",
        "label": "CARDINAL"
      },
      {
        "text": "OPRL1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "post-mortem PNOC (Cohen's d = -0.482) and OPRL1 (Cohen's d = -0.237) expression",
    "entities": [
      {
        "text": "Cohen",
        "label": "PERSON"
      },
      {
        "text": "OPRL1",
        "label": "PERSON"
      },
      {
        "text": "Cohen",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "compared to women. In adjusted models controlling for B&B stage and post-mortem",
    "entities": [
      {
        "text": "B&B",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "interval, PNOC expression significantly correlated with dimensional scores of",
    "entities": []
  },
  {
    "text": "positive valence (\u03b2 = -0.38, p = 0.035) and arousal regulatory systems (\u03b2 =",
    "entities": [
      {
        "text": "-0.38",
        "label": "PERSON"
      },
      {
        "text": "0.035",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "-0.43, p = 0.015) derived from a text classification algorithm applied to",
    "entities": [
      {
        "text": "0.015",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "medical records. OPRL1 showed disrupted circadian rhythmicity in AD cases (p =",
    "entities": [
      {
        "text": "OPRL1",
        "label": "ORG"
      },
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "CONCLUSIONS: These findings suggest distinct roles for PNOC and OPRL1 in AD",
    "entities": [
      {
        "text": "OPRL1",
        "label": "GPE"
      },
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "pathology, with PNOC primarily associated with psychiatric symptoms and OPRL1",
    "entities": [
      {
        "text": "OPRL1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "showing disrupted circadian regulation. Sex-specific expression patterns further",
    "entities": []
  },
  {
    "text": "indicate the need for personalized therapeutic approaches targeting the",
    "entities": []
  },
  {
    "text": "nociceptin system.",
    "entities": [
      {
        "text": "nociceptin",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Boolean Network Modeling Identifies Cognitive Resilience in the First Murine",
    "entities": [
      {
        "text": "Boolean Network Modeling Identifies Cognitive Resilience",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Model of Asymptomatic Alzheimer's Disease.",
    "entities": []
  },
  {
    "text": "Alzheimer's disease (AD) is a progressive neurodegenerative disorder defined by",
    "entities": []
  },
  {
    "text": "amyloid beta (A\u03b2) plaques and neurofibrillary tangles (NFTs), yet approximately",
    "entities": []
  },
  {
    "text": "20-30% of aged individuals exhibit these hallmark lesions without developing",
    "entities": [
      {
        "text": "20-30%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "cognitive impairment-a clinically silent condition termed asymptomatic AD",
    "entities": []
  },
  {
    "text": "(AsymAD). The molecular basis of this cognitive resilience remains poorly",
    "entities": [
      {
        "text": "AsymAD",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "understood due to a lack of mechanistic models. Here, we integrate systems-level",
    "entities": []
  },
  {
    "text": "Boolean network modeling with in vivo validation to define the transcriptomic",
    "entities": [
      {
        "text": "Boolean",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "logic of AsymAD and uncover a novel preclinical model. Using Boolean implication",
    "entities": [
      {
        "text": "AsymAD",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "networks trained on large-scale human cortical RNA-seq datasets, we identified a",
    "entities": []
  },
  {
    "text": "robust and invariant AD gene signature that accurately stratifies disease states",
    "entities": []
  },
  {
    "text": "across independent datasets. Application of this signature to Chromogranin A-",
    "entities": [
      {
        "text": "Chromogranin A-",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "mice developed AD-like molecular and neuropathological profiles in the",
    "entities": []
  },
  {
    "text": "pre-frontal cortex yet retained intact learning and memory. Female CgA-KO/PS19",
    "entities": [
      {
        "text": "CgA-KO",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "mice displayed even greater protection, including reduced Tau phosphorylation",
    "entities": []
  },
  {
    "text": "and preserved synaptic ultrastructure. These findings establish the first",
    "entities": [
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "validated murine model of AsymAD and identify CgA as a modifiable node linking",
    "entities": [
      {
        "text": "AsymAD",
        "label": "GPE"
      },
      {
        "text": "CgA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "neuroendocrine signaling, Tauopathy, and cognitive preservation. This work",
    "entities": [
      {
        "text": "Tauopathy",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "provides a scalable platform to probe sex-specific resilience, uncover",
    "entities": []
  },
  {
    "text": "early-stage biomarkers, and accelerate preventive therapeutic development in AD.",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Uncovering Heterogeneous Effects via Localized Feature Selection.",
    "entities": []
  },
  {
    "text": "Identifying features that interact to trigger disease, while accounting for",
    "entities": []
  },
  {
    "text": "heterogeneity across diverse populations, is essential for the development of",
    "entities": []
  },
  {
    "text": "precision and targeted medicine. Despite the availability of vast and complex",
    "entities": []
  },
  {
    "text": "health-related datasets, most existing works focus on identifying",
    "entities": []
  },
  {
    "text": "disease-associated features at the population level or within a few",
    "entities": []
  },
  {
    "text": "subpopulations, often overlooking individual-level heterogeneity within these",
    "entities": []
  },
  {
    "text": "groups. To address this limitation, we propose a novel framework that utilizes",
    "entities": []
  },
  {
    "text": "localized test statistics to identify disease-associated features tailored to",
    "entities": []
  },
  {
    "text": "individual profiles. Our method leverages the recently developed knockoffs",
    "entities": []
  },
  {
    "text": "methodology to control the noise level of the selection set so that the results",
    "entities": []
  },
  {
    "text": "are replicable. Moreover, it allows for the discovery of hidden heterogeneous",
    "entities": []
  },
  {
    "text": "effects within the data, as demonstrated in an application to single-cell RNA",
    "entities": [
      {
        "text": "RNA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "sequencing data for Alzheimer's disease. By aggregating localized feature",
    "entities": []
  },
  {
    "text": "selection results, our framework also enables powerful population-level feature",
    "entities": []
  },
  {
    "text": "selection. Our framework provides a powerful tool for exploratory studies of",
    "entities": []
  },
  {
    "text": "precision medicine, offering the potential to generate novel hypotheses for",
    "entities": []
  },
  {
    "text": "confirmatory biological experiments.",
    "entities": []
  },
  {
    "text": "Multiplex Proteomics of Lewy Body Dementia Reveals Cerebrospinal Fluid",
    "entities": [
      {
        "text": "Multiplex Proteomics of Lewy Body Dementia Reveals Cerebrospinal Fluid",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "Biomarkers of Disease Pathology and Progression.",
    "entities": [
      {
        "text": "Biomarkers of Disease Pathology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Higginbotham L, Shantaraman A, Guo Q, Fox EJ, Bagchi P, Wu F, Lah JJ, Levey AI,",
    "entities": [
      {
        "text": "Higginbotham L",
        "label": "PERSON"
      },
      {
        "text": "Shantaraman A",
        "label": "PERSON"
      },
      {
        "text": "Guo Q",
        "label": "PERSON"
      },
      {
        "text": "Fox EJ",
        "label": "ORG"
      },
      {
        "text": "Bagchi P",
        "label": "PERSON"
      },
      {
        "text": "Wu F",
        "label": "PERSON"
      },
      {
        "text": "Lah JJ",
        "label": "PERSON"
      },
      {
        "text": "Levey AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Lewy body dementia (LBD), which encompasses Parkinson's disease dementia (PDD)",
    "entities": [
      {
        "text": "LBD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and Dementia with Lewy bodies (DLB), currently lacks established biofluid",
    "entities": [
      {
        "text": "Dementia",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "markers reflective of its complex molecular pathophysiology. Multiplex proteomic",
    "entities": [
      {
        "text": "Multiplex",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "tools, such as the recently released NUcleic acid Linked ImmunoSandwich Assay",
    "entities": [
      {
        "text": "NUcleic",
        "label": "ORG"
      },
      {
        "text": "Linked ImmunoSandwich",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(NULISA TM ), can simultaneously assess a diverse array of neurodegenerative",
    "entities": []
  },
  {
    "text": "targets and address this critical biomarker gap. We used the NULISA CNS disease",
    "entities": [
      {
        "text": "NULISA",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "panel to analyze 852 baseline and longitudinal cerebrospinal fluid (CSF) samples",
    "entities": [
      {
        "text": "852",
        "label": "CARDINAL"
      },
      {
        "text": "CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "from control, PD without cognitive impairment (PD-NCI), PD with cognitive",
    "entities": []
  },
  {
    "text": "impairment (PD-CI), DLB, and Alzheimer's disease (AD) subjects. A subset of",
    "entities": [
      {
        "text": "PD-CI",
        "label": "ORG"
      },
      {
        "text": "DLB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "control and DLB cases also had alpha-synuclein seed amplification assay",
    "entities": [
      {
        "text": "DLB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(\u03b1Syn-SAA) results. Of the 124 panel markers analyzed, nearly half ( n =53) were",
    "entities": [
      {
        "text": "\u03b1Syn-SAA",
        "label": "ORG"
      },
      {
        "text": "124",
        "label": "CARDINAL"
      },
      {
        "text": "nearly half",
        "label": "CARDINAL"
      },
      {
        "text": "53",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "significantly altered in PD-CI and/or DLB compared to controls. Of these",
    "entities": [
      {
        "text": "DLB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "LBD-associated targets, 12 demonstrated divergent abundance trends in AD.",
    "entities": [
      {
        "text": "LBD",
        "label": "ORG"
      },
      {
        "text": "12",
        "label": "CARDINAL"
      },
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Alpha-synuclein (SNCA) as measured by NULISA did not change across clinical LBD",
    "entities": [
      {
        "text": "Alpha",
        "label": "GPE"
      },
      {
        "text": "NULISA",
        "label": "ORG"
      },
      {
        "text": "LBD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "diagnoses but was among proteins significantly altered in subgroup comparisons",
    "entities": []
  },
  {
    "text": "of SAA+ and SAA-cases. Longitudinal analysis revealed five proteins (NEFL, NRGN,",
    "entities": [
      {
        "text": "SAA",
        "label": "ORG"
      },
      {
        "text": "five",
        "label": "CARDINAL"
      },
      {
        "text": "NEFL",
        "label": "ORG"
      },
      {
        "text": "NRGN",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CCL26, CRH, PGF) with baseline changes indicative of subsequent cognitive",
    "entities": [
      {
        "text": "CCL26",
        "label": "GPE"
      },
      {
        "text": "CRH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "progression. Machine learning identified a series of panels, each comprising",
    "entities": []
  },
  {
    "text": "only 10 markers, capable of discriminating clinical diagnoses and SAA positivity",
    "entities": [
      {
        "text": "only 10 markers",
        "label": "QUANTITY"
      },
      {
        "text": "SAA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "with high accuracy (AUC > 0.89). Overall, our results highlight the utility of",
    "entities": [
      {
        "text": "0.89",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "NULISA multiplex proteomic analysis in the identification of diagnostic and",
    "entities": []
  },
  {
    "text": "prognostic CSF biomarkers of LBD that reflect its diverse molecular",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      },
      {
        "text": "LBD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "ONE SENTENCE SUMMARY: This multiplex proteomic analysis using the recently",
    "entities": [
      {
        "text": "ONE",
        "label": "CARDINAL"
      },
      {
        "text": "SENTENCE",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "released NULISA platform revealed unique targets of Lewy body dementia pathology",
    "entities": [
      {
        "text": "Lewy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and progression.",
    "entities": []
  },
  {
    "text": "Brain-derived extracellular vesicle microRNAs in Lewy body and Alzheimer's",
    "entities": []
  },
  {
    "text": "Yang SJ, Lin AA, Shen H, Pappalardo LW, Spychalski GB, Rosario J, Forsberg LK,",
    "entities": [
      {
        "text": "Yang SJ",
        "label": "PERSON"
      },
      {
        "text": "Lin AA",
        "label": "PERSON"
      },
      {
        "text": "Pappalardo LW",
        "label": "ORG"
      },
      {
        "text": "Spychalski GB",
        "label": "PERSON"
      },
      {
        "text": "Rosario J",
        "label": "PERSON"
      },
      {
        "text": "Forsberg LK",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Meaney DF, Boeve BF, Ross OA, McLean PJ, Issadore D.",
    "entities": [
      {
        "text": "Meaney DF",
        "label": "PERSON"
      },
      {
        "text": "Boeve BF",
        "label": "ORG"
      },
      {
        "text": "Ross OA",
        "label": "PERSON"
      },
      {
        "text": "McLean PJ",
        "label": "ORG"
      },
      {
        "text": "D.",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "INTRODUCTION: Robust plasma-based biomarkers to distinguish Lewy body disease",
    "entities": []
  },
  {
    "text": "(LBD) and Alzheimer's disease (AD) are currently lacking. We applied track-etch",
    "entities": [
      {
        "text": "LBD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "magnetic nanopore (TENPO) sorting for enrichment of brain-derived extracellular",
    "entities": [
      {
        "text": "TENPO",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "vesicle (EV) signatures as potential biomarkers to address this gap.",
    "entities": [
      {
        "text": "EV",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "METHODS: We analyzed plasma from 137 autopsy-confirmed patients [30 LBD, 31 AD,",
    "entities": [
      {
        "text": "137",
        "label": "CARDINAL"
      },
      {
        "text": "30",
        "label": "CARDINAL"
      },
      {
        "text": "LBD",
        "label": "ORG"
      },
      {
        "text": "31 AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "30 AD/LBD, 19 AD with amygdala Lewy bodies (AD/ALB), and 27 controls],",
    "entities": [
      {
        "text": "30 AD/LBD",
        "label": "DATE"
      },
      {
        "text": "19 AD",
        "label": "DATE"
      },
      {
        "text": "27",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "sequencing miRNAs from TENPO-isolated GluR2-positive (neuron-enriched) and",
    "entities": [
      {
        "text": "TENPO",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "GLAST-positive (astrocyte-enriched) EVs, and measuring plasma proteins (A\u03b240,",
    "entities": [
      {
        "text": "astrocyte",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RESULTS: We identified 16 GluR2+, 8 GLAST+, and 4 protein biomarkers with",
    "entities": [
      {
        "text": "16",
        "label": "CARDINAL"
      },
      {
        "text": "8",
        "label": "CARDINAL"
      },
      {
        "text": "4",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "differential expression (false discovery rate-corrected P value < .1) between",
    "entities": []
  },
  {
    "text": "LBD and AD. A multimodal 15-feature panel classified LBD versus AD with 10-fold",
    "entities": [
      {
        "text": "LBD",
        "label": "ORG"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "LBD",
        "label": "ORG"
      },
      {
        "text": "10-fold",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "cross-validated accuracy = 0.95 and area under the curve (AUC) = 0.96.",
    "entities": [
      {
        "text": "0.95",
        "label": "CARDINAL"
      },
      {
        "text": "0.96",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "DISCUSSION: Brain-derived EVs offer accurate and accessible miRNA biomarkers for",
    "entities": []
  },
  {
    "text": "the differential diagnosis of LBD and AD.",
    "entities": [
      {
        "text": "LBD",
        "label": "ORG"
      },
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "White matter micro- and macrostructural properties in midlife individuals at",
    "entities": []
  },
  {
    "text": "risk for Alzheimer's disease: Associations with sex and menopausal status.",
    "entities": []
  },
  {
    "text": "Pahlajani S, Williams S, Brinton RD, Mosconi L.",
    "entities": [
      {
        "text": "Pahlajani S",
        "label": "PERSON"
      },
      {
        "text": "Williams S",
        "label": "PERSON"
      },
      {
        "text": "Brinton RD",
        "label": "PERSON"
      },
      {
        "text": "Mosconi L.\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Women are at greater lifetime risk for Alzheimer's disease (AD), potentially due",
    "entities": []
  },
  {
    "text": "to midlife fractional anisotropy (FA) and lower mean diffusivity in fornix and",
    "entities": []
  },
  {
    "text": "corpus callosum, indicating more densely organized white matter. Perimenopausal",
    "entities": []
  },
  {
    "text": "women were the exception, with white matter profiles closely resembling those of",
    "entities": []
  },
  {
    "text": "men. Perimenopausal women exhibited minimal or absent fiber cross-section and",
    "entities": []
  },
  {
    "text": "FDC sex differences and a reversal of the fornix FA advantage observed in pre-",
    "entities": [
      {
        "text": "FDC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and postmenopausal women. These cross-sectional results are consistent with sex",
    "entities": []
  },
  {
    "text": "differences in white matter organization. Importantly, the perimenopause emerges",
    "entities": []
  },
  {
    "text": "as a critical window of neural reorganization in the female midlife aging brain",
    "entities": []
  },
  {
    "text": "characterized by temporary convergence toward male-like white matter",
    "entities": []
  },
  {
    "text": "organization. Longitudinal analyses are key to identifying women who do or do",
    "entities": []
  },
  {
    "text": "not revert to a premenopausal profile, which may inform AD risk.",
    "entities": []
  },
  {
    "text": "Sink-index: a network-based EEG marker for frontotemporal dementia and",
    "entities": [
      {
        "text": "EEG",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Biomedical Engineering, Johns Hopkins University School of",
    "entities": [
      {
        "text": "Biomedical Engineering",
        "label": "ORG"
      },
      {
        "text": "Johns Hopkins University School",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Department of Psychiatry and Behavioral Sciences, Johns Hopkins University",
    "entities": [
      {
        "text": "Psychiatry",
        "label": "ORG"
      },
      {
        "text": "Behavioral Sciences",
        "label": "ORG"
      },
      {
        "text": "Johns Hopkins University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "School of Medicine, Baltimore, MD 21205, USA.",
    "entities": [
      {
        "text": "School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Baltimore",
        "label": "GPE"
      },
      {
        "text": "MD",
        "label": "GPE"
      },
      {
        "text": "21205",
        "label": "DATE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Frontotemporal dementia is a complex neurodegenerative illness characterized by",
    "entities": []
  },
  {
    "text": "communication. Misdiagnosis and late diagnosis occur frequently due to the",
    "entities": [
      {
        "text": "Misdiagnosis",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "complexity of the phenotypes, overlaps of features with other neurodegenerative",
    "entities": []
  },
  {
    "text": "syndromes and psychiatric disorders, and ill-defined preclinical phases of the",
    "entities": []
  },
  {
    "text": "illness. Diagnosis relies on structural or functional brain imaging to show",
    "entities": []
  },
  {
    "text": "characteristic atrophy, hypoperfusion or hypometabolism profiles. The",
    "entities": []
  },
  {
    "text": "sensitivity of neuroimaging is lower in the earliest phases of the illness, and",
    "entities": []
  },
  {
    "text": "there are few alternatives. Scalp electroencephalography (EEG) is a widely",
    "entities": [
      {
        "text": "EEG",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "available, low-cost technology, but its utility in the differential diagnosis of",
    "entities": []
  },
  {
    "text": "dementia will require EEG indices of high sensitivity and discriminatory value.",
    "entities": [
      {
        "text": "EEG",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "We have used scalp EEG to develop subject-specific Dynamic Network Models, from",
    "entities": [
      {
        "text": "EEG",
        "label": "ORG"
      },
      {
        "text": "Dynamic Network Models",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "which we summarize the reciprocal relationships between the nodes (defined by",
    "entities": []
  },
  {
    "text": "the EEG channel). This index, the 'Sink-Index', characterizes how activity in",
    "entities": [
      {
        "text": "EEG",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "each node (or channel) responds to activity in other nodes in the network. In",
    "entities": []
  },
  {
    "text": "this context, 'sources' are nodes that exert significant influence on the",
    "entities": []
  },
  {
    "text": "activity of different regions but are not themselves influenced, whereas 'sinks'",
    "entities": []
  },
  {
    "text": "represent influenced regions that do not affect activity in others. We",
    "entities": []
  },
  {
    "text": "hypothesized that brain regions associated with Frontotemporal dementia and",
    "entities": []
  },
  {
    "text": "Alzheimer's disease syndromes behave as sinks and have higher sink indices than",
    "entities": []
  },
  {
    "text": "healthy brain regions. This hypothesis was tested in a cohort of 88 subjects: 23",
    "entities": [
      {
        "text": "88",
        "label": "CARDINAL"
      },
      {
        "text": "23",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "with frontotemporal dementia, 36 with Alzheimer's disease, and 29 healthy",
    "entities": [
      {
        "text": "36",
        "label": "CARDINAL"
      },
      {
        "text": "29",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "controls. The Sink-Index of nodes in the frontal-temporal and",
    "entities": []
  },
  {
    "text": "central-parietal-occipital brain regions differed between Frontotemporal",
    "entities": [
      {
        "text": "Frontotemporal",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "0.0188 versus 0.7766 \u00b1 0.0158), and healthy controls (0.8978 \u00b1 0.0453 versus",
    "entities": [
      {
        "text": "0.0188",
        "label": "CARDINAL"
      },
      {
        "text": "0.7766",
        "label": "CARDINAL"
      },
      {
        "text": "0.0158",
        "label": "CARDINAL"
      },
      {
        "text": "0.8978 \u00b1",
        "label": "QUANTITY"
      }
    ]
  },
  {
    "text": "0.9116 \u00b1 0.0457). These findings suggest the Sink-Index is an EEG marker with",
    "entities": [
      {
        "text": "0.9116",
        "label": "CARDINAL"
      },
      {
        "text": "0.0457",
        "label": "CARDINAL"
      },
      {
        "text": "EEG",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "utility for the differential diagnosis of dementia syndromes.",
    "entities": []
  },
  {
    "text": "Guarantors of Brain.",
    "entities": [
      {
        "text": "Brain",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "DOI: 10.1093/braincomms/fcaf259",
    "entities": [
      {
        "text": "10.1093",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: The authors report no competing interests.",
    "entities": []
  },
  {
    "text": "Estrogen, menopause, and Alzheimer's disease: understanding the link to",
    "entities": [
      {
        "text": "Estrogen",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Park Avenue Neurology, New York, NY, United States.",
    "entities": [
      {
        "text": "Avenue Neurology",
        "label": "WORK_OF_ART"
      },
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Departments of Neurology, Zucker School of Medicine, Northwell Health, New",
    "entities": [
      {
        "text": "Neurology",
        "label": "ORG"
      },
      {
        "text": "Zucker School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Northwell Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "York, NY, United States.",
    "entities": [
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Departments of Psychiatry, Zucker School of Medicine, Northwell Health, New",
    "entities": [
      {
        "text": "3)Departments",
        "label": "CARDINAL"
      },
      {
        "text": "Psychiatry",
        "label": "ORG"
      },
      {
        "text": "Zucker School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Northwell Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BACKGROUND: Women face a significantly higher lifetime risk of developing",
    "entities": []
  },
  {
    "text": "Alzheimer's disease (AD) than men. This disparity is often attributed to longer",
    "entities": []
  },
  {
    "text": "female longevity, but growing evidence suggests a multifactorial origin,",
    "entities": []
  },
  {
    "text": "including hormonal, vascular, and immunologic contributions. Estrogen plays a",
    "entities": []
  },
  {
    "text": "critical neuroprotective role across multiple systems implicated in AD",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "pathogenesis, including synaptic plasticity, mitochondrial function, and",
    "entities": []
  },
  {
    "text": "cerebrovascular integrity. However, clinical trials investigating hormone",
    "entities": []
  },
  {
    "text": "therapy (HT) for AD prevention have yielded mixed results, in part due to",
    "entities": []
  },
  {
    "text": "variability in study populations, timing of intervention, and formulation of",
    "entities": []
  },
  {
    "text": "hormones.",
    "entities": []
  },
  {
    "text": "AIMS/METHODS: This review examines the biological rationale for estrogen's role",
    "entities": []
  },
  {
    "text": "in cognitive aging, synthesizes clinical and translational data on hormone",
    "entities": []
  },
  {
    "text": "therapy and AD risk, and highlights the importance of vascular comorbidity,",
    "entities": []
  },
  {
    "text": "including cerebral small vessel disease, in mediating AD pathology.",
    "entities": []
  },
  {
    "text": "CONCLUSION: We propose that estrogen's neuroprotective potential may be best",
    "entities": []
  },
  {
    "text": "realized in personalized treatment frameworks that account for age, timing, APOE",
    "entities": []
  },
  {
    "text": "genotype, and vascular burden. Interpretation of estrogen's role in AD is",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "further complicated by variability in diagnostic criteria, which may contribute",
    "entities": []
  },
  {
    "text": "to conflicting findings across studies. Recognition of menopause-related",
    "entities": [
      {
        "text": "Recognition",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cognitive impairment as an early, hormonally modulated risk state may offer",
    "entities": []
  },
  {
    "text": "additional opportunity for timely intervention. Addressing this complexity is",
    "entities": []
  },
  {
    "text": "essential to refining AD prevention strategies in midlife women.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 Mervosh and Devi.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Mervosh",
        "label": "PERSON"
      },
      {
        "text": "Devi",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Biological Age and Age Acceleration Predict Alzheimer's Disease Plasma Biomarker",
    "entities": [
      {
        "text": "Biological Age",
        "label": "LAW"
      },
      {
        "text": "Plasma Biomarker",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Epigenetic clocks can predict pathological aging associated with Alzheimer's",
    "entities": []
  },
  {
    "text": "disease (AD) risk, albeit findings are mixed regarding if clocks are predictive",
    "entities": []
  },
  {
    "text": "in blood and in non-European populations. We constructed epigenetic clocks from",
    "entities": [
      {
        "text": "non-European",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "blood methylation data in 704 older Hispanic adults and tested the association",
    "entities": [
      {
        "text": "704",
        "label": "CARDINAL"
      },
      {
        "text": "Hispanic",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "with a clinical diagnosis of AD and plasma biomarker levels. Biological age and",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      },
      {
        "text": "plasma biomarker",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "age acceleration, the rate of biological aging, were significantly associated",
    "entities": []
  },
  {
    "text": "with sex, clinical diagnosis, and levels of eight plasma biomarkers, including",
    "entities": [
      {
        "text": "eight",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "P-Tau217 levels. Additionally, biomarker associations trended more significant",
    "entities": []
  },
  {
    "text": "among APOE -\u03b54 non-carriers. We also identified that methylation levels in CD4",
    "entities": []
  },
  {
    "text": "and CD8 T-cell types are associated with biological aging and showed slightly",
    "entities": []
  },
  {
    "text": "stronger associations in men. We demonstrate that biological aging, in blood, in",
    "entities": []
  },
  {
    "text": "a Hispanic cohort of both demented and non-demented individuals, can stratify AD",
    "entities": [
      {
        "text": "Hispanic",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "risk, predicting plasma biomarker levels even in preclinical disease.",
    "entities": []
  },
  {
    "text": "Predicting conversion from mild cognitive impairment to Alzheimer's disease",
    "entities": []
  },
  {
    "text": "using a Vision Transformer and hippocampal MRI slices.",
    "entities": [
      {
        "text": "a Vision Transformer",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Convolutional neural networks (CNNs) have been the standard for computer vision",
    "entities": []
  },
  {
    "text": "tasks and are frequently applied in medical conditions, such as in Alzheimer's",
    "entities": []
  },
  {
    "text": "disease (AD). Recently, Vision Transformers (ViTs) have been introduced, which",
    "entities": [
      {
        "text": "Vision Transformers",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "provide a strong alternative to CNNs by discarding the convolution approach in",
    "entities": []
  },
  {
    "text": "favor of the attention mechanism. This allows modeling global and distant",
    "entities": []
  },
  {
    "text": "relationships within distinct parts of an image without relying on the strong",
    "entities": []
  },
  {
    "text": "inductive biases present in CNNs. A common precursor stage of AD is a syndrome",
    "entities": []
  },
  {
    "text": "called mild cognitive impairment (MCI). However, not all individuals diagnosed",
    "entities": [
      {
        "text": "MCI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "with MCI progress to AD. The establishment of reliable classification models",
    "entities": [
      {
        "text": "MCI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "that predict converters versus non-converters would be a valuable tool to",
    "entities": []
  },
  {
    "text": "support clinical decision-making, such as enabling early treatment. Hence, in",
    "entities": []
  },
  {
    "text": "this investigation a transfer learning approach was used by applying a",
    "entities": []
  },
  {
    "text": "pretrained ViT model, fine-tuned on the ADNI dataset comprising 575 subjects",
    "entities": [
      {
        "text": "ViT",
        "label": "ORG"
      },
      {
        "text": "ADNI",
        "label": "ORG"
      },
      {
        "text": "575",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "with MCI. We included baseline T1-weighted structural MRI data from 299 stable",
    "entities": [
      {
        "text": "MCI",
        "label": "ORG"
      },
      {
        "text": "T1",
        "label": "NORP"
      },
      {
        "text": "299",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "MCI and 276 progressive MCI individuals, who developed Alzheimer's disease",
    "entities": [
      {
        "text": "MCI",
        "label": "ORG"
      },
      {
        "text": "276",
        "label": "CARDINAL"
      },
      {
        "text": "MCI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "within 36 months. Inputs to the model were three normalized axial slices",
    "entities": [
      {
        "text": "36 months",
        "label": "DATE"
      },
      {
        "text": "three",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "covering areas of the hippocampal region, consisting of the combined gray and",
    "entities": []
  },
  {
    "text": "white matter segmentations. The final model was evaluated over multiple runs to",
    "entities": []
  },
  {
    "text": "obtain stable performance estimates, yielding an average area under the receiver",
    "entities": []
  },
  {
    "text": "operating characteristic curve (AUC-ROC) on the test set of 0.74 \u00b1 0.02 (mean \u00b1",
    "entities": [
      {
        "text": "0.74",
        "label": "CARDINAL"
      },
      {
        "text": "0.02",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "SD), an accuracy of 0.69 \u00b1 0.03, a sensitivity of 0.65 \u00b1 0.07, a specificity of",
    "entities": [
      {
        "text": "0.69",
        "label": "CARDINAL"
      },
      {
        "text": "0.03",
        "label": "CARDINAL"
      },
      {
        "text": "0.65",
        "label": "CARDINAL"
      },
      {
        "text": "0.07",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "0.72 \u00b1 0.06, and a F1-score for the pMCI class of 0.67 \u00b1 0.04. By specifically",
    "entities": [
      {
        "text": "0.72",
        "label": "CARDINAL"
      },
      {
        "text": "0.06",
        "label": "DATE"
      },
      {
        "text": "F1",
        "label": "CARDINAL"
      },
      {
        "text": "0.67",
        "label": "CARDINAL"
      },
      {
        "text": "0.04",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "focusing on axial slices covering the hippocampal region, we aimed to target the",
    "entities": []
  },
  {
    "text": "brain structure often reported as being the first affected by the disease, while",
    "entities": [
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "our results indicate that a ViT approach achieves reasonable classification",
    "entities": [
      {
        "text": "ViT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "accuracy for predicting the conversion from MCI to AD.",
    "entities": [
      {
        "text": "MCI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Cognitive and Neuroimaging for Neurodegenerative Disorders: A Cohort Study",
    "entities": []
  },
  {
    "text": "Design with Initial Findings.",
    "entities": [
      {
        "text": "Initial Findings",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Hosseini AA, Shao B, Lee AR, Dhillon P, Junaid K, Gran B, Sellars P, Sargisson",
    "entities": [
      {
        "text": "Hosseini AA",
        "label": "PERSON"
      },
      {
        "text": "Shao B",
        "label": "PERSON"
      },
      {
        "text": "Lee AR",
        "label": "PERSON"
      },
      {
        "text": "Dhillon P",
        "label": "ORG"
      },
      {
        "text": "Junaid K",
        "label": "PERSON"
      },
      {
        "text": "Gran B",
        "label": "PERSON"
      },
      {
        "text": "Sellars P",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Introduction: Dementia presents with significant heterogeneity across age",
    "entities": []
  },
  {
    "text": "groups, particularly in early-onset cognitive decline (EOCD), which poses",
    "entities": []
  },
  {
    "text": "diagnostic and management challenges. The Cognitive and Neuroimaging for",
    "entities": [
      {
        "text": "The Cognitive and Neuroimaging",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Neurodegenerative Disorders (CogNID) study aims to characterise clinical,",
    "entities": []
  },
  {
    "text": "cognitive, neuroimaging, and biomarker features across a diverse cohort of",
    "entities": []
  },
  {
    "text": "individuals with cognitive impairment, with a focus on diagnostic complexity,",
    "entities": []
  },
  {
    "text": "biomarker utility, and mortality. Methods: Out of 680 study participants within",
    "entities": [
      {
        "text": "680",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "this prospective cohort enrolled from the real-world clinics within the National",
    "entities": []
  },
  {
    "text": "Health Service, who consented to take part in the study, we analysed data from",
    "entities": [
      {
        "text": "Health Service",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "429 individuals recruited between December 2018 and November 2024 from the",
    "entities": [
      {
        "text": "429",
        "label": "CARDINAL"
      },
      {
        "text": "between December 2018",
        "label": "DATE"
      },
      {
        "text": "November 2024",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Memory Clinics, including the young-onset dementia service and associated",
    "entities": [
      {
        "text": "Memory Clinics",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(MRI/CT), and Cerebrospinal fluid (CSF) biomarker evaluation, where available.",
    "entities": [
      {
        "text": "Cerebrospinal",
        "label": "NORP"
      },
      {
        "text": "CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Diagnoses were made by multidisciplinary consensus. Group comparisons were",
    "entities": []
  },
  {
    "text": "conducted between early-onset (EOCD, <65 years) and late-onset cognitive decline",
    "entities": [
      {
        "text": "EOCD",
        "label": "ORG"
      },
      {
        "text": "65 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(LOCD, \u226565 years). Results: Of the 429 participants, 349 (81.4%) had EOCD and 80",
    "entities": [
      {
        "text": "429",
        "label": "CARDINAL"
      },
      {
        "text": "349",
        "label": "CARDINAL"
      },
      {
        "text": "81.4%",
        "label": "PERCENT"
      },
      {
        "text": "EOCD",
        "label": "ORG"
      },
      {
        "text": "80",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(18.6%) had LOCD. The mean age was 60.05 years, with no significant difference",
    "entities": [
      {
        "text": "18.6%",
        "label": "PERCENT"
      },
      {
        "text": "60.05 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "in sex or ethnicity across groups. Depression and anxiety were common (29.6%),",
    "entities": [
      {
        "text": "29.6%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "as were cardiovascular risk factors. Lumbar punctures were more frequently",
    "entities": []
  },
  {
    "text": "performed in EOCD (p = 0.03), with 36.4% of tested participants demonstrating",
    "entities": [
      {
        "text": "EOCD",
        "label": "ORG"
      },
      {
        "text": "0.03",
        "label": "CARDINAL"
      },
      {
        "text": "36.4%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "biomarker profiles consistent with Alzheimer's disease (A+T+). Functional",
    "entities": []
  },
  {
    "text": "cognitive disorder (FCD) was more common in EOCD (22.3% vs. 5.0%, p < 0.001).",
    "entities": [
      {
        "text": "FCD",
        "label": "ORG"
      },
      {
        "text": "EOCD",
        "label": "ORG"
      },
      {
        "text": "22.3%",
        "label": "PERCENT"
      },
      {
        "text": "5.0%",
        "label": "PERCENT"
      },
      {
        "text": "p < 0.001",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Subgroup analysis revealed significantly lower ACE-III scores and higher",
    "entities": [
      {
        "text": "ACE-III",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "pathological CSF findings in Alzheimer's disease versus FCD. Mortality was",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      },
      {
        "text": "FCD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "higher in the LOCD group (11.3% vs. 4.6%, p = 0.03). Conclusion: The CogNID",
    "entities": [
      {
        "text": "11.3%",
        "label": "PERCENT"
      },
      {
        "text": "4.6%",
        "label": "PERCENT"
      },
      {
        "text": "0.03",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "study highlights the clinical and diagnostic heterogeneity of individuals with",
    "entities": []
  },
  {
    "text": "cognitive impairment, particularly in younger adults. Incorporating neuroimaging",
    "entities": []
  },
  {
    "text": "and CSF biomarkers into routine clinical pathways enhances diagnostic precision",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and reveals distinct phenotypic profiles between EOCD and LOCD. These findings",
    "entities": [
      {
        "text": "EOCD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "underscore the need for harmonised diagnostic protocols, broader biomarker",
    "entities": []
  },
  {
    "text": "accessibility, and inclusive recruitment strategies in dementia research and",
    "entities": []
  },
  {
    "text": "The NIH Toolbox Emotion Battery and Cerebrospinal Fluid Biomarkers in",
    "entities": [
      {
        "text": "NIH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Alzheimer's Disease: Findings from the Multisite ARMADA Study.",
    "entities": [
      {
        "text": "the Multisite ARMADA Study",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Yu K, Gatchel JR, Ho EH, Hajjar I, Arnold SE, Marshall GA, Dodge HH.",
    "entities": [
      {
        "text": "Yu K",
        "label": "PERSON"
      },
      {
        "text": "Gatchel JR",
        "label": "PERSON"
      },
      {
        "text": "Ho EH",
        "label": "GPE"
      },
      {
        "text": "Hajjar",
        "label": "GPE"
      },
      {
        "text": "Arnold SE",
        "label": "PERSON"
      },
      {
        "text": "Marshall GA",
        "label": "ORG"
      },
      {
        "text": "Dodge HH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "OBJECTIVES: Investigating the relationships between socioemotional functioning",
    "entities": []
  },
  {
    "text": "and Alzheimer's Disease (AD) pathology can contribute to screening and early",
    "entities": []
  },
  {
    "text": "detection of AD. This study explored the associations between socioemotional",
    "entities": []
  },
  {
    "text": "functioning and cerebrospinal fluid (CSF) AD biomarkers in older adults.",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "METHODS: We used baseline data from the Advancing Reliable Measurement in",
    "entities": []
  },
  {
    "text": "Alzheimer's Disease and Cognitive Aging (ARMADA) study. ARMADA is a multisite",
    "entities": [
      {
        "text": "ARMADA",
        "label": "ORG"
      },
      {
        "text": "ARMADA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "study with independent protocols for CSF assays at each site. The available",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "sample size with comparable CSF assays had 31 participants with normal cognition",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      },
      {
        "text": "31",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(NC) and 28 with amnestic mild cognitive impairment (aMCI) or early-stage AD",
    "entities": [
      {
        "text": "NC",
        "label": "GPE"
      },
      {
        "text": "28",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "dementia. CSF-derived AD biomarkers included were: phosphorylated-tau 181",
    "entities": [
      {
        "text": "AD",
        "label": "ORG"
      },
      {
        "text": "181",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Socioemotional functioning (negative affect, psychological wellbeing, and social",
    "entities": []
  },
  {
    "text": "satisfaction) was measured with the self-reported NIH Toolbox Emotion Battery",
    "entities": [
      {
        "text": "NIH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(NIHTB-EB). We ran linear regressions by cognitive subgroups (NC and",
    "entities": [
      {
        "text": "linear",
        "label": "ORG"
      },
      {
        "text": "NC",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "aMCI/early-stage AD).",
    "entities": []
  },
  {
    "text": "RESULTS: Among participants with NC, lower social satisfaction was associated",
    "entities": [
      {
        "text": "NC",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "with higher p-Tau181 and t-Tau; higher t-Tau was additionally associated with",
    "entities": []
  },
  {
    "text": "more negative affect. None of the CSF AD biomarkers were associated with the",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "NIHTB-EB outcomes among participants with aMCI or early-stage AD.",
    "entities": []
  },
  {
    "text": "DISCUSSION: These findings suggest that socioemotional functioning may be",
    "entities": []
  },
  {
    "text": "associated with tau pathology. Markers for amyloid were not related to",
    "entities": []
  },
  {
    "text": "socioemotional functioning regardless of disease stages. Future studies with",
    "entities": []
  },
  {
    "text": "larger, more diverse samples and harmonized CSF assay protocols are needed to",
    "entities": [
      {
        "text": "CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "further examine the role of early socioemotional change in early detection and",
    "entities": []
  },
  {
    "text": "prevention of dementia.",
    "entities": []
  },
  {
    "text": "97. Biomed Res Int. 2025 Jul 7;2025:8892801. doi: 10.1155/bmri/8892801.",
    "entities": [
      {
        "text": "97",
        "label": "CARDINAL"
      },
      {
        "text": "Biomed Res Int",
        "label": "PERSON"
      },
      {
        "text": "10.1155",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Unveiling the Therapeutic Potential of Piper chaba Hunter: Computational",
    "entities": [
      {
        "text": "the Therapeutic Potential of Piper",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Approaches Shed Light on Targeting Proteins in Alzheimer's Disease.",
    "entities": []
  },
  {
    "text": "(1)Department of Genetic Engineering and Biotechnology, Jashore University of",
    "entities": [
      {
        "text": "Genetic Engineering and Biotechnology, Jashore University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Science and Technology, Jashore, Bangladesh.",
    "entities": [
      {
        "text": "Science and Technology",
        "label": "ORG"
      },
      {
        "text": "Jashore",
        "label": "GPE"
      },
      {
        "text": "Bangladesh",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Bioinformatics and Microbial Biotechnology Laboratory, Department of Genetic",
    "entities": [
      {
        "text": "Microbial Biotechnology Laboratory",
        "label": "ORG"
      },
      {
        "text": "Department of Genetic",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Engineering and Biotechnology, Jashore University of Science and Technology,",
    "entities": [
      {
        "text": "Biotechnology, Jashore University of Science and Technology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Jashore, Bangladesh.",
    "entities": [
      {
        "text": "Bangladesh",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Physics, Jashore University of Science and Technology, Jashore,",
    "entities": [
      {
        "text": "Physics",
        "label": "ORG"
      },
      {
        "text": "Jashore University of Science and Technology",
        "label": "ORG"
      },
      {
        "text": "Jashore",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Department of Mathematics, Jashore University of Science and Technology,",
    "entities": [
      {
        "text": "Mathematics, Jashore University of Science and Technology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Department of Microbiology, Jahangirnagar University, Savar, Bangladesh.",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Jahangirnagar University",
        "label": "ORG"
      },
      {
        "text": "Savar",
        "label": "GPE"
      },
      {
        "text": "Bangladesh",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Department of Life Sciences, College of BioNano Technology, Gachon",
    "entities": [
      {
        "text": "Life Sciences",
        "label": "ORG"
      },
      {
        "text": "College of BioNano Technology",
        "label": "ORG"
      },
      {
        "text": "Gachon",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University, Seongnam, Republic of Korea.",
    "entities": [
      {
        "text": "Seongnam",
        "label": "GPE"
      },
      {
        "text": "Republic of Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)M Abdur Rahim Medical College Hospital, Dinajpur, Bangladesh.",
    "entities": [
      {
        "text": "7)M",
        "label": "CARDINAL"
      },
      {
        "text": "Abdur Rahim Medical College Hospital",
        "label": "ORG"
      },
      {
        "text": "Bangladesh",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Department of Zoology, College of Science, King Saud University, Riyadh,",
    "entities": [
      {
        "text": "Zoology, College of Science, King Saud University",
        "label": "ORG"
      },
      {
        "text": "Riyadh",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)Global Biotechnology & Biomedical Research Network (GBBRN), Department of",
    "entities": [
      {
        "text": "9)Global Biotechnology & Biomedical Research Network",
        "label": "ORG"
      },
      {
        "text": "Department of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Islamic",
    "entities": [
      {
        "text": "Biotechnology and Genetic Engineering, Faculty of Biological Sciences",
        "label": "ORG"
      },
      {
        "text": "Islamic",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "University, Kushtia, Bangladesh.",
    "entities": [
      {
        "text": "Kushtia",
        "label": "ORG"
      },
      {
        "text": "Bangladesh",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Alzheimer's disease (AD) is a prevalent neurodegenerative disorder, while the",
    "entities": []
  },
  {
    "text": "existing treatments primarily focus on alleviating symptoms rather than",
    "entities": []
  },
  {
    "text": "addressing the underlying pathophysiology. Seeking a safer alternative, the",
    "entities": []
  },
  {
    "text": "study explores the potential of Piper chaba Hunter as a promising drug lead for",
    "entities": [
      {
        "text": "Piper chaba Hunter",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "AD by eliciting the major signaling pathway, key players, and their interaction",
    "entities": []
  },
  {
    "text": "with phytochemicals from the plant extract. Initially, the phytochemicals in the",
    "entities": []
  },
  {
    "text": "P. chaba crude extract were identified using GC-MS, and their physicochemical",
    "entities": [
      {
        "text": "P. chaba",
        "label": "ORG"
      },
      {
        "text": "GC-MS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "properties were verified using SwissADME. Protein-protein interaction (PPI) and",
    "entities": [
      {
        "text": "SwissADME",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "signaling pathways-target proteins-compounds (STC) networks were analyzed to dig",
    "entities": [
      {
        "text": "STC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "out target proteins and effective compounds for AD based on rigorous screening.",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Approximately 60 target proteins that interacted with GC-MS-identified compounds",
    "entities": [
      {
        "text": "Approximately 60",
        "label": "CARDINAL"
      },
      {
        "text": "GC-MS-identified compounds\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "underwent PPI and STC networking which identified five compounds, a signaling",
    "entities": [
      {
        "text": "STC",
        "label": "ORG"
      },
      {
        "text": "five",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "pathway, and three target proteins with therapeutic potential. Three compounds,",
    "entities": [
      {
        "text": "three",
        "label": "CARDINAL"
      },
      {
        "text": "Three",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(E)-3-butylidene-4,5-dihydroisobenzofuran-1(3H)-one, have the potential to",
    "entities": [
      {
        "text": "E)-3-butylidene-4,5",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "modulate PTGS2, PLA2G4A, and CYP2C19 within metabolic signaling pathway, thus",
    "entities": [
      {
        "text": "PTGS2",
        "label": "PERSON"
      },
      {
        "text": "PLA2G4A",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "serving as promising therapeutic agents. Moreover, the drug likeliness and",
    "entities": []
  },
  {
    "text": "efficacy of those phytochemicals were justified by molecular docking tests",
    "entities": []
  },
  {
    "text": "(MDTs), molecular dynamics simulations (MDSs), and quantum chemistry analyses,",
    "entities": [
      {
        "text": "quantum",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "which confirmed their ability to inhibit key targets to mitigate AD-associated",
    "entities": []
  },
  {
    "text": "pathology.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 Md. Sifat Rahi et al. BioMed Research International published",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Md.",
        "label": "GPE"
      },
      {
        "text": "Sifat Rahi",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "by John Wiley & Sons Ltd.",
    "entities": [
      {
        "text": "John Wiley & Sons Ltd.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PMID: 40661231 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40661231",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Integrative approaches in Alzheimer's disease: evaluating the potential of",
    "entities": []
  },
  {
    "text": "traditional, complementary, and integrative medicine (TCIM).",
    "entities": []
  },
  {
    "text": "(1)Department of Pharmacology, Dr. M.G.R. Educational and Research Institute,",
    "entities": [
      {
        "text": "M.G.R. Educational",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(2)Department of Pharmaceutical Analysis, Dr. M.G.R. Educational and Research",
    "entities": [
      {
        "text": "Pharmaceutical Analysis",
        "label": "ORG"
      },
      {
        "text": "M.G.R. Educational",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(3)Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh,",
    "entities": [
      {
        "text": "Pharmaceutical Research",
        "label": "ORG"
      },
      {
        "text": "GLA University",
        "label": "ORG"
      },
      {
        "text": "Mathura",
        "label": "GPE"
      },
      {
        "text": "Uttar Pradesh",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "This review explores the potential of Traditional, Complementary, and",
    "entities": [
      {
        "text": "Traditional, Complementary",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Integrative Medicine (TCIM) as an adjunct to conventional therapies for",
    "entities": []
  },
  {
    "text": "Alzheimer's Disease (AD). Unlike pharmaceutical treatments that primarily offer",
    "entities": []
  },
  {
    "text": "symptomatic relief, TCIM encompasses holistic approaches that target multiple",
    "entities": []
  },
  {
    "text": "pathophysiological pathways involved in AD, including tau pathology, oxidative",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "stress, mitochondrial dysfunction, and neuroinflammation. Herbal therapies such",
    "entities": []
  },
  {
    "text": "as Withania somnifera, Ginkgo biloba, and Curcuma longa have shown promising",
    "entities": [
      {
        "text": "Withania",
        "label": "GPE"
      },
      {
        "text": "Ginkgo",
        "label": "NORP"
      },
      {
        "text": "Curcuma",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "neuroprotective effects in preclinical and limited clinical studies. Mind-body",
    "entities": []
  },
  {
    "text": "practices like Kirtan Kriya meditation have also demonstrated stress-reduction",
    "entities": [
      {
        "text": "Kirtan Kriya",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "benefits, addressing modifiable risk factors for AD. While current evidence",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "highlights the potential of TCIM interventions to complement standard care,",
    "entities": []
  },
  {
    "text": "rigorous validation through high-quality randomized controlled trials remains",
    "entities": []
  },
  {
    "text": "essential. This review underscores the need for integrative, personalized",
    "entities": []
  },
  {
    "text": "approaches that synergize traditional and modern medical systems to enhance",
    "entities": []
  },
  {
    "text": "therapeutic outcomes in AD.",
    "entities": [
      {
        "text": "AD",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Copyright \u00a9 2025 Sneha Sri, Pavithra, Vinciya, Santhosh Kumar, Harikrishnan,",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Sneha Sri",
        "label": "PERSON"
      },
      {
        "text": "Pavithra",
        "label": "PERSON"
      },
      {
        "text": "Vinciya",
        "label": "GPE"
      },
      {
        "text": "Santhosh Kumar",
        "label": "PERSON"
      },
      {
        "text": "Harikrishnan",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "10.1177/13872877251360028. Online ahead of print.",
    "entities": [
      {
        "text": "10.1177/13872877251360028",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Cohort profile: China healthy aging cohort study (China-Aging).",
    "entities": [
      {
        "text": "China",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(1)National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical",
    "entities": [
      {
        "text": "Center for Neurological Disorders",
        "label": "ORG"
      },
      {
        "text": "Xuanwu Hospital",
        "label": "ORG"
      },
      {
        "text": "Capital Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University, Beijing, China.",
    "entities": [
      {
        "text": "Beijing",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Beijing Geriatric Healthcare and Disease Prevention Center, Xuanwu Hospital,",
    "entities": [
      {
        "text": "Geriatric Healthcare",
        "label": "ORG"
      },
      {
        "text": "Disease Prevention Center",
        "label": "ORG"
      },
      {
        "text": "Xuanwu Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Capital Medical University, Beijing, China.",
    "entities": [
      {
        "text": "Capital Medical University",
        "label": "ORG"
      },
      {
        "text": "Beijing",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Evidence-Based Medicine Center, Xuanwu Hospital, Capital Medical University,",
    "entities": [
      {
        "text": "Xuanwu Hospital",
        "label": "ORG"
      },
      {
        "text": "Capital Medical University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Department of Neurology & Innovation Center for Neurological Disorders,",
    "entities": [
      {
        "text": "Neurology & Innovation Center for Neurological Disorders",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Xuanwu Hospital, Capital Medical University, Beijing, China.",
    "entities": [
      {
        "text": "Xuanwu Hospital",
        "label": "ORG"
      },
      {
        "text": "Capital Medical University",
        "label": "ORG"
      },
      {
        "text": "Beijing",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Department of Geriatrics, National Research Center for Geriatric Medicine,",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Geriatrics, National Research Center for Geriatric Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Department of Elderly Health Management, Shenzhen Center for Chronic Disease",
    "entities": [
      {
        "text": "Elderly Health Management",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Control, Shenzhen, China.",
    "entities": [
      {
        "text": "Control,",
        "label": "ORG"
      },
      {
        "text": "Shenzhen",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)College of Biomedical Engineering & Instrument Science, Zhejiang University,",
    "entities": [
      {
        "text": "Biomedical Engineering & Instrument Science, Zhejiang University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(8)Department of Neurology, The First Affiliated Hospital, College of Medicine,",
    "entities": [
      {
        "text": "Neurology",
        "label": "PERSON"
      },
      {
        "text": "The First Affiliated Hospital, College of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Zhejiang University, Hangzhou, China.",
    "entities": [
      {
        "text": "Zhejiang University",
        "label": "ORG"
      },
      {
        "text": "Hangzhou",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)Department of Neurology, the Second Affiliated Hospital of Hainan Medical",
    "entities": [
      {
        "text": "Neurology",
        "label": "PERSON"
      },
      {
        "text": "the Second Affiliated Hospital",
        "label": "ORG"
      },
      {
        "text": "Hainan Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University, Haikou, China.",
    "entities": [
      {
        "text": "Haikou",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(10)School of Public Health, Key Laboratory of Tropical Translational Medicine",
    "entities": []
  },
  {
    "text": "of Ministry of Education, Hainan Medical University, Haikou, China.",
    "entities": [
      {
        "text": "Ministry of Education",
        "label": "ORG"
      },
      {
        "text": "Hainan Medical University",
        "label": "ORG"
      },
      {
        "text": "Haikou",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(11)Research Unit for General Practice, Department of Public Health, University",
    "entities": [
      {
        "text": "11)Research Unit for General Practice",
        "label": "ORG"
      },
      {
        "text": "Department of Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(12)Research Unit for General Practice, Department of Public Health, University",
    "entities": [
      {
        "text": "12)Research Unit for General Practice",
        "label": "ORG"
      },
      {
        "text": "Department of Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(13)Neurodegenerative Laboratory of Ministry of Education of the People's",
    "entities": [
      {
        "text": "13)Neurodegenerative Laboratory of Ministry of Education",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Republic of China, Beijing, China.",
    "entities": [
      {
        "text": "Beijing",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BackgroundAs China undergoes a demographic transition towards an aging society,",
    "entities": [
      {
        "text": "BackgroundAs China",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the prevalence and incidence of age-related disabilities, Alzheimer's disease,",
    "entities": []
  },
  {
    "text": "and various geriatric syndromes are steadily rising.ObjectiveThe China Healthy",
    "entities": [
      {
        "text": "ObjectiveThe",
        "label": "ORG"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Aging Cohort Study (China-Aging) aims to investigate the prevalence and",
    "entities": []
  },
  {
    "text": "associated risk factors of disability and cognitive impairment, and to develop",
    "entities": []
  },
  {
    "text": "predictive models for these conditions by combining traditional risk factors",
    "entities": []
  },
  {
    "text": "with artificial intelligence-derived metrics (such as gait, speech, vision,",
    "entities": []
  },
  {
    "text": "etc.).MethodsThe China-Aging cohort consists of community-dwelling participants",
    "entities": [
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "aged 60 years and older from Beijing, Hangzhou, Shenzhen, and Haikou. The",
    "entities": [
      {
        "text": "60 years",
        "label": "DATE"
      },
      {
        "text": "Beijing",
        "label": "GPE"
      },
      {
        "text": "Hangzhou",
        "label": "GPE"
      },
      {
        "text": "Shenzhen",
        "label": "GPE"
      },
      {
        "text": "Haikou",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "baseline recruitment was from May 16, 2022 to March 19, 2025, with study",
    "entities": [
      {
        "text": "May 16, 2022 to March 19, 2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "participants primarily from urban areas. Follow-up assessment of the cohort will",
    "entities": []
  },
  {
    "text": "occur every 1-3 years from the baseline.ResultsAmong 6283 participants who",
    "entities": [
      {
        "text": "every 1-3 years",
        "label": "DATE"
      },
      {
        "text": "ResultsAmong",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "completed the baseline evaluation (mean age 70.6 years, SD 6.3), 3775 (60.1%)",
    "entities": [
      {
        "text": "age 70.6 years",
        "label": "DATE"
      },
      {
        "text": "6.3",
        "label": "CARDINAL"
      },
      {
        "text": "3775",
        "label": "DATE"
      },
      {
        "text": "60.1%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "were women. The overall prevalence of disability, cognitive impairment, frailty,",
    "entities": []
  },
  {
    "text": "depression, and sarcopenia were 17.8%, 18.5%, 5.9%, 7.1%, and 5.7%,",
    "entities": [
      {
        "text": "17.8%",
        "label": "PERCENT"
      },
      {
        "text": "18.5%",
        "label": "PERCENT"
      },
      {
        "text": "5.9%",
        "label": "PERCENT"
      },
      {
        "text": "7.1%",
        "label": "PERCENT"
      },
      {
        "text": "5.7%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "respectively. The prevalence of disability in the Beijing cohort was higher than",
    "entities": [
      {
        "text": "Beijing",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "and the prevalence of cognitive impairment in the Haikou cohort was higher than",
    "entities": [
      {
        "text": "Haikou",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "in other cohorts (Beijing: 9.5%, Hangzhou: 7.9%, Shenzhen: 16.2%, Haikou:",
    "entities": [
      {
        "text": "Beijing",
        "label": "GPE"
      },
      {
        "text": "9.5%",
        "label": "PERCENT"
      },
      {
        "text": "Hangzhou",
        "label": "GPE"
      },
      {
        "text": "7.9%",
        "label": "PERCENT"
      },
      {
        "text": "Shenzhen",
        "label": "GPE"
      },
      {
        "text": "16.2%",
        "label": "PERCENT"
      },
      {
        "text": "Haikou",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "45.5%).ConclusionsThe prevalence of disability and cognitive impairment is",
    "entities": []
  },
  {
    "text": "relatively high, and notable regional difference exists in China. China-Aging",
    "entities": [
      {
        "text": "China",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "cohort provides crucial evidence for the precise prevention and management of",
    "entities": []
  },
  {
    "text": "disability, cognitive impairment, and other geriatric syndromes in promoting",
    "entities": []
  },
  {
    "text": "active and healthy aging.",
    "entities": []
  },
  {
    "text": "10.1177/13872877251350306. Online ahead of print.",
    "entities": [
      {
        "text": "10.1177/13872877251350306",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Alzheimer's disease classification using mutual information generated graph",
    "entities": []
  },
  {
    "text": "convolutional network for functional MRI.",
    "entities": []
  },
  {
    "text": "Initiative.",
    "entities": []
  },
  {
    "text": "(1)Department of Diagnostic Radiology and Nuclear Medicine, University of",
    "entities": [
      {
        "text": "Diagnostic Radiology and Nuclear Medicine, University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Maryland School of Medicine, Baltimore, MD, USA.",
    "entities": [
      {
        "text": "Maryland School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Baltimore",
        "label": "GPE"
      },
      {
        "text": "MD",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Neurology and Radiology, University of Pennsylvania Perelman School of",
    "entities": [
      {
        "text": "Radiology, University of Pennsylvania Perelman School",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BackgroundHigh-order cognitive functions depend on collaborative actions and",
    "entities": [
      {
        "text": "BackgroundHigh",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "information exchange between multiple brain regions. These inter-regional",
    "entities": []
  },
  {
    "text": "interactions can be characterized by mutual information (MI). Alzheimer's",
    "entities": []
  },
  {
    "text": "disease (AD) is known to affect many high-order cognitive functions, suggesting",
    "entities": []
  },
  {
    "text": "an alteration to inter-regional MI, which remains unstudied.ObjectiveTo examine",
    "entities": [
      {
        "text": "ObjectiveTo examine\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "whether inter-regional MI can effectively distinguish different stages of AD",
    "entities": []
  },
  {
    "text": "from normal control (NC) through a connectome-based graph convolutional network",
    "entities": [
      {
        "text": "NC",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(GCN).MethodsMI was calculated between the mean time series of each pair of",
    "entities": []
  },
  {
    "text": "brain regions, forming the connectome which was input to a multi-level",
    "entities": []
  },
  {
    "text": "connectome based GCN (MLC-GCN) to predict the different stages of AD and NC. The",
    "entities": [
      {
        "text": "GCN",
        "label": "ORG"
      },
      {
        "text": "MLC-GCN",
        "label": "ORG"
      },
      {
        "text": "AD",
        "label": "DATE"
      },
      {
        "text": "NC",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "spatio-temporal feature extraction in MLC-GCN was used to capture multi-level",
    "entities": [
      {
        "text": "MLC-GCN",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "functional connectivity patterns generating connectomes. The GCN predictor",
    "entities": [
      {
        "text": "GCN",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "learns and optimizes graph representations at each level, concatenating the",
    "entities": []
  },
  {
    "text": "representations for final classification. We validated our model on 552 subjects",
    "entities": [
      {
        "text": "552",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "from ADNI and OASIS3. The MI-based model was compared to models with several",
    "entities": [
      {
        "text": "ADNI",
        "label": "GPE"
      },
      {
        "text": "OASIS3",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "different connectomes defined by Kullback-Leibler divergence, cross-entropy,",
    "entities": [
      {
        "text": "Kullback-Leibler",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cross-sample entropy, and correlation coefficient. Model performance was",
    "entities": []
  },
  {
    "text": "evaluated using 5-fold cross-validation.ResultsThe MI-based connectome achieved",
    "entities": [
      {
        "text": "5-fold",
        "label": "CARDINAL"
      },
      {
        "text": "ResultsThe MI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the highest prediction performance for both ADNI2 and OASIS3 where it's",
    "entities": [
      {
        "text": "ADNI2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "accuracy/Area Under the Curve/F1 were 87.72%/0.96/0.88 and 84.11%/0.96/0.91",
    "entities": [
      {
        "text": "87.72%/0.96/0.88",
        "label": "CARDINAL"
      },
      {
        "text": "84.11%/0.96/0.91",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "respectively. Model visualization revealed that prominent MI features located in",
    "entities": []
  },
  {
    "text": "temporal, prefrontal, and parietal cortices.ConclusionsMI-based connectomes can",
    "entities": []
  },
  {
    "text": "reliably differentiate NC, mild cognitive impairment and AD. Compared to other",
    "entities": [
      {
        "text": "NC",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "four measures, MI demonstrated the best performance. The model should be further",
    "entities": [
      {
        "text": "four",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "tested with other independent datasets.",
    "entities": []
  }
]